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1Resumen
El cerebro es el órgano más complejo del organismo, y dada la cantidad de infor-mación que tiene que computar e integrar, no resulta sorprendente la enorme diver-sidad de células y circuitos que lo conforman. Esta diversidad tiene su origen en un 
cantidad relativamente pequeña de células madre indiferenciadas que experimentan un complicado proceso de desarrollo que culmina con un cerebro maduro. Cientos de moléculas y sistemas de señalización celular orquestan sucesivas oleadas de proliferación 
de progenitores neurales, así como su diferenciación en los linajes específicos que pueblan el parénquima cerebral, y la posterior migración de su progenie desde los 
nichos germinativos en los que nace, hacia las áreas definitivas que ocupará en un cerebro adulto. A lo largo de estos procesos, neuronas, astrocitos y oligodendrocitos deben madurar y adquirir las características que las distinguirán como células funcio-
nales, asegurando su inclusión en circuitos cerebrales específicos. Hoy día sabemos que una ligera desviación del programa ontogénico predeterminado puede tener conse-cuencias muy perjudiciales, ya que puede a su vez condicionar la aparición de diferentes malformaciones y patologías, que van desde enfermedades psiquiátricas a retraso men-tal de diversos grados, sin olvidar las enfermedades del espectro epiléptico. Por tanto, 
resulta crucial entender qué sistemas de señalización específicos regulan qué procesos concretos, y cómo se solapan unos con otros durante todo el proceso de desarrollo, para así poder predecir las consecuencias de su alteración y diseñar contramedidas efectivas.Uno de los sistemas de señalización que participa en esta colección de procesos es el de los endocannabinoides. El sistema endocannabinoide regula multitud de funciones ya conocidas en el organismo adulto, funciones que van desde la actividad sináptica al balance energético. Pero su papel durante el desarrollo es un aspecto que, 
pese a estar ya plenamente aceptado, aún necesita ser investigado en profundidad.
Con esto en mente, decidimos investigar la implicación del receptor CB₁ en el desarrollo tanto de neuronas de proyección como de interneuronas GABAérgicas durante la ontoge-
nia cortical. A tal fin, postulamos los siguientes objetivos para la presente Tesis Doctoral:
Objetivo 1: Analizar la conexión entre una función endocannabinoide alterada y la displasia cortical focal, una patología humana asociada con epilepsia infantil, así como 
evaluar si las neuronas de proyección que ven su expresión de CB₁ alterada durante 
el desarrollo experimentan cambios permanentes en su plasticidad y excitabilidad.
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 Objetivo 2: dilucidar la implicación del receptor CB₁ en el establecimiento de las 
interneuronas GABAérgicas, analizando el impacto a largo plazo de la exposición pre-
natal a THC en la población hipocampal de células en cesta CCK-positivas, junto con cualquier correlato comportamental o funcional.Con respecto al Objetivo 1, hemos evaluado la expresión del receptor CB₁ en muestras de tejido provenientes de resecciones de pacientes con displasia cortical focal, así como su posible relación causal con la sobreactivación de la vía mTOR típi-
ca de esta patología. Además, hemos analizado la existencia de polimorfismos de un 
solo nucleótido específicos en genes del sistema endocannabinoide, para abordar la 
cuestión de si existe alguna alteración genética en el sistema endocannabinoide que pueda contribuir a la aparición de la enfermedad. Finalmente, mediante técnicas de electroporación in utero de ARNip en ratones, hemos atenuado transitoriamente la ex-
presión del receptor CB₁ en neuronas corticales de proyección, para después estudiar su estado de maduración en diferentes estadios postnatales.
En resumen, hemos encontrado no solo que el receptor CB₁ se encuentra enriqueci-do en muestras de displasia cortical focal, sino también que su bloqueo farmacológico disminuye la fosforilación de la proteína ribosomal S6, que constituye un marcador 
bona fide de la actividad de mTOR. Además, hemos demostrado la asociación de un 
polimorfismo en el gen DAGLA, que codifica la enzima responsable de la síntesis del 
endocannabinoide 2-araquidonilglicerol, con la aparición de la enfermedad. Por úl-timo, hemos observado un retraso en la migración radial de las células electropora-das con ARNip, que además muestran una maduración alterada, demostrada por sus 
propiedades electrofisiológicas anómalas.Nuestros hallazgos contribuyen a demostrar la implicación del sistema endocanna-binoide en el desarrollo y maduración de neuronas corticales de proyección, y esta-blecen una relación causal entre un defecto en dicho sistema y la aparición de malfor-maciones del desarrollo cortical, como la displasia cortical focal.En relación al Objetivo 2, decidimos administrar una dosis baja de THC a ratonas gestantes durante una ventana temporal restringida del desarrollo embrionario, para después analizar a su descendencia en la edad adulta. Así, hemos comprobado el esta-
do de la población de células en cesta CCK-positivas en la región hipocampal, así como la actividad oscilatoria propia de dicha estructura cerebral mediante el implante de elec-trodos de registro intracerebrales. También hemos evaluado si la descendencia de las 
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ratonas tratadas muestra algún efecto perjudicial del tratamiento sobre la ejecución 
de dos tests de memoria diferentes, así como si su equilibrio excitación-inhibición muestra alguna susceptibilidad diferencial frente a la inyección del fármaco procon-vulsivo pentilenotetrazol. Finalmente, utilizamos el mismo paradigma de adminis-
tración prenatal en ratones que carecen selectivamente de expresión del receptor CB₁ bien en neuronas glutamatérgicas telencefálicas, bien en interneuronas GABAérgicas, 
y verificamos el efecto de la deleción genética condicional sobre los efectos provoca-dos por el THC.
Los datos obtenidos en estos experimentos mostraron que la alteración prenatal 
de la señalización del receptor CB₁ provocada por la administración de THC condicio-
na una disminución a largo plazo en la densidad de células en cesta CCK-positivas en 
la región CA1, disminución que afectó únicamente a la progenie masculina. Esta inter-
neuronopatía específica de los machos ocurre concomitantemente con una alteración 
de las oscilaciones hipocampales y con una mayor frecuencia de rizaduras específi-camente en los machos tratados. También encontramos alteraciones en la memoria espacial dependiente de hipocampo, mientras que la memoria de reconocimiento 
de objetos no sufrió alteraciones. El uso de ratones modificados genéticamente nos 
permitió adscribir los efectos observados exclusivamente a la acción del THC sobre 
receptores CB₁ presentes en neuronas GABAérgicas recién formadas, y no sobre el mismo receptor en neuronas glutamatérgicas nacientes.En conjunto, estos datos señalan la importancia de una función endocannabinoide correcta durante fases tempranas del desarrollo cerebral para el establecimiento de 
una subpoblación GABAérgica específica, así como para la adquisición de una memo-
ria espacial apropiada y un equilibrio excitatorio-inhibitorio estable. Además, nues-tros hallazgos sientan las bases para un mejor entendimiento de las consecuencias a 
largo plazo producidas por la exposición prenatal a cannabinoides.
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The brain is the most complex organ in the body. Given the amount of information that it has to compute and integrate in behavioural and somatic responses, it comes as no surprise the enormous amount of different cells and circuit assemblies that build it up. All this diversity originates from a relatively small amount of undifferentiated 
stem cells that undergo an intricate development proccess culminating with a mature 
brain. Hundreds of molecules and signalling systems orchestrate consecutive waves of 
progenitor cell proliferation, their differentiation in the specific cell lineages that pop-
ulate the cerebral parenchyma, as well as the migration of their progeny from the ger-
minative niches in which they are born to the definitive areas they will occupy in the 
adult brain. Meanwhile, neurons, astrocytes and olygodendrocytes need to maturate and acquire the traits that characterize functional cells, including their assembly in 
specific brain circuits. Today we know that a slight deviation from the default program may lead to deleterious consequences and to the onset of different malformations and 
pathologies, which range from psychiatric diseases to diverse grades of mental retar-
dation, without forgetting conditions belonging to the epileptic spectrum. Thus, it is 
crucial to understand which specific steps are regulated by which specific signalling 
systems, and how they imbricate themselves during the whole developmental pro-cess in order to predict the consequences of their malfunction and design effective countermeasures.
One of the signalling systems participating in this fine-tuned collection of processes 
is the endocannabinoid system. The endocannabinoid system regulates a well-char-acterized plethora of functions in the adult body, ranging from synaptic activity to energy balance, but its role during brain development is an issue that, despite being 
extensively accepted, needs to be further investigated.
Bearing this in mind, we sought to investigate the involvement of the CB₁ receptor in the development of both projection neurons and GABAergic interneurons during cor-
tical ontogeny. To that end, we put forward the following aims for the present Thesis:
Aim 1: To analyse the link between altered endocannabinoid system function and 
focal cortical dysplasia, a human pathology associated with childhood epilepsy, as well 
as to assess if projection neurons that have got their CB₁ receptor signalling geneti-cally disrupted during development suffer from permanent changes in plasticity and 
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excitability.
 Aim 2: To assess the involvement of the CB₁ receptor in the establishment of GAB-
Aergic interneurons, by analysing the long-term impact of prenatal THC exposure in 
the hippocampal CCK-containing basket cell population, along with any cognitive or behavioural outcome.With regard to Aim 1, we evaluated CB₁ receptor expression in tissue samples ob-
tained from focal cortical dysplasia patient resections, as well as its causal link with 
the overactivation of the mTORC1 pathway, which constitutes a hallmark in this pa-
thology. Next, we analysed the existence of specific single nucleotide polymorphisms 
within endocannabinoid system element genes in the same samples in order to ad-
dress if there exists a genetically-encoded endocannabinoid malfunction that can con-tribute to the onset of the disease. Finally, by means of siRNA in utero electroporation, 
we transiently knocked-down CB₁ receptor expression in murine cortical projection neurons, and then studied their maturation state at different postnatal stages.
We found not only that CB₁ receptor is highly enriched in focal cortical dysplasia, 
but also that blocking its signalling attenuates the phosphorylation of a bona fide 
readout of mTORC1 activity, the ribosomal S6 protein. In addition, we demonstrated the association of a single nucleotide polymorphism affecting the DAGLA gene, which encodes the enzyme responsible for synthesizing the endocannabinoid 2-arachido-
noylglicerol, with the occurence of the disease. Last, we observed a delay in the radial 
migration of CB₁-knocked-down neurons, which also show an impaired maturation as 
reflected by altered electrophysiological properties.
Altogether, these findings strongly support the involvement of the endocannabi-noid system in the development and maturation of cortical projection neurons, and 
establish a yet-to-be-studied causal link between its malfunction and the appearance of malformations of cortical development, as focal cortical dysplasia.In respect of Aim 2, we decided to administer a mild dose of THC to pregnant mice 
during a restricted developmental window, and then analyse their offspring at adult 
stages. In this way, we evaluated the state of the CCK-containing basket cell population 
in the hippocampal region, as well as the oscillatory activity arising from that brain structure, by implatation of intracranial recording electrodes. We also assessed if the 
offspring of the treated dams exhibited any detrimental trait in the execution of two 
different memory tasks, and challenged their excitatory-inhibitory balance by inject-
7summaRy
ing a proepileptic drug, pentylenetetrazol. Finally, we used the same administration 
paradigm in mice that lack CB₁ receptor expression selectively in either telencephalic 
glutamatergic neurons or GABAergic interneurons, and verified the effect of the ge-netic deletion over our previously observed THC-elicited effects.
The data obtained from these experiments showed that prenatal disruption of 
CB₁ receptor signalling by THC administration fosters a long-term and male-specific 
decrease in CCK-containing basket cell density in CA1. This sex-dimorphic interneu-
ronopathy ensues along with altered hippocampal oscillations and a higher sharp-
wave ripple rate specifically in the treated males. Hippocampal-dependent spatial 
memory was also impaired in that group, while object recognition memory remained 
unaffected. The use of genetically modified mice let us adscribe these effects exclu-
sively to the action of THC on CB₁ receptors present on developing GABAergic neu-
rons, and not those expressed by nascent projection neurons.
As a whole, these data unveil the importance of a proper endocannabinoid function 
during early brain development for the establishment of a specific GABAergic sub-
population, as well as for the refining of an appropriate spatial memory and a stable 
excitation-inhibition balance. In addition, our findings pave the way to a better under-
standing of the long-term consequences evoked by prenatal cananbinoid exposure.
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HEPES: 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
HFO: high frequency oscillation
IHC: immunohistochemistry
IKM: interkinetic nuclear migration
IN: interneuron
IPC: intermediate progenitor cell
IPSC: inhibitory postsynaptic current
ISH: in situ hybridization
ISI: interspike interval
IUE: in utero electroporation
IZ: intermediate zone
LFP: local field potential
LGE: lateral ganglionic eminence
LTD: long term depression
MCD: malformation of cortical development
MGE: medial ganglionic eminence
MGL: monoacylglycerol lipase
mPFC: medial prefrontal cortex
MRI: magnetic resonance imaging
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mTOR: mammalian target of rapamycin
MZ: marginal zone
NAPE: N-acylphosphatidylethanolamine
NAPE-PLD: NAPE-specific phospholipase D
NEC: neuroepithelial cell
NOR: novel object recognition
NSC: neural stem cell
Oct4: octamer-binding transcription factor 4
OL: object-location
oRGC: outer radial glia cell
oSVZ: outer subventricular zone
Oxt1: orthodenticle homeobox 1
P: postnatal day, as in P1 or P14
Pax6: paired box protein 6
PBS: phosphate buffered saline
PET: positron emission tomography
PFC: prefrontal cortex
PI3K: phosphatidylinositol 3-kinase
PKA: protein kinase A
PN: projection neuron
POA: preoptic area
PP: preplate
pS6: phosphorylated ribosomal protein S6
PTZ: pentylenetetrazol
PV: parvalbumin
qPCR: quantitative PCR
RGC: radial glia cell
Rheb: Ras homolog enriched in brain
RMP: resting membrane potential
S6: ribosomal protein S6
SD: standard deviation
Shh: sonic-hedgehog
ShNP: short neural precursor
SNP: single nucleotide polymorphism
Sox2: SRY-box transcription factor 2
SP: subplate
sp: stratum pyramidale
SST: somatostatin
STD: short term depression
Svet1: subventricular expressed transcript 1
SVZ: subventricular zone
SWR: sharp-wave ripples
Tbr1: T-box brain protein 1
Tbr2: T-box brain protein 2
TF: transcription factor
THC: Δ9-tetrahydrocannabinol
TSC: tuberous sclerosis complex
VIP: vasointestinal peptide
VZ: ventricular zone
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The brain. The organ that orchestrates every single complex behaviour that defines 
us as humans. The flagship of our complexity as mammals. The master operator of the 
body’s functions. An organ composed by several hundred billions of cells, which as-semble in turn billions of circuits. Countless populations and subtypes of neurons, as-trocytes, oligodendrocytes and microglial cells receiving inputs from the surrounding 
world and the body itself, computing herculean amounts of information in order to in-tegrate it in biological responses pursuing one major goal: our adaption and survival.
The ontogeny of the nervous system is a delicate process in which subtle alter-
ations may lead to highly noxious consequences. A slight deviation from the default genetic programs that encode the blueprint for a functional brain may produce out-comes that endanger the survivability of the individual. Hence and not surprisingly, 
brain development has become an area of knowledge that attracts growing attention and effort, in search not only of understanding about the molecular mechanisms un-
derlying this complex process, but also of insight regarding the consequences of its deregulation and the possible treatments or countermeasures.
1 . Ontogeny of the nervous system: the basics
Understanding how a cluster of embryonic undifferentiated neural stem cells (NSCs) gives rise to a fully mature and functional brain is a question that scientists 
have been trying to answer for decades. Pioneer neuroscientists, as Camilo Golgi, 
Korbinian Brodmann and Santiago Ramón y Cajal, among others, fuelled with their 
seminal works the race for brain comprehension. Ramón y Cajal first described the neuron as the functional and cellular unit of the brain (Ramón y Cajal, 1899) and, from 
that point, thousands of neuroscientists have dedicated their lives to understand how 
a mature brain arises from NSCs. Thanks to their efforts, nowadays we have a precise, 
although far from concluded, idea of how brain development works.
The more we know about this field, the more evident becomes that every single developmental step must be meticulously and tightly regulated by multiple genet-ic programs. These programs, established and maintained primarily by molecules 
termed morphogens, give rise to spatiotemporal patterns, which in turn define the 
types and quantities of neural cells that are generated in a given moment in a specific brain region. Morphogens are molecules released by organizers or patterning nodes 
during development in a way that creates a concentration gradient, being higher in the surroundings of the node, and decreasing progressively as the distance to the node 
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increases. A given cell will be exposed to different concentrations of diverse morpho-gens depending on its position relative to distinct nodes. As different morphogens 
trigger specific signalling pathways, the integration of all the morphogen levels that a 
cell receives will determine its molecular identity, since pathways activated or inhibit-
ed by morphogens are related to patterns of transcription factor (TF) expression that 
subsequently regulate gene expression and ultimately control cell fate.
1 .1 . Primordial morphogenesis of the brain
To begin with, and taking a mammalian embryo (like that of human and mouse 
species) as example, at an early stage of ontogeny, a regionalization of the dorsal ec-toderm leads to the formation of the neural plate, a planar sheet of neuroepithelium (Rubenstein et al., 1998). In a later stage [embryonic day 8 (E8) in mice], the neural 
plate will form the neural tube after neurulation (Copp et al., 2003). Although ante-ro-posterior identity is still present in the neural plate, driven by the antagonistic signal-
ling between the embryonic organizer and the anterior visceral endoderm, neural tube 
and subsequent phases of development are characterized by a deeper, more complex 
and irreversible specification and patterning (Hébert and Fishell, 2008). The neural tube suffers a set of constrictions that establish the boundaries of the primary brain 
vesicles: prosencephalon, mesencephalon and rhombencephalon, which will grow into forebrain, midbrain and hindbrain, respectively, as development progresses. The pros-
encephalon will subsequently suffer a new division in order to form the secondary ves-icles: telencephalon (the most rostral) and diencephalon (the most caudal) (Figure 1).
Afterwards, by E10, the telencephalon will 
further specialize in two areas. The dorsal tel-
encephalon, or pallium, will be the origin of the three cortical ultrastructures that characterize 
a mature brain: neocortex, paleocortex (olfac-
tory piriform cortex) and archicortex (subicu-lum, hippocampus, entorhinal and retrosplen-ial cortices) (Figure 2). The vast majority of cortical projection neurons (PNs) are born in this region (O’Leary et al., 2007). On the other hand, the ventral telencephalon, or subpallium, 
will give rise to another three different regions: 
Figure 1 . Early patterning of the central ner-
vous system . Primary and secondary brain vesicles in the developing mammalian brain.
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intRoductionlateral (LGE), medial (MGE) and caudal (CGE) 
ganglionic eminences (GEs), that will serve as the prospective territories for the basal gan-glia and as origin for the majority of inhibitory neurons that populate the forebrain (Figure 3) (Hansen et al., 2013; Huang, 2014; Marín and Müller, 2014).This primordial shaping constitutes only the beginning of a puzzling process, as the developing cerebral tissue needs to further subdivide in order to reach the characteris-
tic complexity of a mature brain.
1 .2 . Radial and tangential patterning within the cortex
The neocortex is the most complex area of the brain, being also the most recent 
in phylogeny. To understand its complexity, one should notice the heterogeneity gen-
erated in its two axes: radial and tangential, the former being perpendicular to the ependymal layer of the lateral ventricles and the latter parallel to it. The tangential 
axis is divided into several areas which are functionally different from each other. 
These differences come along with a characteristic patterning in gene expression, hodology and cytoarchitecture (O’Leary and Sahara, 2008). Four cortical main areas 
Figure 3 . Regional organization of the embryonic subpallium . Developing telencephalic hemisphere (left) as 
viewed from the midline. On its right, three coronal sections depicting the ganglionic eminences. CGE, caudal gan-glionic eminence; LGE, lateral ganglionic eminence; MGE, medial ganglionic eminence (d, dorsal; i, intermediate; cv, 
caudoventral); NCx, neocortex; ob, olfactory bulb; PO, preoptic region; POA, preoptic area; POH, preoptic-hypotha-lamic border; Th, thalamus. From Lim et al., 2018.
Figure 2 . The dorsal telencephalon gives rise to 
three different cortical structures . Cortical struc-
tures in the adult (right) mice brain [(the neocortex, 
the hippocampal formation (Hipp) or archicortex, 
and the olfactory piriform cortex (PC) or paleocor-
tex] originate from specific pallial domains present in the embryonic (left) brain [medial pallium (MP), dorsal pallium (DP), lateral pallium (LP), ventral pallium (VP)]. Adapted from Luzzati, 2015. 
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intRoduction (Figure 4) can be distinguished attending to their functionality: one pledged to mo-tor function (M1), and three engaged in sensory function [auditory (A1), somato-sensory (S1) and visual (V1)] (O’Leary et 
al., 2007). To generate these different ar-
eas, a process known as arealization must 
take place. Arealization is a direct conse-
quence of the existence of morphogen gra-
dients [like those of bone morphogenetic proteins, fibroblast growth factors and son-
ic-hedgehog (Shh)], which determine the expression of TFs such as Pax6, Sp8, Emx2, Coup-TFI and others. These TFs enforce different genetic programs that condition cel-
lular identity of the progenitor cells in the developing cortex and, consequently, the identity of the neural cells derived from them. Although this process is strongly con-
served in different mammalian species, which suggests common programs securing 
the correct patterning of the neocortex, the plasticity shown by neocortex regionaliza-tion after trauma points also to some degree of freedom in the acquisition of cortical identity (Alfano and Studer, 2013).
Regarding the radial axis, within the neocortex, and specifically in mammals, six different 
layers numbered from I (outermost) to VI (innermost) can be distinguished (Box 1), each 
one populated with its own assortment of neurons that differ in gene expression, morphol-
ogy and connectivity (Molyneaux et al., 2007). Amniotes other than mammals possess corti-ces comprising only three layers (Puelles et al., 2000; Cheung et al., 2007).
The first comprehensive theory that brought together the discoveries about ra-
dial and tangential axes was the radial unit theory (Figure 5), which stands that “the 
ependymal layer of the embryonic cerebral ventricle consists of proliferative units that 
provide a proto-map of prospective cytoarchitectonic areas. The output of the prolifer-
ative units is translated via glial guides to the expanding cortex in the form of ontoge-
netic columns, whose final number for each area can be modified through interaction 
with afferent input” (Rakic, 1988; Mountcastle, 1997). Although partially modified and 
amended by recent findings, the cortical column model remains valid today. It is important 
to note that currently we know that the neurons which are born in a particular column are not completely restricted to that column, as, in contrast, they have some plasticity and can 
finally be part of surrounding columns (Torii et al., 2009; Dimidschstein et al., 2013).
Figure 4. Area patterning within the neocortex. 
Embryonic arealization defines four areas that are diver-
gent in gene expression, connectivity pattern and cognitive 
function. Adapted from Bertacchi et al., 2018.
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Figure 5 . Radial unit model: 3D 
representation of the column 
model in the monkey cortex . Migrating neurons (MN), using radial glia (RG) as a scaffold, tra-verse the intermediate zone (IZ) 
and the subplate (SP), where 
they interact with afferents from monoamine nuclei of the brain-stem (MA), from the nucleus basalis (NB), from the thalamic radiation (TR) and from cortico-cortical bundles (CC). MG settle in an inside-out manner, occupying 
always the interface between cor-tical plate (CP) and the marginal 
zone (MZ). In this way, neurons 
arising from a specific “column” in the ventricular zone (VZ) main-tain the topology in the CP, althoug 
there exist lateral displacement at 
some extent. In the schematic, col-
umns in the VZ are identified by numbers, maintained by the corti-cal columns that they give rise to. From Mountcastle, 1997.
BOX 1 . The six-layered neocortex
The neocortex, also known as isocortex, is one of the most complex regions within the brain, its structure and composition differing across the different areas it encompasses. Nevertheless, and 
with some exceptions, it keeps a six-layered composition in almost its whole extension. Each one 
of its layers possess its own microstructure and cell composition, and so its own connectivity pattern.
»Layer I: the molecular layer, populated by scattered GABAergic INs. It also contains glial cells 
and the dendritic arborisation and horizontally oriented axons from neurons populating the other layers.
»Layer II: the external granular layer, vastly occupied by small pyramidal neurons that receive af-
ferences from the contralateral hemisphere also projecting onto it, as well as by numerous stellate neurons.
»Layer III: the external pyramidal layer, populated by small and medium-sized pyramidal neurons that form the main corticocortical efferences.
»Layer IV: the internal granular layer, in which pyramidal and stellate neurons receive thalamo-cortical and intrahemispheric corticocortical afferents.
»Layer V: the internal pyramidal layer, which contains large pyramidal neurons that project to subcortical (other than thalamic) and subcerebral structures.
»Layer VI: the multiform or polymorphic layer, occupied by a few large pyramidal neurons and 
many small spindle-like pyramidal and multiform neurons. From this layer the efferences to the thalamic region depart.
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2 . Establishing cortical diversity: one step beyond
After introducing neocortical heterogeneity, it is time to try to understand where 
it stems from. Briefly, the whole brain primordium, which is composed at first by a 
homogenous neuroepithelium, will undergo different expansion and specification 
processes to give rise to the cortex and other structures. In this point, it becomes con-
venient to introduce some topological terms that will be extensively used, terms that 
correspond to the different strata in the early telencephalic wall. Spanning from the 
dorsalmost part of the neural tube, underlying what will become the pial surface, and until the ventralmost part of pallium, just over the embryonic ventricle, the different zones that compose the developing brain receive the names of marginal zone (MZ), intermediate zone (IZ), subventricular zone (SVZ) and ventricular zone (VZ). These zones contain, in different time points, the diverse progenitor populations that shape the origin of cortical cell diversity.
2 .1 . Diversity of progenitor cells
As stated, the homogenous neuroepithelial population will undergo consecutive 
rounds of symmetric divisions, each one further refining their genetic program, which 
will guide the cells through a complex process that culminates with neurogenesis. During that process, several types of progenitors can be distinguished attending to 
their genetic profile and mitotic behaviour.
2 .1 .1 . Neuroepithelial cells
Cells forming the brain primordium are known as neuroepithelial cells (NECs). These cells have their bipolar soma so elongated that they contact both surfaces of 
the developing cortex, pial and ventricular surfaces, with their basal and apical pro-
cess, respectively (Sidman and Rakic, 1973). Even if NECs are committed to neural lineage, they retain some attributes typical from epithelia: they are highly polarized and strongly attached, as they form tight junctions to each other in the apical part, 
and are affixed to basal part through integrins (Aaku-Saraste et al., 1996; Graus-Porta 
et al., 2001). NECs experience a process called interkinetic nuclear migration (INM), 
during which their nuclei move along the apicobasal axis depending on the specific 
phase of the cell cycle that they are in. Hence, during G1, the bulk of their soma, con-taining the nucleus, moves to the basal pole, near the pial surface. Once there, the cell 
undergoes S phase, and then, while proceeding to G2, the soma moves to the opposite 
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pole, the apical wall, where the M phase will take place. This way, cell divisions happen 
only in the VZ (Sauer, 1934; Takahashi et al., 2018). NECs divide almost exclusively in a symmetric fashion, thus increasing the size of the NSCs pool. In a later phase, NECs start losing their epithelial identity and gradually transform in radial glia cells (RGCs), 
with molecular markers more typical of astrocytes. That point marks the outbreak of 
neurogenesis (Kriegstein and Alvarez-Buylla, 2009).
2 .1 .2 . Radial glia cells
RGCs take their name from the fact that they form radial processes to the apical and basal edges of the cortical primordium (Figure 6). In this stage, the characteris-tic tight junctions from NECs are replaced by adherens junctions (Martynoga et al., 
2012). RGCs also undergo INM and retain some of the protein expression from NECs, 
as Pax6, nestin or vimentin can be found in both cell types (Götz et al., 2002; Osumi et 
al., 2008). On the other hand, RGCs express astrocyte markers such as GFAP, GLAST or BLBP (Hartfuss et al., 2001). The main difference between NECs and RGCs is that the 
latter are capable not only of symmetrical division, which yields two identical RGCs, 
but also of two modes of asymmetrical self-renewing divisions: non-neurogenic, in 
which one of the offspring cells is a RGC and the other is an intermediate progenitor 
Figure 6 . Overview of neocortical development in rodents and humans . Schematic depicting different types 
of necortical progenitor cells and the compartments in which they reside. In rodents (left), radial glia (RG) cells 
divide in the VZ, while intermediate progenitor (IP) cells undergo their division processes in the SVZ. Only a small fraction of RG detach from the VZ, creating an incidental outer SVZ (OSVZ). In contrast, humans (right) develop a 
thick OSVZ, which is populated by its own cohort of outer IP cells (OSVZ IP). Given the huge expansion achieved by a 
thick OSVZ, tissue expands not only radially from the column units in the VZ, but also tangentially, giving rise to the 
folded neocortex that defines gyrencephalic animals. Adapted from Lui et al., 2011.
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cell (IPC); and neurogenic, which yields a RGC and a newborn neuron (Noctor et al., 2004). At the time RGCs appear and start their asymmetrical divisions, the once sin-
gle-layered neuroepithelium grows in thickness and complexity, and the neurons aris-ing in the apical compartments start their migration to the cortical plate using RGCs as a radial scaffold (Malatesta et al., 2000; Miyata et al., 2001; Noctor et al., 2001).
2 .1 .3 . Intermediate progenitor cells
Also known as basal progenitors because they translocate their soma to the SVZ, 
thus making them “basal” with respect to RGCs, which are typically located in the VZ 
(Takahashi et al., 1995), these cells work as a secondary population of progenitor cells. Once they are born, they lose their processes and adopt a multipolar morphology. IPs 
will not undergo INM anymore (Noctor et al., 2008; Borrell et al., 2012; Wilsch-Brau-ninger et al., 2012). They switch their expression profile from that of RGCs to a new 
one without epithelial markers like Pax6, as instead, IPCs start expressing the TFs 
Svet1 and Tbr2/Eomes (Tarabykin et al., 2001; Englund et al., 2005). IPCs experience 
in most cases symmetrical division in their first stages, shifting to self-consuming 
neurogenic divisions later. Thus, the SVZ, which by mouse E13 is barely emerging, 
becomes the main contributor to neurogenesis by E16, when the IPC pool has reached 
its maximum size after several amplifying symmetric divisions. Currently, the fact that 
the majority of cortical neurons, regardless of their specific lineage, originate from 
IPCs is something generally accepted in the field (Noctor et al., 2004; Kowalczyk et al., 2009; Mihalas et al., 2016).
2 .1 .4 . Other progenitor populations in the dorsal telencephalonAlthough NECs, RGCs and IPCs constitute the main populations of progenitor cells 
in the developing brain, at least two additional populations are worth to be men-tioned: short neural precursors (ShNPs) and outer radial glia cells (oRGCs).
ShNPs are a special population of RGCs that have lost their basal process, while retaining the apical one (Gal et al., 2006). In spite of expressing Pax6 and not Tbr2, 
and being located in the VZ, ShNPs behave like IPCs in that they are likely to directly 
generate neurons in the VZ (Stancik et al., 2010). They also respond to niche-derived 
cues, like Notch, which are typical from IPCs (Mizutani et al., 2007). Thus, some con-sider them as a population of RGCs undergoing the transformation into IPCs.
oRGCs are another population of RGCs located in a zone known as outer subven-
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tricular zone (oSVZ). The oSVZ was once believed to be present only in gyrencephalic 
mammals, although its existence has been confirmed to a lesser extent in the mouse 
cortex (Shitamukai et al., 2011). oRGCs resemble RGCs without their apical process, 
thus losing their connection with the ventricular wall. They retain the basal process, 
Pax6 expression and self-renewal capacity. They are considered to be the population 
that gives rise to the massive tangential expansion in the cortex of primates, otherwise 
hardly explained (Reillo et al., 2011).
2 .2 . Neurogenic waves and projection neuron diversity
Different progenitor cells populate the primordium of the cortex at different time points, but each one of them participates in a series of spatiotemporal events that drive the onset of neurogenesis. Neurons generated from pallial progenitors belong 
to subpopulations which will colonise specific layers of the neocortex, depending on 
the exact day when they are born. This event occurs in an inside-out fashion, so that 
the neurons which are born in early embryonic days populate the layers near VZ and 
SVZ (deep layers), while the ones born later will migrate through the previously estab-
lished deep layers and will populate the upper ones.
Approximately from E10 to E12, cortical progenitors start undergoing asymmetri-
cal divisions which will generate neurons. These neurons will radially migrate using 
RGCs as scaffold, forming the preplate (PP). PP neurons will, in a later developmental 
stage, establish transient glutamatergic synapses with newly generated neurons to 
regulate their multipolar-to-bipolar morphology transition, a step that will be crucial 
for their migration towards neocortical layers (Ohtaka-Maruyama et al., 2018). At the same time, the Cajal-Retzius cells (CRCs) originating from different foci at the borders 
of pallium colonise the pial surface of the developing cortex and transiently establish in the MZ (Marín-Padilla, 1998; Soriano and Del Río, 2005). Once there, they start re-leasing reelin, that acts as a directional cue for migrating neurons. 
A second surge of newborn neurons arises at E12. After migrating through the PP 
[which is splitting into the MZ and a deep subplate (SP) by that time], they form the 
cortical plate (CP), the real primordium of the six-layered neocortex. Concomitantly, 
the SVZ makes its debut, and starts growing in size and progenitor cell number that 
will subsequently boost the growth of the CP.
In the next five days, overlapping neurogenic waves will generate diverse PN popu-lations (Figure 7), as previously stated, in an inside-out fashion, giving origin to rough-
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ly 80 % of the neurons that populate the cortex. Peaking at E12, the birth of neurons destined to migrate to layer VI gives rise to corticothalamic PNs (CThPNs) and callosal 
PNs (CPNs). Then, with peak at E13, layer V neurons, including corticospinal motor 
neurons (CSMNs) and more CPNs, are born. Layer IV neurons, which include locally 
projecting stellate cells, appear at E14. Between E15 and E17, diverse subpopulations 
of CPNs and intracortical PNs bound for layers II/III arise. Layer I, which originates 
from MZ, lacks PN somata, and will be populated only by GABAergic interneurons (INs) and glial cells in the mature brain, as CRCs disappear gradually in early postnatal life (Martynoga et al., 2012; Greig et al., 2013; Huang, 2014).
This clockwork mechanism defining the fate of newborn neurons also affects the 
generation of the rest of cell types that conform the cortex (with the exception of mi-
Figure 7 . Sequential neurogenic waves give rise to projection neurons populating the neocortex . Cortical PNs generate sequentially from different progenitor types in the VZ/SVZ. RGCs begin to produce neurons around E11.5, 
while also producing Ips and oRGCs. CRCs populate layer I from non-cortical areas. According to their birthdate, 
PNs acquire a specific subtype and migrate to their corresponding cortical layer, populating and thickening the CP 
in an inside-out manner. Briefly, subplate neurons (SPN) are born around E11.5, just before the peak of CThPNs and 
SCPNs (E12.5 and E13.5, respectively) Layer IV granular neurons (GN) are born around E14.5, while most CPNs are 
generated between E14.5 and E16.5. Peak sizes in the lower diagram ara proportional with the estimate number of neurons born each day. Adapted from Greig et al., 2013.
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croglia, whose origin is myeloid): NSCs generate neurons, astrocytes and oligodendro-cytes in a sequential manner (Abney et al., 1981; Qian et al., 2000). Although astroglio-genesis starts during embryonic development (around E16 in mice) and oligodendro-genesis begins just after birth, both cell types have the main part of their populations 
generated in the first postnatal month (Cameron and Rakic, 1991; Misson et al., 1991; 
Rowitch and Kriegstein, 2010).
2 .3 . Interneurons in the cortex: origin and diversityInhibitory neurons constitute the remaining 20% of cortical neurons. The majority 
of them hold γ-aminobutyric acid (GABA) as their main neurotransmitter. They typ-ically dampen neurotransmitter release in closely located neurons, and so they are termed INs. Different criteria have been proposed in the past years in order to classify 
them, but single and simple criteria appear to be insufficient to apprehend their full diversity (Figure 8) (Ascoli et al., 2008; Bartolini et al., 2013; DeFelipe et al., 2013).
The vast majority of INs populating the neocortex arises from the subpallial re-
gions known as GEs (Figure 3), which act as the proliferative niche in the subpalli-um. GEs possess, as their pallial counterpart, VZ and SVZ compartments that contain progenitor cells very similar to those found in the pallium not only in morphology and time-restricted presence, but also in their proliferative and neurogenic behaviour 
(Flames and Marín, 2005). However, neurons derived from these progenitors are emi-
nently INs. Although these traits are valid for GEs as a whole, GEs is a term that encom-
passes three spatially segregated regions characterized by the expression of different 
TFs: LGE, MGE and CGE. The latter two give rise to the INs that will afterwards migrate 
to the cortex. The MGE is believed to give rise to roughly 60% of cortical INs, including parvalbumin- (PV) and somatostatin- (SST) containing INs. As for the CGE, it produces 
cholecystokinin- (CCK), calretinin- (CR) and vasointestinal peptide (VIP)- containing INs. Additionally, a small percentage (less than 10%) of cortical INs are born in a different sub-
pallial area, the preoptic area (POA), which is the origin of a small though diverse group 
of SST-, PV- and neuropeptide Y (NPY)- containing INs, with different morphological idio-syncrasy from those born in MGE in the SST and PV groups (Figure 8) (Lim et al., 2018).The mechanisms underlying the generation of IN diversity seem to be similar to 
those responsible for PN diversity in the cortex. Both pallial and subpallial progenitor 
cells’ potentiality are determined by the area from which they derive, that provides 
them in turn with a specific molecular identity (spatial patterning). The final lineage 
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a given neuron arising from a progenitor belongs to (and so, the cortical layer it will 
migrate to) is then also determined by the specific moment at which its progenitor cell undergoes the neurogenic division that originates that neuron (temporal patterning), as different moments of the developmental time line also determine slightly different programs and potentialities in a given progenitor cell. Spatial and temporal pattern-ing operating together greatly amplify the number of different populations that arise 
from a progenitor pool, which otherwise may seem insufficient to explain cortical di-versity (Greig et al., 2013; Marín and Müller, 2014; Lim et al., 2018).
Figure 8 . Diversity of GABAergic neurons in the neocortex . Upper panel depicts major IN clases according 
to their expression profile. Three extensive groups [PV-, SST- and serotonin receptor 3A (Htr3a)-containing INs] may be distinguished and subsequently subdivided attending to morphology, laminar identity, electrophysiological 
properties and the expression of markers other than the abovementioned. Lower panel links specific IN types with 
their prospective area, as well as with the TF signature that characterizes their progenitor cells. CB, calbindin; NOS, 
nitric oxide synthase; POH, preoptic region. Adapted from Lim et al., 2018.
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3 . Neuronal migration: a pilgrimage for diversity
PNs and INs populating the cortex arise from distant progenitor pools; therefore, they undergo distinct migration processes (Figure 9) to reach their destiny: the spe-
cific cortical layer to which they are bound for according to their birthdate. Neuronal 
migration is a very complex process, during which cells need to integrate a plethora 
of auto- and paracrine signals that work as permissive/repulsive or directional cues. 
Those signals trigger downstream cascades that foster dynamic cytoskeletal reorgani-
zations in a way that facilitates nucleokinesis and translocation of the soma using the 
extracellular matrix, the somata of other neurons, and the processes emitted by RGCs, 
as a scaffold (Rakic, 1972; Nguyen and Hippenmeyer, 2014).
Although intermediate filaments are also important to maintain cell morphology 
and to determine migration mode, microtubules, and especially actin filaments, are 
the leading players in neuronal migration. While microtubules are key regulators of 
the elongation of the leading process and nucleokinesis, actin filaments work as the crucial driving force for cell migration, given their strong capacity to physically trans-
locate the soma while they rearrange (Heng et al., 2010; Govek, Hatten and Van Aelst, 2011).
Figure 9 . Neurons arising from 
distant proliferative areas under-
go different types of migration to 
reach the neocortex . In order to ar-
rive to their final destination, PNs aris-ing from pallial germinal niches (VZ and SVZ, green regions) migrate radi-
ally (green arrows) towards their spe-
cific cortical layer, whereas INs born in the subpallial progenitor pools (as the MGE, red regions) undergo a lon-
ger tangential migration (red arrows) 
following migratory streams to reach 
the cortex, followed by a subsequent radial migration step to correctly al-
locate themselves within neocortical 
layers when they arrive to the specific area they are bound to. Adapted from Nguyen and Hippenmeyer, 2014.
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3 .1 . Pyramidal neurons and radial migrationAs PNs are born in the pallial VZ or SVZ, their migration is shorter than that of 
INs and relies almost exclusively in radial migration steps. Thus, a PN travels from its 
birthplace, near the ventricle, to the neocortical layer in which it may establish in ac-
cordance with its birthdate. Thus, early-born neurons will form the deep layers of the 
cortex, whereas late-born neurons will populate the upper ones.As the regions a PN has to travel through display a strong heterogeneity, both de-
fined by the position in the dorsoventral axis and the specific moment of development, 
the migration mode used within each compartment also varies (Figure 10). Thus, in 
early stages of development (between E10 and E14 in the murine brain), when the 
cortical wall is still relatively thin, neurons and sometimes RGCs may undergo direct somal translocation (Miyata et al., 2001; Nadarajah et al., 2001). During somal translo-
cation, the cell exhibits a long radial process that reaches the pial surface and a shorter 
trailing process that detaches from the ventricular wall. The basal process constantly 
shrinks, thus provoking a fast nucleokinesis in the same direction (Noctor et al., 2004; Taverna et al., 2014).
In contrast, when cortical thickness expands (from E14 onwards), newborn cells rely on the scaffold composed by their mother RGC and its process to properly migrate. 
During this event, known as RGC-aided locomotion, migrating neurons possess a leading process and a short trailing process, none of them attached to the pial or ventricular surfaces. Both pro-
cesses seem to embrace the radial fibre of the RGC during migration (Nguyen and Hippenmeyer, 2014).Lastly, a different mode of migration is transiently observed in neurons in 
the SVZ and IZ, while they detach from 
radial fibres and pause their migration. At this moment, they acquire multipolar morphology, more appropriate to sense cues from several directions. After a 
Figure 10 . Sequence followed 
by cortical projection neu-
rons during their radial mi-
gration . Newborn PNs detach, if yet attached, from the ventric-ular surface and travel through VZ/SVZ (1). After undergoing multi-to-bipolar shift (2), neu-rons, engage RGC-aided migra-tion (3) using the basal process of their mother cell as a scaf-fold, until they reach the SP and enter their target CP area (4). Then, neurons further migrate 
towards their corresponding 
cortical layer (5), where they detach from the RGC (6), and 
execute terminal somal translo-cation (7). During this sequen-
tial steps, PNs follow different cues present both in the millieu and in the surface of neigh-bouring cells (not represent-ed). Adapted from Nguyen and Hippenmeyer, 2014.
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RGC other than their mother cell (Tabata and Nakajima, 2003).
Putting everything together, newborn PNs must first detach from the apical surface 
and migrate towards the SVZ/IZ, where they acquire a transient multipolar morpholo-
gy, which helps them to sense the extracellular milieu in search for promigratory cues. 
Later, they re-engage RGC-aided locomotion and invade the CP (Tabata and Nakajima, 2003; Noctor et al., 2004; Nguyen and Hippenmeyer, 2014). It is important to note that, in this last step, as they recover the bipolar morphology needed to migrate to-
wards CP, they also establish neuronal (i.e., axon-dendrite) polarity, as it derives from 
the leading-trailing process polarization (Barnes and Polleux, 2009).
3 .2 . Interneurons and tangential migrationAs opposed to PN, cortical INs are born in the subpallium. They need to reach the 
cortex, migrating through the developing telencephalon, and then acquire their lami-nar identity, establishing in the proper neocortical layer. IN migration is also a hetero-geneous process that can be subdivided in three major phases: tangential migration to the pallium, intracortical dispersion and laminar allocation, covering consecutive 
steps of the whole journey (Marín, 2013; Lim et al., 2018).
INs migrating to the pallium need to find their route from their birthplaces (name-ly CGE, MGE and POA) to the pallium-subpallium boundary. Although their TF signa-ture is different, and so is the subset of guidance factors they respond to, INs arising 
from these distinct regions exhibit an undistinguishable morphology while migrating (Marín et al., 2006), being the major feature the formation of a leading process that 
is permanently branching while migration cycle goes on (Yanagida et al., 2012). This 
process senses the extracellular milieu in search for chemorepulsive or chemoattrac-
tant cues that help the cell to find its route to the cortex. INs from different origins 
seem to follow differential paths to reach the cortex, supporting the idea that each 
progenitor pool generates INs that use their own unique subset of extracellular sig-
nals. As an example, Slit1 and Sema3A work as repulsive signals for MGE-derived INs, 
while Nrg1 constitutes an attractant for them. Little is known about the specific cues that CGE- and POA-derived INs need to complete a proper migration, although some neurotransmitters have been proposed (Riccio et al., 2012; Zimmer-Bensch, 2018). 
Interestingly, cannabinoid receptor type 1 (CB₁R) has been proposed to regulate CCK-IN migration (Berghuis et al., 2005).
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Once they reach the pallial-subpallial boundary, cortical INs enter a new phase of 
their migration: the so-called intracortical dispersion (Figure 11), in which the sub-pallium becomes repulsive to them, and they organize into migratory streams. The 
two main migratory streams course through the MZ and SVZ, respectively, although a small fraction of INs migrate through the SP. A common trait of intracortical disper-sion seems to be that INs actively avoid entering the CP (Marín and Rubenstein, 2001; Wichterle et al., 2001). Whether a given IN selects a migratory stream over another 
responds to the specific complement of guidance receptors it possess, and, as their or-igin (MGE versus CGE versus POA) does not seem to influence this decision, it has been 
proposed, though not demonstrated, that specific IN subtypes use specific migratory streams to travel (Miyoshi and Fishell, 2011).
The last step of cortical IN migration is their laminar allocation. This last process 
requires that INs switch from a tangential migration mode to a radial one, a shift which 
is believed to be triggered by the loss of responsiveness to the attractant Cxcl12 (Li et 
al., 2008). This radial migration step allows INs to enter the CP, where they will final-
ly migrate into the cortical layer that constitutes their final destination. Even though some classes of IN appear equally distributed across many layers, the majority of them 
have a more restricted pattern within cortical layers, a trend that is strongly echoed in 
the hippocampus (Klausberger and Somogyi, 2008; Ciceri et al., 2013).
Figure 11 . Interneurons colonising the cortex follow three consecutive phases of migration . When migrating 
INs reach the pallium, they join one of the stereotyped migratory streams in order to travel towards their target 
region (tangential dispersion, left). Subsequently, they switch their migration type and engage radial migration in 
order to invade the CP (center). Finally, INs translocate to their final destination (right) following chemoattractive 
cues expressed by PNs. Adapted from Marín, 2013.
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3 .3 . Neuronal migration defects and malformations of cortical development
Neuronal migration is a tightly regulated succession of processes that ends with 
PNs and INs residing in their definitive neocortical layer. Belonging to a specific layer 
determines not only the physical proximity to a specific subset of neurons, but also 
establishes the microenvironment surrounding a neuron, its ability to create specific interactions (its efferences), and the origin of the connections it receives (its affer-
ences), thus conditioning the microcircuits that it can, and will, assemble. But, what happens if something fails?
Disruption of neuronal migration causes cortical malformations, whose severity 
and features depend on the specific process that becomes disrupted and on the specif-
ic brain region in which it occurs. There is a wide spectrum of potential functional con-sequences: from mental retardation and intellectual disabilities, to autism or epilepsy 
(Guerrini and Parrini, 2010; Barkovich et al., 2012). Clinically, this broad selection of 
alterations and pathologies is gathered under the extensive term “malformations of 
cortical development” (MCDs; Box 2). The general classification scheme of MCDs in-cludes three major types of malformations, attending to the developmental step at 
which a healthy development becomes first disrupted: malformations of cell prolifer-ation, of neuronal migration, and of postmigrational cortical organisation and connec-
tivity (Guerrini and Dobyns, 2014). These entities comprise a bulk of pathologies that 
are also highly heterogeneous and in constant change, as knowledge about their caus-
es and features advances. Remarkable examples of these conditions are lissencephaly, polymicrogyria, periventricular heterotopia, hemimegalencephaly and focal cortical 
dysplasia (FCD). Only the latter will be extensively introduced here.FCD is also a heterogeneous group of disorders that are characterized by relatively 
localized histological alterations in any cortical region, and can appear with a hugely 
varying size range. The common trait that identifies an FCD is that it courses with epilepsy. FCDs that differ in size, location or shape cause diverse degrees of epilepsy. Debut age and seizure semiology vary among patients, although it is very common 
that first seizures appear in early childhood. Children affected by FCD may also show behavioural disturbances, and their seizures tend to be antiepileptic drug-resistant. A set of electroencephalographic recordings is frequently used in order to diagnose FCD, 
which is characterized by focal and rhythmic epileptiform discharges that correlate 
spatially with the lesion (Gambardella et al., 1996).
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Attending to the nature of each specific alteration, three subtypes of FCD may 
be distinguished (Blümcke et al., 2011; Najm et al., 2018). FCD Type I consists on 
malformations that affect cortical layering, whether in a radial (FCD Type Ia) or 
a tangential (FCD Type Ib) fashion. In some cases, both kinds of malformations 
appear at the same time (FCD Type Ic). FCD Type I usually shows a less sharply de-
marcated white matter border, due to the presence of ectopic neurons. Although 
BOX 2 . Malformations of cortical development
A wide range of conditions affecting the cortex fall under this denomination. What they have in common, though, is that they originate from the disruption of different steps in the 
ontogeny of the neocortex. Their severity and functional out-come vary, depending on the area they occupy, their size, and their intrinsic nature, but the most common consequences 
are some extent of neurological disability and epilepsy with an early onset. Although multiple criteria have been pro-posed to classify MCDs, their heterogeneity and the fact that in some occasions a single lesion displays features typical of 
different clinical categories make them hard to apprehend. A 
short description of the most common and well-established 
MCDs other than focal cortical dysplasia, reviewed in the 
main text, is included here.
»Megalencephaly: this term refers to an abnormally large 
brain, exceeding the mean for age and gender by 3 standard deviations (SD). The origin of this abnormal size is believed 
to be an excessive neural progenitor proliferation and/or a reduced rate of apoptosis. It is relatively common that mega-
lencephaly appears combined with MCDs such as polymicro-
gyria, as explained below.
»Microcephaly: opposite to megalencephaly, this condition includes brains smaller than the mean by 3 SDs. Its causes 
are also believed to be related with defects in progenitor proliferation and/or cell survival. It also courses commonly 
with polymicrogyria.
»Polymicrogyria: in this case, the major feature is that cortical surface appears irregular or pebbled. It size varies ranging from a small cortical area to both hemispheres, and 
it usually shows microscopically overfolded cortices (thus, 
excessive gyration at the microscopic scale, although mac-
roscopically, the altered structure may be confounded with pachygyria). It is also common that the affected area possess an altered or absent lamination.
»Lissencephaly: at some extent, it can be considered the opposite to polymicrogyria, as it comprises cases in 
which the cortical folding and sulcation are reduced (pachygyria) or absent (agyria). Sometimes, both pheno-
types are present in distinct areas of the same patient. In a subset of lissencephalies, known as cobblestone, 
neurons overflow from the meninges, creating a “bumpy” appearance.
»Subcortical band heterotopia: although the gyral pattern is often altered in subcortical band heterotopias, 
its main feature is a smooth band of grey matter in the superficial and middle portions of the subcortical white matter, composed of dense nodes of heterotopic neurons. In most cases, the neocortical portion just atop the heterotopia appears normal in lamination.
»Periventricular nodular heterotopia: in this case, patients show nodular masses of grey matter that line the 
ventricular walls and protrude into its lumen. The number of nodules varies amply among patients. Individual nodules may possess a rudimentary lamination.
Adapted from Nguyen and Hippenmeyer, 2014.
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ations that display not only cortical layering defects, but also specific cytological 
abnormalities that define its both subtypes: FCD Types IIa and IIb. The hallmark 
of FCD Type IIa is the presence of dysmorphic neurons (DNs), with an enlarged 
cell body and nucleus, malorientation and accumulation of neurofilament pro-
teins 2F11 and SMI-32 in their cytoplasm. On the other hand, FCD Type IIb shows the presence not only of DN identical to those found in FCD Type IIa, but also of 
balloon cells (BCs). BCs are cells with a large rounded cell body that possess a 
glassy eosinophilic cytoplasm. They tend to accumulate vimentin and nestin fila-
ments and may show a concomitant expression of neuronal and glial markers, as 
neurofilaments and GFAP. Although contribution of DNs and BCs to epileptiform 
activity is not well established, it has been demonstrated that DNs may possess 
hyperexcitable intrinsic membrane properties (Cepeda et al., 2006; André et al., 2007). A third type of FCD, FCD Type III, is characterized by cortical lamination 
abnormalities which are associated with a primary lesion that defines its subtype. 
Thus, FCD Type IIIa is associated with hippocampal sclerosis, FCD Type IIIb with 
tumours, FCD Type IIIc with vascular malformations, and FCD Type IIId with any other lesion acquired during early life.
Even though a genetic origin has been proposed for FCD, and a growing body of evidence points to mutations on genes involved in the mammalian target of 
rapamycin (mTOR) pathway as one of the major candidates to FCD etiopathology (Crino, 2015; Lim et al., 2015; Majolo et al., 2018), there is no general consensus yet, 
and it is very likely that a heterogeneous spectrum of abnormalities, as those found in FCD cases, is caused by different mutations in each case. mTOR-related mutations 
have been mainly associated with FCD Type II, which possess some resemblances to 
tuberous sclerosis complex (TSC), a genetic disorder caused by mutations affecting TSC1 and TSC2 proteins that lead to an overactivation of mTOR signalling. Important 
to note, mTOR-related mutations have been also identified in hemimegalencephaly 
cases. This finding has taken some authors to theorize that hemimegalencephaly and 
FCD are, in fact, a continuum of the same pathology, in which the extent of the dysplas-
tic lesion is determined by the specific moment and area in which mutations appear (D'Gama et al., 2017), with an earlier onset resulting in a larger and more severe dys-plastic areas, as those observed in hemimegalencephaly cases.
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4 . The endocannabinoid system and brain developmentBeing a highly intricate process, it comes as no surprise that hundreds of signalling 
pathways are implicated (and imbricated) in brain development. From early morpho-
gens as Shh or Wnt to late pathfinding signals as netrins and semaphorins, a profusion of different molecules participates in the control of the central nervous system (CNS) ontogeny. One of the signalling systems that orchestrates its appropriate completion is the endocannabinoid system (ECS), composed by endocannabinoid (eCBs) ligands, 
cannabinoid receptors (CBRs) and eCB-metabolising enzymes that are, as a whole, 
amply expressed throughout the body, although with varying relevance depending on 
the specific tissue. In particular, CB₁R, a protein that humans have been engaging with 
plant-derived compounds due to its psychoactive potential since ancient times (Box 3), 
The vascular plant Cannabis sativa L., also known as cannabis, marijuana, or hemp, among others, has been cul-
tivated since times as ancient as the Neolithic. By 5000 years ago, in the ancient China, it was recognized as an 
herbal medicine for multiple afflictions. Later, by 2000 BC, it was used by Assyrians with similar applications, 
and its acknowledgment gradually shifted its influence area towards the Middle East and India, until circa 
1800 AC, when French soldiers returning from Egypt introduced it definitely in Europe. By that time, its uses 
where not only medicinal, but also textile (as hemp fibres were the main component of ropes and sails) and 
recreational, its most-widely application nowadays. C. sativa and its subspecies are to date the only ones among 
the whole plant kingdom that produce cannabinoids (phytocannabinoids attending to their origin). Although a single plant may produce more than a hundred different phytocannabinoid compounds, the most relevant 
ones, both in abundance and in pharmacological action, are Δ9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD). Although THC was structurally characterized by Raphael Mechoulam and his group in the 1960s, it was 
not until 30 years later that its molecular targets (the cannabinoid receptors) in the mammalian brain were 
discovered. Thus, the receptor stimulated by THC, responsible for its psychoactive effects, was named after the 
plant that produces THC: type-1 cannabinoid receptor, and when the full signalling system was discovered, it maintained the name, thus becoming the endogenous cannabinoid system, or endocannabinoid system.
BOX 3 . Cannabis sativa
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captures most of the attention when it comes to CNS, as the other known CBR (CB₂R) 
is less represented in brain tissue. See Box 4 for a description of the ECS and its com-
ponents other than CB₁R. 
The ECS is a biological system which participates in the control of diverse functions throughout the body. It acts as an attenuator of neurotransmitter release in virtually every single synapse in the brain, thus regulat-
ing a wide range of brain processes, but it is also involved in immune modulation and the control of energy 
balance, among others. Its name comes from the fact that its receptors were first identified as the endogenous 
targets of the phytocannabinoid THC in the brain, not being until a few years later that the endogenous ligands 
were isolated. As a cell signalling system, the ECS is composed by an assortment of receptors (CBRs), ligands (eCBs), and the enzymes responsible of their synthesis, degradation and bioconversion.
»Cannabinoid receptors: the two main cannabinoid receptors are known as type-1 and type-2 cannabinoid 
receptors, or CB₁ and CB₂ receptors (CB₁R and CB₂R, respectively). Both are classical GPCRs with seven trans-
membrane helixes, and signal through their coupling to different G proteins, although non-canonical signal-
ling through their interaction with other intracellular proteins and membrane receptors has been described. 
Although CB₁R and CB₂R have typically been considered brain- and immune system-bound, respectively, it 
is now accepted that they are expressed in multiple tissues. They share not only 42 % of their amino acid 
sequence, but also the collection of ligands by which they are engaged. Nevertheless, even if they share their 
ability to bind both phytocannabinoids and eCBs, binding affinity and specificity is different for each receptor. 
This, together with their distinct tendency to select intracellular interacting partners, give each CBR a unique 
signalling signature. In addition to CB₁R and CB₂R, other receptors as TRPV1, GPR18, GPR55 and GPR119 are 
known to bind eCBs, but are no formally considered as cannabinoid receptors because they do not fulfil all the 
“official” IUPHAR requirements.
»Endocannabinoids: they are a diverse group of lipid molecules derived from arachidonic acid that share the 
ability to engage CBRs. The two main eCBs, by abundance and relevance, are N-arachidonoylethanolamine 
(anandamide, AEA) and 2-arachidonoylglicerol (2-AG). Even though both are capable of binding to CB₁R and 
CB₂R, their affinity for the receptors differs, as it does its potency (AEA is, in fact, a partial agonist, while 
2-AG is a full one); furthermore, their bioavailability depends on the specific tissue in which they exert their functions. There might be additional, less classical, and still controversial (since they have not been univocally 
proven to bind CBRs and exert CBR-evoked biological actions) examples of eCBs, such as oleoylethanolamide, virodhamine and N-arachidonoyldopamine.
»Synthesis enzymes: as already mentioned, the main eCBs are arachidonic acid derivatives. Their dynam-
ics are different to those of the classical neurotransmitter synthesing enzymes, as eCBs are synthesized “on demand”, not stored in vesicles until an action potential determines their release to the synaptic cleft. The 
enzymes responsible for eCB synthesis are mainly the N-acylphosphatidylethanolamine (NAPE)-specific phos-
pholipase D (NAPE-PLD), which gives rise to AEA after hydrolysing NAPÊs, and diacylglycerol lipase (DAGL; 
from which two isoforms, α and β, are known), which produces 2-AG from diacylglycerol (DAG). Both enzymes are sensitive to neuronal activity, as they are activated upon intracellular Ca2+ increases.
»Degradation enzymes: after binding to their receptors and triggering their signalling, eCBs are inactivated 
by specific intracellular serine hydrolases: fatty acid amide hydrolase (FAAH) degrades AEA, while monoacyl-
glycerol lipase (MGL) breaks down 2-AG. eCBs and their deactivation products are themselves precursors of 
other lipid mediators, such as prostaglandins, prostamides and other eicosanoids, which increases the com-
plexity of eCB bioconversion and ECS signalling.
BOX 4 . The endocannabinoid system
Adapted from Blankmann and Cravatt, 2013.
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CB₁R is one of the, if not the, most abundant metabotropic G protein-coupled re-
ceptors (GPCRs) in the adult mammalian brain (Herkenham et al., 1990). As CB₂R, it 
belongs to the Class A GPCR superfamily, which defines it as an integral membrane 
protein with its N-terminal region oriented to the extracellular space. It also possess 
seven transmembrane domains, connected by six loops, of which one half is intra-
cellular and the other half is extracellular. Finally, the C-terminal domain is located 
towards the cytoplasm. Both CBRs share 42 % of their amino acid sequence, a per-
centage that increases to 70 % when taking into account only the transmembrane 
regions, which are key for ligand binding, affinity and specificity (Munro et al., 1993; Hua et al., 2016, 2017; Shao et al., 2016). CB₁R usually couples to Gi/o heterotrimeric proteins, and thus its activation typically dampens adenylyl ciclase (AC) activity, thus 
Figure 12. Intracellular signalling through CB₁ receptor. CB₁R exerts pleiotropic effects upon activation, as it 
is involved in a wide range of sinalling cascades. The most classical downstream effects of CB₁R activation are the 
inhibition of PKA through Gαi/o-dependent inactivation of AC and the activation of MAPKs (MEK, Erk1/2) by means 
of βγ subunits, althoug its contribution to mTORC1 activation via PI3K-Akt recruitment is also well established. 
Less canonical pathways are also depicted, as its interaction with cofilin through RhoA activation, the inactivation 
of voltage-dependent calcium channels (VDCCs) or the activation of G protein-copuled inward rectifying potassium 
channels (GIRKs). From Keimpema et al. 2011.
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lowering cAMP levels (Howlett, 1985). Nevertheless, CB₁R signalling also activates ex-
tracellular signal-regulated kinase (ERK) by protein kinase A (PKA) inhibition (Davis 
et al., 2003; Howlett et al., 2004) or by βγ-dependent activation of phosphatidylinosi-
tol 3-kinase (PI3K) (Galve-Roperh et al., 2002), as well as interacting with β-arrestins, 
which are not only involved in GPCR internalization but also trigger G protein-inde-pendent signalling (Figure 12) (Jin et al., 1999; Laporte and Scott, 2019). Its plausi-
ble signalling cascades, though, are even more complex, as CBRs are able to couple to 
other heterotrimeric G proteins (Lauckner et al., 2005; Roland et al., 2014), and they 
have been shown to homo- (with additional CBR molecules) or heteromerize (with 
other GPCRs or even with tyrosine kinase receptors), increasing the intricacy of their signalling (Moreno et al., 2018; Blasco-Benito et al., 2019).
4.1. CB₁ receptor in the adult brain
CB₁R is profusely expressed throughout the mature mammalian CNS (Figure 13). 
Specifically, it is particularly enriched in the striatum, hippocampus, cerebellum and 
olfactory bulb, but it can also be easily detected in the cortex, as in other subcortical 
regions like the amygdala, septum, hypothalamus and some nuclei in the brainstem 
and dorsal spinal cord (Kano et al., 2009). Nonetheless, although CB₁R expression covers virtually every single region in the brain, its pattern highly differs from one cell 
type to other. GABAergic INs possess the highest CB₁R-expression levels among brain 
cell types, while PNs tend to show a much lower, though remarkably functional, CB₁R 
load (Marsicano and Lutz, 1999). Thus, although PNs exhibit lower CB₁R levels than 
INs, it appears that the coupling of the receptor is much more efficient in the former 
Figure 13. CB₁ receptor ubiquitous expression in the rat brain. Image showing autoradiography of 10 nM 3H-
CP55,940, a radioactively marked CB₁R agonist, in a sagital section of an adult rat brain. Purple indicates saturation 
whereas dark blue indicates low signal. SNR, substantia nigra pars reticulata. Adapted from Herkenham et al., 1991.
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astrocytes, where it might play a key role in astrocyte-dependent neuronal plasticity (Martín et al., 2015); oligodendrocytes (Molina-Holgado et al., 2002); microglia (Stel-la, 2010) and neural progenitors present in the adult brain (Aguado et al., 2005, Khatri 
et al., 2018, Zimmerman et al., 2018, Aguareles et al., 2019). Noteworthy, CB₁R levels in a given cell are not the only feature that predicts its ability to respond to agonists, 
as the efficiency in its coupling to G proteins is also important, as well as the presence 
of additional CB₁R-interacting proteins, as CRIP1a (Guggenhuber et al., 2016; Blume 
et al., 2017). 
Regarding the processes in which CB₁R is involved, they can be analysed at both 
the circuit and the behavioural level. On the one hand, CB₁R is broadly known because 
of its role in cannabinoid retrograde signalling, the well-established mechanism by 
which eCBs produced by a postsynaptic neuron bind to presynaptic CB₁R, initiating an intracellular cascade that results in a decrease in intracellular free Ca2+ concentra-
tion, turning down neurotransmitter release by the presynaptic neuron. In this way, 
CB₁R controls synaptic plasticity, thereby participating in short- and long-term de-
pression (STD and LTD, respectively) processes (Katona and Freund, 2008; Ohno-Sho-
saku et al., 2012). During STD, as abovementioned, the increment in postsynaptic Ca2+ 
triggers the production of DAG by phospholipase C-β. DAG is then used by DAGLα to 
synthetize 2-AG, which signals backwards and targets presynaptic CB₁R, inhibiting 
Figure 14 . Endocannabinoid system mediates short- and long-term depression in the adult central nervous 
system . CB₁R signalling induces retrograde synaptic plasticity upon activation by 2-AG. STD relies on inactivation 
of voltage-gated calcium channels (VGGC), while LTD depends on inhibition of AC. Adapted from Castillo et al., 2012.
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which inhibits AC, rendering PKA inactive, which in turn also prevents neurotransmit-ter release (Figure 14) (Castillo, 2012).
In a higher organizational level, CB₁R physiological engagement regulates a vast 
number of complex functions (Figure 15), like memory consolidation (Puighermanal 
et al., 2012) or extinction (Marsicano et al., 2002), control of nociception together 
with CB₂R (Cravatt and Lichtman, 2004), control of stress (Morena et al., 2016), ener-gy balance (Quarta et al., 2010), feeding behaviour (Bellocchio et al., 2010; Soria-Gó-mez et al., 2014), motor learning (Kishimoto and Masanobu, 2006), protection against 
excitotoxicity (Gutiérrez et al., 2003; Monory et al., 2006; Chiarlone et al., 2014; Bra-vo-Ferrer et al., 2017), to list only a fraction of the whole picture (Mechoulam and 
Parker, 2013; Piazza et al., 2017).
4.2. CB₁ receptor during brain developmentThe presence of ECS elements during brain development, including regional CBRs 
distribution and eCBs levels, has been well characterized for some time now. Summa-rizing, ECS function is patent at stages as early as neural plate formation (Psychoyos et 
al., 2008). eCB levels in the developing CNS, especially in the case of 2-AG, are compa-rable to those in an adult brain (Fernández-Ruiz et al., 2000; Keimpema et al., 2010), 
whereas the embryonic CB₁R distribution, although evident in numerous brain areas 
Figure 15 . Main physiological functions regulated by endocannabinoid system . CB₁R is involved in the regu-
lation of a multitude of behavioural functions, from which the best-established are shown in the schematic. Purple 
intensity correlates with CB₁R protein expression levels. Adapted from Flores et al., 2013.
40
intRoduction(Berrendero et al., 1998, 1999; Fernández-Ruiz et al., 2000), is clearly different from 
its expression pattern in the mature CNS. At early stages, CB₁R is atypically detect-
ed in the white matter (Romero et al., 1997; Fernández-Ruiz et al., 2000), which is 
strikingly devoid of its mRNA. This suggests that the observed CB₁R protein belongs 
to immature projections of neuronal-lineage committed cells (Harkany et al., 2007). 
Altogether, these findings paved the way to theorize, as it has been extensively demon-
strated, that the ECS exerts a complex role during brain development. In fact, evidence 
has been growing during the last twenty years showing that the early presence of the 
ECS in the developing brain is not a mere seed of its characteristic expression in the mature CNS, but it is in fact crucial for the appropriate consecution of several devel-opmental processes (Galve-Roperh et al., 2006; Harkany et al., 2007). Nowadays it is 
widely recognised that eCBs, by acting through CB₁R, have a relevant role in diverse processes ranging from NSC proliferation to neuronal differentiation and migration.
4.2.1. CB₁ receptor regulation of neural progenitor proliferation
Despite being hard to assess at the time that ECS first came to the neural develop-
ment scene, CBRs expression have been now extensively documented in NSCs (Figure 16) (Molina-Holgado et al., 2007; Palazuelos et al., 2012; Compagnucci et al., 2013; Maccarrone et al., 2014). From early stages, CB₁R activation has been linked with in-cremented NSC proliferation and neurogenesis, a positive association being found in both embryonic and adult brains (Jin et al., 2004; Galve-Roperh et al., 2013; Díaz-Alon-so et al., 2015), upon both pharmacological manipulation and increasing eCB tone 
Figure 16 . Endocannabinoid system is present in neural stem cells, as well as in immature synapses . ECS has 
been confirmed to play multiple roles during brain development. Thus, it is to be expected that at least some of its 
components are expressed by neural progenitor cells and developing neurons. The image summarizes the evidence 
found so far regarding to ECS expression in the immature brain. Adapted from Maccarrone et al., 2014.
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by FAAH genetic ablation. Consequently, CB₁R knockout mice show impaired neural progenitor proliferation in the embryonic VZ/SVZ (Mulder et al., 2008; Díaz-Alonso 
et al., 2015). CB₁R seems to fulfil this role through diverse intracellular cascades (as 
activation of ERK or PI3K), which gives it the potential to regulate, for instance, the 
transition from apical progenitor (Pax6+) to basal progenitor (Tbr2+) in the develop-
ing cortex by engaging mTORC1 signalling (Díaz-Alonso et al., 2015).
4.2.2. CB₁ receptor regulation of neural differentiation
One step ahead from NSC proliferation, CB₁R is also involved in cell-fate acquisi-tion, not only in the transition from one type of progenitor to another, but also in neu-ronal (Mulder et al., 2008; Díaz-Alonso et al., 2012), astroglial (Aguado et al., 2006; Soltys et al., 2010) and oligodendroglial (Gómez et al., 2010) differentiation and mat-
uration. Focusing on its role in neuronal specification, CB₁R promotes long-range PN fate (Mulder et al., 2008; Stanslowsky et al., 2017), specifically by regulating the bal-
ance between the antagonic TFs Ctip2 and Satb2, thus favouring the activation of the 
former in detriment of the latter, which drives the expansion of CSMN pool. According-
ly, CB₁R-deficient mice exhibit an increased number of Satb2+ cells, decreased CSMN 
numbers, and impaired skilled motor function (Díaz-Alonso et al., 2012).
4.2.3. CB₁ receptor regulation of neuronal migration
After neuroblasts have been specified, they have to reach their final destination by 
means of neuronal migration, a process that is also regulated by CB₁R. Even though the 
engagement of the receptor has been positively linked with CCK-containing IN migra-tion (Berghuis et al., 2005), other studies have shown antithetical effects, confirming 
a relation between cannabinoid function and neuronal migration (Oudin et al., 2011; Tortoriello et al., 2014; Vargish et al., 2016). In addition, although pharmacological stim-
ulation of CB₁R signalling also impairs tangential migration (Sáez et al., 2014), it has not 
been until recently that a molecular mechanism has been proposed to explain the asso-
ciation between CB₁R activation and migration of pyramidal neurons (Díaz-Alonso et al., 2017). This study not only proposes degradation of the monomeric G protein RhoA as a 
downstream CB₁R effector that mediates its promigratory action, but also demonstrates 
that transient CB₁R loss of function exerts a deleterious effect in neural development independently of the classical neuromodulatory role of the receptor.
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4.2.4. CB₁ receptor regulation of neuronal maturation
CB₁R signalling also participates in the various steps that a neuron must follow in 
order to reach a mature and functional stage. For instance, CB₁R activation regulates 
neurite outgrowth, although different studies have reported opposite effects (Jordan 
et al., 2005; Vitalis et al., 2008), thus pointing to a complex and context-dependent 
effect. In addition, there is an increasing body of studies supporting a CB₁R-dependent 
regulation of axon-related events like growth cone collapse (Argaw et al., 2011), spe-cialization of the initial segment (Tapia et al., 2017) and axonal pathfinding (Berghuis 
et al., 2007). Disruption of CB₁R function in this context leads to significant fascicula-
tion deficits (Mulder et al., 2008; Wu et al., 2010; Tortoriello et al., 2014), although lit-
tle is known about neuronal functionality and electrophysiological properties under these circumstances.
4 .3 . Consequences of prenatal exposure to cannabinoidsAs the ECS regulates several steps of cortical neuron development, it is easy to hy-pothesize that prenatal disruption of cannabinoid signalling may lead to deleterious consequences for the developing brain. The fact that marijuana is the most commonly 
used illegal drug by pregnant women (Figure 17) (Young-Wolff et al., 2017), together 
with the increase of THC content in the smoked cannabis observed in the last two decades (Pijlman et al., 2005; Mehmedic et al., 2010), make this topic even more rel-evant. A raising cohort of longitudinal studies in humans (Fried, 1980; Day and Rich-ardson, 1991; Hofman et al., 2004) and their subsequent reviews (Goldschmidt et al., 
2000; Jutras-Aswad et al., 2009; Goldschmidt et al., 2012) have pointed that prenatal 
cannabinoid exposure is associated with a full range of paediatric and adolescent al-
terations, as lower short-term memory, increased aggressive behaviours, higher im-
pulsivity, hyperactivity, problems in visual and abstract reasoning, and increased risk 
to develop addictions. In addition, research conducted with human samples has found opioid and dopaminergic neurotransmission systems altered (Wang et al., 2006; Mor-ris et al., 2011), which may have a conceivable causative link with the abovementioned 
long-term outcomes, and which may emerge from epigenetic disturbances as changes in histone metilation and shifts in the microRNA load (Morris et al., 2011).Furthermore, multiple studies encompassing prenatal administration of differ-
ent cannabinoid molecules to animal models show numerous long-lasting conse-
quences in neurotransmitter systems and animal behaviour (Pinky et al., 2019). 
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Summarizing, prenatal cannabinoid exposure has been linked with decreased CSMN 
generation and impaired skilled motor function, as well as increased seizure suscep-tibility that persist in the adulthood (de Salas-Quiroga et al., 2015); disrupted fascic-
ulation and miswiring of cortical circuits (Tortoriello et al., 2014); altered memory 
retention and glutamatergic transmission in the hippocampus and prefrontal cortex (PFC) (Mereu et al., 2003; Antonelli et al., 2004); reduced GABA outflow in the hippo-campus (Beggiato et al., 2017); persistent disruption of social behaviour and reduced 
numbers of CCK-containing INs in the hippocampus (Vargish et al., 2016); increased 
brain tyrosine hydroxylase activity (Bonnin et al., 1995); sex-dimorphic alterations in opioid transmission (Pérez-Rosado et al., 2000, 2002); and a male-specific impair-ment of social behaviour and synaptic plasticity in the PFC (Bara et al., 2018), to name 
just some processes. Remarkably, the described alterations show a tendency to gather 
on cortical and hippocampal regions, and some of them have a marked sexually di-
morphic trend (Pinky et al., 2019).Altogether, this body of evidence supports the importance of fully addressing the 
short- and long-term consequences of prenatal exposure to cannabinoids, as they may 
have great impact in the modern society, which is nowadays struggling under intense 
debate to find a proper regulation for cannabis consumption.
4 .4 . Cannabinoids as therapeutic agentsOn the other side of the coin, the implication of the ECS on a profuse collection of 
physiological processes and its striking pleiotropic capacity give CBRs the potential to 
be therapeutic targets in a wide range of diseases (Kaur et al., 2016). In humans, the ECS participates not only in central and peripheral nervous system functions, but is 
Figure 17 . Increasing trends in marijuana use among pregnant females . Graphs show Poisson regresion mod-
els regarding self-reported and positive toxicology screening of marijuana use by ≈280 thousand pregnant women 
between 2009 and 2016. From Young-Wolff et al., 2017.
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also involved in immune modulation, as well as control of blood pressure, bronchodi-lation, energy balance, and emesis, among others. But, although the ECS could be out 
forward as a therapeutic target aiming to alleviate symptoms of diseases affecting the cited body functions, clinical and preclinical evidence points to the ECS as a promising target in many other conditions, such as cancer (Velasco et al., 2016; Blasco-Benito 
et al., 2018; López-Valero et al., 2018); chronic pain (Romero-Sandoval et al., 2017; Sun et al., 2017); brain trauma derived from stroke or neurodegenerative diseases (Blázquez et al., 2015; Fernández-Ruiz et al., 2015); anxiety (Bergamaschi et al., 2011; Piper et al., 2017); fragile X syndrome (Busquets-García et al., 2013; Tartaglia et al., 
2019); to mention but a few.Although from a theoretical perspective, both synthetic cannabinoids and phytocan-nabinoids could be developed and distributed as treatments, the use of the former is 
usually not favourable in terms of efficacy/safety balance (Ozturk et al., 2019; Yeruva 
et al., 2019). Thus, phytocannabinoid extracts, which are easily isolated and accurately standardized from C. sativa cultivars, are becoming the actual investment in the med-
ical cannabis framework. In fact, among the cannabinoid drugs approved in different 
countries, the vast majority are exclusively composed of phytocannabinoids. THC, under 
the trademark of dronabinol (and also its synthetic analogue, nabilone) is approved for palliative therapy in cancer patients, for the treatment of nausea driven by chemothera-
pies, and for the anorexic syndrome secondary to AIDS or cancer (Velasco et al., 2012). 
Nabiximols, a standardized cannabinoid extract containing CBD and THC in a 1:1 ratio, 
has been approved, under the trademark of Sativex, to alleviate spasticity and overac-
tive bladder derived from multiple sclerosis. Sativex is also utilised for the treatment of neuropathic and cancer-associated pain (Giacoppo et al., 2017). More recently, a CBD 
preparation (Epidiolex) has been approved by the FDA for the treatment of seizures in 
two paediatric epileptic syndromes (Dravet and Lennox-Gastaut), while its use for other conditions associated to refractory epilepsy, as TSC or febrile-infection related epilepsy 
syndrome, also looks promising (O’Connell et al., 2017).
In a context in which cannabinoid therapeutic potential is starting to prevail over 
its social stigma, both sides of cannabis should be taken into account to elaborate a 
rational and well-informed verdict about whether, when and how targeting CBRs to 
maximize positive effects on each given condition while reducing side effects as much as possible.
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Aims of this Thesis
In the past decades, multiple groups have shown that CB₁R regulates different steps of both cortical PNs and INs development. In particular, our group has demon-
strated that both genetic and pharmacological disruption of CB₁R signalling during brain ontogeny impairs the establishment and migration of cortical PNs, concomitant-
ly increasing seizure susceptibility. Nevertheless, a link between ECS malfunction and the onset of epileptic pathologies has been not yet established, as neither has been a 
mechanistic explanation for the observed seizure-prone phenotype. In addition, the susceptibility of GABAergic INs to the appearance of persistent effects upon early ECS 
disturbance has not been extensively studied.
In this regard, we defined the following objectives for this Doctoral Thesis:
Aim 1: To analyse the link between altered ECS function and FCD, a human pathol-
ogy associated with childhood epilepsy, as well as to assess if PNs that have got their 
CB₁R signalling genetically disrupted during development suffer from permanent 
changes in plasticity and excitability.
 Aim 2: To assess the involvement of CB₁R in the establishment of GABAergic in-
terneurons, by analysing the long-term impact of prenatal THC exposure in the hippo-
campal CCK-containing basket cell population, along with any cognitive or behavioural outcome.

Materials & Methods
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ConstructsFor in utero electroporation (IUE) experiments, pCAG-Green fluorescent protein (GFP) 
expression vector was kindly provided by Dr. François Guillemot (The Francis Crick In-
stitute, London, UK). Regarding transfection experiments in P19 cells, pCAG-RHEB and 
pCAG-RHEB Q64L (a constitutively active Rheb mutant) expression vectors were kindly 
provided by Dr. Tomohiko Maehama (Kobe University, Kobe, Japan). pCAG-Tbr2 was kind-ly provided by Prof. Robert F. Hevner (University of California, San Diego, CA, USA).
Animals
Experimental designs and procedures were approved by the Complutense Univer-
sity Animal Research Committee in accordance with the European Commission regu-
lations. All efforts were made to minimize the number of animals and their suffering 
throughout the experiments. Nex-CB₁-/- and Dlx5/6-CB₁-/- colony-founding mice were provided by Prof. Beat Lutz (Johannes Gutenberg University, Mainz, Germany). Mice 
were maintained in standard conditions, keeping littermates grouped in breeding 
cages, at a constant temperature (20±2 °C) on a 12 hours light/dark cycle with food 
and water ad libitum. The generation and genotyping of Nex-CB₁-/-, Dlx5/6-CB₁-/- and 
wild-type littermates has been reported elsewhere, and was performed accordingly (Monory et al., 2007). Mouse embryonic tissues were obtained upon timed mating as assessed by vaginal plug observation (E0).
Human samples
The FCD cases included in this thesis were obtained from the archives of the De-partments of Neuropathology of the Academic Medical Center (University of Amster-dam, The Netherlands), the University Medical Center in Utrecht (The Netherlands), 
Hospital Infantil Niño Jesús (Madrid, Spain) and Hospital Sant Joan de Déu (Barcelona, Spain). A total of 30 surgical specimens (10 FCD Type I and 20 FCD Type II), resect-
ed from patients undergoing surgery for intractable epilepsy, were examined (Table 1). 
Tissue was obtained and used in accordance with the Declaration of Helsinki and in-
formed consent was obtained for the use of brain tissue and for access to medical re-
cords for research purposes. All cases were reviewed by the corresponding neuropathol-
ogist and the diagnosis was confirmed according to ILAE classification system (Blümcke 
et al., 2011; Najm et al., 2018). Control brains from patients that were not diagnosed with 
neurologic disorders were also employed [n = 6; age (years) = 53; 40; 34; 21; 51; 25]. 
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Formalin-fixed, paraffin-embedded tissue (one representative paraffin block per case containing the complete lesion or the largest part of the lesion resected at surgery) 
was sectioned at 6 µm and mounted on pre-coated glass slides (Star Frost, Waldemar 
Knittel GmbH, Braunschweig, Germany). Sections of all specimens were processed for 
haematoxylin-eosin, luxol-fast blue and Nissl stainings and neuronal and glial mark-
ers for classification and selection.
Table 1 . Clinical features of patients analysed in this Thesis .
Patient Age at surgery (years) Duration of epilepsy (years) Diagnosis Location Engel's class01 14.0 8.0 FCD Ia Parietal II02 19.0 10.0 FCD Ia Frontal I03 23.0 16.0 FCD Ia Temporal I04 16.0 11.0 FCD Ia Frontal I05 24.0 17.0 FCD Ia Temporal I06 16.0 12.0 FCD Ia Frontal II07 4.5 4.0 FCD Ia Temporal I08 3.0 3.0 FCD Ia Frontal I09 2.0 1.5 FCD Ia Multilobar IV10 3.0 2.0 FCD Ia Frontal I11 29.0 21.0 FCD IIb Temporal I12 23.0 18.0 FCD IIb Temporal I13 21.0 19.0 FCD IIb Frontal I14 17.0 9.0 FCD IIb Temporal I15 13.0 10.0 FCD IIb Frontal I16 5.0 5.0 FCD IIb Multilobar II17 8.0 5.0 FCD IIb Multilobar III18 8.0 7.5 FCD IIb Frontal II19 0.5 0.5 FCD IIb Multilobar III20 19.0 17.0 FCD IIb Multilobar II21 1.0 0.5 FCD IIb Multilobar II22 21.0 21.0 FCD IIb Multilobar III23 3.5 2.5 FCD IIb Temporal I24 15.0 15.0 FCD IIb Parietal II25 12.0 6.0 FCD IIb Occipital I26 6.0 5.0 FCD IIb Frontal I27 0.5 0.5 FCD IIa Occipital II28 6.0 5.0 FCD IIa Temporal I29 7.0 5.0 FCD IIa Multilobar I30 3.0 3.0 FCD IIb Frontal I
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Focal cortical dysplasia organotypic cultures
Resected brain tissue was transported from the operating theatre to the laboratory 
in a solution containing 310 mM sucrose, 25 mM NaHCO₃, 3 mM KCl, 1 mM CaCl₂, 10 
mM MgCl₂ and 10 mM D-glucose, equilibrated with carbogen, maintained at 2-10 °C. 
Capillaries and damaged tissue were dissected away from the tissue block in the cold 
sucrose-based solution in sterile conditions while equilibrating with carbogen. Slices 
were cut at thickness 300 µm in a vibratome (VT1200S; Leica, Wetzlar, Germany). 
Slices were then placed on an semiporous insert in sterile conditions (insert diameter = 
30 mm, pore diameter = 0.4 µm; Merck Millipore, Burlington, MA, USA) at the interface be-
tween air and a medium containing 20 mM HEPES and the antibiotics penicillin and strep-
tomycin (50 U/mL). They were maintained in an incubator, at 37 °C in 95 % O₂/5 % CO₂. 
After 1 hour, slices on inserts were transferred to a six-well plate, pre-equilibrated in 
the incubator and containing the same solution except that HEPES was omitted. The 
medium was changed on a daily basis during 7 days. Slices were then subjected to 
pharmacological regulation and, after incubation, they were fixed and sectioned for 
immunofluorescence characterization. Alternatively, proteins were extracted after cell lysis in a buffer containing 50 mM Tris, 0.1 % Triton X-100, 1 mM ethylenedi-aminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid (EGTA), 50 mM NaF, 
10 mM sodium β-glicerophosphate, 5 mM sodium pyrophosphate and 1 mM sodium 
orthovanadate (pH 7.5) supplemented with a protease inhibitor cocktail (Roche, Ba-
sel, Switzerland), 0.1 mM phenylmethane-sulphonylfluoride, 0.1 % β-mercaptoetha-
nol and 1 µM microcystin for Western blot analyses.
Immunofluorescence and confocal microscopyP19 murine carcinoma cells, coronal embryonic and postnatal murine brain slices 
(14 and 30 µm-thick, respectively), organotypic human brain slices (20 µm-thick) and 
FCD samples were fixed in paraformaldehyde solution [4 % in phosphate buffered 
saline (PBS)] at 4 °C and immunofluorescence performed. 
After a 2 hours blockade with 5 % goat serum, overnight incubation at 4 °C with 
the indicated primary antibodies was performed (Table 2). Samples were subsequent-
ly incubated for 2 hours at room temperature with the appropriate highly cross-ad-
sorbed anti-mouse, rat, guinea pig, and rabbit AlexaFluor 488, AlexaFluor 546, Alexa 
Fluor 594, and AlexaFluor 647 secondary antibodies (1:500 in every case; Invitrogen, 
Carlsbad, CA, USA). Confocal fluorescence images were acquired by using either Leica 
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TCS-SP2 or LAS-X software with a SP2 or a SP8 microscope respectively, with 3 passes 
by Kalman filter and a 1024x1024 or a 2048x2048 collection box respectively. Immu-
nofluorescence data were obtained in a blinded manner and sample code remained 
unsealed during the whole data processing and analysis.
Table 2 . Primary antibodies used in this Thesis .
Target Host species Application Concentration Company
β-actin Rabbit WB 1:5000 Cell Signaling Technology (Barcelona, Spain)
CB₁R Rabbit IF, WB 1:500 Frontier Institute (Hokkai-do, Japan)
CB₁R Guinea Pig IF 1:500 Frontier Institute
c-Myc Mouse IF 1:500 Sigma-Aldrich España (Ma-drid, Spain)GABA Mouse IHC 1:100 Sigma-Aldrich España
NeuN Mouse IHC 1:500 Merck Millipore
pS6 S235/S236 Rabbit IF, WB 1:100, 1:1000 Cell Signaling Technology
pS6 S240/S244 Rabbit IF, WB 1:800, 1:1000 Cell Signaling Technology
Immunoreactivity was measured using Fiji open source software establishing a 
threshold to measure only specific signal. The resulting binary mask was then used along the built-in measure function to acquire the total integrated grey density among 
all the pixels inside the binary mask overlaid on top of the original image. The obtained 
value was then referred to the number of DAPI+ cell nuclei present in the optic field.
In CB₁R knockdown experiments by IUE, cell migration was measured by determining the position of GFP+ cells along the cortical wall, assigning each cell to their corresponding 
cortical compartment attending to histological criteria defined by DAPI staining.
Western blot assays
Protein extracts were prepared as abovementioned. Equal amount of protein samples 
were electrophoretically separated and transferred to polyvinylidene difluoride membranes. 
After blocking with 5 % BSA, membranes were incubated overnight at 4 °C with the indicated 
primary antibodies (Table 2). PVDF membranes were then incubated with the corresponding 
secondary antibodies coupled to horseradish peroxidase for 1.5 hours at room temperature. 
Optical density of the specific immunoreactive band was quantified with Fiji software and nor-
malized to those β-actin for the corresponding samples in the same membranes.
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CB₁ receptor promoter transcriptional assays
Embryonic carcinoma P19 cells were transfected with Lipofectamine 2000 (Thermo 
Fisher Scientific, Waltham, MA, USA) following manufacturer’s instructions. Cells were 
co-transfected with one of the following constructions: pCAG-RHEB, pCAG-RHEB Q64L, pCAG-Tbr2, mouse TSC2 short hairpin RNA (shRNA, 5’-TGAGCCTTGCTGGAAGTTGAT-
GCGTAACC-3’) or control (scrambled) shRNA (Origene, Rockville, MD, USA) and a 
construct encoding the -3016 to +142 sequence (referring to the first nucleotide of 
exon 1) of the human CNR1 gene promoter fused to the chloramphenicol acetyltrans-
ferase (CAT) reporter gene (phCB₁-3016-CAT) (Blázquez et al., 2011). The reporter 
gene construct was based on the pBLCAT2/pBLCAT3 system, in which the thymidine 
kinase minimal promoter was replaced for the human CNR1 promoter upstream of 
CAT. CAT levels were subsequently analysed with CAT ELISA kit (Roche, distributed by 
Sigma-Aldrich España) following manufacturer’s instructions.
DNA single nucleotide polymorphisms analyses and sequencing
Genomic DNA was obtained by standard methods and Sequenom single nucleotide 
polymorphism (SNP) analyses were performed by Centro Nacional de Genotipado 
(CEGEN-PRB2 USC node, Santiago de Compostela, Spain) using the iPlex Gold chem-istry and MassARRAY platform, according to manufacturer’s instructions (Sequen-
om, San Diego, CA, USA). 48 SNPs within different ECS element genes were analysed 
(Table 3). Genotyping assays were designed using the Sequenom MassARRAY Assay 
Designer 4.1 software. SNPs were genotyped in 3 assays, PCR reactions were set up 
in a 5 µL volume and contained 20 ng of template DNA, 1x PCR buffer, 2 mM MgCl₂, 
500 µM dNTPs and 1 U/reaction of PCR enzyme. A pool of PCR primers (Metabion, 
Steinkirchen, Germany) was made at a final concentration of each primer of 100 nM. The thermal cycling conditions for the reaction consisted on an initial denaturation 
step at 94 °C for 2 minutes, followed by 45 cycles of 94 °C for 30 seconds, 56 °C for 30 
seconds and 72 °C for 1 minute, and a final extension step of 72 °C for 1 minute. PCR 
products were treated with 0.5 U shrimp alkaline phosphatase, followed by enzyme inactivation to neutralize unincorporated dNTPs.
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Table 3 . SNPs analysed in this Thesis . Table includes the gene within each specific SNP is located and their func-
tional consecuence, if known.
Gene SNP Functional consequence
CNR1 rs806365 unknown
CNR1 rs7766029 unknown
CNR1 rs806366 unknown
CNR1 rs806368 utr variant 3 prime
CNR1 rs12720071 utr variant 3 prime
CNR1 rs4707436 utr variant 3 prime
CNR1 rs1049353 synonymous codon
CNR1 rs806369 intron variant, upstream variant 2KB
CNR1 rs2023239 intron variant
CNR1 rs1535255 intron variant
CNR1 rs806379 intron variant
CNR1 rs9444584 intron variant
CNR1 rs9450898 intron variant
CNR1 rs806380 intron variant
CNR1 rs6454674 intron variant, utr variant 5 prime
CNR1 rs2180619 upstream variant 2KB
DAGLA rs4963304 upstream variant 2KB
DAGLA rs7931563 upstream variant 2KB
DAGLA rs7942387 upstream variant 2KB
DAGLA rs198430 synonymous codon
DAGLA rs198444 synonymous codon
DAGLA rs34365114 synonymous codon
DAGLA rs144674730 missense
DAGLB rs143650244 downstream variant 500B
DAGLB rs187296513 downstream variant 500B
DAGLB rs3813518 downstream variant 500B
DAGLB rs3813517 downstream variant 500B
DAGLB rs836559 utr variant 3 prime
DAGLB rs2303361 missense
MGL rs76802560 downstream variant 500B
MGL rs6801421 downstream variant 500B
MGL rs72969613 utr variant 3 prime
MGL rs4881 synonymous codon
MGL rs115970931 utr variant 3 prime
FAAH rs932816 upstream variant 2KB
FAAH rs4141964 intron variant
FAAH rs324420 missense
FAAH rs324419 synonymous codon
FAAH rs2295632 downstream variant 500B
FAAH rs12029329 downstream variant 500B
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Gene SNP Functional consequence
CNR2 rs12744386 unknown
CNR2 rs1130321 utr variant 3 prime
CNR2 rs1106 utr variant 3 prime
CNR2 rs2229579 missense
CNR2 rs2501431 synonymous codon
CNR2 rs41311993 missense
CNR2 rs35761398 missense
CNR2 rs2501432 missense
The iPLEX GOLD reactions were set up in a final 9 µL volume and contained 0.222x 
iPLEX buffer Plus, 1x iPLEX termination mix and 1x iPLEX enzyme. An extension primer 
mix (Metabion) was made to give a final concentration of each primer between 0.52 µM 
and 1.57 µM. The thermal cycling conditions for the reaction included an initial dena-
turation step at 94 °C for 30 seconds, followed by 40 cycles of 94 °C for 5 seconds, with 
an internal 5 cycles loop at 52 °C for 5 seconds and 80 °C for 5 seconds, followed by 
a final extension step of 72 °C for 3 minutes. The iPLEX Gold reaction products were desalted, dispensed onto a 384 Spectrochip II using an RS1000 Nanodispenser and 
spectra were acquired using the MA4 mass spectrometer, followed by manual inspec-
tion of spectra by trained personnel using MassARRAY Typer software, version 4.0. 
All assays were performed in 384-well plates, including negative controls and a trio of Coriell samples (Na10830, Na10831 and Na12147) for quality control. Seven samples 
were tested in duplicate and they were 100 % concordant. Genomic DNA sequencing of the CNR1 gene coding exon was performed by the Sanger method under standard conditions by Secugen (Madrid, Spain).
Quantitative PCR
RNA was isolated using RNeasy Plus kit (Qiagen, Hilden, Germany) following man-
ufacturer’s instructions. cDNA was obtained with Transcriptor (Roche). Real-time 
quantitative PCR (qPCR) assays were performed using the FastStart Master Mix with 
Rox (Roche) and probes were obtained from the Universal Probe Library Set (Roche). 
Amplifications were run in a 7900 HT-Fast Real-Time PCR System (Applied Biosyste-
ms, Foster City, CA, USA). Each value was adjusted by using 18S RNA and β-actin levels as reference.
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In utero electroporation
Timed-pregnant C57Bl/6J mice were injected subcutaneously with buprenorphine 
(0.1 mg/kg) and meloxicam (1 mg/kg) 30 minutes before surgery at E14. The surgery 
was performed on a heating blanket and breathing and temperature were monitored 
throughout. Under isoflurane anaesthesia (induction: 4 %, maintenance: 2.5 %), the 
eyes of the dam were covered with eye ointment to prevent damage just before the 
uterine horns were exposed and moistened with warm sterile PBS (37 °C). Solution 
containing pCAG-GFP (0.5 µg/µL) and ON-TARGETplus mouse Cnr1 siRNA smart pool (target sequences 5’-GGUAGUCCCUUCCAAGAAA-3’, 5’-CCACAGAAAUUCCCUCUAA-3’, 5’-GGGAAGAUGAACAAGCUUA-3’, 5’-GUGUUUGCCUUCUGUAGUA-3’; further referred 
as siCB₁) or control siRNA (further referred as siCo; Dharmacon, Lafayette, CO, USA), 
as well as 0.1 % Fast Green was injected into the lateral ventricle of individual em-
bryos using pulled borosilicate glass capillaries with a sharp and long tip. Plasmid 
DNA was purified with NucleoBond EF (Macherey-Nagel, Düren, Germany) in order 
to assure the absence of endotoxin. Injected embryos were then placed between the 
electroporation tweezer-type paddles (5 mm diameter; Sonidel Limited, Dublin, Ire-
land) that were oriented at a rough 20° leftward angle from the midline and a rough 
10° angle downward from anterior to posterior. By these means, neural precursor 
cells from the SVZ, which radially migrate into the medial prefrontal cortex (mPFC), 
were transfected. Electrode pulses (30 V, 50 ms) were applied five times at intervals of 950 ms controlled by an electroporator (NEPA21; Sonidel Limited). Uterine horns 
were placed back into the abdominal cavity after electroporation. The abdominal cav-
ity was filled with warm sterile PBS (37 °C) and abdominal muscles and skin were 
sutured individually with absorbable and non-absorbable suture thread, respective-
ly. After recovery, pregnant mice were returned to their home cages. After birth, GFP 
expression was assessed in the pups with a portable fluorescent flashlight (Nightsea, 
Lexington, MA, USA) or under a fluorescence binocular through the intact skull and 
skin at P1-P3. Pups without expression in the mPFC were excluded from the analysis. 
Mice of both sexes were used.
Patch clamp and electrophysiological recordings
Mice electroporated with either siCB₁ or siCo at E14 were sacrificed at different ages 
(P7, P14, P21 and P60) and their brains were quickly removed and immediately placed 
in oxygenated (95 % O₂/5 % CO₂), ice-cold (4 °C) slicing artificial cerebrospinal fluid 
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(sACSF) containing 120 mM choline chloride, 10 mM D-glucose, 25 mM NaHCO₃, 6 mM MgSO₄, 
3.5 mM KCl, 1.25 mM NaH₂PO₄ and 0.5 mM CaCl₂. Brain was then sliced using a vibratome 
(VT1200S; Leica). Coronal slices (300 µm) of the mPFC were selected and transferred 
to a holding chamber placed in a water bath at 32 °C. Slices were kept in oxygenated re-
cording ACSF (rACSF) for 15-30 min. rACSF contained 120 mM NaCl, 3.5 mM KCl, 1.3 mM MgSO₄, 
1.25 mM NaH₂PO₄, 2.5 mM CaCl₂, 10 mM D-glucose and 25 mM NaHCO₃. Subsequently, slices recovered at room temperature for at least 30 minutes before recording.
Recordings were made using either an EPC-10 amplifier controlled by PatchMas-
ter Software (HEKA, Lambrecht, Germany) or an Axopatch 200b (Molecular Devices, 
San José, CA, USA) and an in-house software running under Matlab 9.3 (MathWorks, 
Natick, MA, USA). Signals were low-pass filtered at 2.9 kHz and sampled at 10 kHz. All 
experiments were performed at 30-32 °C. Whole-cell current clamp recordings were made from the soma of GFP+ upper layer II/III neurons that visually appeared pyrami-
dal in shape. Patch pipettes were pulled from borosilicate glass capillaries to an open 
pipette resistance of 2-4 MΩ when filled with pipette solution. Pipette solution con-
tained 110 mM potassium gluconate, 30 mM KCl, 0.5 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP and 0.5 mM Na-GTP and biocytin at a concentration of 2 mg/mL. Series resis-
tance ranged from two to three times the pipette resistance (4-12 MΩ) and was com-
pensated to 70 %. Signals were corrected for liquid junction potential (+15 mV). Neurons 
were excluded from the analysis when their series resistance changed by more than 
50 % during an experiment. Actual recordings started after 5 minutes of stabilization. 
The protocols mentioned below were used to determine firing properties (average 
firing frequency and time constant of adaptation for firing), passive (RMP, input resis-
tance and membrane time constant) and active cell properties (spike properties, volt-
age sag and rheobase), as well as spontaneuos synaptic activity. In order to achieve 
appropriate filling of the recorded neurons with biocytin the whole-cell configuration 
was maintained for at least 15-20 minutes. Subsequently, the pipette was retracted carefully to avoid damaging or removing the cell.
For the passive cell properties, current-voltage relationship was used for the cal-
culation of the input resistance. Input resistance was determined as the slope of the 
linear fit between -60 and -70 mV. The membrane time constant was determined with 
a mono-exponential fit of the voltage response after a current step of -10 pA. RMP was read in current clamp immediately after rupturing the cell membrane.
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Regarding active cell properties, rheobase, which is the minimal current that 
evoked an action potential (AP), was estimated using small current steps of 10 pA. 
The voltage sag was measured at a hyperpolarizing current injection of -100 pA. The 
AP threshold was determined using the membrane potential at the peak of the second 
derivative in a phase plot. The AP amplitude was calculated as the voltage difference 
between the AP peak and the threshold. The AP half-width was measured as the width 
in ms at the half-maximal spike amplitude. The amplitude of the afterhyperpolariza-
tion (AHP) was calculated as the voltage difference between the AP threshold and the most negative voltage reached during the AHP. As for AP threshold, AP amplitude 
and AP half-width, the average of all spikes that occurred during the first five current 
steps where spikes were detected was taken. When the first five sweeps comprised 
less than 10 spikes more sweeps were included to average at least 10 spikes. For the 
average of the AHP amplitude all spikes from repetitive AP firing traces were included.
Respecting spike firing properties, the frequency of the firing rate was determined 
by counting the spikes during current injection step. The interspike interval (ISI) was 
calculated as the time between subsequent spikes. ISIs were used to determine the 
instantaneous spike frequency, which was in turn plotted against the time points of 
the spikes for every current step. The time constant of adaptation was estimated by 
fitting a standard exponential function to the instantaneous frequency for all current 
injections that resulted in repetitive firing of at least five spikes. In the end, one time 
constant of adaptation was obtained for each current step.
Finally, when assessing spontanueos synaptic activity, miniature postsynaptic cur-
rents were isolated. The amplitude and instantaneous frequency were determined for every miniature synaptic event, detected using a combined threshold and template 
matching procedure. Distribution of binned inhibitory and excitatory postsynaptic currents (IPSCs and EPSCs, respectively), instantaneous frequencies and amplitudes 
(40–50 bins) were constructed for every cell and then averaged. For IPSCs, at least 
100 events were analysed per cell; while at least 250 events were analysed per cell for 
EPSCs. Average amplitudes and frequencies were calculated per 5 minutes.
THC administration 
THC (≥99 % HPLC; THC Pharm, Frankfurt am Main, Germany) was diluted in 
0.9 % NaCl (saline) solution containing 3 % (v/v) DMSO and 2 % (v/v) Tween-80 
and administered intraperitoneally (i.p.) at a final dose of 3 mg/kg to pregnant 
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dams (at 10 µL/g) for 8 consecutive days, from E10 to E17. Control mice were 
injected with vehicle solution.
In situ hybridization
Coronal sections (30 µm) of P60 mouse brains were mounted on SuperFrost Ultra 
Plus glass slides (Thermo Fisher Scientific). When completely dry, they were subject-ed to in situ hybridization (ISH) using CCK digoxygenin-labelled riboprobes obtained 
by PCR amplification and retrotranscription (forward primer 5’-AGAGAGCGGCGTAT-
GTCTGT-3’, reverse primer 5’-CTGCATTGCACACTCTGGAC-3’). Briefly, samples were 
acetylated and then incubated in a hybridization buffer containing 0.5-1.0 µg/mL 
DIG-labelled riboprobes at 65 °C overnight. Sections were sequentially washed twice 
in a medium containing 2x standard saline citrate and 50% formamide for 1 hour at 
60 °C and then 20 minutes at 37 °C in 2x SSC. The hybridized probe was detected after 
incubation with alkaline phosphatase-conjugated anti-digoxygenin antibody (Roche) 
and subsequent incubation with NBT/BCIP (Roche) in alkaline buffer (pH 9.5). The 
resulting blue precipitate was post-fixed by incubation in PFA 4% during 10 minutes. 
There were no apparent signal in control sections with the sense probes.
Immunohistochemistry
Samples from ISH assays were subsequently used for immunohistochemistry 
(IHC). Briefly, after washing, slides were subjected to a heat-induced antigen retrieval 
step with sodium citrate buffer (10 mM, pH 6) at 96 °C, as well as a 1 hour blockade, 
prior to exposure to a mouse anti-GABA primary antibody (A0310; Sigma-Aldrich 
España). Immunodetection was achieved using the Envision+ Dual Link System-HRP 
(DAB+) kit (Dako-Agilent Technologies, Santa Clara, CA, USA), following manufactur-
er’s instructions. Samples were then mounted using Entellan resin.
Stereological analysis of cell density
Samples stained by CCK ISH and GABA IHC were analysed using a Olympus BX61 
microscope (Olympus, Tokyo, Japan) operated by VIS software with newCAST incor-
porated (Visiopharm, Hoersholm, Denmark). Hippocampal strata were manually 
delineated within CA1 region before performing a stereological counting of the total 
number of CCK+GABA+ cells. The frame area was set to 625 μm2 with a sampling in-
terval of 120 μm at the z level. Results are expressed as the number of double posi-tive cells per mm2. Gundersen’s coefficient of error was always below 0.1. Data were 
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obtained in a blinded manner and sample code remained unsealed during the whole data processing and analysis.
THC determination
Analysis of THC in embryonic brain tissue was performed as follows: samples were 
homogenized on ice with 700 μL of a mixture of 50 mM Tris-HCl buffer (pH 7.4):metha-
nol (1:1) and the homogenates were transferred to 12 mL glass tubes. The homogenizer 
was washed twice with 0.9 mL of the same mixture and the contents were combined 
into the tube giving an approximate volume of 2.5 mL of homogenate. The homoge-
nization process took less than 5 minutes per sample and homogenates were kept on 
ice until organic extraction. After the homogenization step, 5 mL of hexane:ethyl acetate 
was added into each 12 mL glass tube and were placed in a rocking mixer over 20 minutes. 
Tubes were centrifuged at 1700 g over 5 minutes at room temperature and organic 
phase was then transferred to clean tubes, and evaporated under nitrogen stream. 
Extracts were subjected to a derivatization step using dansyl chloride. This reaction is selective for phenol functions present in THC and improves the separation and ioniza-
tion efficiency. Extracts were reconstituted in 100 µL of a mixture of water:acetonitrile 
(1:9, v/v) with 0.1% formic acid (v/v) and transferred to HPLC vials. 20 µL were in-
jected into an Agilent 6410 Triple Quadrupole Liquid-Chromatograph equipped with a 1200 series binary pump, a column oven and a cooled autosampler at 4 °C (Agilent 
Technologies). Chromatographic separation was carried out with a Waters C18-CSH 
column (3.1 x 100 mm, 1.8 μm particle size; Waters, Milford, MA, USA) maintained at 
40 °C with a mobile phase flow rate of 0.4 mL/min. The composition of the mobile 
phase was: A: 0.1 % (v/v) formic acid in water; B: 0.1 % (v/v) formic acid in acetoni-
trile. THC was separated by gradient chromatography.
WIN-55,212-2 stimulated [35S]GTPγS binding assays
Tissue samples were homogenized using a Teflon-glass grinder in 30 volumes of 
homogenization buffer (1 mM EGTA, 3 mM MgCl₂, 1 mM dithiothreitol (DTT), and 
50 mM Tris-HCl, pH 7.4) supplemented with 250 mM sucrose. The crude homogenate 
was centrifuged for 5 minutes at 1000 g (4 °C). The resulting supernatant was centri-
fuged at the same conditions. Pellet was washed twice in 20 volumes of homogeniza-
tion buffer and centrifuged in similar conditions. Binding assays were carried out 
in a final volume of 250 µL in 96 well plates, containing 1 mM EGTA, 3 mM MgCl₂, 
100 mM NaCl, 0.2 mM DTT, 50 μM guanosine 5′-GDP, 50 mM Tris-HCl at pH 7.4 and 
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curves were carried out by incubating increasing concentrations of the CB₁R ag-onist WIN-55,212-2 (10-12-10-4 M). The incubation started by addition of the mem-
brane suspension (30 µg of membrane proteins per well) and was performed at 30 °C 
for 2 hours with shaking (600 rpm). Incubations were terminated by rapid filtration 
under vacuum (Perkin Elmer Life Sciences) through GF/C glass fibre filters (Perkin 
Elmer Life Sciences) pre-soaked in ice-cold incubation buffer. The filters were then rinsed, air dried, and counted for radioactivity (5 minutes) by liquid scintillation spec-
trometry using a MicroBeta TriLux counter (Perkin Elmer Life Sciences). Non-specific 
binding was defined as the remaining [35S]GTPγS binding in the presence of 10 µM 
unlabelled GTPγS, and the basal binding as the signal in the absence of WIN-55,212-2.
Intrahippocampal electric field recording
Mice were implanted with fixation bars under isoflurane anaesthesia (1.5-2 %). 
The recording chamber was aligned to target the right dorsal hippocampus at -1.8 mm 
posterior from Bregma and -1.25 mm lateral from midline. At least two jeweller’s screws 
were inserted into the skull for providing additional anchoring and reference/ground 
connections (over the cerebellum). If required, an additional screw was located over 
the frontal skull. The implant was secured with dental cement.
One week after surgery, mice were habituated to the head-fixed setup con-sisting on a cylinder (20 cm radius) coupled to a stereotactic frame. Habituation sessions included handling, running freely around the setup and mounting/dis-
mounting the head during brief periods of time. After 2-3 days, animals were wa-
ter deprived, and they started daily sessions of 10 minutes running for reward 
(water), till they were fully habituated to the procedure. Once they consistently 
run for water in the 10 minutes session, time in the setup was increased over steps of 5 minutes, until animals got habituated to behave freely. They typically alter-
nated periods of running and immobility during a maximum of 60 minutes each 
day. Water port was removed after the first 10 minutes session to keep depriva-
tion level. Once mice were habituated to 30-60 minutes sessions, they were briefly 
anesthetized under isoflurane to open the craniotomy. Afterwards, craniotomy was 
covered with low toxicity silicone elastomer (Kwik-Sil; World Precision Instruments, 
Sarasota, FL, USA) and recordings started the following day. Every animal was record-
ed in two independent sessions of 1 hour.
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For recordings, 16-channels silicon probes (100 µm resolution, 413 µm2 elec-
trode area) were used (Neuronexus, Anne Arbor, MI, USA). Extracellular signals were 
pre-amplified (4x) and recorded with a 16-channel AC amplifier (Multichannel Sys-
tems, Reutlingen, Germany), further amplified by 100, filtered by analogous means 
at 1 Hz to 5 kHz, and sampled at 20 kHz/channel with 12 bits precision. The animal 
speed was stored to evaluate periods of running and immobility. 
Analysis of electrophysiological signals was implemented in Matlab 9.3. Local field potential (LFP) signals from sites at stratum lacunosum moleculare were used for 
identifying theta periods during running (band-pass 4-12 Hz). Forward-backward-ze-
ro-phase finite impulse response filters of order 512 were used to preserve temporal 
relationships between channels and signals. The mean power spectra during theta 
was fitted to the 1/f decay for frequencies > 60 Hz and a reference level was estab-
lished at 0 dB. Spectral values fitted to 1/f were similar between groups and were dis-
carded for the analysis. Consequently, only the theta (4-12 Hz) and low gamma bands 
(30-60 Hz) were included in the analysis.
For detection of sharp-wave ripples (SWR), LFP signals from stratum radiatum were 
low-pass filtered (100 Hz) while signals from stratum pyramidale (sp) were bandpass fil-
tered (100-600 Hz). Filtered signals were smoothed by a Gaussian kernel and candidate 
events were detected by thresholding (> 4 SDs). The power spectra was evaluated in a 
window of ±0.2 ms around each detected event. Time-frequency analysis was performed 
by applying the multitaper spectral estimation in sliding windows with 97.7 % overlap and 
frequency resolution of 10 Hz in the 90-600 Hz frequency range. The normalized power 
in the 90-600 Hz band was treated as a statistical distribution, from which we extracted 
the mode to estimate the oscillatory frequency peak, the entropy and fast ripple index, as previously described (Foffani et al., 2007). Slow (90-120 Hz) and fast ripples (>120 Hz) 
were separated using individual spectra for visualization purposes.
Pentylenetetrazol-induced seizures assay
Pentylenetetrazol (PTZ) (Sigma-Aldrich España) was dissolved in 0.9 % saline and ad-
ministered i.p. to mice at P60 at a concentration of 22.5 mg/kg (at 10 µL/g). Mice were then 
placed in Plexiglas cages and re-injected with the PTZ-containing solution every 10 minutes 
until generalized seizures occurred. This was considered the end of the experiment. All the 
procedure was video-recorded and analysed later by an experimenter blinded to the experi-
mental groups, who determined the precise moment of generalized seizure onset.
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Novel object recognition task
P60 mice were habituated to an arena consisting on a grey methacrylate open field of 70 x 
70 x 40 cm under uniform lightning conditions of 25 lux. Mice were allowed to freely explore the arena for 10 minutes the day before the novel object recognition (NOR) test to let them 
familiarize with the arena and minimize cage-exploring-derived distractions during the sub-
sequent test. Test consisted of two parts: training and test sessions. During the former mice 
were allowed to individually explore two objects for 10 minutes. Then mice were returned to 
the home cage and the open field and objects were cleaned to avoid olfactory cues. After an 
inter-trial interval of 50 minutes, mice were placed back into the same open field for the test 
session, in which one of the familiar objects had been replaced by a novel object. Mice were 
allowed to explore the objects for 10 minutes. Mice did not show preference for any object 
before trials. Mice were excluded from the analysis only if the total time of exploration for each 
mouse was lower than 5 seconds in the test session. Object exploration was defined as the 
mouse being within 2 cm of an object, directing its nose at the object, and being involved in ac-
tive exploration such as sniffing. A discrimination index was calculated to measure recognition 
memory as follows:  Id = (tnew object - tfamiliar object)/(tnew object + tfamiliar object)
All tests were video-recorded and systematically analysed by mean of the SMART 3.0 video 
tracking software (Panlab, Barcelona, Spain).
Object location task
The day after NOR test, mice were subjected to an object-place recognition, or object lo-
cation (OL), task in the same open field arena. This test was also structured in two sessions: 
similar to NOR, mice were first exposed to two identical objects that they were left to explore 
during 10 minutes. After that, mice were placed back in their home cage and the arena and 
object were cleaned to remove any odour cue. After 50 minutes, in the test session, one of the 
objects was placed in a different position maintaining its distance relative to the walls, and mice 
were allowed to explore the objects for an additional 10 minutes. Mice were excluded from the 
analysis only if the total time of exploration for each mouse was lower than 5 seconds in the 
test session. A discrimination index was calculated to measure recognition memory as follows: Id = (tdisplaced object - tundisplaced object)/(tdisplaced object + tundisplaced object)
All tests were video-recorded and systematically analysed by mean of the SMART 3.0 video 
tracking software (Panlab).
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Cannabinoid-induced tetrad
A classical cannabinoid tetrad test (Metna-Laurent et al., 2017) was performed 
on P60 mice, which were injected i.p. with THC (10 mg/kg) or its vehicle following 
the same preparation protocol as abovementioned. Basal temperature was measured 
with a rectal probe just before injection. 45 minutes after injection mice were placed 
in an open field arena and recorded for 10 minutes to evaluate hypolocomotion. Just 
after removing the mice from the open field arena, rectal temperature was taken again 
to assess hypothermia. 60 minutes after injection, mice were subjected to a catalepsy 
test. Briefly, mice were set up in a standing position with both forepaws resting on a 
horizontal bar separated 3 cm from the floor of a standard cage. Time until mice de-
scended from the bar (i.e. both forepaws are touching the floor) was measured with a 
cut-off time of 2 minutes. Lastly, 90 minutes after injection, mice were placed in a hot 
plate set at 52 ºC and time until first sign of pain was quantified. In absence of signs 
of pain, mice were removed from the hot plate at a cut-off time of 30 seconds in order 
to avoid wounds to the animals. A naive cohort from each genotype was injected with vehicle and used to establish the baseline for both parameters.
Data and statistical analyses
Results shown represent the means ± S.E.M., and the number of experiments is in-
dicated in every case. Statistical analysis was performed with GraphPad Prism 6.07 
(GraphPad Software, La Jolla, CA, USA). All variables were first tested for nomality 
(Kolmogorov-Smirnov test) and homocedasticity (Levene's test). When variables satis-
fied these conditions, one-way or two-way ANOVA and Student-Newman-Keuls or LSD Fisher post hoc tests were used to assess differences between groups. Disease-Genotype 
association test was performed by the SNPator online tool (Morcillo-Suárez et al., 2008) 
to examine genotype and allele frequencies between patients and controls. p values 
of < 0.05 were regarded as statistically significant.
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Aim 1: Summary
MCDs are associated with refractory epilepsy in children and young adults (Iffland 
and Crino, 2017). These alterations are originated by the disruption of key processes during brain development, such as neural progenitor cell proliferation or neuronal 
migration. Within MCD, some types of FCD are associated with overactivation of the 
mTORC1 signalling pathway (Aronica and Crino, 2014; Najm et al., 2018). Whereas the origin of the different FCD subtypes is still unclear, recent research has demon-
strated the involvement of alterations of the PI3K/Akt/mTORC1 pathway particularly in FCD Type II (Jansen et al., 2015; Lim et al., 2015; D’Gama et al., 2017). Nevertheless, 
further investigation on the mechanisms responsible for the epileptogenic network is required for the development of novel therapeutic strategies aimed to manage FCDs. 
The ECS, and especially CB₁R, exerts an essential neuromodulatory role in the adult brain via the retrograde lipid messengers 2-AG and AEA (Soltesz et al., 2015). In 
addition, CB₁Rs are expressed during human cortical development (Mato et al., 2003; Wang et al., 2003). During early stages in brain development, CB₁Rs are required for proper radial migration during cortical development, and their genetic inactivation 
induces brain hyperexcitability (Díaz-Alonso et al., 2017). Interestingly, CB₁R is ex-pressed in FCD (Zurolo et al., 2010), a pathology that may be related to PN migra-
tion defects, although its contribution to FCD severity remains unclear. Thus, here we sought to investigate the potential contribution of aberrant cannabinoid signalling to 
FCD developmental pathogenesis. Additionally, we aimed to characterize the long-
term electrophysiological alterations of PNs that suffer embryonic CB₁R signalling 
disruption in order to find the mechanism underlying the hyperexcitability found in previous studies.
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Aim 1 . Impact of altered endocannabinoid signalling in focal cortical 
dysplasia and in projection neuron maturation
R1.1. CB₁ receptor expression in focal cortical dysplasia is associated with 
overactive mTORC1 pathway
To assess the pathophysiological relevance of CB₁R signalling in MCDs we analysed 
CB₁R immunoreactivity in control and dysplastic brain areas (Figure R1.1). FCD cases 
(n=30) were included with a mean patient age of 11.4 years and a male/female dis-
tribution of n=18 and 12, respectively (Table 1). Double immunofluorescence analysis 
with anti-pS6 (recognizing the phosphoS240/S244 sites) and anti-CB₁R antibodies con-
firmed the selective overactivation of the mTORC1 pathway in FCD Type II but not FCD 
Type I samples (Figure R1.1A, B). Quantification of CB₁R immunoreactivity revealed 
that receptor expression is notably enriched in the dysplastic areas of FCD Type II when 
compared with control brain tissue, but not in FCD type I (Figure R1.1A, C). A more de-
tailed analysis of double immunofluorescence images showed that CB₁R+ cells largely 
colocalized with pS6 immunoreactivity in FCD Type II, and CB₁R+pS6+ cells were highly 
enriched in the dysplastic areas when compared to control cortical tissue (Figure R1.1D). 
Moreover, the intensity of pS6 immunoreactivity was selectively increased when com-paring FCD Type II and I (1.61 ± 0.14 versus 1.00 ± 0.07 respectively; p < 0.018, n = 4).
Next we analysed CB₁R expression in BCs and DNs based in morphological character-ization and mTORC1 overactivation (Figure R1.2A). This indicated that 2.43 ± 0.92 and 
0.57 ± 0.29 % of total CB₁R tissue immunoreactivity corresponded to these cell subpopu-
lations, respectively. FCD Type II is characterized by the expression of undifferentiated 
markers in BC including Sox2, Oct4, Pax6, Tbr1, Otx1 and others (Hadjivassiliou et al., 2010; Orlova et al., 2010; Arai et al., 2012; Yao et al., 2016). Thus, we analysed the ex-
pression of CB₁Rs in FCD Type II neurons together with undifferentiated-cell markers. Whereas in FCD Type II sparse c-Myc+ cells could be detected, this was never the case in FCD Type I samples. Importantly, c-Myc+ cells expressed CB₁R and showed active mTORC1 signalling (pS6+) (Figure R1.2B). Hence, in FCD Type II we determined that 72.74 ± 11.04 % c-Myc+ cells were also pS6+.
R1.2. CB₁ receptor expression is not induced by mTORC1 signalling
To determine if CB₁R enrichment in FCD lesions was a cause or a consequence 
of mTORC1 overactivation we analysed if this signalling pathway can regulate CB₁R 
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expression. P19 cells were transfected with a plasmid encoding a constitutively ac-
tive mutant of the mTORC1 upstream activator Rheb (RhebQ64L) or a Tsc2 specific short-hairpin RNA coding plasmid (shTSC2). In these conditions, as compared to con-
trol cells, mTORC1 pathway activity increased as evidenced by the strong increase of pS6+ immunoreactive cells (Figure R1.3A). However, under the same conditions of 
overactive mTORC1 signalling, CB₁R protein levels were not induced (Figure R1.3B). 
We also performed CB₁R promoter transcriptional assays by co-transfection 
with a CAT gene reporter in frame with a minimal CNR1 promoter (Blázquez et al., 
2011). Again, in cells with overactive mTORC1 pathway CNR1 promoter activity was not induced (Figure R1.3C). As a control of the sensitivity of this assay, P19 cells 
Figure R1.1. CB₁ receptor is enriched in focal cortical dysplasia Type II in cells with overactive mTORC1 sig-
nalling . (A) Representative immunofluorescence images showing the presence of CB₁R in samples from Type I and 
II FCD and control brains, revealed with an anti-CB₁R antibody (red). Cells with over-active mTORC1 signalling are 
stained with anti-pS6 S240/244 antibody (green). High magnification images of CB₁R expression associated with 
mTORC1 overactivation in FCD Type II are shown. (B-C) pS6+ cells and CB₁R immunoreactivity (IR) were quanti-
fied in the dysplastic area and referred to total cell number (DAPI counterstaining). Control, FCD Type I and FCD Type II cases (B, n = 4, 7 and 18, respectively; C, n = 6, 8, 13). (D) CB₁R+pS6+ double-labelled cells were quantified and referred to total pS6+ cells. Control, FCD Type I and FCD Type II cases (n = 4, 7 and 18, respectively). Statistical comparison versus control samples: ***, p < 0.001. Statistical comparison versus FCD Type I samples: ###, p < 0.001. 
Scale bars: 45 μm; inset: 10 μm.
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Figure R1.2. CB₁ receptor is present in undifferentiated cells. (A) DNs (A1, A1’ and A1’’) and BCs (A2, A2’ and 
A2’’) were identified based in morphological criteria in hematoxylin/eosin sections stained with anti-NeuN anti-body (A1, A2). CB₁R expression and mTORC1 activity status was analysed by immunofluorescence with anti-CB₁R and anti-pS6 antibodies, respectively (A1’, A1’’, A2’ and A2’’). (B) Representative immunofluorescence images 
showing co-expression of CB₁R (red) and the undifferentiated cell marker c-Myc (blue), as well as pS6 as a readout 
of mTORC1 activity (green). High magnification insets are shown (lower panels). Scale bar: 25 μm, insets, 6.5 μm.
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were transfected with the intermediate progenitor transcription factor Tbr2. The CNR1 
promoter has several putative Tbr2-binding sites (Table 4), and its expression was indeed 
sufficient to increase the promoter reporter activity (Figure R1.3C), but failed to increase 
protein levels (Figure R1.3B). In summary, these results indicate that the increased CB₁R 
levels in FCD are not a direct consequence of an overactive mTORC1 pathway.
R1 .3 . Genetic characterization of the endocannabinoid system in focal cortical 
dysplasia
The observation that CB₁R levels are increased in the dysplastic cells of FCD Type 
II cases prompted us to expand the analyses to other elements of the ECS that may contribute to cannabinoid signalling deregulation. Genomic DNA and messenger RNA
Figure R1.3. The mTORC1 pathway does not regulate CB₁ receptor expression. (A) Representative images and 
quantification of mTORC1 activation in P19 cells after transfection with the Rheb constitutively active mutant Q64L, 
shTSC2, a scrambled shRNA-encoding vector (shCo), or a GFP-encoding plasmid. mTORC1 activation was analysed by means of pS6+ cells quantification. (B) Western blot analysis of CB₁R levels in the same conditions as above. 
Representative immunoblot luminograms and quantification for CB₁R and β-actin as loading control are shown 
(mean ± SEM is provided, n = 3). (C) CNR1 promoter activity was analysed using a CAT construct 24 hours after 
transfection (n = 6). Statistical comparison versus the corresponding control samples: **, p < 0.01. Scale bar: 50 µm.
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Table 4 . Putative Tbr2 binding sites within CNR1 locus . Detected using Matinspector (Genomatix, München, Germany)).
Species Gene location
Binding site position
Strand Matrix simi-larityStart End
Human 6q15
88164872 88164900 + 0.94188166737 88166765 + 0.96388166645 88166673 + 0.98988166554 88166568 + 0.90288168289 88168317 + 0.990
Mouse 4A5 33936594 33936608 - 0.89633925880 33925908 + 0.90133944561 33944589 - 0.999
Table 5 . Endocannabinoid system elements analysed by qPCR in FCD Type II and control samples . (n = 4 and 22, control and FCD Type II, respectively, for CNR1 transcript; 4 and 8, control and FCD Type II, for the rest). Statistical comparison versus control samples: *, p < 0.05; ns, non significant.
Transcript Condition Mean SEM Statistical signifi-cance
CNR1
Control 1.00 0.2397
*FCD Type II 33.70 5.3080
DAGLA
Control 1.00 0.0004 nsFCD Type II 0.45 0.1286
DAGLB
Control 1.00 0.0106 nsFCD Type II 0.84 0.2274
MGL
Control 1.00 0.0005 nsFCD Type II 0.88 0.3061
NAPE-PLD
Control 1.00 0.0264 nsFCD Type II 0.72 0.1176
FAAH
Control 1.00 0.0182 nsFCD Type II 0.36 0.1910
from the FCD collection were obtained. Real time PCR expression analysis confirmed in-
creased levels of CB₁R transcripts in FCD Type II versus control brain extracts (Table 5), 
further supporting the results obtained at the protein level by immunofluorescence 
characterization (Figure R1.1). Transcript levels of other elements of the ECS (DAGLα, 
DAGLβ, MGL, FAAH and NAPE-PLD) were also quantified and no differences were ob-served (Table 5). To further characterize if cannabinoid signalling alterations may 
contribute to overactive mTORC1 in FCD Type II, we performed SNP analysis of vari-
ous genes of ECS elements including CB₁R, DAGLα and β, MGL, FAAH and CB₂R. A total 
48 SNPs of the ECS were selected (Table 3), based on previous evidences that point to their potential involvement in different nervous system disorders. Genotype disease 
association analysis revealed the existence of 3 polymorphisms in the DAGLA gene 
differentially expressed in FCD Type II versus control specimens (Table 6). 
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Table 6 . SNPs . analysed in focal cortical dysplasia Type II and control brain genomic DNA extracts . SNPs 
appear listed in the same order as in Table 3. (n= 4 and 22, control and FCD Type II, respectively). Disease-Genotype association test carried out by SNPator online tool. *, p < 0.05.
SNP Major/minor alleles
% major homozygosity % heterozygosity % minor homozygosity Disease
associationControl FCD Control FCD Control FCDrs806365 C/T 20.0 36.4 70.0 45.4 10.0 18.2rs7766029 T/C 20.0 31.8 50.0 54.5 30.0 13.6rs806366 T/C 40.0 31.8 40.0 31.8 20.0 36.4rs806368 T/C 60.0 54.5 20.0 36.4 20.0 9.0rs12720071 A/G 60.0 86.4 40.0 13.6 0.0 0.0rs4707436 G/A 60.0 59.1 30.0 40.9 10.0 0.0rs1049353 G/A 80.0 68.2 10.0 31.8 10.0 0.0rs806369 C/T 60.0 45.5 30.0 40.9 10.0 13.6rs2023239 T/C 60.0 63.6 40.0 36.4 0.0 0.0rs1535255 T/G 70.0 63.6 30.0 36.4 0.0 0.0rs806379 A/T 30.0 18.2 60.0 77.3 10.0 4.5rs9444584 C/T 60.0 54.5 30.0 45.5 10.0 0.0rs9450898 C/T 70.0 63.6 30.0 36.4 0.0 0.0rs806380 A/G 60.0 54.5 30.0 40.9 10.0 4.5rs6454674 T/G 40.0 63.6 40.0 31.8 20.0 4.5rs2180619 A/G 30.0 31.8 50.0 45.5 20.0 22.7rs4963304 G/A 10.0 68.2 50.0 31.8 40.0 0.0 *rs7931563 T/G 50.0 40.9 50.0 40.9 0.0 18.2rs7942387 C/A 90.0 100.0 10.0 0.0 0.0 0.0rs198430 C/T 30.0 77.3 40.0 22.7 30.0 0.0 *rs198444 T/C 40.0 4.5 60.0 45.5 0.0 50.0 *rs34365114 G/A 100.0 95.5 0.0 4.5 0.0 0.0rs144674730 C/T 100.0 100.0 0.0 0.0 0.0 0.0rs143650244 AAA/- 90.0 100.0 10.0 0.0 0.0 0.0rs187296513 C/T 100.0 100.0 0.0 0.0 0.0 0.0rs3813518 G/A 50.0 77.3 50.0 18.2 0.0 4.5rs3813517 A/G 100.0 95.5 0.0 4.5 0.0 0.0rs836559 C/G 10.0 36.4 40.0 45.4 50.0 18.2rs2303361 T/C 40.0 72.8 30.0 22.7 30.0 4.5rs76802560 G/T 100.0 100.0 0.0 0.0 0.0 0.0rs6801421 G/A 90.0 63.6 10.0 36.4 0.0 0.0rs72969613 C/T 100.0 100.0 0.0 0.0 0.0 0.0rs4881 A/G 70.0 81.8 20.0 18.2 10.0 0.0rs115970931 A/G 100.0 100.0 0.0 0.0 0.0 0.0rs932816 G/A 80.0 50.0 20.0 45.5 0.0 4.5rs4141964 G/A 30.0 40.9 30.0 40.9 40.0 18.2rs324420 C/A 30.0 59.1 50.0 22.7 20.0 18.2rs324419 G/A 80.0 81.8 20.0 18.2 0.0 0.0rs2295632 C/A 30.0 54.5 40.0 27.3 30.0 18.2rs12029329 G/C 30.0 54.5 40.0 27.3 30.0 18.2
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SNP Major/minor alleles
% major homozygosity % heterozygosity % minor homozygosity Disease
associationControl FCD Control FCD Control FCDrs12744386 C/T 10.0 31.8 70.0 50.0 20.0 18.2rs1130321 A/G 20.0 27.3 80.0 54.5 20.0 18.2rs1106 G/C 20.0 27.3 80.0 54.5 20.0 18.2rs2229579 C/T 70.0 63.6 30.0 27.3 0.0 9.1rs2501431 A/G 20.0 27.3 80.0 54.5 20.0 18.2rs41311993 G/T 100.0 100.0 0.0 0.0 0.0 0.0rs35761398 CC/TT 20.0 23.8 80.0 57.2 20.0 19.0rs2501432 C/T 20.0 27.3 80.0 54.5 20.0 18.2The rest of SNPs analysed for CNR1, DAGLB, MGL, FAAH and CNR2 did not show any 
difference between pathologic samples and controls. To further investigate the poten-
tial involvement of CB₁R in FCD we sequenced the CNR1 gene exon in FCD and control genomic DNA samples. CNR1 exon 1 sequencing revealed normal wild-type sequence 
in most samples and only rs1049353 SNP (c.1359G>A; p.Thr453) was identified with similar distribution among dysplastic and control DNA.
In summary, these results suggest that the DAGLα-evoked generation of the en-docannabinoid 2-AG might be altered in FCD Type II and can contribute to its etiopa-
thology. However, the exact contribution of endocannabinoid tone alterations in MCDs 
would require more complex genetic studies to identify its potential association with the origin of the disease.
R1.4. CB₁ receptor crosstalk with the mTORC1 pathway in focal cortical 
dysplasia resections
Additional specimens derived from surgical resection for intractable epilepsy were analysed ex vivo for mechanistic studies. 3T magnetic resonance imaging (MRI), positron 
emission tomography with fluorodeoxyglucose (FDG-PET) scan, scalp electroenceph-
alography (EEG) recording and invasive neurophysiological studies were employed to identify the origin of epileptic seizures (Figure R1.4A). Representative images of one case 
prior and after surgery are shown. In this particular patient, a small FCD Type II involving 
the left rolandic region and superior frontal gyrus (arrowheads, Figure R1.4A) was asso-
ciated with daily focal motor seizures and Epilepsia Partialis Continua involving the left arm and the face. Scalp EEG analyses revealed continuous focal epileptiform discharges 
(arrowhead, Figure R1.4B) in accordance with a hypermetabolic FDG-PET focus. Intra-
craneal EEG exploration of the dysplastic lesion, using a combination of subdural electrodes 
and depth electrodes, better defined a characteristic EEG pattern, indicative of FCD. 
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Figure R1 .4 . EEG characterization of a representative FCD case subject to surgery . (A) FDG-PET scan (A1) 
co-registered with 3T MRI imaging (A2, an inset is included in A3) of a 5 years old affected by a “malignant rolandic 
epilepsy” with daily motor seizures and Epilepsia Partialis Continua. (A4) Representative example of the electrode grid used during surgeries. (A5) MRI one year after epilepsy surgery. White arrowheads indicate hypermetabolic FDG-PET focus (red zone, A1), small FCD involving the left rolandic region and superior frontal gyrus (A2), grey-
white matter blurring (A3), and resected tissue (A5). (B-C) Scalp and intracraneal EEG recording, respectively, of the previous patient, using a combination of subdural electrodes and depth electrodes, prior resection of the epi-
leptogenic zone. Black arrowheads indicate epileptiform activity.
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This characteristic EEG pattern shows continuous repetitive burst of epileptiform 
activity turning into focal EEG ictal patterns (arrowhead, Figure R1.4C), in association 
with the onset of clinical seizure signs. After tailored resection of the epileptogenic 
zone, one year follow-up after surgery revealed a seizure-free clinical status, MRI and 
EEG showed absence of the lesion and normalization of hyperexcitability.
Considering the regulatory role of CB₁R in cortical progenitor cell identity via mTORC1 signalling (Díaz-Alonso et al., 2015), we next sought to investigate the im-pact of the receptor in FCD-derived neurons. We obtained FCD Type II organotypic 
cultures derived from fresh resections that were maintained for 7 days in vitro and 
subjected to pharmacological manipulation. Quantification of pS6 immunoreactivity 
revealed that CB₁R activation with the cannabinoid agonist HU-210 was without ef-
fect on mTORC1 activation, whereas the mTORC1 inhibitor rapamycin was effective 
in reducing mTORC1 overactivation (Figure R1.5A). Western blot analysis confirmed 
that CB₁R agonism did not influence mTORC1 activation, whereas the CB₁R inverse 
Figure R1.5. CB₁ receptor blockade attenuates mTORC1 overactivation in FCD organotypic cultures. 
Organotypic cultures of FCD resections were cultured 7 days in vitro and exposed to the CB₁R agonist HU-210 (1 
µM), and rapamycin (1 µM) for 90 min. (A) Representative images of immunofluorescence characterization with 
anti-pS6 S240/244 antibody were quantified and pS6 immunoreactivity was referred to the total number of cells 
revealed by DAPI counterstaining (n = 4 experiments). (B) Western blot analysis of pS6 S240/244 levels was per-
formed in slice extracts after 90 min incubation with HU-210 alone or together with SR141716 (25 µM), SR141716 
alone or rapamycin (n = 4 experiments). Statistical comparison versus vehicle samples: *p < 0.05; **, p < 0.01. Scale 
bar: 80 µm.
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agonist SR141716 (rimonabant), as well as rapamycin, reduced mTORC1 activation as assessed by pS6 S240/244 levels (Figure R1.5B). Overall, these results indicate that 
inhibition, but not activation of the CB₁R, may tune the overactive mTORC1 pathway found in FCD Type II dysplastic brain.
R1.5. Transient CB₁ receptor knockdown alters maturation and impaired 
circuit integration in upper-layer neurons
The added value of experiments with human tissue obtained from resections of 
MCDs cases is hampered by the extreme difficulty inherent to use this kind of material 
as well as the limitations that it offers in terms of approaching mechanistic questions. 
Hence, the use of human derived tissue generally does not allow to fully address if the observed alterations are a primary direct consequence of the disease or just a 
secondary maladaptation. With this in mind, we moved to a developmental approach 
by performing IUE experiments in animal models. Previous findings have demonstrat-
ed that embryonic CB₁R acute knockdown fosters a delay in the radial migration of 
cortical PNs, which in turn increases seizure susceptibility (Díaz-Alonso et al., 2017). 
However, the impact of this migration delay in the acquisition of a mature neuronal 
phenotype, in regard of excitability, remains unknown. Thus, we decided to perform 
whole-cell patch-clamp experiments on acute brain slices obtained at different time 
points (P7, P14, P21, P60) from wild type mice subjected to IUE in the mPFC with ei-
ther siCB₁ or siCo at E14, in order to determine if there is a causal link between an ear-ly ECS malfunctioning and the seizure-prone phenotype observed in animal models.
After confirming that a radial migration delay was apparent at E17 (Figure R1.6A), 
we verified that in adult stages (P60) the majority of the GFP+ neurons had properly reached the upper layers, the laminar fate determined by their birthdate, as neurons 
born at E14 are bound to migrate towards layers II/III (Greig et al., 2013). We first characterized these properly-migrated neurons.
By means of current-clamp experiments, we analysed passive properties of GFP+ neuron membranes (Figure R1.6B, C). In general terms, RMP became hyperpolarized 
with age in both experimental conditions, due to maturation of neurons and cortical 
circuits, although we recorded a slight depolarization in adults from the control group 
with respect of the immediate preceding age (P21). When comparing conditions, we 
found a depolarized RMP in CB₁R-knocked down cells at P7 and in the adult mice (P60) 
(Figure R1.6B). Input resistance also decreased with age, although showing different 
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trends in the two groups. While control neurons reached a plateau at P21, siCB₁-targeted 
cells stabilized earlier, at P14. After showing a 2-fold increase at P7 with respect to the 
control group, input resistance of the siCB₁-targeted neurons quickly decreased and by P14 it had reached its stabilization value (Figure R1.6C). Changes in passive membrane 
properties may indicate a shift in the neuronal ionic channel expression profile, a trait that 
evolves with neuronal maturation. Thus, these findings, especially when their age pattern 
is taken into account, support that the migration delay elicited by acute CB₁R-knockdown 
provokes in turn a disruption in the maturation pace of developing neurons.
Still in current-clamp configuration, we evaluated the active electrophysiological prop-
erties of the targeted cells (Figure R1.7). We determined the firing frequency in the three 
Figure R1.6. Transient CB₁ receptor knockdown impairs radial migration and alters passive electrophysi-
ological properties . Murine embryos were electroporated at E14 with either siCB₁ or siCo. Brains were dissected 
at different ages and analysed by immunofluorescence or whole-cell patch clamp. (A) Representative immunoflu-
orescence images and quantification showing altered neuronal migration at E17, expressed as percentage of GFP+ 
cells located within each compartment of the developing cortical wall (VZ/SVZ, IZ and CP). At P60, although most of the cells have reached the upper cortical layers, GFP+ cells arrested in the deep layers can be observed only in siC-B₁-electroporated animals. (n = 5 animals per group). (B) RMP measured in whole-cell current clamp experiments 
at four different ages (P7, P14, P21, P60). [n = (siCo: 17, 29, 19 and 13 cells; P7, P14, P21 and P60, respectively); (siCB₁: 22, 20, 13 and 16 cells; P7, P14, P21 and P60, respectively)]. (C) Input resistance measured in the same con-ditions. Same dataset as RMP. Statistical comparison versus the corresponding siCo group: *, p < 0.05; **, p < 0.01. 
Scale bars: E17: 100 µm, P60: 150 µm.
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older time points (P14, P21, P60), as patched cells in P7, even though they were able to 
develop APs, did it in a much slower and irregular pace. Nevertheless, firing frequency 
was similar in the two conditions across all the different ages (Figure R1.7A). We found 
similar age-dependent tendencies in both groups for AP threshold, AP half-width and AP 
amplitude. While the two former showed higher values at P7 that decreased and stabi-
lized at P14 (Figure R1.7B, D), the latter exhibited the opposite trend, stabilizing at P14 after increasing from P7 (Figure R1.7C). Among all the time points studied in the three 
parameters, we found differences in the AP amplitude at P14 (higher in knocked down 
cells) and the AP half-width at adulthood (lower in siCB₁-targeted cells). We also mea-
sured the amplitude of the AHP that follows an AP and its voltage sag (Figure R1.7E, F). 
Figure R1.7. Transient CB₁ receptor knockdown alters the maturation pace of properly migrated neurons. 
Active electrophysiological properties were evaluated in the same cells, also in whole-cell current clamp config-uration. (A) AP firing rate was measured at P14, P21 and P60, as it was inconsistent at P7. (B-F) Other active 
properties were recorded in the four time points, including P7. Specifically, we evaluated: (B) AP threshold, (C) AP amplitude, (D) AP halfwidth, (E) AHP amplitude and (F) voltage sag. The trends observed among the different time 
stages point to a differential expression of ionic channels, which suggest a divergent maturation rate upon transi-
tory CB₁R-expression reduction by siCB₁ electroporation. [n = (siCo: 17, 29, 19 and 13 cells; P7, P14, P21 and P60, respectively); (siCB₁: 10, 20, 13 and 16 cells; P7, P14, P21 and P60, respectively)]. Statistical comparison versus the corresponding siCo group: *, p < 0.05.
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Although AHP in both groups presented again similar age-related trends (a slight increase 
and stabilization from P7 to P14), it was increased in adult neurons from the siCB₁-targeted 
group. Voltage sag, which decreased with age, was lower in siCB₁-electroporated cells at P14 
with respect to siCo neurons. These data reinforces the rationale that the transient depletion 
of CB₁R during embryonic development influences neuronal maturation and likely modifies 
the the ion channel expression signature.
Moving to a voltage-clamp configuration, we determined the spontaneous synaptic ac-tivity (i.e. IPSCs and EPSCs) that patched cells developed in response to synaptic inputs 
coming from the circuits in which they assemble, to assess if there was any difference in 
circuit integration among both conditions (Figure R1.8). While IPSCs frequency was de-
creased at P14 and increased in adult CB₁R-knocked down neurons (Figure R1.8A), no 
changes were appreciable in EPSCs (Figure R1.8B). Conversely, IPSCs amplitude was in-
creased in P21 in siCB₁-electroporated cells (Figure R1.8A), but also EPSCs amplitude was higher in those cells both at P14 and P21 (Figure R1.8B). These observations point that 
transient CB₁R knockdown alters not only the maturation pace of cortical PNs, but also the 
way in which they integrate in their corresponding cortical circuits.
Figure R1 .8 . Neurons that reach their proper laminar destination show a defective integration in cortical 
circuits . Cells analysed in current clamp configuration were also studied under voltage clamp conditions in order to 
assess the frequency and amplitude of postsynaptic events affecting them. Both parameters were analysed for (A) IPSC events, and (B) EPSC events. The differences found when comparing both experimental conditions at multiple stages suggest that siCB₁-electroporated neurons, even if they reach their destination, do not integrate in circuit 
assemblies in the same way as their siCo-electroporated counterparts. [n = (siCo: 10, 31, 12 and 4 cells; P7, P14, P21 and P60, respectively); (siCB₁: 3, 16, 9 and 12 cells; P7, P14, P21 and P60, respectively)]. Statistical comparison 
versus the corresponding siCo group: *, p < 0.05.
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Aim 2: Summary
Exposure of the immature brain to cannabinoids exerts deleterious functional con-
sequences in adulthood by interfering with neural cell development, as well as with neuronal differentiation and connectivity (Grant et al., 2018). Thus, perinatal THC 
exposure induces changes in glutamatergic and noradrenergic signalling that are, 
at least in part, responsible of the cognitive deficits observed in adults (Mereu et al., 2003; Campolongo et al., 2007). Embryonic THC exposure impairs NMDAR-depen-dent LTD (Tortoriello et al., 2014). Similarly, maternal cannabis consumption results in a selective dopaminergic D2R (but not D1R) impairment in the mesolimbic system (Dinieri et al., 2011; Morris et al., 2011).
THC interferes with the neurodevelopmental role of the ECS (Galve-Roperh et al., 2013; Maccarrone et al., 2014). CB₁R, upon engagement by 2-AG and AEA, regulates crucial steps of cortical development as IN migration and morphogenesis. Thus, the 
number of hippocampal CCK-containing basket cells can be influenced by embryonic THC (Berghuis et al., 2005), or WIN-55,212-2 (Vargish et al., 2016) exposure. Howev-
er, embryonic THC administration can also interfere with pyramidal neuron develop-ment (de Salas-Quiroga et al., 2015), which leads to an unbalanced excitation/inhibi-
tion state and higher susceptibility to seizures. Studies using both conditional CB₁R 
knock-out and CB₁R-rescue in a null background demonstrated that THC-induced proconvulsive status relies at least in part in alterations in both PNs and GABAergic 
INs. In this chapter, we investigated the neurodevelopmental consequences of prena-
tal THC exposure by focusing on hippocampal plasticity and sex-dependent dimorphic sensitivity, given the role of temporal lobe circuits in memory function and epilepsy. 
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Aim 2. Implication of CB₁ receptor in the establishment of CCK-
containing interneurons in the hippocampus
R2 .1 . Embryonic THC exposure evokes long-term interneuronal alterations in 
a sex-dimorphic mannerTo assess the impact of prenatal THC administration throughout IN embryonic de-
velopment, we defined the temporal window of drug delivery at 3 mg/kg (i.p.) from 
E10 to E17. At P20, analysis of CB₁R immunoreactivity in the dorsal hippocampus of 
wild type mice prenatally exposed to THC showed a male-specific decrease of CB₁R 
levels with respect to vehicle-treated mice (Figures R2.1A and R2.2A, B). Interestingly, 
no significant differences were found for sex or treatment in other areas as the PFC or 
somatosensory cortex (SSC) (Figure R2.2C, D). Of note, the vast majority of immuno-
reactivity that is detected under these experimental conditions corresponds to CB₁R+ terminals of GABAergic INs (Monory et al., 2006; de Salas-Quiroga et al., 2015). Hence, 
we decided to focus on CA1 CCK-containing basket cells, the population of hippocampal 
INs that expresses the highest levels of CB₁R in the mouse forebrain (Marsicano and 
Lutz, 1999). Perisomatic CB₁R immunoreactivity at CA1 sp was reduced in the THC-ex-posed male progeny compared to its vehicle-treated counterpart (Figure R2.1B). No dif-
ferences were found for females treated with either THC or its vehicle. 
Next, we evaluated whether these alterations are due to a previously described 
morphogenetic role of CB₁R in developing INs (Berghuis et al., 2007) or to a decrease 
in the total numbers of CCK+ INs. To address this question, we performed ISH with 
a riboprobe against CCK, combined with anti-GABA IHC, to unequivocally identify 
CCK-containing hippocampal INs, given the broad expression of CCK by CA1 pyra-
midal neurons (Figures R2.1C and R2.2E). Stereological analysis showed a selective 
reduction of CA1 CCK+ IN density in THC-treated males as compared either to vehi-
cle-treated males, or to females, irrespective of the treatment. Taken together, these 
findings support that adult mice exposed to THC during embryonic development ex-
hibit an overt interneuronopathy with a remarkable sexual dimorphism. To rule out 
the possibility that sexual differences emerge from pharmacokinetic factors, such as 
THC bioavailability, we measured THC levels in E17-brain tissue (i.e., 12 hours after 
the last THC injection) and found similar values in both sexes (Figure R2.2F). In ad-
dition, as protracted embryonic THC exposure leads to a transient downregulation of 
CB₁R (de Salas-Quiroga et al., 2015), we asked whether a sex-dimorphic CB₁R down-
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regulation might be responsible for the observed effects. [35S]GTPγS binding analysis 
in E17-brain tissue revealed an evident downregulation of CB₁R after embryonic THC 
exposure, but comparable curves were obtained for both sexes (Figure R2.2G). 
R2 .2 . Prenatal THC exposure alters main hippocampal oscillations in adult 
males
CCK-containing basket cells are essential for proper hippocampal physiology and function (del Pino et al., 2017). Hence, we decided to further characterize the 
aforementioned THC-induced deficits via intrahippocampal recordings. Specifi-
cally, we performed in vivo electrophysiological recordings of the LFP throughout 
CA1 in the hippocampus of head-fixed freely moving P60 mice (Figure R2.3A). 
Figure R2.1. Prenatal THC exposure induces a sex dimorphic long-lasting hippocampal CB₁ receptor adap-
tation and CCK+ basket cell interneuronopathy . (A) Representative images and quantification of CB₁R immuno-
reactivity (IR) measured in the CA1 hippocampal region of P20 mice prenatally exposed to THC (3 mg/kg) or its vehicle. (B) CB₁R immunoreactivity quantified in the sp of CA1 in the same mice. (C) Representative images of CCK 
ISH and GABA IHC in the hippocampus, and quantification of basket cells identified as CCK+/GABA+ double-positive 
cells (black arrowhead). CCK+/GABA- (arrow) and GABA+/CCK- (hollow arrowhead) cells were excluded from the 
quantification. (n = 7 animals per group). Statistical comparison versus the corresponding vehicle group: *, p < 0.05. Scale bars: A: 50 µm; B: 10 µm; C: left: 150 µm, center: 25 µm, right: 5 µm.
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Figure R2.2. Sex divergent and long-lasting CB₁ receptor expression plasticity affects selectively hippocam-
pal region . (A-D) CB₁R immunoreactivity (IR) quantification in the progeny of vehicle- or THC- treated pregnant 
dams. CB₁R levels were analysed in the whole hippocampus (A), dentate gyrus (B), prefrontal (C) and somatosen-sory (D) cortices (n= 5 animals per group). (E) Hippocampal formation stained by CCK ISH without GABA IHC. Inset: positive cells outside sp (arrowhead) can be considered as CCK+ basket cells safely, whereas positive cells inside sp (arrow) may be basket or pyramidal cells, needing an additional interneuronal marker as GABA to be fully 
identified. (F) THC levels were determined in brain extracts from E17 embryos after prenatal exposure to THC or 
its vehicle (n = 6 animals per group). (G) [35S]GTPγS binding was determined in brain membrane extracts obtained 
from the same embryo cohorts (n = 6 pooled samples per group, each pool consisting of 3 E17.5 brains). Statistical comparison versus corresponding vehicle group: *, p < 0.05; **, p < 0.01. Scale bars: 150 µm; inset: 25 µm.
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During running, theta (4-12 Hz) and gamma oscillations (30-60 Hz) typical of ex-
ploratory behaviour were recorded across layers (Figure R2.3B). Spectral analyses 
of the LFP signal revealed changes in the theta band that were confined to the sp of CA1 
(Figures R2.3C, D and R2.4A, B). THC treatment was associated with a non-significant 
reduction of the gamma power at sp in both males and females, thus suggesting that some alterations may not have a dimorphic component (Figure R2.3E). These data are 
consistent with the idea of a complementary role of CCK-containing basket cells in hip-
pocampal theta and gamma oscillations (Klausberger et al., 2005).
Next, we analysed SWR (Figure R2.3F), a major hippocampal high-frequency os-cillation (HFO) recorded during immobility and sleep that is crucial for learning and 
memory consolidation (Buzsáki, 2015). SWR emerge from the oscillatory firing of 
pyramidal cell ensembles, controlled by the interplay between excitation and basket 
cell-mediated inhibition (Stark et al., 2014). In diseases affecting the hippocampal for-mation, such as temporal lobe epilepsy and Alzheimer’s disease, SWR are pathological 
and associated to severe cognitive deficits and epileptiform activities (Gillespie et al., 2016; Valero et al., 2017). Spectral analysis of SWR in mice treated with THC con-
firmed some differences with a clear sex dimorphism (Figure R2.3G). First, the SWR 
rate was significantly higher in males exposed to THC as compared to females or vehi-cle-treated males, independently of the detection threshold (Figure R2.3H, I). Second, 
the typical bimodality of the spectral SWR peaks (Sullivan et al., 2011) was remarked 
in THC-treated male mice (Figure R2.3G), with many more slower (<120 Hz) than fast 
events (>120 Hz) (Figure2.3J). This reflects a larger proportion of high-gamma SWR 
in THC-exposed males as compared to the other groups (Figure R2.3K). No significant 
changes were found in other measures of spectral distribution such as entropy and 
fast ripple index (Figure R2.4C-F). Taken together, these observations provide func-tional evidence for aberrant hippocampal microcircuit function caused by a persistent 
reduction of CCK-containing INs and oscillatory defects that predict cognitive alter-
ations in males prenatally exposed to THC. To test this idea further, we conducted NOR and OL memory tests. The former evaluates non-spatial, conceptual learning of 
object identity, which depends on multiple brain regions, while the latter provides a 
measure of spatial learning, which strongly relies on hippocampal function (Langston and Wood, 2010). We did not observe any interference of prenatal THC in the NOR paradigm, but THC-treated males performed poorly in the OL test as compared to 
females or their vehicle-treated counterparts (Figure R2.3L, M), consistent with the 
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Figure R2 .3 . Prenatal THC exposure induces sex-dimorphic alterations of hippocampal oscillations and spa-
tial cognitive deficits. See next page for detailed description.
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aforementioned electrophysiological data. In addition, we analysed susceptibility to PTZ-induced seizures and found selective effects in the male offspring (Figure R2.3N). 
Altogether, these data support deleterious sex-dimorphic effects of prenatal THC ex-
posure caused by a CCK interneuronopathy.
R2.3. CB₁ receptor located on GABAergic neurons is responsible for the sex-
dimorphic interneuronopathy induced by embryonic THC exposure
To understand better the developmental mechanisms leading to CCK interneuronop-
athy in adulthood, we sought for a direct link between THC action and specific cellu-
lar targets. CB₁R are expressed in various neuronal lineages throughout development (Galve-Roperh et al., 2013). To unequivocally assess the involvement of a specific sub-
set of CB₁R in the abovementioned defects, we made use of conditional knockout mice (Monory et al., 2006) lacking CB₁R exclusively in dorsal telencephalic glutamatergic py-
ramidal cells (CB₁Rfloxed/floxed::Nex-Cre+/- mice; herein referred to as Glu-CB₁R-KO) or in 
forebrain GABAergic neurons (CB₁Rfloxed/floxed::Dlx5/6-Cre+/- mice; herein referred to as 
GABA-CB₁R-KO). Immunofluorescence analysis of perisomatic CB₁R+ basket cell syn-apses at CA1 sp revealed a selective long-term decrease in CB₁Rf/f males exposed to THC 
that was preserved in Glu-CB₁R-KO animals, pointing to an involvement of CB₁R located on developing GABAergic INs in mediating THC actions (Figure R2.5A). In contrast, the 
remnant hippocampal CB₁R immunoreactivity of GABA-CB₁R-KO mice exhibited no 
differences by sex or treatment. Additionally, we carried out anti-CCK ISH combined 
with anti-GABA IHC to label CCK+ hippocampal INs in every genotype, sex, and treat-
ment. Stereological analysis confirmed a persistent reduction of CCK+ INs in CB₁Rf/f 
Figure R2 .3 . Prenatal THC exposure induces sex-dimorphic alterations of hippocampal oscillations and spa-
tial cognitive deficits. (A) Scheme of experimental set up. Mice were recorded head-fixed while running freely in 
a wheel. (B) Laminar recordings of LFP signals from a representative male mouse from each group (vehicle and 
THC). The running speed is shown at bottom. so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; slm, 
stratum lacunosum moleculare. (C) Mean power spectra of running episodes show representative peaks at theta and gamma recorded at the pyramidal cell layer (sp). [n = (males: 15 and 15, vehicle- and THC-treated, respectively); (females: 8 and 4, vehicle- and THC treated, respectively)]. (D) Group differences of theta power were specific for male THC mice. Same dataset as above. (E) No differences were found in gamma power. (F) SWR events were re-corded during immobility. Note higher event rate in THC treated males. (G) Distribution of spectral peaks per SWR 
events in the different groups. Note more number of events in THC-treated males and a larger contribution of slow ripple events. (H) SWR mean rate was higher in THC-treated males. (I) Consistent larger SWR rate across detection thresholds (in number of SD). (J) Examples of mean traces of slow (80-110 Hz) and fast (110-200 Hz) SRW events. (K) The proportion of slow SWR was significantly higher in the THC-treated male group. Same dataset as above. (L) 
Discrimination index in the NOR task was unchanged accross groups. [n = (males: 6 and 7, vehicle- and THC-treated, respectively); (females: 3 and 5, vehicle- and THC treated, respectively)]. (M) Discrimination index in the OL task 
was reduced specifically in THC-treated male mice. Same dataset as NOR task. (N) Latency to PTZ-induced seizures 
was significantly lower in the male THC group. [n = (males: 6 and 6, vehicle- and THC-treated, respectively); (fe-males: 6 and 8, vehicle- and THC treated, respectively)]. Statistical comparison versus the corresponding vehicle group: *, p < 0.05; **, p < 0.01.
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Figure R2 .4 . Analysis of hippocampal oscillations . (A) Mean power spectra of running episodes recorded at 
stratum radiatum (left) with mean group values for the theta and gamma band (right). (B) Mean power spectra of running episodes recorded at stratum lacunosum moleculare (left) with mean group values for the theta and gamma band (right). (C) Distribution of the spectral entropy and fast ripple index of all SWR events recorded from different groups. (D) Mean group histograms of spectral entropy of SWR show no overt differences. (E) Same for fast ripple 
index. (F) Mean traces of slow and fast SWR recorded from representative mice from each group.
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Figure R2.5. Sex specific interneuronopathy elicited by prenatal THC exposure requires CB₁ receptor locat-
ed on GABAergic neurons . (A) Representative images and quantification of CB₁R immunofluorescence in the sp of 
the CA1 region of Glu-CB₁R-KO, GABA-CB₁R-KO and CB₁Rf/f P60 mice prenatally exposed to THC or its vehicle. (n = 5 animals per group). (B) Quantification of CCK+ INs in the same animal groups. (n = 5 animals per group). Statistical comparison versus the corresponding vehicle group: **, p < 0.05; ***, p < 0.001. Statistical comparison versus the 
corresponding CB₁Rf/f vehicle group: ##, p < 0.01; ###, p < 0.001. Scale bar: 10 µm.
94
Results
males prenatally exposed to THC compared to vehicle-treated ones (Figure R2.5B), 
while CB₁Rf/f females exhibited comparable densities irrespective of treatment. Like-
wise, similar data were obtained in Glu-CB₁R-KO mice, whereas GABA-CB₁R-KO mice 
appeared refractory to THC impact in both males and females. Remarkably, condition-
al deletion of CB₁R in the GABAergic lineage per se led to a decrease in the density of 
CCK+ hippocampal INs, only reaching statistical significance in the male population. 
These findings demonstrate the involvement of CB₁R located on hippocampal GAB-
Aergic INs as a main cellular substrate for the sex-dimorphic impact of embryonic 
THC exposure.
R2.4. Cell-type specific sex dimorphism of CB₁R signalling is critical for adult 
hippocampal functionTo unequivocally identify the neuronal population responsible for the prenatal 
THC-induced cognitive impairment, we performed the NOR and OL tests in condi-
Figure R2 .6 . Hippocampal-dependent spatial memory, but no object recognition memory, is altered by pre-
natal THC exposure specifically in males that preserve CB₁ receptor in GABAergic neurons. (A) Novel object 
recognition test was performed in Glu-CB₁R-KO, GABA-CB₁R-KO and CB₁Rf/f P60 mice, and a discrimination index 
was calculated for both males and females. (n = 5 animals per group). (B) Object location test was performed in the 
mentioned groups, a similar index was then calculated for males and females. (n = 5 animals per group). Statistical comparison versus the corresponding vehicle group: *, p < 0.05; **, p < 0.01. Statistical comparison versus the corre-
sponding CB₁Rf/f vehicle group: #, p < 0.05; ##, p < 0.01.
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Figure R2 .7 . THC-induced actions that depend on neurons other than GABAergic are not sex-dimorphic . A clas-
sical THC-induced cannabinoid tetrad experiment consisting on (A) analgesia, (B) hypothermia, (C) hypolocomotion, and (D) catalepsy, was analysed in vehicle and THC-treated Glu-CB₁R-KO, GABA-CB₁R-KO and CB₁Rf/f P60 male and 
female mice. (n= 5 animals per group). Statistical comparison versus the corresponding vehicle group: *, p < 0.05; **, p < 0.01; ***, p < 0.001. Statistical comparison versus the corresponding vehicle CB₁f/f group: #, p < 0.05; ###, p < 0.001. Statistical comparison versus the corresponding naive control group: $, p < 0.05; $$, p < 0.01; $$$, p < 0.001.
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tional CB₁R-deficient mice. Prenatal THC administration did not induce significant 
differences in the NOR task by sex or treatment in CB₁Rf/f and Glu-CB₁R-KO mice (Fig-
ure R2.6A). In contrast, we found robust spatial memory impairment in THC-treated 
CB₁Rf/f and Glu-CB₁R-KO male mice in the OL task (Figure R2.6B). THC exerted no 
effect in GABA-CB₁R-KO males, which exhibited worse spatial memory as compared 
to vehicle-treated CB₁Rf/f and Glu-CB₁R-KO males. Surprisingly, a different mechanism 
seems to operate in females, which exhibited an interaction between genotype and 
treatment. Interestingly, both vehicle-treated GABA-CB₁R-KO male and female mice 
presented impairment of conceptual memory (statistically significant only in males), 
which was not evident upon embryonic THC administration. Together, these data sup-
port a requirement of CB₁R signalling in developing GABAergic neurons for the ade-
quate maturation of CCK-dependent hippocampal function in male mice, and so point 
to remarkable sex-dimorphic actions of CB₁R signalling along development.
To further assess the specific involvement of CB₁R located on GABAergic INs in 
the sex-dimorphic developmental consequences of THC exposure, we analysed the 
impact of THC on the so-called “cannabinoid tetrad” that corresponds to well-estab-
lished CB₁R-mediated actions: hypothermia, hypolocomotion, analgesia, and catalep-
sy. These behavioural traits have been ascribed to CB₁R located on particular neuronal 
populations (Monory et al., 2007), and so they are informative of the status of CB₁R in those neurons. 
Regardless of sex or treatment, no differences were observed in THC-induced an-
algesia, a trait that relies on PNs located outside the neocortex (Figure R2.7A). More-
over, cannabinoid-induced hypothermia, which is mediated mainly by CB₁R on dorsal 
telencephalic glutamatergic neurons, did not reveal sex- or treatment-dependent ef-
fect in Glu-CB₁R-KO mice, but was differentially affected by treatment, in a non sex-di-
morphic way, in GABA-CB₁R-KO animals (Figure R2.7B). Regarding cannabinoid-in-
duced hypolocomotion, Glu-CB₁R-KO males prenatally exposed to THC exhibited an 
enhanced response to acute THC (Figure R2.7C), while no differences were found in 
females. Finally, the cataleptic effect of acute THC is believed to result from a complex 
and concerted action of THC on CB₁R located on neurons of the basal ganglia, as well as on principal serotonergic and noradrenergic cells (Monory et al. 2007). We found 
a sex dimorphic effect of acute THC on catalepsy as well as differential contribution 
of glutamatergic and GABA INs (Figure R2.7D). Noteworthy, GABA-CB₁R-KO females 
were resistant to embryonic THC action.
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Overall, our results reveal, on the one hand, a striking increase of CB₁R expression 
levels in FCD Type II, an enrichment that occurs selectively in neurons with overac-tive mTORC1 signalling. In addition, characterization of genomic DNA in dysplastic 
human brain resections unveiled the differential expression of three SNPs affecting the DAGLA gene in FCD Type II patients. Furthermore, pharmacological manipulation 
of organotypic slices from human resections demonstrated that CB₁R signalling con-
tributes to overactive mTORC1 signalling, one of the major hallmarks of the disease. 
Finally, altered maturation and integration of transiently CB₁R knocked-down PNs 
points to an abnormal wiring of cortical circuits that may contribute to an imbalance 
in excitation/inhibition.
On the other hand, our data confirm a pivotal and sex-dimorphic role of embryonic 
CB₁R in the development of hippocampal CCK-containing basket cell populations, as 
prenatal THC exposure led to a persistent interneuronopathy that affected only the 
male progeny. We also found a concomitant sex-dimorphic decrease in perisomatic 
CB₁R innervating pyramidal cells within the sp and a deficit in spatial memory, both persisting in the adulthood.
CB₁ receptor overexpression in focal cortical dysplasia. Cause or consequence?
Here we report highly increased CB₁R levels in BCs and DNs in FCD samples. As 
ECS activity is coupled to the mTORC1 signalling pathway both at early stages of neo-
cortex formation (Díaz-Alonso et al., 2015) and in the adult brain (Puighermanal et al., 
2009), it is important to address whether the overexpression of CB₁R is a direct con-sequence of an altered cellular state elicited by overactive mTORC1 or if, conversely, it 
can be one of the causes of mTORC1 overactivation. Gene expression assays indicated 
that CB₁R enrichment is not a direct consequence of an overactive mTORC1 pathway, 
pointing to other signalling events as up-regulators of CB₁R levels in this context.
We therefore analysed CB₁R downstream signalling in FCD-derived organotypic 
slices. The CB₁R agonist HU-210 was unable to further increase mTORC1 activation, 
suggesting that the pathway is already saturated. Nevertheless, the CB₁R inverse 
agonist rimonabant was as efficient as rapamycin in reducing S6 protein phosphor-
ylation, suggesting that a basal cannabinoid signalling tone sustains exacerbated 
mTORC1 activity in FCD Type II. It would be worth assessing whether this CB₁R-de-pendent mTORC1 overactivation contributes to epileptic activity or not, as dampening 
overactive CB₁R activity with rimonabant in other settings, as the Fmr1 knockout mice, 
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efficiently decreases not only exacerbated mTORC1 activity but also disease symptoms (Busquets-García et al., 2013; Navarro-Romero et al., 2019). In the adult brain, presyn-
aptic CB₁R engaged by retrograde eCBs constitutes an efficient regulatory mechanism 
of excessive neurotransmitter release. Hence, ECS signalling is a crucial pathway con-
trolling neuronal activity, and its activation or blockade modulates seizures and epi-lepsy development (Soltesz et al., 2015). It has been shown that patients with tempo-
ral lobe epilepsy have decreased CB₁R expression (Ludányi et al., 2008; Goffin et al., 
2011), and, likewise, selective loss of function of presynaptic CB₁Rs in PN populations 
in the mouse brain results in an imbalance of the excitatory/inhibitory tone and a higher susceptibility to seizures (Monory et al., 2006). Thus, the enrichment in CB₁R 
expression observed in FCD samples could also represent a compensatory mecha-
nism aimed to attenuate the imbalance of excitatory/inhibitory neuronal activity. As 
stated, ECS signalling is linked to mTORC1 stimulation, and, therefore, a deregulation 
in this compensatory ECS activity could become a drawback by further overactivating 
mTORC1 pathway.
The endocannabinoid system and the genetic origin of focal cortical dysplasia
Somatic mutations of mTOR signalling pathway, including upstream regulators as 
PI3K/Akt, TSC1, TSC2 and DEPDC5, have been recently found in FCD Type II (Jansen et al., 2015; Lim et al., 2015; Ricos et al., 2016). This led us to assess if a similar association with ECS-related mutations may be established. SNPs analyses and genomic DNA sequencing of the CNR1 exon did not reveal any mutation associated with FCD Type II. However, we con-
firmed the existence of a selective enrichment in three SNPs of the DAGLA gene, suggesting the potential involvement of 2-AG metabolism in FCD Type II. The impact of these DAGLA 
SNPs in 2-AG production is still unknown, as they correspond to non-coding regions of the gene. Nevertheless, DAGLA transcript levels were slightly reduced in FCD when compared to control tissue. This is important to note, as decreased 2-AG, either caused by diminished 
DAGLα levels or activity, may foster a CB₁R upregulation similar to that found in FCD sam-
ples. In addition, these results are in agreement with a recent study that described DAGLA 
polymorphisms associated with neurodevelopmental disorders and seizures in humans, 
while CNR1 polymorphisms were associated with pain sensitivity, sleep, memory deficit 
or anxiety, but not seizures (Smith et al., 2017). Bearing this in mind, although a clear link is far from being established, the possibility that some FCD cases could be associated to mutations in ECS genes may not be completely dismissed.
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The impact of transient loss of CB₁ receptor function in projection neuron 
maturation and excitabilityFCD Type II is believed to originate from the dorsal telencephalic progenitor pool 
and their excitatory neuronal progeny, the PNs (D’Gama et al., 2017). Noteworthy, in ex-
perimental models of MCDs mimicking mTORopathies, unbalanced deep and upper lay-
er neuronal development occurs as a consequence of aberrant expression of neural fate 
determinants. Hence, a contribution of CB₁R signalling to neural precursor alterations 
responsible for FCD Type II cannot be excluded, as during embryonic development, 
CB₁R controls the RGC-to-IP transition via mTORC1 signalling (Díaz-Alonso et al., 2015), deep cortical neuron differentiation (Mulder et al., 2008; Díaz-Alonso et al., 2012) and neuronal migration (Díaz-Alonso et al., 2017). A transient prenatal ablation of CB₁R as that used in this Thesis, results in ectopic neuron accumulations and increased seizure 
susceptibility. Here, we targeted mPFC and observed a long-term effect in cortical cir-
cuit integration that was accompanied by an impaired neuronal maturation in the siR-NA-targeted cells, subsequent to a delay in neuronal migration. As the developing brain 
is a tissue in constant change, we hypothesize that, as they travel, neurons delayed in 
migration are exposed to a different extracellular context than properly-migrating neu-
rons. The same applies for the context that delayed neurons would find when they final-
ly arrive to their laminar destination, for they can reach a layer in which afferents and 
efferents have been already formed. These different contexts may condition specific and 
divergent protein-expression profiles, which, in turn, may account for the alterations 
in electrophysiological properties we observed. Additionally, as CB₁R have been shown 
to modulate transcriptional activity in different developmental contexts (Díaz-Alonso 
et al., 2012; Alpár et al., 2014; Tortoriello et al., 2014) and CB₁R knockout mice show 
altered expression of synaptic activity-related markers, as enkephalin or glutamic acid 
decarboxylase (Steiner et al., 1999), it is worth to further investigate if CB₁R activity 
regulates the expression of proteins (i.e. ionic channels, neurotransmitter receptors, and others) that determine the electrophysiological behaviour and/or the synaptic activity 
of specific neuronal subpopulations.
Taken together, the consequences of our genetic manipulation resemble some traits 
found in FCD cases. Therefore, either hyper- or hypoactive CB₁R signalling during cor-tical development may have the potential to elicit cortical alterations, thus driving long-
term neuronal plasticity and abnormalities that underlie FCD hyperexcitability.
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The precise contribution of CB₁R activity to the hyperexcitable neuronal circuits 
of the dysplastic brain remain unknown. Among other mechanisms involved in FCD, decreased hyperpolarization-activated cation currents contribute to pyramidal lay-
er V hyperexcitability (Albertson et al., 2011) near dysplastic lesions. Interestingly, a 
particular pool of somatodendritic CB₁Rs can regulate Ih currents and this explains 
in turn some of the cognitive consequences of CB₁R signalling (Maroso et al., 2016). 
Ih current, which is determined by the presence of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, also determines the amplitude of voltage sag (Alb-ertson et al., 2017), a trait we have found altered at different time points upon siCB₁ 
IUE, further supporting a conceptual link between an ECS malfunction and miswired 
dysplastic circuits. Important to note, our analyses were restricted to the well-posi-
tioned neurons, those that finally reach their laminar destination. It would be of great 
interest to characterize misplaced neurons and elucidate whether they electrophysi-ologically behave as upper-layer neurons (their identity according to their birthdate) 
or deep-layer neurons (the compartment in which they stop their migration); and if 
they contribute to altered cortical excitability.
Ribosomal S6 protein phosphorylation: in search for a better treatmentRibosomal S6 protein is regulated by phosphorylation at multiple sites (Meyuhas, 
2015). S6 phosphorylation at Ser240/244 is selectively mediated by S6-kinases 1 and 2, providing a bona fide readout of mTORC1 upstream activation, whereas Ser235/236 
phosphorylation is regulated by different signalling pathways (cAMP/PKA, casein ki-
nase 1, MAPK-activated protein kinase-1 and mTORC1 via S6 kinases 1 and 2). Initial studies have revealed increased levels of S6 protein phosphorylated at Ser235/236 in FCD and TSC (Baybis et al., 2004; Aronica et al., 2007), which suggests that pathways other than mTORC1 may contribute to the increased levels found of pS6 in FCD, and that different mechanisms phosphorylating S6 protein may have different functional consequences in FCD (Ljungberg et al., 2006; Biever et al., 2015).
Considering the finding that CB₁R antagonism attenuates the phosphorylation of S6 protein at different amino acid residues (Ser235/236 and Ser240/244) in the same 
magnitude observed upon mTOR inhibition with rapamycin (Discussion Figure 1), this could indicate that the mTOR overactivation observed in FCD Type II samples requires 
the existence of active CB₁R signalling, although the precise crosstalk between CB₁R 
downstream effectors and the PI3K/Akt/mTOR altered context remains unknown. 
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Discussion Figure 1 . Findings previ-
ously observed are replicated when 
using anti-pS6 Ser235/Ser236, a 
non-selective for mTOR activity an-
tibody . (A) Representative immunoflu-
orescence images showing the presence 
of CB₁R in samples from FCD Type I, II 
and control brains, stained with an an-
ti-CB₁R antibody (red) and an anti pS6 Ser235/Ser236 antibody (green). High 
magnification images of CB₁R expres-
sion associated with S6 phosphorylation 
in FCD Type II are shown. (B) pS6+ cells 
were quantified in the dysplastic area and referred to total cell number (DAPI counterstaining). Control, FCD Type I and FCD Type II cases. (C) CB₁R+pS6+ 
double-labelled cells were quantified and referred to total pS6+ cells. Control, 
FCD Type I and FCD Type II cases (n= 6, 8 and 9, respectively). Statistical com-parison versus control samples: **, p < 0.01; ***, p < 0.001. Statistical compar-ison versus FCD Type I samples: ##, p < 0.01; ###, p < 0.001. (D, E) Organotypic 
cultures of FCD resections were cultured 7 days in vitro and exposed to HU-210 
(1 µM), and rapamycin (1 µM) for 90 minutes. (D) Representative images of 
immunofluorescence characterization 
with anti-pS6 Ser235/236 antibody. pS6+ cells were quantified and referred to the total number of cells revealed by DAPI counterstaining. (E) Western blot 
analysis of pS6 Ser235/236 was per-
formed in slice extracts after 90 min-
utes of incubation with HU-210 alone 
or together with SR141716 (25 µM), 
SR141716 alone or rapamycin (n= 4 
experiments). Statistical comparison 
versus vehicle samples: *, p < 0.05. Scale bars: A: low magnification: 25 µm; inset: 
10 µm. D: 50 µm.
106
discussionHence, regulation of cannabinoid signalling could constitute an attractive target for var-
ious mTORopathies. In the past years, CBD, a non-psychotomimetic cannabinoid with 
multiple targets, marketed as Epidiolex, has demonstrated its efficacy as antiepileptic 
drug in refractory epilepsies including TSC, Dravet and Lennox-Gastaut syndromes, and 
is under clinical trial for FCDs (Devinsky et al., 2016; Hess et al., 2016; Thiele et al., 2018).
Together with our previous findings (Mulder et al., 2008; Díaz-Alonso et al., 2012, 
2017), this Thesis reinforces the role of developmental CB₁R function in the correct establishment of cortical PN populations and highlight the pathological implication of altered developmental cannabinoid signalling in refractory epilepsy.
Impact of prenatal exposure to cannabinoids on GABAergic transmission: from 
laboratory animals to humansThe demonstration of a functional endocannabinoid signalling in modulating cru-cial neurodevelopmental processes (Galve-Roperh et al., 2013; Maccarrone et al., 2014) has contributed to the understanding of the consequences of prenatal cannabi-
noid exposure in developing neuronal circuits. In the present Thesis, we demonstrate 
that prenatal THC exposure exerts a sex-dimorphic interference with CCK-containing 
basket cell development, leading to a long-term interneuronopathy, altered hippo-campal function, and impaired spatial cognition. Our results are in partial agreement 
with previous findings showing that prenatal WIN-55,212-2 administration interferes 
with the development of CCK-containing basket cells, which in turn impacts feedfor-
ward and feedback inhibition, an effect that was associated with reduced social inter-action (Vargish et al., 2016). Likewise, WIN-55,212-2 administration during early and 
mid, but not late, adolescence interferes with maturation of GABAergic function, lead-
ing to layer V prefrontal cortex disinhibition (Cass et al., 2014). Hence, both perinatal 
and adolescent exposure to cannabinoids result in GABAergic hypofunction in animal 
models. Strikingly, a recent study demonstrated that lactational exposure to THC or 
WIN-55,212-2 delays the excitatory-to-inhibitory switch that GABAergic transmission undergoes during perinatal development, a process that is determined by a shift in 
the expression ratio of two ionic transporters: KCC2, which increases as development 
progresses, and NKCC1, which decreases (Scheyer et al., 2018).
In humans, among the neuropsychiatric traits induced by early cannabinoid expo-
sure, the increased risk of psychosis and schizophrenia has been mainly associated to 
GABAergic hypofunction (Volk and Lewis, 2016). Alternatively, cannabinoid-induced 
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remodelling and plasticity of GABAergic circuits can contribute to explain cognitive 
impairment, as CB₁R signalling is critical in modulating cognition and memory and 
hence cannabis use interferes with working and episodic memory (Curran et al., 
2016). Nevertheless, while in adult animals acute and chronic THC administration im-
pairs novel object recognition, our results indicate that embryonic THC exposure does not affect conceptual learning, but instead blunts spatial memory, and this occurs in a 
striking sex-dimorphic manner.
We did not find psychotic-like features in the THC-exposed offspring (startle re-
sponse and prepulse inhibition were unaffected; data not shown). One possible expla-
nation is that cannabinoid agonists used in the laboratory, as WIN-55,212-2, are likely to induce a stronger impact than THC and other phytocannabinoid molecules. Phyto-cannabinoids possess important differences in solubility, potency, and hence pharma-
cokinetic and pharmacodynamic behaviour from other synthetic cannabinoid drugs (e.g., WIN-55,212-2, HU-210). Moreover, different cannabinoid ligands contribute dif-
ferentially to biased CB₁R signalling and can target additional receptors and binding proteins (Al-Zoubi et al., 2019). Noteworthy, a severe cannabinoid-induced impair-
ment of cortical oscillations was observed upon administration of the WIN-55,212-2 compound (Cass et al., 2014; Raver and Keller, 2014). Hence, it would be desirable 
that, when attempting to extrapolate to humans the consequences of cannabinoid ex-
posure from experimental models based on small laboratory animals, exquisite care 
is taken in the pharmacological regulation strategy and the experimental design that 
were used. Evidence for the impact of sex-dimorphic cannabinoid prenatal exposure 
on human brain development is scarce, and its interpretation is extremely complex 
due to a wide array of confounding factors. Nonetheless, it has been suggested that 
early cannabinoid exposure may promote the development of aggressiveness differ-ently in girls and boys (Marroun et al., 2011).
CB₁ receptor, hippocampal function and spatial memory processing
At the circuit level, and consistent with the role of CCK-containing basket cells in 
hippocampal oscillations (Klausberger et al., 2005; del Pino et al., 2017), we found 
changes in the theta and the low ripple band exclusively in THC-treated male mice. As 
theta-nested gamma oscillations were not affected, we confirmed that these effects 
were frequency- and circuit-specific. Within the hippocampus, CB₁R differentially 
contributes to perisomatic inhibition of superficial versus deep CA1 pyramidal cells 
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of THC-treated males can be associated with the emerging concept of different micro-
circuit organization along the deep-superficial hippocampal sublayers (Soltesz and Losonczy, 2018; Valero and de la Prida, 2018).
At the cellular level, CCK-containing basket cells in the CA1 region are known to control the activity of place cells. These hippocampal pyramidal neurons encode 
the cognitive map of the surrounding space, and specific groups (or spatial units) of 
place cells fire when the individual is located in the specific spatial context they en-
code within the map (Moser et al., 2015). CCK-containing basket cells, which main-
tain a perisomatic tonic inhibition over place cells, determine when (and where) to 
suppress inhibition in order to permit the firing from specific place cells (del Pino et 
al., 2017). Thus, a reduced number of CCK-containing basket cells, as that observed in this Thesis, may condition a lesser ability to regulate clusters of place cells, sub-sequently reducing the number of spatial units. This, in turn, impairs spatial memo-
ry encoding and discrimination. Additionally, other groups have proposed that CB₁R controls spatial memory by regulating HCN channels and Ih current, an effect that is 
specific of CA1 superficial PNs (Maroso et al., 2016). Interestingly, the immediate/
early gene transcription factor NPAS4, whose expression is triggered in a sensory ex-
perience-driven manner, mediates recruitment of CCK-evoked cannabinoid inhibition (Hartzell et al., 2018). Thus, enriched environment may constitute a valuable strategy 
to counteract the detrimental consequences of prenatal cannabinoid exposure, as an alternative to ongoing studies aimed to prevent deleterious cannabinoid maladaptive plasticity by pharmacological manipulation (Vallée et al., 2014). Overall, our findings 
underline the influence that ECS signalling possess over spatial processing, and es-
tablish a connection between the observed THC-induced interneuronopathy and the decline in spatial memory. 
Sex-dimorphic trends in endocannabinoid system function
The findings presented here highlight the importance of addressing sex differences 
when investigating the neurodevelopmental changes induced by cannabis exposure and 
the functional consequences in the offspring (Sanchis-Segura and Becker, 2016). Males 
and females exhibit different expression levels for diverse ECS elements, and respond differently to THC (Rubino and Parolaro, 2011; Cuttler et al., 2016). In animal models, 
prenatal cannabinoid exposure induces sex-dimorphic changes in pyramidal neuron 
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action deficits (Bara et al., 2018). Our data show that sex-dimorphic and THC-induced 
CCK-containing basket cell interneuronopathy contributes to the observed spatial cog-nitive impairment.
Interestingly, there is a collection of different studies describing prenatal exposure to diverse chemicals or stressors that elicit deleterious consequences only in males, 
or with male-biased intensity (Sickmann et al., 2014; Chalkiadaki et al., 2019; Winter-bottom et al., 2019). This general trend could be explained by a generalist mechanism 
dependent on sex hormones and their concentration/functionality in the developing 
brain, although a specific mechanism underlying each prenatal insult may not be exclud-
ed. Brain-wide-mapping studies have recently revealed cell-type specific contributions 
to cortical and subcortical sexual dimorphism (Kim et al., 2017), suggesting that many 
effects should be identified at the system level.
CB₁ receptor-dependent cell-autonomous regulation of interneuron development
This Thesis demonstrates that conditional CB₁R ablation in the telencephalic IN 
lineage mimics the consequences of THC treatment, thus pointing to CB₁R downreg-
ulation as the main mechanism of THC action in the studied context. Repeated can-
nabinoid exposure in the immature brain results in functional antagonism of CB₁R 
Discussion Figure 2. Sex-dimorphic seizure susceptibility in CB₁R rescue mice. (A, B) Seizure susceptibility 
to subconvulsive doses of PTZ was determined in the offspring of mice that had been prenatally exposed to vehicle 
or THC [data taken from their original source (de Salas-Quiroga et al., 2015) and herein just segregated in males 
and females]. Latency to seizures was determined in CB₁R-RS, Glu-CB₁R-RS, GABA-CB₁R-RS and CB₁R-STOP, which 
express CB₁R globally, in the glutamatergic neuronal lineage, in the GABAergic neuronal lineage, or lack CB₁R ex-
pression, respectively. [n = (males: 9 and 9, vehicle- and THC-treated CB₁R-RS, respectively; 12 and 7, vehicle- and 
THC-treated CB₁R-STOP, respectively; 4 and 4, vehicle- and THC-treated Glu-CB₁R-RS, respectively; 4 and 6, vehi-
cle- and THC-treated GABA-CB₁R-RS, respectively); (females: 9 and 10, vehicle- and THC-treated CB₁R-RS, respec-
tively; 7 and 7 , vehicle- and THC-treated CB₁R-STOP, respectively; 5 and 2, vehicle- and THC-treated Glu-CB₁R-RS, 
respectively; 5 and 6, vehicle- and THC-treated GABA-CB₁R-RS, respectively)]. Statistical comparison versus the cor-responding vehicle group: *, p < 0.05. Statistical comparison versus the corresponding CB₁R-RS vehicle group: ##, p < 0.01; ###, p < 0.01. Statistical comparison versus the corresponding CB₁R-STOP vehicle group: $$$, p < 0.001.
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ket cells (present results). As a consequence of THC-elicited activation, CB₁R desensi-
tizes, and cannabinoid signalling becomes impaired, which favours the development 
of seizures and spatial cognitive deficits in a sex-dimorphic manner. In fact, post hoc 
sex-segregated analysis of a dataset in which both sexes were previously pooled (de Salas-Quiroga et al., 2015), further supports the involvement of GABAergic INs, but 
not PNs, in prenatal THC-induced hyperexcitability, as measured by PTZ-evoked sei-
zure susceptibility and by using a lineage-specific CB₁R-rescue mice model generated 
in a null background and subjected to a prenatal THC treatment similar to that used in the present Thesis (Discussion Figure 2). In summary, the study of functional con-
sequences (hyperexcitability, cognition, and other behavioural traits), in vivo electro-
physiological recordings, and neuron-lineage tracking in conditional CB₁R-deficient 
mice, as shown herein, provides a strong support to the idea that neurodevelopmental 
exposure to THC exerts selective actions in different neuronal populations with a re-
markable sex dimorphism.
Taken together, the results presented in this Thesis reinforce the pivotal role that ECS signalling possess in the development of both PNs and INs. We have demon-
strated that CB₁R disruption during embryonic periods may trigger long-term del-
eterious consequences, whose extent and severity depend on the specific neuronal 
population and the precise step of development that becomes targeted, as well as 
on the sex of the animal. Thus, our findings contribute to pave the way for the un-derstanding of the neurodevelopmental role of the ECS, and provide fundamental 
knowledge for evidence-based decision regarding the benefits and risks that the use 
of medical cannabis may imply, which is crucial when deciding if therapeutic canna-
bis may be chosen over other therapies when treating a specific condition.
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conclusions
The following conclusions summarize the main findings presented and discussed 
within this Doctoral Thesis:
I. Endocannabinoid signalling is altered in focal cortical dysplasia type II. In-
creased expression of the CB₁ receptor is associated with an overactivation of 
the mTORC1 pathway, which, in turn, is dampened upon CB₁ receptor antag-onism. Thus, the endocannabinoid system might be explored as a therapeutic target in this pathology. 
II. The existence of genetic polymorphisms affecting the DAGLA gene in focal cor-
tical dysplasia type II suggests that a causal link between early disrupted endo-
cannabinoid function and the onset of the disease might not be excluded.
III. The CB₁ receptor participates in the maturation of neocortical projection neu-rons, as a transient developmental loss of its function fosters a delay in cell migra-
tion. This delay occurs concomitantly with a long-term impairment of neuronal 
excitability.
IV. The endocannabinoid system regulates the establishment of CCK-containing interneurons in the hippocampus, since prenatal exposure to THC evokes a long-lasting interneuronopathy affecting this GABAergic subpopulation.
V. THC-elicited interneuronopathy, which relies exclusively on CB₁ receptors lo-cated on GABAergic neurons, shows a striking sex dimorphism, affecting solely 
the male progeny. This finding points to an endocannabinoid system-dependent 
regulation of interneuron development, which operates divergently among sexes.
VI. A correct endocannabinoid signalling during early development seems to be crucial for the proper acquisition of adult brain functions such as hippocampal 
oscillatory activity, spatial memory processing, and fine-tuned brain excitabi-
lity, as transient interference with prenatal endocannabinoid signalling exerts 
marked detrimental effects on them that persist in adulthood.
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The CB1 cannabinoid receptor signals striatal
neuroprotection via a PI3K/Akt/mTORC1/BDNF
pathway
C Blázquez1,2, A Chiarlone1,2, L Bellocchio1,2, E Resel1,2, P Pruunsild3, D García-Rincón1,2, M Sendtner4, T Timmusk3, B Lutz5,
I Galve-Roperh1,2 and M Guzmán*,1,2
The CB1 cannabinoid receptor, the main molecular target of endocannabinoids and cannabis active components, is the most
abundant G protein-coupled receptor in the mammalian brain. In particular, the CB1 receptor is highly expressed in the basal
ganglia, mostly on terminals of medium-sized spiny neurons, where it plays a key neuromodulatory function. The CB1 receptor also
confers neuroprotection in various experimental models of striatal damage. However, the assessment of the physiological
relevance and therapeutic potential of the CB1 receptor in basal ganglia-related diseases is hampered, at least in part, by the lack of
knowledge of the precise mechanism of CB1 receptor neuroprotective activity. Here, by using an array of pharmacological, genetic
and pharmacogenetic (designer receptor exclusively activated by designer drug) approaches, we show that (1) CB1 receptor
engagement protects striatal cells from excitotoxic death via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin
complex 1 pathway, which, in turn, (2) induces brain-derived neurotrophic factor (BDNF) expression through the selective
activation of BDNF gene promoter IV, an effect that is mediated by multiple transcription factors. To assess the possible functional
impact of the CB1/BDNF axis in a neurodegenerative-disease context in vivo, we conducted experiments in the R6/2 mouse,
a well-established model of Huntington’s disease, in which the CB1 receptor and BDNF are known to be severely downregulated in
the dorsolateral striatum. Adeno-associated viral vector-enforced re-expression of the CB1 receptor in the dorsolateral striatum of
R6/2 mice allowed the re-expression of BDNF and the concerted rescue of the neuropathological deficits in these animals.
Collectively, these findings unravel a molecular link between CB1 receptor activation and BDNF expression, and support the
relevance of the CB1/BDNF axis in promoting striatal neuron survival.
Cell Death and Differentiation advance online publication, 20 February 2015; doi:10.1038/cdd.2015.11
The CB1 receptor is the most abundant G protein-coupled
receptor in the mammalian brain.1 This receptor is engaged by
endocannabinoids, a family of prostanoid-like neural messen-
gers, as well as by Δ9-tetrahydrocannabinol (THC), the main
active component of the hemp plant Cannabis sativa.1–3
Endocannabinoid signaling serves as a major feedback
mechanismaimedat preventing excessive pre-synaptic activity,
thereby tuning the functionality and plasticity ofmany synapses.
In particular, the CB1 receptor is very highly expressed in
GABAergic terminals of the forebrain, where it mediates
endocannabinoid-dependent inhibition of GABA release.1
In concert with this well-established neuromodulatory
function, one of the most remarkable biological actions of
the CB1 receptor is to prevent neuronal death. This effect has
been reported in many different animal models of acute brain
damage and chronic neurodegeneration, and has raised hope
about the possible clinical use of cannabinoids as neuropro-
tective drugs.1,4–6 However, the assessment of the physiolo-
gical relevance and therapeutic potential of the CB1 receptor in
neurological diseases is hampered, at least in part, by the lack
of knowledge on the precise molecular mechanisms of CB1
receptor neuroprotective activity.5,7 It is well established that
CB1 receptor engagement inhibits excitotoxic neurotrans-
mission by blunting pre-synaptic glutamate release, and this
has been put forward as amajor event underlying CB1 receptor-
mediated neuroprotection.1,6,8,9 However, it is plausible that
additional processes contribute to the neuroprotective activity
of the CB1 receptor. Specifically, studies conducted in the
mouse and rat brain have reported a close association
between CB1 receptor activity and the expression of brain-
derived neurotrophic factor (BDNF),5,7 one of the master
neurotrophins in the mammalian forebrain.10 Moreover, acute
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intravenous administration of THC to healthy volunteers
increases BDNF levels in the serum,11 thus suggesting that
a CB1/BDNF connection could also exist in humans.
A putative CB1/BDNF connection might be particularly
relevant in the striatum, and influence their related motor
disorders (e.g., Huntington’s disease (HD) and Parkinson’s
disease), as, for example, (1) the CB1 receptor is highly
expressed in medium-sized spiny neurons (MSNs), the cells
that constitute ~ 90% of total striatal neurons, and plays a key
role in the control of motor behavior by basal ganglia
circuitry;4,12 (2) BDNF and its high-affinity receptor,
TrkB, exert a pivotal function in MSN generation, survival
and plasticity;13–15 and (3) striatal CB1 receptor,
16
BDNF17 and TrkB18 expression declines along disease
progression in animal models of HD, and restoration of CB1
receptor,19 BDNF20 or TrkB21,22 function prevents HD-like
neurodegeneration.
In spite of these concerted changes in CB1 receptor activity
and BDNF expression, no causative link between the two
events has been defined yet. Hence, here we sought to
establish a molecular connection between CB1 receptor
activation and BDNF expression in the striatum, and to assess
the possible neuroprotective relevance of this putative
CB1/BDNF axis.
Results
The CB1 receptor protects cultured striatal cells from
excitoxicity via PI3K/Akt/mTORC1/BDNF. The CB1 canna-
binoid receptor is a pleiotropic G protein-coupled receptor
that modulates various pathways potentially involved in the
control of cell survival such as phosphatidylinositol 3-kinase
(PI3K)/Akt, mitogen-activated protein kinases (extracellular
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK)
and p38) and cAMP/protein kinase A (PKA).23 To study the
mechanism of CB1 receptor-mediated neuroprotection, we
first used STHdhQ7/Q7 mouse striatal neuroblasts, a widely
used neuron-like cell line24 that expresses functional CB1
receptors.19 Cells were incubated with two paradigmatic
cannabinoid receptor agonists (THC, the major active
ingredient of marijuana, and HU-210, a highly-potent syn-
thetic derivative of THC) and evaluated how the aforemen-
tioned pathways were affected. Exposure of cells to
cannabinoids led to a rapid (15min) and transient (15–30min)
phosphorylation (activation) of Akt, which was followed by a
transient (30 min) phosphorylation (activation) of ribosomal
S6 protein, a canonical substrate of the Akt/mammalian
target of rapamycin complex 1 (mTORC1) pathway
(Figure 1a and Supplementary Figure S1a). This effect was
dose dependent (Supplementary Figure S1b). In contrast,
the phosphorylation status of ERK, JNK, p38 and PKA
substrates was not changed by cannabinoids (Figure 1a).
These findings prompted us to test the involvement of the
PI3K/Akt/mTORC1 pathway in CB1 receptor-mediated neuro-
protection. We used STHdhQ7/Q7 cells exposed to the
well-established excitotoxin N-methyl-D-aspartate (NMDA)
because the CB1 receptor is known to exert cytoprotection in
that experimental system.19 In agreement with some
authors,25,26 but, owing to unobvious reasons, in
disagreement with others,27 we could readily detect tran-
scripts encoding NMDA receptor subunits in STHdhQ7/Q7 cells
(threshold cycle (Ct) values: NR1, 35; NR2A, 35; NR2B, 27;
NR2C, 32; and NR2D, 34). These values support that NR2B
andNR2Cmight be responsible for NMDA-induced responses
in STHdhQ7/Q7 cells, and that these cells express very low
levels of other NMDA receptor subunits. Our STHdhQ7/Q7 cells
were sensitive to NMDA in a dose-dependent manner
(Supplementary Figure S2). From these dose-dependency
assays, which were similar to those previously reported by
Xifro et al.,26 we selected the standard dose of 1mMNMDA for
further experiments. THC and HU-210 rescued cells from
1-mM NMDA induced death, and blockade of PI3K (with
wortmannin), Akt (with Akti-1/2) or mTORC1 (with rapamycin)
abrogated cannabinoid-evoked cytoprotection (Figure 1b).
As BDNF plays a key protective role on MSNs, and an
association between BDNF expression and CB1 receptor
function occurs in several pathophysiological settings,5,7 we
examined the possible involvement of BDNF in cannabinoid-
induced neuroprotection. K252a, an inhibitor of the tyrosine
kinase activity of the BDNF receptor TrkB, abrogated THC-
and HU-210-induced neuroprotection (Figure 1c). A similar
preventive effect was observed when BDNF or TrkB expres-
sion was silenced with specific siRNAs (which diminished total
BDNF or TrkBmRNA levels to 29± 10% or 47± 10% of control
siRNA-transfected cells, respectively; n= 4–6 experiments,
Po0.01; Figure 1d). Likewise, the involvement of the PI3K/
Akt/mTORC1/BDNF axis in CB1 receptor-evoked neuropro-
tection was also evident (1) when quinolinic acid instead of
NMDA was used as excitotoxin (Supplementary Figure S3),
and (2) when primary mouse striatal neurons (Ct values of
NMDA receptor subunits: NR1, 28; NR2A, 31; NR2B, 26;
NR2C, 32; and NR2D, 30) instead of STHdhQ7/Q7 cells were
used as cellular model (Figure 1e). Specifically, the protective
effect of cannabinoids in those two experimental systems was
prevented by the CB1-selective antagonist SR141716 (rimo-
nabant) or upon blockade of the PI3K/Akt/mTORC1/BDNF
pathway (Supplementary Figure S3 and Figure 1e).
The CB1 receptor induces BDNF promoter IV via PI3K/
Akt/mTORC1. The BDNF gene consists of multiple promo-
ters and 5′ untranslated exons, together with a common 3′
protein-coding exon. After transcription and splicing, one of
the 5′ exons is joined to the single coding exon, therefore
resulting in different BDNF mRNA forms but an identical
BDNF protein.28,29 To obtain direct evidence for the CB1
receptor-mediated control of BDNF expression in STHdhQ7/Q7
cells, we evaluated the effect of cannabinoids on the best
characterized Bdnf gene promoters by using exon-specific
qPCR primers. THC upregulated total BDNF transcripts
(Ct=23) and, specifically, exon IV-containing BDNF
transcripts (Ct= 27; Figure 2a). Hence, Bdnf promoter
IV was subsequently studied in further detail. THC-induced
accumulation of exon IV-containing transcripts was mimicked
by HU-210 and prevented by SR141716 (Figure 2b).
As for cannabinoid-evoked neuroprotection (see above),
blockade of the PI3K/Akt/mTORC1 pathway prevented
the cannabinoid-induced increase of exon IV-containing
transcripts (Figure 2b).
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We next used additional approaches to substantiate a CB1
receptor-induced activation of BDNF promoter IV. (1) We
transfected STHdhQ7/Q7 cells with a construct that contains a
human BDNF promoter IV fused to the luciferase reporter
gene,30 and found that promoter IV activity was enhanced by
THC and HU-210, this effect being abrogated by blockade of
Akt or mTORC1 (Figure 2c). (2) BDNF protein levels, as
determined by ELISA in STHdhQ7/Q7 cell-culture extracts, were
also increased by THC and HU-210 in an Akt- and mTORC1-
dependent manner (Figure 2d). (3) We isolated primary mouse
striatal neurons and found thatCB1 receptor agonism increased
both exon IV-containing (Ct=29) and total BDNF transcripts
(Ct=27), as determined by qPCR (Figure 2e), aswell as BDNF
protein levels, as determined by western blot (Figure 2f; we
were unable to reliably quantify BDNF by ELISA in neuron-
culture supernatants). These neuron cultures had only ~5%
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Figure 1 The CB1 receptor protects cultured striatal cells from NMDA-induced excitoxicity via PI3K/Akt/mTORC1/BDNF. (a) STHdh
Q7/Q7 cells were incubated for the times
indicated with vehicle, 0.5-μM THC or 10-nM HU-210. Cells were lysed and western blot analyses were conducted. Quantification of mean optical density (O.D.) values relative to
those of loading controls (respective total proteins, or α-tubulin in the case of PKA phosphorylated substrates) as well as representative blots are shown (n= 3–4 experiments).
(b, c) STHdhQ7/Q7 cells were preincubated for 5 h in Locke’s solution with or without 1-mM NMDA together with vehicle, 0.5-μM THC, 10-nM HU-210, 0.2-μM wortmanin, 0.1-μM
Akti-1/2, 30-nM rapamycin and/or 25-nM K252a, and subsequently incubated for 24 h in NMDA-free medium. Relative cell viability is shown (n= 6–8 experiments). (d) STHdhQ7/Q7
cells were transfected with a non-targeted siRNA or with siRNAs directed against BDNF or TrkB, and subsequently incubated for 5 h with or without NMDA, THC and/or HU-210 as
in b. Relative cell viability is shown (n= 4–6 experiments). (e) Primary mouse striatal neurons were incubated for 30 min in Locke’s medium with or without 50-μM NMDA,
together with vehicle, 0.3-μM THC, 10-nM HU-210, 0.25-μM SR141716, 0.1-μM Akti-1/2, 20-nM rapamycin and/or 10-nM K252a, and subsequently incubated for 2 h in
NMDA-free medium. Relative cell viability is shown (n= 4–6 experiments). Data were analyzed using ANOVA with post hoc Student-Newman-Keuls test. *Po0.05 and
**Po0.01 from the corresponding vehicle-treated cells
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We next used additional approaches to substantiate a CB1
receptor-induced activation of BDNF promoter IV. (1) We
transfected STHdhQ7/Q7 cells with a construct that contains a
human BDNF promoter IV fused to the luciferase reporter
gene,30 and found that promoter IV activity was enhanced by
THC and HU-210, this effect being abrogated by blockade of
Akt or mTORC1 (Figure 2c). (2) BDNF protein levels, as
determined by ELISA in STHdhQ7/Q7 cell-culture extracts, were
also increased by THC and HU-210 in an Akt- and mTORC1-
dependent manner (Figure 2d). (3) We isolated primary mouse
striatal neurons and found thatCB1 receptor agonism increased
both exon IV-containing (Ct=29) and total BDNF transcripts
(Ct=27), as determined by qPCR (Figure 2e), aswell as BDNF
protein levels, as determined by western blot (Figure 2f; we
were unable to reliably quantify BDNF by ELISA in neuron-
culture supernatants). These neuron cultures had only ~5%
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Q7/Q7 cells were incubated for the times
indicated with vehicle, 0.5-μM THC or 10-nM HU-210. Cells were lysed and western blot analyses were conducted. Quantification of mean optical density (O.D.) values relative to
those of loading controls (respective total proteins, or α-tubulin in the case of PKA phosphorylated substrates) as well as representative blots are shown (n= 3–4 experiments).
(b, c) STHdhQ7/Q7 cells were preincubated for 5 h in Locke’s solution with or without 1-mM NMDA together with vehicle, 0.5-μM THC, 10-nM HU-210, 0.2-μM wortmanin, 0.1-μM
Akti-1/2, 30-nM rapamycin and/or 25-nM K252a, and subsequently incubated for 24 h in NMDA-free medium. Relative cell viability is shown (n= 6–8 experiments). (d) STHdhQ7/Q7
cells were transfected with a non-targeted siRNA or with siRNAs directed against BDNF or TrkB, and subsequently incubated for 5 h with or without NMDA, THC and/or HU-210 as
in b. Relative cell viability is shown (n= 4–6 experiments). (e) Primary mouse striatal neurons were incubated for 30 min in Locke’s medium with or without 50-μM NMDA,
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**Po0.01 from the corresponding vehicle-treated cells
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(n=3 cultures) of contaminating glial fibrillary acidic protein
(GFAP)-positive cells (assumed to be astroglia), and their
content in BDNF/GFAP-double-positive cells relative to total
BDNF-positive cells was negligible (Supplementary Figure S4).
(4) We prepared mouse-brain organotypic cultures and found
that THC increased striatal BDNF protein expression, as
evidenced by western blot and immunofluorescence
(Supplementary Figure S5).
Multiple transcription factors are involved in the CB1
receptor-mediated induction of BDNF promoter IV. We
next aimed at characterizing the specific regions of BDNF
promoter IV involved in the CB1 receptor-dependent control of
gene transcription. For this purpose, STHdhQ7/Q7 cells were
transfected with BDNF promoter IV-luciferase reporter con-
structs containing mutations in cis-elements that control
neuronal BDNF promoter IV upon different stimuli.30,31 The
cannabinoid-evoked activation of wild-type BDNF promoter IV
was not evident when mutations were introduced in (1) bHLH-
PAS transcription factor-response element (PasRE), to which
neuronal PAS domain protein 4 (NPAS4)-aryl hydrocarbon
receptor nuclear translocator 2 (ARNT2) dimers bind; (2) Ca2+
-response element 1 (CaRE1), to which calcium-responsive
transcription factor (CaRF) binds; (3) upstream stimulatory
factor-binding element (UBE), to which upstream stimulatory
factors (USFs) bind; (4) cAMP/Ca2+-response element (CRE),
to which cAMP response element-binding protein (CREB)
binds; (5) basic helix-loop-helix B2 (BHLHB2)-response
element (BHLHB2-RE); and (6) conserved E-box element 2
(cEbox2; Figure 3a). Cannabinoid action on BDNF promoter
IV was not affected when the NFκB-response element
(NFκB-RE) was mutated (Figure 3a).
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Figure 2 The CB1 receptor induces BDNF promoter IV via PI3K/Akt/mTORC1. (a) STHdh
Q7/Q7 cells were incubated for 15 h with vehicle or 0.5-μM THC and the levels of
BDNF transcripts with the indicated 5′ exons were determined (n= 3–4 experiments). (b) STHdhQ7/Q7 cells were incubated for 15 h with vehicle or 0.5-μM THC, 10-nM HU-210,
0.25-μM SR141716, 0.2-μM wortmannin, 0.1-μM Akti-1/2 and/or 30-nM rapamycin, and the levels of BDNF transcripts containing exon IV were determined (n= 3–4
experiments). (c) STHdhQ7/Q7 cells were transfected with a construct harboring a 0.5-kb human BDNF promoter IV fused to the luciferase reporter gene and subsequently
incubated for 15 h with 0.5-μM THC, 10-nM HU-210, 0.1-μM Akti-1/2 and/or 30-nM rapamycin. Relative promoter activity is shown (n= 4–6 experiments). (d) STHdhQ7/Q7 cells
were incubated for 24 h with vehicle or 0.5-μM THC,10-nM HU-210, 0.1-μM Akti-1/2 and/or 30-nM rapamycin, and the levels of BDNF protein were determined (n= 3–4
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shown). Data were analyzed using ANOVA with post hoc Student-Newman-Keuls test. *Po0.05 and **Po0.01 from the corresponding vehicle-treated cells
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To evaluate the involvement of the best-defined transcription
factors that bind to the aforementioned BDNF promoter IV
regulatory elements, we silenced the expression of NPAS4,
CaRF, USF and CREB with specific siRNAs and measured
cannabinoid-evoked activation of the wild-type BDNF
promoter IV. Knocking-down the expression of any of these
transcription factors abrogated the cannabinoid-induced
activation of BDNF promoter IV (Figure 3b), thus suggesting
that all of them are necessary for the latter process to occur.
Accordingly, CREB phosphorylation in its critical activatory
S133 residue was enhanced by cannabinoid challenge
(Figure 3c).
CB1 receptor antagonism attenuates BDNF upregulation
induced by pharmacogenetic activation of striatal
neurons. To evaluate the relevance of the CB1 receptor in
the physiological control of striatal BDNF expression, we
selectively manipulated MSN activity by the designer receptor
exclusively activated by designer drug (DREADD) pharma-
cogenetic technique. This tool is based on the molecular
evolution of muscarinic acetylcholine receptors, leading to a
Gq protein-coupled receptor with negligible affinity for the
native agonist (acetylcholine) but to which the pharmacolo-
gically inert agonist clozapine-N-oxide (CNO) binds with high
potency and efficacy,32 thus allowing the remote control of
neuronal activity in specific cell populations in vivo.33
First, we validated this experimental approach in vitro.
STHdhQ7/Q7 cells were nucleofected with a plasmid encoding
a DREADD-Gq (hM3Dq) fused to mCherry (or only mCherry)
and subsequently treated with CNO (or vehicle). CNO-
induced activation of hM3Dq led to an accumulation of both
exon IV-containing and total BDNF transcripts, and SR141716
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Figure 3 Multiple transcription factors are involved in the CB1 receptor-mediated induction of BDNF promoter IV. (a) STHdh
Q7/Q7 cells were transfected with a construct
harboring a WT 0.5-kb human BDNF promoter IV fused to the luciferase reporter gene or with the same construct containing mutations (m) in the indicated response elements
(RE). Cells were subsequently incubated for 15 h with vehicle, 0.5-μM THC or 10-nM HU-210. Promoter activity relative to vehicle incubations is shown (n= 4–6 experiments).
(b) STHdhQ7/Q7 cells were transfected with a non-targeted siRNA or siRNAs directed against the indicated transcription factors. After 24 h, they were transfected with the
aforementioned WT BDNF promoter IV reporter construct, and, after an additional 24-h period, cells were incubated with vehicle, 0.5-μM THC or 10-nM HU-210 for 15 h. Left:
promoter activity relative to vehicle incubations; right: knock-down (KD) efficacy of the siRNAs directed against the corresponding transcription factor (siTF; n= 4–6 experiments).
Data were analyzed using unpaired Student’s t-test. *Po0.05 and **Po0.01 from the corresponding vehicle-treated cells or siControl-transfected cells (b, left). (c) STHdhQ7/Q7
cells were incubated for 30 min with vehicle, 0.5-μM THC or 10-nM HU-210, lysed and used for western blot analyses. Quantification of mean optical density (O.D.) values of
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prevented this effect (Figure 4a). Next, we injected stereo-
tactically C57BL/6J mice with a recombinant adeno-
associated viral vector encoding hM3Dq-mCherry (or only
mCherry) into the dorsolateral (motor) striatum (Figure 4b).
The expression of the transgene was driven by the calcium/
calmodulin-dependent protein kinase II-α (CaMKIIα) promoter
in order to confine it to MSNs and avoid other cell populations
(e.g., interneurons and glia). Animals were subsequently
treated with CNO (or vehicle) in conditions that evoke neuronal
activation (one injection of CNO at 10mg/kg body weight).34
This procedure triggered the expression of exon IV-containing
and total BDNF transcripts in the striatum in situ, and, of note,
treatment with SR141716 (one injection at 1 mg/kg
body weight) produced per se the opposite effect to CNO
and attenuated the CNO-triggered upregulation of BDNF
expression (Figure 4b).
Pathophysiological relevance of CB1 receptor-mediated
striatal BDNF upregulation in HD. To assess the functional
impact of the CB1/BDNF axis in a neurodegenerative-disease
context in vivo, we used the R6/2 mouse, a well-established
model of HD.35 This devastating disease constitutes so far
the best paradigm to study the neuroprotective role of the
CB1 receptor as this receptor is highly expressed in the basal
ganglia by MSNs, the cells that constitute ~ 90% of total
striatal neurons and primarily degenerate in HD, and plays a
key role in the control of motor behavior, one of the processes
that is typically affected in HD.4,12 In addition, an early and
remarkable downregulation of CB1 receptor expression has
been documented as one of the most characteristic
neurochemical alterations of MSNs in HD animal
models36–38 and HD patients.39,40 Moreover, we19 and
others41 have provided genetic evidence for a neuroprotec-
tive role of the CB1 receptor in HD mouse models.
To test whether this neuroprotective effect relies on BDNF
signaling, we injected sterotactically 3.5- to 4-week-old R6/2
mice (or wild-type littermates) with a recombinant adeno-
associated viral vector encoding CB1 receptor (or empty vector)
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into the dorsolateral striatum. This procedure allowed the
subsequent re-expression of the CB1 receptor (Figure 5a) as
well as BDNF protein (Figure 5b), total BDNF mRNA
(Figure 5c; Ct= 26) and exon IV-containing BDNF mRNA
(Figure 5d; Ct=29). Reactivation of the CB1/BDNF axis also
normalized the HD-like molecular-pathology profile of these
animals, as determined by the recovered levels of the MSN
marker dopamine- and cAMP-regulated phosphoprotein of
32 KDa (DARPP-32; Figure 6a; confirmation by stereological
counting shown in Supplementary Figure S6), the
pan-GABAergic-neuron marker glutamic acid decarboxylase
67 kDa isoform (GAD-67; Figure 6b), the post-synaptic marker
post-synaptic density protein 95 (PSD-95; Figure 6c) and the
mTORC1-activity marker phosphorylated (activated) riboso-
mal S6 protein (Figure 6d). In addition, CB1 receptor re-
expression rescued striatal atrophy, the main neuropatho-
logical hallmark of HD, as determined by MRI analysis
(Figure 7). Cortical and hippocampal volumes, used as
controls, were not significantly different in 8-week-old
wild-type and R6/2 mice injected with CB1 receptor-encoding
or empty viral vectors (Supplementary Figure S7). (We note
that overexpression of the CB1 receptor in the striata of
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0 *
CB
1+
 
a
re
a
/to
ta
l n
u
cl
ei
 (a
.u.
)
BD
N
F+
 
a
re
a
/to
ta
l n
u
cl
ei
 (a
.u.
)
*
*
##
AAV-Empty
AAV-CB1
1.0
0.8
1.2
1.4
##
WT
R6/2
50µm
AAV-Empty AAV-HA-CB1 CB1 KO
AAV-Empty AAV-HA-CB1 BDNF KO
CB1 DAPI CB1 DAPI CB1 DAPIHA Merged
BDNF DAPI BDNF DAPI BDNF DAPIHA Merged
50µm
WT
0
0.2
0.4
0.6
**
R6/2
BD
N
F 
to
ta
l m
R
N
A 
(a.
u.)
BD
N
F-
IV
 m
R
N
A 
(a.
u.)
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
**
##
1.6
*
##
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Figure 5 Enforced re-expression of the CB1 receptor rescues BDNF expression in the striata of R6/2 mice. R6/2 mice (3.5–4 weeks old) and WT littermates were injected
stereotactically into the dorsolateral striatum with a recombinant adeno-associated virus (AAV) encoding HA-tagged CB1 receptor or the empty vector as control (n= 10–12
animals per group). At week 8 of age, animals were killed for histological and qPCR analyses in the striatum. (a) CB1 receptor immunoreactivity (relative values of CB1 receptor-
positive area/total cell nuclei). Slices from the dorsolateral striatum of CB1
− /− mice70 were used as control of staining specificity. Representative images are shown. (b) BDNF
immunoreactivity (relative values of BDNF-positive area/total cell nuclei). Slices from the dorsolateral striatum of neuron-specific, neurofilament L-conditional BDNF knockout
(Bdnffloxed/-;Nefl-Cre/+) mice (generated at Michael Sendtner’s laboratory, University of Würzburg, Germany) were used as control of staining specificity. Representative images are
shown. (c) Levels of total BDNF transcripts. (d) Levels of exon IV-containing BDNF transcripts. Data were analyzed using unpaired Student’s t-test. *Po0.05 and **Po0.01 from
the corresponding WT-empty group; ##Po0.01 from the corresponding R6/2-empty group
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into the dorsolateral striatum. This procedure allowed the
subsequent re-expression of the CB1 receptor (Figure 5a) as
well as BDNF protein (Figure 5b), total BDNF mRNA
(Figure 5c; Ct= 26) and exon IV-containing BDNF mRNA
(Figure 5d; Ct=29). Reactivation of the CB1/BDNF axis also
normalized the HD-like molecular-pathology profile of these
animals, as determined by the recovered levels of the MSN
marker dopamine- and cAMP-regulated phosphoprotein of
32 KDa (DARPP-32; Figure 6a; confirmation by stereological
counting shown in Supplementary Figure S6), the
pan-GABAergic-neuron marker glutamic acid decarboxylase
67 kDa isoform (GAD-67; Figure 6b), the post-synaptic marker
post-synaptic density protein 95 (PSD-95; Figure 6c) and the
mTORC1-activity marker phosphorylated (activated) riboso-
mal S6 protein (Figure 6d). In addition, CB1 receptor re-
expression rescued striatal atrophy, the main neuropatho-
logical hallmark of HD, as determined by MRI analysis
(Figure 7). Cortical and hippocampal volumes, used as
controls, were not significantly different in 8-week-old
wild-type and R6/2 mice injected with CB1 receptor-encoding
or empty viral vectors (Supplementary Figure S7). (We note
that overexpression of the CB1 receptor in the striata of
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Figure 5 Enforced re-expression of the CB1 receptor rescues BDNF expression in the striata of R6/2 mice. R6/2 mice (3.5–4 weeks old) and WT littermates were injected
stereotactically into the dorsolateral striatum with a recombinant adeno-associated virus (AAV) encoding HA-tagged CB1 receptor or the empty vector as control (n= 10–12
animals per group). At week 8 of age, animals were killed for histological and qPCR analyses in the striatum. (a) CB1 receptor immunoreactivity (relative values of CB1 receptor-
positive area/total cell nuclei). Slices from the dorsolateral striatum of CB1
− /− mice70 were used as control of staining specificity. Representative images are shown. (b) BDNF
immunoreactivity (relative values of BDNF-positive area/total cell nuclei). Slices from the dorsolateral striatum of neuron-specific, neurofilament L-conditional BDNF knockout
(Bdnffloxed/-;Nefl-Cre/+) mice (generated at Michael Sendtner’s laboratory, University of Würzburg, Germany) were used as control of staining specificity. Representative images are
shown. (c) Levels of total BDNF transcripts. (d) Levels of exon IV-containing BDNF transcripts. Data were analyzed using unpaired Student’s t-test. *Po0.05 and **Po0.01 from
the corresponding WT-empty group; ##Po0.01 from the corresponding R6/2-empty group
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wild-type mice did not lead to a significant upregulation of
BDNF or other markers of neuronal integrity/functionality. As
MSNs express very large amounts of CB1 receptors, it is
conceivable that the CB1 receptor-response system would be
essentially saturated in the normal setting but not in conditions
of restricted receptor function such as HD. In this regard,
agonist-stimulated [35S]GTPγS-binding studies have shown
that when higher expression levels of CB1 receptors occur, for
example, in the striatum versus other brain regions,42 in
GABAergic versus glutamatergic terminals43 or in CB1
+/+
versus CB1
+/− mice,44 the receptors couple with little efficacy
to G proteins, thus making signaling in CB1 highly expressing
systems refractory to stimulation by mere increases in total
receptor numbers.)
Finally, we analyzed a series of post-mortem human
caudate-putamen samples for concerted changes in CB1
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littermates were injected stereotactically into the dorsolateral striatum with a recombinant adeno-associated virus (AAV) encoding HA-tagged CB1 receptor or the empty vector as
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DARPP-32-positive cells/total cell nuclei). Representative images are shown. (b) GAD-67 immunoreactivity (relative values of GAD-67-positive area/total cell nuclei). (c) PSD-95
immunoreactivity (relative values of PSD-95-positive area/total cell nuclei). (d) Phospho-S6 immunoreactivity (relative values of pS6-positive cells/total cell nuclei). Data were
analyzed using unpaired Student’s t-test. *Po0.05 and **Po0.01 from the corresponding WT-empty group; #Po0.05 and ##Po0.01 from the corresponding R6/2-empty group
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Figure 7 Enforced re-expression of the CB1 receptor rescues HD-like striatal atrophy in R6/2 mice. R6/2 mice (3.5–4 weeks old) and WT littermates were injected
stereotactically into the dorsolateral striatum with a recombinant adeno-associated virus (AAV) encoding HA-tagged CB1 receptor or empty vector as control (n= 10–12 animals
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wild-type mice did not lead to a significant upregulation of
BDNF or other markers of neuronal integrity/functionality. As
MSNs express very large amounts of CB1 receptors, it is
conceivable that the CB1 receptor-response system would be
essentially saturated in the normal setting but not in conditions
of restricted receptor function such as HD. In this regard,
agonist-stimulated [35S]GTPγS-binding studies have shown
that when higher expression levels of CB1 receptors occur, for
example, in the striatum versus other brain regions,42 in
GABAergic versus glutamatergic terminals43 or in CB1
+/+
versus CB1
+/− mice,44 the receptors couple with little efficacy
to G proteins, thus making signaling in CB1 highly expressing
systems refractory to stimulation by mere increases in total
receptor numbers.)
Finally, we analyzed a series of post-mortem human
caudate-putamen samples for concerted changes in CB1
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receptor and BDNF immunoreactivity. In line with Zuccato and
Cattaneo,17 we found a significant reduction of CB1 receptor-
positive, BDNF-positive and CB1/BDNF-double-positive
neurons in HD patients compared to control subjects
(Supplementary Figure S8a). Western blot analyses, which
had previously shown a decrease in CB1 receptor protein
expression in caudate-putamen specimens of HD patients,19
evidenced a parallel reduction of BDNF protein expression in
those samples (Supplementary Figure S8b). This was
associated to a concomitant decrease in the levels of pCREB
(Supplementary Figure S8b), a key signaling marker of the
CB1/BDNF axis described above. These findings therefore
suggest that a functional link between the CB1 receptor and
BDNF could also occur in the human brain.
Discussion
Here we show that, in the mouse striatum, CB1 receptor
engagement upregulates BDNF expression, through which it
can confer neuroprotection against excitotoxicity in vitro and
mutant huntingtin-induced toxicity in vivo. On mechanistic
grounds, this CB1 receptor-mediated induction of BDNF gene
expression relies on the activation of the PI3K/Akt/mTORC1
pathway, which, in turn, targets BDNF promoter IV, a promoter
that is also responsive to various types of neuronal activity-
related stimuli in the mouse, rat and human BDNF
gene.10,29,30 The induction of BDNF promoter IV evoked by
the CB1 receptor-mediated activation of the PI3K/Akt/
mTORC1 pathway appears to be a complex process, as
several responsive elements and transcription factors are
involved. The observation that CREB is necessary for the CB1
receptor-mediated induction of BDNF promoter IV fits with the
pivotal role of this transcription factor in the regulation of BDNF
action.10,45 In fact, mice with a specific knock-in mutation
in the CRE of Bdnf promoter IV display impaired sensory
experience-induced expression of BDNF and defective deve-
lopment of cortical inhibitory circuits.46 It is thus conceivable
that the rapid and pleiotropic triggering of Ca2+-, cAMP-, ERK-
and/or Akt-related signals will converge in the immediate/early
activation of CREB and CaRF, which, by binding to CRE30 and
CaRE1,31,47 respectively, could initiate BDNF promoter IV
transcription. Of note, and in line with our data, the Ca2+ influx-
dependent early activation of CRE/CaRE3 (via CREB) and
CaRE1 (via CaRF) in the rat BDNF promoter IV is abrogated
by genetic or pharmacological blockade of PI3K signaling.31
Upon CREB and CaRF activation, at later time points other
transcription factors, such as NPAS4 via PasRE,30,48 could be
important for sustaining the transcriptional activity of BDNF
promoter IV under different conditions, including CB1 receptor
activation, as reported here.
The relation between CB1 receptor activation and BDNF
expression appears to be a region-specific process. Thus, this
association has been clearly established in the mouse
hippocampus by experiments involving CB1 receptor gain of
function (CB1 receptor pharmacological agonism) and loss of
function (CB1 receptor genetic inactivation, CB1 receptor
pharmacological antagonism) conducted in various in vitro
(tissue slices, cell cultures) and in vivo (whole mice)
experimental systems.8,49–54 In line with our present study in
the mouse dorsolateral striatum, THC administration
increased BDNF expression in the rat ventral striatum.55
However, and in striking contrast with the hippocampus and
the striatum, BDNF expression in the mouse cortex, which
expresses high levels of the CB1 receptor,
1 was unaffected by
either THC administration19,51 or CB1 receptor genetic
ablation,19,52 while another study found only very marginal
increases in BDNF levels in the medial prefrontal cortex and
the frontoparietal cortex upon THC injection to rats.55 Hence,
albeit for hitherto unknown molecular reasons, BDNF expres-
sion seems to be much more refractory to CB1 receptor
activation in the cortex than in the striatum or hippocampus.
This zonation of the CB1/BDNF axis in the brain is certainly
relevant in the context of our findings because MSNs are known
to receive BDNF from the cortex via the well-established
corticostriatal pathway.56 In addition, significant amounts of
BDNF mRNA have been found in the striatum, thus indicating
that striatal BDNF can also be produced in situ.19,29,57,58
Moreover, our DREADD experiments, by allowing the remote
and selective control of MSNactivity, provide robust evidence for
the activity-dependent production of BDNF in mouse MSNs
in vivo. Further support to this notion comes from the findings
that mutant huntingtin affects axonal transport of BDNF in
striatal neurons but not in cortical neurons,59 and that dopamine
receptor heteromers control BDNF production by striatal
neurons in situ.60 All these observations do not downplay the
corticostriatal pathway as a key source of BDNF for MSNs in the
normal brain. For example, in our hands, significant amounts of
BDNF transcripts are readily detected in the adult-mouse
striatum, but their levels are lower than those found in the
cortex (mRNA levels in the striatum relative to the cortex: total
BDNF, 24±2%; BDNF-IV, 20±4%; n=8 animals). However, it
is likely that, under particular pathophysiological situations,
BDNF production can increase in the striatum in situ, thereby
complementing the bulk supply of BDNF from the cortex with a
local –and thus spatially privileged- extra source of the
neurotrophin for MSNs. The multiple lines of evidence provided
by this study, together with the aforementioned lack of effect of
CB1 receptor activation on cortical BDNF expression, strongly
support that the CB1 receptor-mediated upregulation of striatal
BDNF is a striatum-autonomous effect rather than the conse-
quence of an enhanced anterograde supply of BDNF from the
cortex. Nonetheless, theCB1/BDNF connection inMSNs can be
more complex and be accompanied, for example, by a
reciprocal BDNF-dependent control of CB1 receptor function.
61
A key unanswered question in many neurodegenerative
diseases is what precise factors dictate the selective damage
of a particular neuronal population. Regarding HD, the disease
has long been known to be caused by an expanded
polyglutamine tract in the N-terminal domain of the huntingtin
protein,62 but the mechanisms by which MSNs are highly
vulnerable to mutant huntingtin are still incompletely under-
stood.We19 and others41 have provided genetic evidence for a
neuroprotective role of the CB1 receptor in two transgenic
models of HD, which could open similar studies on
other neurodegenerative diseases, such as Alzheimer’s
disease,63–65 in which CB1 receptor levels are known to be
downregulated during disease state. Unfortunately, the pre-
cise relevance of CB1 receptor and BDNF downregulation in
HD pathology are not completely understood. For example,
regarding the latter issue, Plotkin et al.66 have recently shown
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that, although reduced BDNF availability in the striatum may
contribute to HD pathology,17 a major pathogenic mechanism
seems to rely on an aberrant BDNF signaling via p75
neurotrophin receptors located on indirect-pathway MSNs,
which adds to the previously reported alterations of BDNF
signaling via TrkB.21,22 These possibilities notwithstanding,
here we cogently show that, in the striatum of the R6/2 mouse
in vivo, changes in CB1 receptor expression parallel changes
in the expression of BDNF and key markers of disease
neuropathology, thus supporting the notion that BDNF may be
a bona fide marker not only of HD neurodegeneration17 but
also of CB1 receptor-evoked neuroprotection.
Materials and Methods
Animals. Hemizygous male mice transgenic for exon 1 of the human huntingtin
gene with a greatly expanded CAG tract (R6/2 mice; 155–175 CAG repeats)35 and
wild-type littermates were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). C57BL/6J mice (Harlan, Barcelona, Spain) were used to obtain
organotypic and cell cultures, as well as to conduct DREADD experiments. Animals
were maintained as described.19 All animal handling procedures were approved by
the Complutense University Animal Research Committee in accordance with the
directives of the European Commission.
Cell cultures. Conditionally, immortalized mouse striatal neuroblasts expressing
wild-type huntingtin and infected with a defective retrovirus transducing the
temperature-sensitive A58/U19 large T antigen (designated as STHdhQ7/Q7 cells),24
were grown at 33°C in DMEM supplemented with 10% fetal bovine serum, 1 mM
sodium pyruvate, 2 mM L-glutamine and 400 μg/ml geneticin.
Primary striatal neurons were obtained from 2-day-old C57BL/6J mice using a
papain dissociation system (Worthington, NJ, USA). Striata were dissected and cells
were seeded on plates pre-coated with 0.1 mg/ml poly-D-lysine at 200 000 cells/cm2
in the Neurobasal medium supplemented with B27 and GlutaMax (Gibco, Carlsbad,
CA, USA).
Cell viability. STHdhQ7/Q7 cells were transferred to a serum-free medium for
24 h and incubated for a further 5 h in home-made Locke’s solution (154-mM NaCl,
5.6-mM KCl, 2.3-mM CaCl2, 3.6-mM NaHCO3, 5-mM HEPES (Lonza, Verviers,
Belgium), 20-mM glucose and 10-μM glycine), supplemented or not with NMDA,
together with the cannabinoid receptor agonists THC (The Health Concept,
Richelbach, Germany) or HU-210 (Tocris, Bristol, UK), the PI3K inhibitor
wortmannin (Sigma-Aldrich, Barcelona, Spain), the Akt inhibitor Akti-1/2
(Calbiochem, San Diego, CA, USA), the mTORC1 inhibitor rapamycin (Tecoland,
Irvine, CA, USA), the tyrosine kinase inhibitor K252a (Calbiochem) or the respective
vehicle (DMSO, 0.1–0.2% (v/v) final concentration). The medium was subsequently
replaced by NMDA/serum-free DMEM supplemented with the corresponding drugs,
and cell viability was determined after 24 h by the 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) test.
Another set of STHdhQ7/Q7 cell-viability experiments was conducted with quinolinic
acid (Sigma-Aldrich) as neurotoxic agent. STHdhQ7/Q7 cells were transferred to serum-
free DMEM for 24 h and subsequently incubated in this medium, supplemented or not
with quinolinic acid, together with THC, HU-210, the CB1-selective antagonist
SR141716 (rimonabant; kindly given by Sanofi-Aventis, Montpellier, France), Akti-1/2,
rapamycin and K252a, or the respective vehicle (DMSO, 0.1–0.2% (v/v) final
concentration) for 24 h. Cell viability was determined by the MTT test.
Primary C57/BL6J-mouse striatal neurons, grown for 2 days in vitro, were
incubated for 30 min in the aforementioned Locke’s solution, supplemented or not
with NMDA, together with THC, HU-210, SR141716, Akti-1/2, rapamycin and K252a,
or the respective vehicle (DMSO, 0.1–0.2% (v/v) final concentration). The medium
was subsequently replaced by NMDA-free Neurobasal medium supplemented with
B27 and GlutaMax (Gibco), plus the corresponding drugs, and cell viability was
determined after 2 h by the MTT test.
Cell transfection/nucleofection. Cells were transfected transiently with an
ON-TARGETplus SMARTpool mBdnf siRNA (Re. L-042566-00) or mTrkB
(= mNtrk2) siRNA (Re. L-048017-00), or a non-targeted SMARTpool siRNA
(Re. D-001810-10), using the DharmaFECT 1 transfection reagent (Thermo Fisher,
Lafayette, CO, USA).
For the luciferase reporter assays, cells were transfected transiently with
constructs expressing a 524-bp human BDNF promoter IV cloned into pGL4.15
(luc2P/Hygro), or the same promoter with mutated PasRE, CaRE, UBE, CRE,
BHLHB2-RE, NFκB-RE or cEbox II sites also cloned into pGL4.15 (luc2P/Hygro), as
described,30 using Lipofectamine 2000 (Invitrogen, Madrid, Spain). For normalization,
a renilla/pGL4.83 construct (driven by the thymidine kinase promoter) was
cotransfected. Luciferase assays were performed with the Dual-Glo luciferase assay
system (Promega Biotech Ibérica, Barcelona, Spain).
Other promoter activity experiments were conducted in cells transfected transiently
with ON-TARGETplus SMARTpool mNpas4 (Re. L-054722-01), mCarf (Re.
L-051736-01), mUsf1 (Ref. L-040656-00) or mCreb1 (Re. L-040959-01) siRNAs, or
the aforementioned non-targeted SMARTpool siRNA, using the DharmaFECT 1
transfection reagent (Thermo Fisher).
For DREADD experiments in vitro, cells were nucleofected with a construct
expressing the hM3Dq receptor fused to mCherry (kindly provided by Bryan L Roth,
University of North Carolina, Chapel Hill, NC, USA),34 or mCherry alone as control
vector, under the CAG promoter, by using an Amaxa mouse-neuron nucleofector kit
(Lonza, Madrid, Spain). Cells were treated in the serum-free medium, 2 days after
nucleofection, with CNO (or H2O as vehicle) plus SR141716 (or 0.1%DMSO as vehicle).
Organotypic cultures. Corticostriatal slices (300-μm thick) were obtained
from adult (8 weeks old) C57/BL6J mice, and cultured under semidry conditions in
the Neurobasal medium supplemented with B27 (1%), N2 (1%), glutamine (1%),
penicillin/streptomycin (1%), Fungizone (1%; Gibco) and ciprofloxacin (5 μg/ml), as
described.19 Slices were incubated for 24 h with THC or vehicle (DMSO, 0.1% (v/v)
final concentration) and subsequently fixed with formalin and processed in 15-μm
sections, which were analyzed at equivalent regions of the rostral to caudal axis.
Counting of BDNF and NeuN immunoreactivity (see below) was conducted in the
dorsolateral striatum in a 1-in-6 series per slice.
Real-time PCR. RNA was isolated using TRIzol reagent or RNeasy (Invitrogen,
Carlsbad, CA, USA). cDNA was obtained using Transcriptor (Roche, Basel,
Switzerland). Real-time PCR (qPCR) assays were performed using the FastStart
SYBR Green Master (Roche) and probes were obtained from the Universal Probe
Library Set (Roche). The mRNA levels of the different BDNF exons were determined
with previously described primers.29,30 Other primers used are shown in Supplementary
Table SI. Amplifications were run in a 7900 HT-Fast Real-time PCR system (Applied
Biosystems, Foster City, CA, USA). Relative gene expression data were determined by
the 2−ΔΔCt method. Each value was adjusted to β-actin levels as reference.
Viral vectors. HA-tagged rat CB1 cannabinoid receptor was subcloned in a rAAV
expression vector with a CAG promoter by using standard molecular cloning
techniques. Vectors were of an AAV1/AAV2-mixed serotype, and were generated by
calcium phosphate transfection of HEK293T cells and subsequent purification as
described.67,68 R6/2 mice (3.5–4 weeks old) and their wild-type littermates were
injected stereotactically with the viral vectors (in 1.5 μl PBS) into the dorsolateral
striatum. Each animal received one bilateral injection at coordinates (to bregma):
anteroposterior −0.5, lateral ± 1.4, dorso-ventral − 2.7. MRI analyses were
conducted at 8 weeks of age. Mice were subsequently killed by intracardial perfusion
and their brains were excised for immunofluorescence and qPCR analyses.
For DREADD experiments in vivo, 8-week-old male C57BL/6J animals were injected
stereotactically with viral vectors expressing the hM3Dq receptor fused to mCherry (or
mCherry as control) under a minimal CaMKIIα promoter into the dorsolateral striatum as
described before.9 Six weeks after surgery, animals were injected with SR141716 (1 mg/
kg body weight, i.p.) or vehicle (1% (v/v) DMSO in Tween 20 (Panreac, Barcelona,
Spain)/saline (1 : 18, v/v)) and, 10 min later, with CNO (10 mg/kg body weight, i.p.) or
vehicle (PBS). Animals were killed 4 h after the CNO injection, and their dorsolateral
striata were quickly dissected on ice and frozen at − 80°C for subsequent analyses.
Western blot. Western blot analysis was conducted with antibodies raised
against phosphorylated Akt (1 : 1000; Cell Signaling, Danvers, MA, USA), total Akt
(1 : 1000; Cell Signaling), phosphorylated S6 ribosomal protein (1 : 1000; Cell
Signaling), total S6 ribosomal protein (1 : 1000; Cell Signaling), phosphorylated
ERK (1 : 1000; Cell Signaling), total ERK (1 : 1000; Cell Signaling), phosphorylated
JNK (1 : 1000; Cell Signaling), total JNK (1 : 1000; Cell Signaling), phosphorylated p38
(1 : 1000; Cell Signaling), total p38 (1 : 1000 Cell Signaling), PKA phosphorylated
substrates (1 : 1000; Cell Signaling), phosphorylated CREB (1 : 1000, Cell Signaling),
total CREB (1 : 1000, Cell Signaling), BDNF (1 : 1000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), α-tubulin (1 : 4000, Sigma-Aldrich) and β-actin (1 : 4000,
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that, although reduced BDNF availability in the striatum may
contribute to HD pathology,17 a major pathogenic mechanism
seems to rely on an aberrant BDNF signaling via p75
neurotrophin receptors located on indirect-pathway MSNs,
which adds to the previously reported alterations of BDNF
signaling via TrkB.21,22 These possibilities notwithstanding,
here we cogently show that, in the striatum of the R6/2 mouse
in vivo, changes in CB1 receptor expression parallel changes
in the expression of BDNF and key markers of disease
neuropathology, thus supporting the notion that BDNF may be
a bona fide marker not only of HD neurodegeneration17 but
also of CB1 receptor-evoked neuroprotection.
Materials and Methods
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gene with a greatly expanded CAG tract (R6/2 mice; 155–175 CAG repeats)35 and
wild-type littermates were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). C57BL/6J mice (Harlan, Barcelona, Spain) were used to obtain
organotypic and cell cultures, as well as to conduct DREADD experiments. Animals
were maintained as described.19 All animal handling procedures were approved by
the Complutense University Animal Research Committee in accordance with the
directives of the European Commission.
Cell cultures. Conditionally, immortalized mouse striatal neuroblasts expressing
wild-type huntingtin and infected with a defective retrovirus transducing the
temperature-sensitive A58/U19 large T antigen (designated as STHdhQ7/Q7 cells),24
were grown at 33°C in DMEM supplemented with 10% fetal bovine serum, 1 mM
sodium pyruvate, 2 mM L-glutamine and 400 μg/ml geneticin.
Primary striatal neurons were obtained from 2-day-old C57BL/6J mice using a
papain dissociation system (Worthington, NJ, USA). Striata were dissected and cells
were seeded on plates pre-coated with 0.1 mg/ml poly-D-lysine at 200 000 cells/cm2
in the Neurobasal medium supplemented with B27 and GlutaMax (Gibco, Carlsbad,
CA, USA).
Cell viability. STHdhQ7/Q7 cells were transferred to a serum-free medium for
24 h and incubated for a further 5 h in home-made Locke’s solution (154-mM NaCl,
5.6-mM KCl, 2.3-mM CaCl2, 3.6-mM NaHCO3, 5-mM HEPES (Lonza, Verviers,
Belgium), 20-mM glucose and 10-μM glycine), supplemented or not with NMDA,
together with the cannabinoid receptor agonists THC (The Health Concept,
Richelbach, Germany) or HU-210 (Tocris, Bristol, UK), the PI3K inhibitor
wortmannin (Sigma-Aldrich, Barcelona, Spain), the Akt inhibitor Akti-1/2
(Calbiochem, San Diego, CA, USA), the mTORC1 inhibitor rapamycin (Tecoland,
Irvine, CA, USA), the tyrosine kinase inhibitor K252a (Calbiochem) or the respective
vehicle (DMSO, 0.1–0.2% (v/v) final concentration). The medium was subsequently
replaced by NMDA/serum-free DMEM supplemented with the corresponding drugs,
and cell viability was determined after 24 h by the 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) test.
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University of North Carolina, Chapel Hill, NC, USA),34 or mCherry alone as control
vector, under the CAG promoter, by using an Amaxa mouse-neuron nucleofector kit
(Lonza, Madrid, Spain). Cells were treated in the serum-free medium, 2 days after
nucleofection, with CNO (or H2O as vehicle) plus SR141716 (or 0.1%DMSO as vehicle).
Organotypic cultures. Corticostriatal slices (300-μm thick) were obtained
from adult (8 weeks old) C57/BL6J mice, and cultured under semidry conditions in
the Neurobasal medium supplemented with B27 (1%), N2 (1%), glutamine (1%),
penicillin/streptomycin (1%), Fungizone (1%; Gibco) and ciprofloxacin (5 μg/ml), as
described.19 Slices were incubated for 24 h with THC or vehicle (DMSO, 0.1% (v/v)
final concentration) and subsequently fixed with formalin and processed in 15-μm
sections, which were analyzed at equivalent regions of the rostral to caudal axis.
Counting of BDNF and NeuN immunoreactivity (see below) was conducted in the
dorsolateral striatum in a 1-in-6 series per slice.
Real-time PCR. RNA was isolated using TRIzol reagent or RNeasy (Invitrogen,
Carlsbad, CA, USA). cDNA was obtained using Transcriptor (Roche, Basel,
Switzerland). Real-time PCR (qPCR) assays were performed using the FastStart
SYBR Green Master (Roche) and probes were obtained from the Universal Probe
Library Set (Roche). The mRNA levels of the different BDNF exons were determined
with previously described primers.29,30 Other primers used are shown in Supplementary
Table SI. Amplifications were run in a 7900 HT-Fast Real-time PCR system (Applied
Biosystems, Foster City, CA, USA). Relative gene expression data were determined by
the 2−ΔΔCt method. Each value was adjusted to β-actin levels as reference.
Viral vectors. HA-tagged rat CB1 cannabinoid receptor was subcloned in a rAAV
expression vector with a CAG promoter by using standard molecular cloning
techniques. Vectors were of an AAV1/AAV2-mixed serotype, and were generated by
calcium phosphate transfection of HEK293T cells and subsequent purification as
described.67,68 R6/2 mice (3.5–4 weeks old) and their wild-type littermates were
injected stereotactically with the viral vectors (in 1.5 μl PBS) into the dorsolateral
striatum. Each animal received one bilateral injection at coordinates (to bregma):
anteroposterior −0.5, lateral ± 1.4, dorso-ventral − 2.7. MRI analyses were
conducted at 8 weeks of age. Mice were subsequently killed by intracardial perfusion
and their brains were excised for immunofluorescence and qPCR analyses.
For DREADD experiments in vivo, 8-week-old male C57BL/6J animals were injected
stereotactically with viral vectors expressing the hM3Dq receptor fused to mCherry (or
mCherry as control) under a minimal CaMKIIα promoter into the dorsolateral striatum as
described before.9 Six weeks after surgery, animals were injected with SR141716 (1 mg/
kg body weight, i.p.) or vehicle (1% (v/v) DMSO in Tween 20 (Panreac, Barcelona,
Spain)/saline (1 : 18, v/v)) and, 10 min later, with CNO (10 mg/kg body weight, i.p.) or
vehicle (PBS). Animals were killed 4 h after the CNO injection, and their dorsolateral
striata were quickly dissected on ice and frozen at − 80°C for subsequent analyses.
Western blot. Western blot analysis was conducted with antibodies raised
against phosphorylated Akt (1 : 1000; Cell Signaling, Danvers, MA, USA), total Akt
(1 : 1000; Cell Signaling), phosphorylated S6 ribosomal protein (1 : 1000; Cell
Signaling), total S6 ribosomal protein (1 : 1000; Cell Signaling), phosphorylated
ERK (1 : 1000; Cell Signaling), total ERK (1 : 1000; Cell Signaling), phosphorylated
JNK (1 : 1000; Cell Signaling), total JNK (1 : 1000; Cell Signaling), phosphorylated p38
(1 : 1000; Cell Signaling), total p38 (1 : 1000 Cell Signaling), PKA phosphorylated
substrates (1 : 1000; Cell Signaling), phosphorylated CREB (1 : 1000, Cell Signaling),
total CREB (1 : 1000, Cell Signaling), BDNF (1 : 1000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), α-tubulin (1 : 4000, Sigma-Aldrich) and β-actin (1 : 4000,
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Sigma-Aldrich), following standard procedures. Specifically, samples from cell cultures,
organotypic cultures and human post-mortem brains (obtained from the Banco de
Tejidos para Investigación Neurológica, Madrid, Spain, as previously described)19
were lysed in a buffer containing 50-mM Tris, 0.3% CHAPS, 1-mM EDTA, 1-mM
EGTA, 50-mM NaF, 10-mM sodium β-glycerophosphate, 5-mM sodium pyrophosphate
and 1-mM sodium orthovanadate (pH 7.5) supplemented with a protease inhibitor
cocktail (Roche, Madrid, Spain), 0.1-mM PMSF and 1-μM microcystin. The running
buffer consisted of 200-mM glycine, 25-mM Tris and 0.1% SDS (pH 8.3), and the
transfer buffer contained 200-mM glycine, 25-mM Tris and 20% methanol (pH 8.3).
Blots were incubated with Tris-buffered saline (20-mM Tris and 0.5-mM NaCl, pH 7.5)/
Tween 20 (0.05%) supplemented with 1% bovine serum albumin. Densitometric
analysis was performed with Quantity One software (Bio-Rad, Hercules, CA, USA).
Immunomicroscopy (mouse samples). Coronal free-floating sections
(30 μm-thick) were obtained from paraformaldehyde-perfused mouse brains.
Organotipic cultures were obtained as described before. Samples were incubated
with antibodies against CB1 cannabinoid receptor (1 : 500; Frontier Science, Hokkaido,
Japan), HA (1 : 500, Roche), BDNF (1 : 300; generated at Michael Sendtner’s
laboratory, University of Würzburg, Germany),19 DARPP-32 (1 : 1000; BD, Franklin
Lakes, NJ, USA), GAD-67 (1 : 250; Chemicon, Temecula, CA, USA), PSD-95 (1 : 1000,
Abcam, Cambridge, UK), phosphorylated S6 ribosomal protein (1 : 200; Cell Signaling)
or NeuN (1 : 400; Chemicon), followed by staining with the corresponding highly cross-
adsorbed Alexa Fluor 488, 594 or 647 antibodies (1 : 500; Molecular Probes, Leyden,
The Netherlands).19 GFAP was stained with an anti-GFAP-Cy3 antibody (1 : 1000,
Sigma-Aldrich). Samples were subsequently incubated with DAPI (1 : 10 000, Roche)
for 10 min, washed with PBS and mounted in Mowiol (Calbiochem, Madrid, Spain).
Counting of brain sections was conducted in the caudate-putamen area in a 1-in-10
series per animal, ranging from bregma +1.5 mm to − 0.5 mm coronal coordinates.
Data were calculated as immunoreactive area per total cell nuclei, except for
DARPP-32, phospho-S6 and NeuN, in which immunoreactive cells per total cell nuclei
were counted. Confocal fluorescence images were acquired using TCS-SP2 software
and a SP2 AOBS microscope (Leica, Wetzlar, Germany). Pixel quantification and co-
localization were analyzed with ImageJ software (National Institutes of Health,
Bethesda, MA, USA).
Stereological counting of the total number of DARPP-32-positive cells in the rAAV-
infected region of the mouse dorsolateral striatum (Supplementary Figure S6) was
performed in 30-μm-thick sections with the aforementioned DARPP-32/HA/DAPI
staining conditions and within the aforementioned coronal coordinates using the
optical fractionator method. A 1-in-8 series per animal was analyzed in an Olympus
BX61 microscope (Olympus, Tokyo, Japan) with newCAST software (Visiopharm,
Horsholm, Denmark). Volumes were calculated by applying the Cavalieri estimator.
The frame area was set to 5625 μm2 with a sampling interval of 240 μm at the x and y
level, and the optical dissector constituting a 13-μm-thick fraction of the total section
thickness. Results are expressed as number of DARPP-32-immunoreactive cells per
mm3 of rAAV-infected region. Gundersen’s coefficient of error was always below 0.1.
Immunomicroscopy (human samples). Paraffin-embedded post-mortem
4-μm-thick brain sections containing caudate-putamen were provided by the Tissue
Bank at Hospital Universitario Fundación Alcorcón (Madrid, Spain), and were obtained
and handled following the ethical guidelines of that institution. Samples (four sections
per individual) were obtained from HD donors (grades 3–4; n= 9; age (years old) and
sex: 55♂, 47♀, 45♂, 45♂, 51♂, 51♀, 44♂, 77♀ and 49♂) and control subjects with
no background of neuropsychiatric disease (n= 7; age (years old) and sex: 45♂,
62♀, 36♂, 74♂, 79♂, 75♀ and 69♂). For immunofluorescence analyses,69 sections
were incubated with anti-BDNF antibody (1 : 50; generated at Michael Sendtner’s
laboratory) and subsequently with Alexa Fluor 546 antibody (Molecular Probes).
Samples were then incubated with anti-CB1 cannabinoid receptor antibody (1 : 50;
Affinity Bioreagents, Golden, CO, USA), followed by incubation with Alexa Fluor 488
antibody (Molecular Probes), and finally incubated with DAPI (1 : 10 000) for 10 min
and washed with PBS. Then, sections were treated with 1% Sudan Black (Sigma-
Aldrich) in 70% ethanol to quench endogenous autofluorescence and finally mounted
in Mowiol.
ELISA. STHdhQ7/Q7 cells were transferred to the serum-free medium and
incubated with vehicle (DMSO, 0.1–0.2% (v/v) final concentration) or THC, HU-210,
Akti-1/2 and rapamycin for 24 h as described above. BDNF protein levels were
determined upon scraping the cell culture well and combining it with its medium by
using a BDNF ELISA System (Promega Biotech Ibérica).
Magnetic resonance imaging. The volume of the striatum, ventricles,
cortex (comprising somatosensory and motor areas) and hippocampus was
measured by magnetic resonance imaging in a BIOSPEC BMT 47/40 (Bruker,
Ettlingen, Germany) operating at 4.7 T as described.19
Statistics. Data are presented as mean±S.E.M. Statistical comparisons were
made by ANOVA with post hoc Student-Newman-Keuls test or by unpaired
Student’s t-test, as indicated in each figure legend.
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Prenatal exposure to cannabinoids evokes long-lasting
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developing cortical neurons
Adán de Salas-Quirogaa,b,c,1, Javier Díaz-Alonsoa,b,c,1,2, Daniel García-Rincóna,b,c, Floortje Remmersd, David Vegaa,c,
María Gómez-Cañasa,b,e, Beat Lutzd, Manuel Guzmána,b,c, and Ismael Galve-Roperha,b,c,3
aCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28049 Madrid, Spain; bInstituto de Investigación Sanitaria
Ramón y Cajal (IRYCIS), 28034 Madrid, Spain; cDepartment of Biochemistry and Molecular Biology I, Complutense University, 28040 Madrid, Spain; dInstitute
of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, 55128 Mainz, Germany; and eDepartment of
Biochemistry and Molecular Biology III, Complutense University, 28040 Madrid, Spain
Edited by Leslie Lars Iversen, University of Oxford, Oxford, United Kingdom, and approved September 16, 2015 (received for review August 3, 2015)
The CB1 cannabinoid receptor, the main target of Δ9-tetrahydrocan-
nabinol (THC), the most prominent psychoactive compound of
marijuana, plays a crucial regulatory role in brain development as
evidenced by the neurodevelopmental consequences of its manip-
ulation in animal models. Likewise, recreational cannabis use during
pregnancy affects brain structure and function of the progeny.
However, the precise neurobiological substrates underlying the con-
sequences of prenatal THC exposure remain unknown. As CB1 sig-
naling is known to modulate long-range corticofugal connectivity,
we analyzed the impact of THC exposure on cortical projection
neuron development. THC administration to pregnant mice in a
restricted time window interfered with subcerebral projection
neuron generation, thereby altering corticospinal connectivity, and
produced long-lasting alterations in the fine motor performance of
the adult offspring. Consequences of THC exposure were reminis-
cent of those elicited by CB1 receptor genetic ablation, and CB1-null
mice were resistant to THC-induced alterations. The identity of em-
bryonic THC neuronal targets was determined by a Cre-mediated,
lineage-specific, CB1 expression-rescue strategy in a CB1-null back-
ground. Early and selective CB1 reexpression in dorsal telencephalic
glutamatergic neurons but not forebrain GABAergic neurons res-
cued the deficits in corticospinal motor neuron development of
CB1-null mice and restored susceptibility to THC-induced motor
alterations. In addition, THC administration induced an increase
in seizure susceptibility that was mediated by its interference with
CB1-dependent regulation of both glutamatergic and GABAergic
neuron development. These findings demonstrate that prenatal ex-
posure to THC has long-lasting deleterious consequences in the
adult offspring solely mediated by its ability to disrupt the neuro-
developmental role of CB1 signaling.
cannabis | CB1 cannabinoid receptor | corticospinal | neurodevelopment |
seizures
Recreational cannabis consumption during pregnancy canexert deleterious consequences in the progeny, including
anxiety, depression, psychosis risk, and cognitive and social im-
pairments (1, 2). In the last two decades, important advances in
our understanding of the endocannabinoid system have paved
the way to elucidate the particular neurobiological substrates
responsible for some cannabinoid-induced neurological alter-
ations in adult animals and humans (3). The currently accepted
scenario is that the CB1 cannabinoid receptor (CB1R), the
main target of marijuana-derived cannabinoids, is located
presynaptically and, upon engagement by endocannabinoids
[2-arachidonoylglycerol (2-AG) and anandamide], can act as a
key neuromodulatory and plasticity-tuning signaling platform
at many different mature synapses (4). In fact, CB1R constitutes
one of the most abundant and functionally relevant G protein-
coupled receptors in several regions of the adult mammalian
brain (3, 4).
Manipulation of CB1R function in animal models, either di-
rectly or indirectly, by modulating 2-AG or anandamide levels
through the main endocannabinoid-synthesizing [diacylglycerol
lipase (DAGL) α/β] or degrading enzymes [monoacylglycerol li-
pase (MAGL) and fatty acid amide hydrolase (FAAH)], in-
fluences key processes of forebrain development, including (i)
progenitor cell expansion and neurogenesis, (ii) neuronal and glial
specification, and (iii) axonal pathfinding (5–7). Alterations of
these developmental processes may conceivably underlie the
functional deficits observed in the offspring upon prenatal expo-
sure to THC. A crucial role has been assigned to CB1R in the
development of long-range axonal connectivity by regulating cor-
ticofugal axon navigation and fasciculation (8, 9). In particular,
CB1R is essential for subcerebral projection neuron development,
as it regulates the appropriate balance between the transcription
factors Ctip2 and Satb2 (10), which is responsible for corticospinal
motor neuron (CSMN) specification (11).
In this study, we modeled prenatal cannabis consumption in
mice to identify the particular neurodevelopmental substrates
responsible for cannabinoid-induced functional alterations that
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sumption constitutes a serious health concern. The psycho-
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gaging CB1 cannabinoid receptors. Despite the large knowl-
edge accumulated on how THC affects the adult brain, its
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remains obscure. This study demonstrates that remarkable
detrimental consequences of embryonic THC exposure on adult-
brain function, which are evident long after THC withdrawal,
are solely due to the impact of THC on CB1 receptors located on
developing cortical neurons. Our findings thus delineate the
risk of cannabis consumption during pregnancy and contribute
to identify precise neuronal lineages targeted by prenatal
THC exposure.
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The CB1 cannabinoid receptor, the main target of Δ9-tetrahydrocan-
nabinol (THC), the most prominent psychoactive compound of
marijuana, plays a crucial regulatory role in brain development as
evidenced by the neurodevelopmental consequences of its manip-
ulation in animal models. Likewise, recreational cannabis use during
pregnancy affects brain structure and function of the progeny.
However, the precise neurobiological substrates underlying the con-
sequences of prenatal THC exposure remain unknown. As CB1 sig-
naling is known to modulate long-range corticofugal connectivity,
we analyzed the impact of THC exposure on cortical projection
neuron development. THC administration to pregnant mice in a
restricted time window interfered with subcerebral projection
neuron generation, thereby altering corticospinal connectivity, and
produced long-lasting alterations in the fine motor performance of
the adult offspring. Consequences of THC exposure were reminis-
cent of those elicited by CB1 receptor genetic ablation, and CB1-null
mice were resistant to THC-induced alterations. The identity of em-
bryonic THC neuronal targets was determined by a Cre-mediated,
lineage-specific, CB1 expression-rescue strategy in a CB1-null back-
ground. Early and selective CB1 reexpression in dorsal telencephalic
glutamatergic neurons but not forebrain GABAergic neurons res-
cued the deficits in corticospinal motor neuron development of
CB1-null mice and restored susceptibility to THC-induced motor
alterations. In addition, THC administration induced an increase
in seizure susceptibility that was mediated by its interference with
CB1-dependent regulation of both glutamatergic and GABAergic
neuron development. These findings demonstrate that prenatal ex-
posure to THC has long-lasting deleterious consequences in the
adult offspring solely mediated by its ability to disrupt the neuro-
developmental role of CB1 signaling.
cannabis | CB1 cannabinoid receptor | corticospinal | neurodevelopment |
seizures
Recreational cannabis consumption during pregnancy canexert deleterious consequences in the progeny, including
anxiety, depression, psychosis risk, and cognitive and social im-
pairments (1, 2). In the last two decades, important advances in
our understanding of the endocannabinoid system have paved
the way to elucidate the particular neurobiological substrates
responsible for some cannabinoid-induced neurological alter-
ations in adult animals and humans (3). The currently accepted
scenario is that the CB1 cannabinoid receptor (CB1R), the
main target of marijuana-derived cannabinoids, is located
presynaptically and, upon engagement by endocannabinoids
[2-arachidonoylglycerol (2-AG) and anandamide], can act as a
key neuromodulatory and plasticity-tuning signaling platform
at many different mature synapses (4). In fact, CB1R constitutes
one of the most abundant and functionally relevant G protein-
coupled receptors in several regions of the adult mammalian
brain (3, 4).
Manipulation of CB1R function in animal models, either di-
rectly or indirectly, by modulating 2-AG or anandamide levels
through the main endocannabinoid-synthesizing [diacylglycerol
lipase (DAGL) α/β] or degrading enzymes [monoacylglycerol li-
pase (MAGL) and fatty acid amide hydrolase (FAAH)], in-
fluences key processes of forebrain development, including (i)
progenitor cell expansion and neurogenesis, (ii) neuronal and glial
specification, and (iii) axonal pathfinding (5–7). Alterations of
these developmental processes may conceivably underlie the
functional deficits observed in the offspring upon prenatal expo-
sure to THC. A crucial role has been assigned to CB1R in the
development of long-range axonal connectivity by regulating cor-
ticofugal axon navigation and fasciculation (8, 9). In particular,
CB1R is essential for subcerebral projection neuron development,
as it regulates the appropriate balance between the transcription
factors Ctip2 and Satb2 (10), which is responsible for corticospinal
motor neuron (CSMN) specification (11).
In this study, we modeled prenatal cannabis consumption in
mice to identify the particular neurodevelopmental substrates
responsible for cannabinoid-induced functional alterations that
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remain overt in adult animals. Administration of THC was con-
ducted during a restricted embryonic time window, coinciding with
the active period of glutamatergic neuron generation in the tel-
encephalon (11). To unequivocally assess the role of CB1R sig-
naling in THC-induced alterations, we used CB1R-deficient mice,
which were resistant to THC-induced developmental effects. Next,
by using a Cre-mediated, lineage-specific, CB1R expression-rescue
strategy in a CB1R-null background, we were able to selectively
rescue the deficits in CSMN development of CB1R-deficient mice
and, in turn, fully restore the susceptibility to THC-induced motor
alterations in adulthood. We also found that embryonic THC
exposure induced an increase in seizure susceptibility that was
mediated by CB1R present in developing dorsal telencephalic
pyramidal neurons and forebrain GABAergic neurons. Hence,
targeting CB1R with the most prominent marijuana-derived psy-
choactive compound in a particular neuronal population and time
frame during embryonic development can evoke remarkable long-
lasting neurological alterations.
Results
Prenatal THC Exposure Interferes with Cortical Projection Neuron
Development. To investigate the impact of prenatal THC expo-
sure on cortical development and to avoid the confounding
influence that the cannabinoid could exert during very early
gestational stages (12, 13), we administered one daily i.p. injection
of THC or its vehicle to pregnant wild-type mice from E12.5 to
E16.5. To minimize potential CB1R off-targets, a low dose of
THC (3 mg/kg) was used. Of note, maternal and neonate body
weight was unaffected by THC treatment, thus indicating that the
dose used did not induce deleterious effects on general physical
status. As the CB1R is essential for CSMN specification (10), the
effects of embryonic THC exposure on the developing cortex were
first assessed by quantifying the generation of subcerebral projection
neurons. Confocal immunofluorescence analysis of Ets-related
protein 81 (ER81), a bona fide marker of subcerebral projection
neurons (11), was performed in the treated offspring at P20. ER81+
neurons were decreased in THC-exposed animals compared with
their vehicle-treated controls (Fig. 1 A and B). The impact of THC
on CSMN development was also analyzed at the level of cortico-
spinal axon projections. For this purpose, we performed fluorescent
retrograde labeling (Red RetroBeads) from the cervical spinal cord
to unequivocally identify CSMNs (14) (Fig. 1C). Red-labeled so-
mata in deep cortical layer V were shown to express ER81, thus
confirming the validity of ER81 as an appropriate marker of
CSMNs (Fig. 1D). We also found a significant reduction in the
number of labeled CSMN somata in THC-treated mice compared
with their controls, pointing to an alteration of CSMN development
and subcerebral connectivity (Fig. 1 E and F).
Prenatal THC Exposure Induces Long-Lasting Alterations in Skilled
Motor Function and Seizure Susceptibility. To examine the func-
tional consequences of the impaired subcerebral projection neu-
ron development induced by prenatal cannabinoid exposure, we
first used the skilled reaching test, which allows the dissection of
CSMN-dependent motor function as reflected by the ability to
retrieve a pellet of palatable food with a forelimb through a nar-
row slit (15). To rule out potential unspecific developmental al-
terations in the offspring owing to maternal care induced by THC
administration (16), we used CB1
−/− females, devoid of the be-
havioral impact of THC, which were mated with heterozygous
CB1
+/− males. Therefore, we analyzed skilled motor function in
the CB1
+/− and CB1
−/− offspring. CB1
+/−mice have been shown to
exhibit an increased efficacy of agonist-induced G protein-coupled
receptor signaling, which becomes comparable to that of wild-type
CB1
+/+ mice, thus supporting the validity of this experimental
approach (17). THC-exposed CB1
+/− animals showed a significant
impairment in skilled motor function compared with their vehicle-
treated counterparts (Fig. 2A). Remarkably, CB1
−/− mice, which
consistently with our previous report showed an impairment in this
task compared with their vehicle-treated CB1
+/− littermates (10),
did not suffer from any worsening in their skilled motor perfor-
mance upon THC exposure (Fig. 2A). Importantly, neither the
number of trials (Fig. 2B) nor the success in unskilled conditions
was changed among groups, ruling out generalized motivational or
unspecific motor alterations in the observed skilled motor deficits.
Corticospinal function was also assessed with the staircase test,
and again, a decreased performance was evident in THC-exposed
CB1
+/− mice compared with their vehicle-treated controls (Fig.
2C). In addition, CB1
−/− control mice performed worse than their
CB1
+/− littermates, and THC treatment did not significantly worsen
their ability to reach the pellets. Control quantifications of un-
skilled reaching did not show significant differences among
groups (Fig. 2D). Altogether, these data demonstrate the CB1R
dependency of embryonic THC-evoked motor alterations.
Developmental THC administration induces alterations in
synaptic connectivity and plasticity (18, 19), but its long-lasting
functional consequences remain largely unknown. Therefore, we
analyzed whether seizure susceptibility was affected in the adult
offspring of THC-administered pregnant mice by using a penty-
lenetetrazole (PTZ) administration paradigm. Of note, latency to
seizures was significantly decreased in prenatally THC-exposed
CB1
+/− mice compared with their vehicle-treated counterparts
(Fig. 2E; 31.8 ± 1.4 and 37.0 ± 1.3 min, respectively; P < 0.01).
Fig. 1. Embryonic THC exposure impairs subcerebral projection neuron
development. (A) Subcerebral projection neurons in embryonically vehicle-
and THC-administered mice at P15 were stained with an anti-ER81 antibody
(n = 7 and 5, respectively). (B) ER81+ cell number was quantified and re-
ferred to the total cell number (DAPI) per cortical column. (C) CSMNs were
labeled by injecting retrogradelly transported red fluorescent beads (RetroBeads)
in the cervical spinal cord at P10. (D) Representative image showing Retro-
Bead colocalization with the subcerebral projection neuron marker ER81.
(E) Representative images of retrogradelly labeled somata in cortical layer V
at P15. (F) RetroBead-labeled somata per cortical column were quantified in
vehicle- and THC-exposed mice (n = 5 and 4, respectively). *P < 0.05, **P <
0.01 vs. vehicle-treated mice. [Scale bar, (A and E) 200 μm (Insets, 60 μm) and
(D) 10 μm.]
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remain overt in adult animals. Administration of THC was con-
ducted during a restricted embryonic time window, coinciding with
the active period of glutamatergic neuron generation in the tel-
encephalon (11). To unequivocally assess the role of CB1R sig-
naling in THC-induced alterations, we used CB1R-deficient mice,
which were resistant to THC-induced developmental effects. Next,
by using a Cre-mediated, lineage-specific, CB1R expression-rescue
strategy in a CB1R-null background, we were able to selectively
rescue the deficits in CSMN development of CB1R-deficient mice
and, in turn, fully restore the susceptibility to THC-induced motor
alterations in adulthood. We also found that embryonic THC
exposure induced an increase in seizure susceptibility that was
mediated by CB1R present in developing dorsal telencephalic
pyramidal neurons and forebrain GABAergic neurons. Hence,
targeting CB1R with the most prominent marijuana-derived psy-
choactive compound in a particular neuronal population and time
frame during embryonic development can evoke remarkable long-
lasting neurological alterations.
Results
Prenatal THC Exposure Interferes with Cortical Projection Neuron
Development. To investigate the impact of prenatal THC expo-
sure on cortical development and to avoid the confounding
influence that the cannabinoid could exert during very early
gestational stages (12, 13), we administered one daily i.p. injection
of THC or its vehicle to pregnant wild-type mice from E12.5 to
E16.5. To minimize potential CB1R off-targets, a low dose of
THC (3 mg/kg) was used. Of note, maternal and neonate body
weight was unaffected by THC treatment, thus indicating that the
dose used did not induce deleterious effects on general physical
status. As the CB1R is essential for CSMN specification (10), the
effects of embryonic THC exposure on the developing cortex were
first assessed by quantifying the generation of subcerebral projection
neurons. Confocal immunofluorescence analysis of Ets-related
protein 81 (ER81), a bona fide marker of subcerebral projection
neurons (11), was performed in the treated offspring at P20. ER81+
neurons were decreased in THC-exposed animals compared with
their vehicle-treated controls (Fig. 1 A and B). The impact of THC
on CSMN development was also analyzed at the level of cortico-
spinal axon projections. For this purpose, we performed fluorescent
retrograde labeling (Red RetroBeads) from the cervical spinal cord
to unequivocally identify CSMNs (14) (Fig. 1C). Red-labeled so-
mata in deep cortical layer V were shown to express ER81, thus
confirming the validity of ER81 as an appropriate marker of
CSMNs (Fig. 1D). We also found a significant reduction in the
number of labeled CSMN somata in THC-treated mice compared
with their controls, pointing to an alteration of CSMN development
and subcerebral connectivity (Fig. 1 E and F).
Prenatal THC Exposure Induces Long-Lasting Alterations in Skilled
Motor Function and Seizure Susceptibility. To examine the func-
tional consequences of the impaired subcerebral projection neu-
ron development induced by prenatal cannabinoid exposure, we
first used the skilled reaching test, which allows the dissection of
CSMN-dependent motor function as reflected by the ability to
retrieve a pellet of palatable food with a forelimb through a nar-
row slit (15). To rule out potential unspecific developmental al-
terations in the offspring owing to maternal care induced by THC
administration (16), we used CB1
−/− females, devoid of the be-
havioral impact of THC, which were mated with heterozygous
CB1
+/− males. Therefore, we analyzed skilled motor function in
the CB1
+/− and CB1
−/− offspring. CB1
+/−mice have been shown to
exhibit an increased efficacy of agonist-induced G protein-coupled
receptor signaling, which becomes comparable to that of wild-type
CB1
+/+ mice, thus supporting the validity of this experimental
approach (17). THC-exposed CB1
+/− animals showed a significant
impairment in skilled motor function compared with their vehicle-
treated counterparts (Fig. 2A). Remarkably, CB1
−/− mice, which
consistently with our previous report showed an impairment in this
task compared with their vehicle-treated CB1
+/− littermates (10),
did not suffer from any worsening in their skilled motor perfor-
mance upon THC exposure (Fig. 2A). Importantly, neither the
number of trials (Fig. 2B) nor the success in unskilled conditions
was changed among groups, ruling out generalized motivational or
unspecific motor alterations in the observed skilled motor deficits.
Corticospinal function was also assessed with the staircase test,
and again, a decreased performance was evident in THC-exposed
CB1
+/− mice compared with their vehicle-treated controls (Fig.
2C). In addition, CB1
−/− control mice performed worse than their
CB1
+/− littermates, and THC treatment did not significantly worsen
their ability to reach the pellets. Control quantifications of un-
skilled reaching did not show significant differences among
groups (Fig. 2D). Altogether, these data demonstrate the CB1R
dependency of embryonic THC-evoked motor alterations.
Developmental THC administration induces alterations in
synaptic connectivity and plasticity (18, 19), but its long-lasting
functional consequences remain largely unknown. Therefore, we
analyzed whether seizure susceptibility was affected in the adult
offspring of THC-administered pregnant mice by using a penty-
lenetetrazole (PTZ) administration paradigm. Of note, latency to
seizures was significantly decreased in prenatally THC-exposed
CB1
+/− mice compared with their vehicle-treated counterparts
(Fig. 2E; 31.8 ± 1.4 and 37.0 ± 1.3 min, respectively; P < 0.01).
Fig. 1. Embryonic THC exposure impairs subcerebral projection neuron
development. (A) Subcerebral projection neurons in embryonically vehicle-
and THC-administered mice at P15 were stained with an anti-ER81 antibody
(n = 7 and 5, respectively). (B) ER81+ cell number was quantified and re-
ferred to the total cell number (DAPI) per cortical column. (C) CSMNs were
labeled by injecting retrogradelly transported red fluorescent beads (RetroBeads)
in the cervical spinal cord at P10. (D) Representative image showing Retro-
Bead colocalization with the subcerebral projection neuron marker ER81.
(E) Representative images of retrogradelly labeled somata in cortical layer V
at P15. (F) RetroBead-labeled somata per cortical column were quantified in
vehicle- and THC-exposed mice (n = 5 and 4, respectively). *P < 0.05, **P <
0.01 vs. vehicle-treated mice. [Scale bar, (A and E) 200 μm (Insets, 60 μm) and
(D) 10 μm.]
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Consequently, a reduced PTZ cumulative dose was required to
induce generalized seizures in the THC-treated offspring (Fig. 2F;
THC vs. vehicle, 81.3 ± 4.1 and 96.0 ± 3.5 mg/kg, respectively; P <
0.01). This effect of prenatal cannabinoid administration was
reminiscent of the adult CB1
−/− mice phenotype, which displays
increased seizure susceptibility in the kainic acid model (20, 21).
Importantly, we found no further enhancement of PTZ suscepti-
bility in THC-treated CB1
−/− mice with respect to their vehicle-
treated counterparts, thus confirming the CB1R specificity of THC
action (Fig. 2F; THC vs. vehicle, 30.2 ± 0.7 and 30.1 ± 1.0 min,
respectively). Overall, the neuronal and functional analyses of
prenatally THC-administered mice showed a similar phenotype to
CB1R-null mice, thus indicating that embryonic THC exposure
interferes with the neurodevelopmental role of CB1R signaling.
Prenatal THC Exposure Transiently Impairs CB1R Signaling. We next
analyzed the consequences of prenatal THC administration on
CB1R expression. CB1R protein levels, as determined by Western
blot, were significantly down regulated in THC-treated embryonic
brains at E17.5 compared with controls (Fig. 3 A and C). Notably,
at a perinatal stage (P2.5), CB1R levels returned to those of the
vehicle condition (Fig. 3 B and D), indicating that CB1Rs are al-
tered only transiently in our embryonic THC-exposure paradigm.
The presence of functional plasma membrane-exposed CB1R was
next analyzed by the binding of the radioactively labeled CB1R
agonist [3H]CP-55,940. A reduced cannabinoid binding was ob-
served in the brains of THC-treated embryos at E17.5 (Fig. 3 E
and G), and its values recovered to the level of vehicle-treated
animals at P2.5 (Fig. 3 F and H). Overall, these findings support
that embryonic THC administration transiently disrupts appro-
priate CB1R function in the developing brain.
Neuronal Lineage-Specific CB1R Reexpression Selectively Rescues the
Behavioral Traits of Embryonic THC Exposure. To unequivocally de-
termine the neuronal identity of embryonic THC-exposure ac-
tions, we made use of a Cre-mediated, lineage-specific, embryonic
CB1R expression-rescue strategy in a CB1R-null background
(Stop-CB1 mice) (21). The selective expression of CB1R in dorsal
telencephalic glutamatergic neurons (Glu-CB1-RS mice) was
achieved by expressing Cre under the regulatory elements of the
Nex gene (21). In addition, we rescued CB1R expression in fore-
brain GABAergic neurons (GABA-CB1-RS mice) by using the
Dlx5/6-Cre mouse line (20). As a control, a global CB1R expression
Fig. 2. Embryonic THC exposure impairs corticospinal motor function.
(A and B) The skilled pellet-reaching test was evaluated in adult CB1
+/− and
CB1
−/− littermates prenatally exposed to vehicle or THC from E12.5 to E16.5.
The success ratio of pellets retrieved in the skilled paradigm (A) and the total
number of trials performed (B) were quantified [n = 11 and 8 (CB1
+/− vehicle-
and THC-treated mice, respectively); n = 6 and 4 (CB1
−/− vehicle- and THC-
treated mice, respectively)]. (C and D) Mice were subjected to the staircase
pellet-reaching test, and the sum of pellets retrieved from skilled steps (from
four to eight) was compared between vehicle- and THC-administered mice
(C). As a control, the number of pellets reached in unskilled steps 1–3 was
calculated (D) [n = 8 and 12 (CB1
+/− vehicle- and THC-treated mice, re-
spectively); n = 5 and 3 (CB1
−/− vehicle- and THC-treated mice, respectively)].
(E and F) THC- and vehicle-treated CB1
+/− and CB1
−/− mice were subjected to
a PTZ administration paradigm. Latency to tonic-clonic seizure appearance
after the first PTZ injection (E) and the cumulative dose of PTZ required (F)
were calculated [n = 15 and 18 (CB1
+/− vehicle- and THC-treated mice, re-
spectively); n = 13 and 11 (CB1
−/− vehicle- and THC-treated mice, re-
spectively)]. *P < 0.05, **P < 0.01 vs. vehicle-treated CB1
+/− mice.
Fig. 3. Embryonic THC exposure transiently down-regulates CB1Rs. (A–D)
CB1R protein levels were determined by Western blot in brain samples at
E17.5 (A and C) and P2.5 (B and D) after THC or vehicle administration from
E12.5 to E16.5. The optical density of the CB1R band was quantified and
normalized to β-actin [n = 9 and 6 (E17.5 vehicle- and THC-treated brain
samples, respectively); n = 7 and 7 (P2.5 vehicle- and THC-treated brain
samples, respectively)]. (E–H) Radiolabeled CP-55,940 binding was quantified
in coronal brain sections at E17.5 (E and G) and P2.5 (F and H) [n = 4 and 6
(E17.5 vehicle- and THC-treated brains, respectively); n = 8 and 8 (P2.5 vehicle-
and THC-treated brains, respectively)]. **P < 0.01 vs. vehicle-treated mice.
(Scale bar, 2 mm.)
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rescue approach driven by EIIa-Cre (CB1-RS) was also used (21).
Characterization of CB1R expression by immunofluorescence was
performed in the different mouse lines. In a Stop-CB1 mice-only
background, a nonspecific signal was detected, whereas in Glu-
CB1-RS and GABA-CB1-RS animals, CB1R immunoreactivity was
observed with a distinctive pattern of expression (Fig. 4 A–C). Glu-
CB1-RS mice at P2.5 revealed a significant CB1R expression in
descending corticofugal axons, whereas in GABA-CB1-RS mice a
prominent CB1R expression was observed in the immature hip-
pocampal formation (Fig. 4 A, A1–A4). Cortical CB1R expression
at P20 in Glu-CB1-RS mice appeared as scarce immunopositive
puncta, in agreement with the low expression of the receptor in
mature projection neurons (4), whereas most CB1R expression
corresponded to GABAergic neurons (Fig. 4 B, B1–B4). Double
immunofluorescence with VGLUT1 and VGAT, presynaptic
markers of glutamatergic and GABAergic terminals, respectively,
confirmed the selectivity of the CB1R expression-rescue strategy
(Fig. 4C). Thus, in Glu-CB1-RS mice, the small puncta of CB1R
did not colocalize with VGAT immunoreactivity, in agreement
with their presynaptic location in glutamatergic neurons (Fig. 4C).
To assess the reestablishment of the neurobiological substrate
of THC-induced alterations, we quantified the number of ER81-
positive cells in cortical layer V. Remarkably, in vehicle-treated
Glu-CB1-RS mice, the number of deep-layer ER81-positive cells
per cortical column was significantly rescued compared with
Stop-CB1 animals (96.8 ± 6.6 and 71.7 ± 4.9, respectively; P <
0.05), and in concert, Glu-CB1-RS mice gained susceptibility to
THC-induced impairment of subcerebral projection-neuron de-
velopment (73.2 ± 5.5; P < 0.05 vs. vehicle-treated Glu-CB1-
RS mice).
Once the lineage selectivity of the CB1R expression-rescue
strategy at the cellular level was proved, we investigated the
functional impact of embryonic THC exposure in adulthood.
THC or vehicle was administered to pregnant mice coming from
crosses of Stop-CB1 with Nex-Cre (Glu-CB1-RS) or Dlx5/6-Cre
(GABA-CB1-RS) animals, and their respective offspring were
analyzed at an adult age. CB1R reexpression in Glu-CB1-RS
mice, but not in GABA-CB1-RS mice, rescued the skilled motor
deficits of Stop-CB1 mice as assessed by both the skilled-reaching
test (Fig. 5A) and the staircase test (Fig. 5B). Global rescue of
CB1R expression in CB1-RS mice also abolished the skilled
motor deficits observed in Stop-CB1 mice. Overall, CB1R ex-
pression rescue in dorsal telencephalic glutamatergic neurons is
necessary and sufficient to confer THC susceptibility to corti-
cospinal motor function.
Finally, we also analyzed PTZ-induced seizure susceptibility in
the various CB1R expression-rescued mice. Stop-CB1 mice
showed a seizure-prone phenotype that was fully restored when
the CB1R was expressed systemically in CB1-RS mice, whereas
seizure susceptibility was partially restored in both Glu-CB1-RS
and GABA-CB1-RS (Fig. 5 C and D; latency to seizures in THC-
treated mice, Glu-CB1-RS vs. CB1-RS, 34.0 ± 5.0 and 42.7 ± 2.2 min,
respectively, P < 0.05; GABA-CB1-RS vs. CB1-RS, 33.6 ± 2.2
and 42.7 ± 2.2 min, respectively, P < 0.05; cumulative PTZ
dose, Glu-CB1-RS vs. CB1-RS, 90.0 ± 10 and 106.6 ± 5.1 mg/kg,
respectively, P < 0.05; GABA-CB1-RS vs. CB1-RS, 87.2 ±
6.6 mg/kg and 106.6 ± 5.1 mg/kg, respectively, P < 0.01). Notably,
upon THC administration, only CB1-RS mice showed increases
in seizure latency and PTZ cumulative dose, whereas no signifi-
cant differences were found among Stop-CB1, Glu-CB1-RS, and
GABA-CB1-RS mice (Fig. 5 C and D). These findings support the
notion that prenatal CB1R signaling in both glutamatergic and
GABAergic cell lineages is required for the appropriate balance of
neuronal activity.
Discussion
The present study reveals that embryonic THC exposure exerts
long-lasting consequences in the offspring owing to a transient
disruption of CB1R signaling that impedes the adequate tem-
porally and spatially confined function of the receptor in cortical
neuron development. Remarkably, the deleterious consequences
of prenatal THC exposure in the progeny are independent of the
classical neuromodulatory role of CB1R signaling in the adult
brain and emerge exclusively as a consequence of the transient
disruption of physiological CB1R signaling during prenatal de-
velopment, when synaptic neuronal activity is not yet established.
These findings provide previously unidentified preclinical evi-
dence for the risk of cannabis consumption during pregnancy.
Cannabis is, by far, the most commonly consumed illicit drug
during pregnancy in Western countries, and therefore its use
Fig. 4. Characterization of selective CB1R expression rescue in dorsal glu-
tamatergic neurons and forebrain GABAergic neurons. (A) Immunofluores-
cence analysis of CB1R reexpression driven by Nex (Glu-CB1-RS) (A3), Dlx5/6
(GABA-CB1-RS) (A4), or EIIa (CB1-RS) (A2) promoters in Stop-CB1 mice (A1)
was performed in P2.5 coronal brain sections. (B) Cortical CB1R expression
analysis in the same mouse strains was performed at P20 (B1–B4). (C) Double
immunofluorescence was performed with anti-CB1 antibody combined with
anti-VGLUT1 (C1–C4) or anti-VGAT (C1’–C4’) antibodies. Arrowheads point
to the glutamatergic CB1R signal, which is abundant in pyramidal neuron
fibers at P2.5 (A) and to scarce immunopositive puncta corresponding to
glutamatergic (VGLUT1-positive) terminals at P20 (B and C). Arrows point to
the abundant CB1R signal corresponding to GABAergic (VGAT-positive)
neurons within the hippocampal formation at P2.5 (A) and the mature
cortex at P20 (B and C). [Scale bars, (A) 200 μm, (B) 50 μm (Inset, 10 μm), and
(C) 5 μm.]
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constitutes a considerable public health issue (1, 2, 16). Over the
last few decades, longitudinal studies on human cohorts (1, 2), as
well as research using animal models (22), have addressed the
impact of early cannabinoid exposure in adulthood. The majority
of these studies suggest that early cannabinoid exposure sensitizes
the CNS to cognitive impairments, increases the risk of neuro-
psychiatric disorders such as schizophrenia and anxiety, induces
motor alterations, and enhances drug-addiction susceptibility (23–
25). Our findings show that exposure to low doses of THC in a
narrow temporal window during prenatal development negatively
impacts mouse cortical development, and this, in turn, has long-
term functional consequences on the mature offspring. Specifically,
we unequivocally identify the pool of CB1R located on developing
cortical glutamatergic neurons as the sole reason for the deficits in
corticospinal function induced by embryonic THC exposure.
The CB1R plays a pivotal neurodevelopmental role by trans-
ducing information from the endocannabinoid ligands present in
the neurogenic niche into the coordination of the intrinsic de-
velopmental program of developing neurons (6, 26). In agree-
ment, early developmental exposure of chicken embryos to a
THC analog (27) and genetic manipulation of the CB1R-inter-
acting protein CRIP1 (28) have been shown to disrupt the ap-
propriate balance of transcription factors that intrinsically drive
neuronal development. Thus, CB1R signaling refines the mo-
lecular, laminar, and hodological identity of projection neurons
in the pre- and postnatal cerebral cortex (5, 6). The present
findings support that THC can act as a functional suppressor of
CB1R signaling, as restricted exposure to THC interferes with
developmental CB1R function in a transient but functionally
impacting manner. Therefore, prenatal cannabinoid exposure
recapitulates the long-term structural and functional deficits in
corticospinal connectivity previously demonstrated in CB1R-
knockout mice (10). The susceptibility of axonal connectivity to
embryonic CB1R loss of function (present report) may persist at
later developmental stages in critically susceptible areas, as it has
been demonstrated that THC consumption in adolescents can
also result in axonal connectivity deficits (29). Nevertheless, in
another study, daily marijuana consumption did not induce vol-
umetric changes in several brain areas (30).
Our findings are in partial agreement with a previous study
reporting that chronic prenatal THC administration alters neu-
ronal connectivity by disrupting cytoskeletal dynamics in motile
axons. Specifically, prolonged THC administration (E5.5 to
E17.5) was shown to disrupt cannabinoid signaling by interfering
with 2-AG–metabolizing enzymes, MAGL, and DAGL, but did
not induce CB1R desensitization (18). In that study, the functional
consequences of chronic prenatal THC administration on axonal
projections were not determined. Manipulation of endocannabi-
noid levels in perinatal stages by chronic pharmacological in-
hibition of FAAH, the main anandamide-degrading enzyme,
induced depressive and cognitive impairment traits, despite the
fact that no specific neuronal development alterations could be
demonstrated (9). On the other hand, pharmacological inhibition
of MAGL increased 2-AG levels and induced axon fasciculation
alterations by interfering with Slit2/Robo1 signaling, but the
functional consequences of these actions remain unknown (31).
Other studies have also shown that perinatal cannabinoid admin-
istration induces cognitive deficits that can be linked to neuronal
transmission adaptations, particularly plasticity of glutamatergic
neuron activity (19, 25, 32, 33) and aberrant synaptic organization
(18, 34). In humans, prenatal cannabis exposure interferes with
executive function (2) and increases children’s depressive symp-
toms when excluding identified covariate factors such as maternal
tobacco use, education, and child composite IQ (35). Moreover,
prenatal cannabis exposure interferes with prefrontal cortex-me-
diated response inhibition as revealed by functional MRI, which
may reflect delayed cortical maturation (36). Thus, whereas it is
already known that postnatal cannabinoid exposure has negative
consequences on neurological functions in the adult brain (1), this
study unveils long-lasting functional neuronal alterations induced
by restricted prenatal cannabinoid administration that can be un-
equivocally ascribed to specific developing neuronal lineages. No-
tably, our findings reveal a direct impact of THC exposure on the
developing embryo that does not rely on indirect consequences of
maternal programming and that is evident without the requirement
of a second hit, as proposed for cannabis-induced risk of psychosis
(16). In any case, translating the long-term implications of de-
velopmental cannabis exposure into humans requires a very
stringent control of confounding factors (37, 38), and this is more
important when analyzing cognitive and psychiatric traits than
merely determining plastic adaptations of neuronal activity or
drug abuse sensitivity.
In addition to corticospinal motor function alterations, em-
bryonic THC exposure increased seizure susceptibility in adult
mice, even when CB1Rs return to normal levels shortly after
cessation of THC exposure. The neuromodulatory role of CB1R
in the mature brain exerts overall an anticonvulsant action (4). In
addition, great interest has recently emerged in the potential
application of cannabis preparations enriched in cannabidiol for
the management of pediatric epilepsy disorders such as Dravet
and Gaston–Leroux syndromes (39). However, results presented
herein demonstrate that THC interferes with the developmental
role of CB1R signaling and induces a proepileptogenic neural
Fig. 5. Selective CB1R expression rescue restores functional alterations and
reestablishes THC susceptibility in Stop-CB1 mice. (A and B) Skilled motor
activity was assessed by the skilled pellet-reaching (A) and staircase (B) tests
in adult CB1R-rescued mice [n = 15 and 15 (Stop-CB1 vehicle- and THC-treated
mice, respectively); n = 20 and 17 (CB1-RS vehicle- and THC-treated mice,
respectively); n = 9 and 6 (Glu-CB1-RS vehicle- and THC-treated mice, re-
spectively); n = 5 and 7 (GABA-CB1-RS vehicle- and THC-treated mice, re-
spectively)]. (C and D) Seizure susceptibility to subconvulsive doses of PTZ
was determined. Latency to seizures (C) and the cumulative dose of PTZ
required (D) are shown [n = 13 and 19 (Stop-CB1 vehicle- and THC-treated
mice, respectively); n = 18 and 19 (CB1-RS vehicle- and THC-treated mice,
respectively); n = 9 and 5 (Glu-CB1-RS vehicle- and THC-treated mice, re-
spectively); n = 9 and 8 (GABA-CB1-RS vehicle- and THC-treated mice, re-
spectively)]. *P < 0.05, **P < 0.01 vs. corresponding Stop-CB1 mice;
#P < 0.05,
##P < 0.01 vs. corresponding vehicle-treated group.
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circuitry configuration independently of its neuromodulatory
role in the adult brain. Our CB1R expression-rescue experiments
show that the THC-induced increase in PTZ-evoked seizure
susceptibility relies on alterations not only of projection neurons
but also of GABAergic neurons. Further investigations are
required to underscore the potential contribution of these and
perhaps other neuronal lineages targeted by prenatal cannabi-
noid exposure. In any event, our preclinical observations support
that although cannabis preparations can exert anticonvulsive
actions in children and adults, they can also enhance the risk of
seizures by suppressing CB1R signaling in the developing brain,
thus raising a note of caution that might be considered when the
potential therapeutic uses of cannabinoid-based medicines are
defined and regulated for pregnant women.
Materials and Methods
THC Administration. Ultrapure THC (≥99% HPLC; THC Pharm) was adminis-
tered i.p. to pregnant female mice at a final dose of 3 mg/kg for 5 consec-
utive days from E12.5 to E16.5.
Cellular Analyses and Behavioral Determinations. CSMN immunofluorescence
and retrograde labeling analyses were performed at P20. Skilled motor func-
tion (skilled-reaching and staircase) tests were carried out in 2-month-old mice
prenatally exposed to THC or its vehicle. Seizure susceptibility was assessed by
injecting PTZ (22.5 mg/kg) every 10 min until generalized seizures occurred.
CB1R Biochemical Characterization. CB1R levels were analyzed by Western blot as
well as binding of radiolabeled CP-55,940 in E17.5- and P2.5-treated brain samples.
Genetic CB1R Rescue. CB1R expression rescue was performed in Stop-CB1 mice
by using Nex-Cre, Dlx5/6-Cre, and EIIa-Cre–driven recombination (20, 21).
Immunohistological characterization of different CB1R-rescue mice was per-
formed in P2.5 and P20 brain samples. Corticospinal motor function as well as
seizure susceptibility were assessed in THC- and vehicle-treated 2-month-old
CB1R-rescue mice.
Animals. Experimental designs and procedures were approved by the Com-
plutense University Animal Research Committee in accordance with the Eu-
ropeanCommission regulations. All efforts weremade tominimize the number
of animals and their suffering throughout the experiments.
Additional experimental procedures are described in SI Materials and
Methods.
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Abstract
Neuronal migration is a fundamental process of brain development, and its disruption underlies devastating
neurodevelopmental disorders. The transcriptional programs governing this process are relatively well characterized.
However, how environmental cues instruct neuronal migration remains poorly understood. Here, we demonstrate that the
cannabinoid CB1 receptor is strictly required for appropriate pyramidal neuron migration in the developing cortex. Acute
silencing of the CB1 receptor alters neuronal morphology and impairs radial migration. Consequently, CB1 siRNA-
electroporated mice display cortical malformations mimicking subcortical band heterotopias and increased seizure
susceptibility in adulthood. Importantly, rescuing the CB1 deﬁciency-induced radial migration arrest by knockdown of the
GTPase protein RhoA restored the hyperexcitable neuronal network and seizure susceptibility. Our ﬁndings show that CB1
receptor/RhoA signaling regulates pyramidal neuron migration, and that deﬁcient CB1 receptor signaling may contribute to
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
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Animals
Experimental designs and procedures were approved by the
Complutense University Animal Research Committee in
accordance with the European Commission regulations. All
efforts were made to minimize the number of animals and
their suffering throughout the experiments. CB1
−/−, Nex-CB1
−/−
and Dlx5/6-CB1
−/− colony-founding mice were provided by Prof
B. Lutz (Johannes Gutemberg University, Mainz, Germany).
Mouse embryonic tissues were obtained upon timed mating as
assessed by vaginal plug observation (E0.5).
Immunoﬂuorescence and Confocal Microscopy
Cell proliferation was determined after intraperitoneal bromo-
deoxyuridine (BrdU) injection (50 μg/g body weight) of pregnant
females at E14.5. Coronal embryonic and postnatal brain slices
(14 and 30 μm thick, respectively) were processed as previously
described (Palazuelos et al. 2009; Díaz-Alonso et al. 2012).
Immunoﬂuorescence was performed, after blockade with 5%
goat serum, by overnight incubation at 4°C with the indicated
primary antibodies (see Supplementary Information).
In Situ Hybridization
Coronal sections (20 μm) of E16.5 and E17.5 embryonic mouse
brains were obtained and processed for ISH as described (Díaz-
Alonso et al. 2012) using antisense and sense CB1 riboprobes
(Marsicano and Lutz 1999). Further details are provided in
Supplementary Information.
In Utero Electroporation
The indicated siRNAs or expression constructs (see
Supplementary Information) were electroporated at a ﬁnal con-
centration of 10 μM or 1 μg/μl, respectively, into the lateral ven-
tricle of E13.5 or E14.5 embryos as described previously (Pacary
et al. 2011). All electroporations shown include a constitutive
GFP overexpression plasmid (pCAG-GFP) to allow proper
visualization.
Explant Migration Assays
Cortical explants were prepared from E14.5 embryonic fore-
brain slices. Brieﬂy, small cortical fragments of about 400 µm
were dissected with scalpel and incubated for 1 h in Minimum
Essential Medium Eagle EMEM (Lonza) containing 10% FBS, 1%
glucose at 37°C in 5% CO2. COS7 cell aggregates transfected
with the indicated expression vectors (see Supplementary
Information) were prepared by diluting a pellet of transfected
cells with Matrigel (BD) in a 1:1 proportion. After jelliﬁcation,
cell aggregates were cut with a scalpel in small cubes of
~600 µm. Subsequently, cortical explants were placed in a
Matrigel 3-dimensional matrix facing the corresponding COS7-
transfected cell aggregates. Cocultures were maintained in
Neurobasal culture medium (Gibco), supplemented with N2
(Millipore) and B-27 (Invitrogen) for 72 h, and then ﬁxed. Cell
migration from the explants was analyzed in 4 quadrants by
quantiﬁcation of cell nuclei counterstained with DAPI, and the
proximal/distal ratio with respect to the corresponding cell
aggregate was calculated.
RhoA Activity Measurement
Dorsal telencephali from E17.5 Nex-CB1
−/− and CB1
f/f littermates
were carefully dissected and directly processed for active RhoA
quantiﬁcation with the G-LISA kit (Cytoskeleton Inc.), following
the manufacturer’s instructions.
Susceptibility to PTZ
Mice were placed in Plexiglas cages and monitored by an
experimenter blinded to their treatment and genotype. PTZ
(Sigma-Aldrich) was dissolved in 0.9% saline and administered
intraperitoneally to mice at P60 at a concentration of 22.5mg/
kg every 10min until generalized seizures occurred. Seizure
severity was monitored as described (Manent et al. 2009; de
Salas-Quiroga et al. 2015). Mice placed in Plexiglas cages were
injected with the PTZ-containing solution every 10min, with
consecutive injections of PTZ until generalized seizures
occurred. This was considered the end of the experiment. All
the procedure was video-recorded and analyzed later by an
experimenter blinded to the experimental groups, who deter-
mined the precise moment of generalized seizure onset. There
was no statistically signiﬁcant difference in weight or sex ratio
between the different groups of mice.
Statistical Analysis
Results shown represent the means ± SEM, and the number of
independent experiments or biological samples is indicated in
every case. Statistical analyses were performed by Student–
Newman–Keuls post hoc test.
Experimental procedures are further described in
Supplementary Methods. That section includes a detailed
description of animal procedures, antibodies employed for
immunoﬂuorescence and confocal microscopy, ISH, sequences
of siRNAs and constructs employed in in utero electroporation
(IUE) and explant migration assays, adherent cortical progeni-
tor cell culture, quantitative PCR, immunoblot assays and data
analysis and statistics.
Results
Acute Cannabinoid CB1 Receptor Knockdown Blocks
Radial Migration
To evaluate the role of the CB1 receptor in neuronal migration,
we initially conﬁrmed CB1 receptor expression in the develop-
ing cortex at E17.5. CB1 receptor mRNA and protein show a gra-
dient with increased levels in postmitotic compartments of the
developing cortex, that is, the intermediate zone (IZ) and
the CP (Supplementary Fig. 1A–C), suggesting that CB1 receptor
expression is upregulated in newborn pyramidal neurons after
cell cycle exit and radial migration initiation (Mulder et al. 2008;
Díaz-Alonso et al. 2014). We also explored the presence of CB1
receptor in developing pyramidal neurons by combining CB1
ISH with Satb2 immunoﬂuorescence (Supplementary Fig. 1A,
right panel). Confocal analysis further conﬁrmed CB1 receptor
protein expression in immature Satb2+ pyramidal neurons in
E17.5 embryonic cortices, a large proportion of which are
undergoing radial migration at this developmental stage
(Supplementary Fig. 1C). During development, the CB1 protein
is enriched in axons of immature pyramidal neurons
(Supplementary Fig. 1C) (Berrendero et al. 1999; Mulder et al.
2008), making extremely difﬁcult to estimate the contribution
of somatic CB1 immunostaining in migrating neurons to the
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cortical development malformations leading to refractory epilepsy independently of its canonical neuromodulatory role in
the adult brain.
Key words: endocannabinoid system, epileptogenesis, radial migration, small GTPases, subcortical band heterotopia
Introduction
During development, cortical projection neurons are generated
in the ventricular and subventricular zones (VZ/SVZ), 2 prolif-
erative niches that surround the lateral ventricles. After exiting
cell cycle, pyramidal neurons undergo radial migration toward
the cortical plate (CP) to ﬁnally occupy their corresponding cor-
tical layer. Proper migration of neurons is essential as it estab-
lishes the basis for the subsequent wiring of the cortical
circuitry. Not surprisingly, brain organization abnormalities
emerge as a consequence of disrupted neuronal migration,
which can have devastating consequences on adult brain func-
tion, including mental retardation, cognitive disorders, and epi-
lepsy. Double cortex syndrome or subcortical band heterotopia
(SBH) is a type of migration disorder consisting in heterotopic
accumulations of cortical neurons within the subcortical white
matter (WM) (Valiente and Marín 2010; Barkovich et al. 2012).
SBH is believed to increase seizure susceptibility by causing
focal hyperexcitability of cortical areas directly connected with
the subcortical lesions (Shaﬁ et al. 2015).
Pyramidal neuron migration requires the adoption of differ-
ent morphologies along their transition through the various
cortical compartments (Noctor et al. 2004). Actin ﬁlaments and
microtubules control complementary aspects of neuronal
migration. Overall, the actin cytoskeleton plays an essential
role in cell polarization and leading process extension, while
the microtubular network is fundamental for nucleokinesis.
Nowadays, we know a number of genes encoding cytoskeletal
or cytoskeleton-associated proteins, such as TUBA1A,
Doublecortin (DCX) Lissencephaly-1 (LIS 1), and FilaminA,
whose mutations underlie severe human malformations of cor-
tical development (MCDs), including SBH, X-linked periven-
tricular heterotopia (PH) and lissencephaly (Barkovich et al.
2012). Additionally, Rho GTPases are crucial regulators of actin
cytoskeleton dynamics (Heasman and Ridley 2008) and there-
fore, several members of this protein family play a pivotal role
in neuronal migration (Govek et al. 2011; Azzarelli et al. 2014a).
Speciﬁcally, Rac1 and Cdc42 modulate different phases of cor-
tical neuron migration in a cell-autonomous fashion (Konno
et al. 2005), while RhoA exerts a key non-cell autonomous con-
tribution to pyramidal neuron migration, its expression being
required in radial glial cells but not in migrating neurons
(Cappello et al. 2012). The inactivation of RhoA emerges as a
critical requirement for the polarization of cortical projection
neurons during migration, and different cell-autonomous and
extrinsic factors converge in RhoA inhibition to promote migra-
tion (Hand et al. 2005; Nguyen et al. 2006; Pacary et al. 2011;
Tang et al. 2014; Azzarelli et al. 2014b). How promigratory extra-
cellular signals modulate the intrinsic regulators responsible
for neuronal migration is beginning to be understood.
Semaphorins, by acting through PlexinB2 receptors, modulate
RhoA activity to favor a promigratory cytoskeletal conﬁguration
(Azzarelli et al. 2014b). Some G protein-coupled receptors
(GPCRs), such as the GABAB receptor (Bony et al. 2013) and the
serotonin 5-HT6 receptor, also promote radial migration of pyr-
amidal neurons, in the latter case in a ligand-independent
manner (Jacobshagen et al. 2014). Other GPCRs have been
associated with neuronal migration disorders, for example
GPR56 with polymicrogyria, but their mechanism of action
remains unknown (Piao et al. 2004).
The cannabinoid CB1 receptor is a GPCR physiologically
engaged by a family of lipid ligands, the endocannabinoids
(eCBs), among which 2-arachidonoylglicerol (2-AG) and
N-arachidonoylethanolamine (anandamide) are the best
characterized. Besides its well-known neuromodulatory role
mediating retrograde suppression of neuronal activity at
adult synaptic terminals (Soltesz et al. 2015), the CB1 receptor
plays several roles during CNS development. The CB1 recep-
tor is expressed in the developing cerebral cortex, where it
controls the proliferation and phenotype of cortical neural
precursor cells (Díaz-Alonso et al. 2014), the speciﬁcation of
pyramidal neurons (Díaz-Alonso et al. 2012), and axon guid-
ance and synaptogenesis (Mulder et al. 2008; Vitalis et al.
2008; Keimpema et al. 2010; Argaw et al. 2011). In addition,
the CB1 receptor regulates neuronal migration in the embry-
onic brain (Mulder et al. 2008), and eCB signaling promotes
migration of newborn neurons along the rostral migratory
stream in the postnatal mouse brain (Oudin et al. 2011).
However, the molecular mechanisms and pathophysiological
implications of CB1 receptor signaling-mediated regulation of
pyramidal neuron migration remain unknown. Given that
cannabis is the most widely used illicit drug during preg-
nancy (Jutras-Aswad et al. 2009), deciphering how its main
molecular target—the CB1 receptor—signals in the develop-
ing brain is critical for understanding the neurobiological
processes potentially affected in the fetus upon cannabis
consumption during pregnancy.
In this study, we performed transient siRNA-mediated CB1
receptor knockdown in newborn pyramidal neurons to reveal
the impact of developmentally restricted, short-term CB1 recep-
tor loss of function in their migration. We observed a migration
arrest that led to profound and long-lasting alterations in cor-
tical neuron positioning, including SBH. Consequently, seizure
susceptibility was increased in adult mice. Biochemical and cel-
lular analyses showed that loss of CB1 receptor function led to
an abnormal RhoA protein accumulation in newborn pyramidal
neurons, thereby disrupting the morphology of migrating cells.
Remarkably, migration deﬁcits elicited by loss of CB1 receptor
function were fully rescued by RhoA knockdown. Collectively,
our ﬁndings pave the way toward a better understanding of the
physiological role of eCB signaling in brain development, and
provide relevant molecular mechanistic insights into human
MCDs caused by altered neuronal migration.
Materials and Methods
Materials
pCAG-DAGL expression vector and CB1 receptor in situ hybrid-
ization (ISH) probes (sense and antisense) were kindly provided
by Prof. Pat Doherty (Wolfson Age Research Center, London,
UK) and Prof. Beat Lutz (Johannes Gutemberg University, Mainz,
Germany), respectively.
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Animals
Experimental designs and procedures were approved by the
Complutense University Animal Research Committee in
accordance with the European Commission regulations. All
efforts were made to minimize the number of animals and
their suffering throughout the experiments. CB1
−/−, Nex-CB1
−/−
and Dlx5/6-CB1
−/− colony-founding mice were provided by Prof
B. Lutz (Johannes Gutemberg University, Mainz, Germany).
Mouse embryonic tissues were obtained upon timed mating as
assessed by vaginal plug observation (E0.5).
Immunoﬂuorescence and Confocal Microscopy
Cell proliferation was determined after intraperitoneal bromo-
deoxyuridine (BrdU) injection (50 μg/g body weight) of pregnant
females at E14.5. Coronal embryonic and postnatal brain slices
(14 and 30 μm thick, respectively) were processed as previously
described (Palazuelos et al. 2009; Díaz-Alonso et al. 2012).
Immunoﬂuorescence was performed, after blockade with 5%
goat serum, by overnight incubation at 4°C with the indicated
primary antibodies (see Supplementary Information).
In Situ Hybridization
Coronal sections (20 μm) of E16.5 and E17.5 embryonic mouse
brains were obtained and processed for ISH as described (Díaz-
Alonso et al. 2012) using antisense and sense CB1 riboprobes
(Marsicano and Lutz 1999). Further details are provided in
Supplementary Information.
In Utero Electroporation
The indicated siRNAs or expression constructs (see
Supplementary Information) were electroporated at a ﬁnal con-
centration of 10 μM or 1 μg/μl, respectively, into the lateral ven-
tricle of E13.5 or E14.5 embryos as described previously (Pacary
et al. 2011). All electroporations shown include a constitutive
GFP overexpression plasmid (pCAG-GFP) to allow proper
visualization.
Explant Migration Assays
Cortical explants were prepared from E14.5 embryonic fore-
brain slices. Brieﬂy, small cortical fragments of about 400 µm
were dissected with scalpel and incubated for 1 h in Minimum
Essential Medium Eagle EMEM (Lonza) containing 10% FBS, 1%
glucose at 37°C in 5% CO2. COS7 cell aggregates transfected
with the indicated expression vectors (see Supplementary
Information) were prepared by diluting a pellet of transfected
cells with Matrigel (BD) in a 1:1 proportion. After jelliﬁcation,
cell aggregates were cut with a scalpel in small cubes of
~600 µm. Subsequently, cortical explants were placed in a
Matrigel 3-dimensional matrix facing the corresponding COS7-
transfected cell aggregates. Cocultures were maintained in
Neurobasal culture medium (Gibco), supplemented with N2
(Millipore) and B-27 (Invitrogen) for 72 h, and then ﬁxed. Cell
migration from the explants was analyzed in 4 quadrants by
quantiﬁcation of cell nuclei counterstained with DAPI, and the
proximal/distal ratio with respect to the corresponding cell
aggregate was calculated.
RhoA Activity Measurement
Dorsal telencephali from E17.5 Nex-CB1
−/− and CB1
f/f littermates
were carefully dissected and directly processed for active RhoA
quantiﬁcation with the G-LISA kit (Cytoskeleton Inc.), following
the manufacturer’s instructions.
Susceptibility to PTZ
Mice were placed in Plexiglas cages and monitored by an
experimenter blinded to their treatment and genotype. PTZ
(Sigma-Aldrich) was dissolved in 0.9% saline and administered
intraperitoneally to mice at P60 at a concentration of 22.5mg/
kg every 10min until generalized seizures occurred. Seizure
severity was monitored as described (Manent et al. 2009; de
Salas-Quiroga et al. 2015). Mice placed in Plexiglas cages were
injected with the PTZ-containing solution every 10min, with
consecutive injections of PTZ until generalized seizures
occurred. This was considered the end of the experiment. All
the procedure was video-recorded and analyzed later by an
experimenter blinded to the experimental groups, who deter-
mined the precise moment of generalized seizure onset. There
was no statistically signiﬁcant difference in weight or sex ratio
between the different groups of mice.
Statistical Analysis
Results shown represent the means ± SEM, and the number of
independent experiments or biological samples is indicated in
every case. Statistical analyses were performed by Student–
Newman–Keuls post hoc test.
Experimental procedures are further described in
Supplementary Methods. That section includes a detailed
description of animal procedures, antibodies employed for
immunoﬂuorescence and confocal microscopy, ISH, sequences
of siRNAs and constructs employed in in utero electroporation
(IUE) and explant migration assays, adherent cortical progeni-
tor cell culture, quantitative PCR, immunoblot assays and data
analysis and statistics.
Results
Acute Cannabinoid CB1 Receptor Knockdown Blocks
Radial Migration
To evaluate the role of the CB1 receptor in neuronal migration,
we initially conﬁrmed CB1 receptor expression in the develop-
ing cortex at E17.5. CB1 receptor mRNA and protein show a gra-
dient with increased levels in postmitotic compartments of the
developing cortex, that is, the intermediate zone (IZ) and
the CP (Supplementary Fig. 1A–C), suggesting that CB1 receptor
expression is upregulated in newborn pyramidal neurons after
cell cycle exit and radial migration initiation (Mulder et al. 2008;
Díaz-Alonso et al. 2014). We also explored the presence of CB1
receptor in developing pyramidal neurons by combining CB1
ISH with Satb2 immunoﬂuorescence (Supplementary Fig. 1A,
right panel). Confocal analysis further conﬁrmed CB1 receptor
protein expression in immature Satb2+ pyramidal neurons in
E17.5 embryonic cortices, a large proportion of which are
undergoing radial migration at this developmental stage
(Supplementary Fig. 1C). During development, the CB1 protein
is enriched in axons of immature pyramidal neurons
(Supplementary Fig. 1C) (Berrendero et al. 1999; Mulder et al.
2008), making extremely difﬁcult to estimate the contribution
of somatic CB1 immunostaining in migrating neurons to the
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Manent et al. 2009), we extended our IUE experiments until
early postnatal life (P2 and P10), when the siRNA is no longer
active. In P2 brains, the migration arrest observed upon CB1
expression manipulation was still present (Fig. 2A,B), thus
conﬁrming that temporally restricted CB1 receptor loss of func-
tion compromises radial migration of newborn neurons in the
developing cortex. In P10 brains, we observed a greater propor-
tion of GFP+ cells in the upper layers of CB1 siRNA-
Figure 2. Transient CB1 receptor knockdown generates long-lasting aberrant neuronal positioning and SBH. (A,B) Migration analysis of cortical neurons electroporated in
utero with CB1 siRNA or a control siRNA together with a GFP expression plasmid at E14.5 and analyzed at P2. Electroporated cell distribution was analyzed in the indicated
cortical layers and WM. (C,D) Brains electroporated at E14.5 were analyzed as above at P10. (E,F) Migration-arrested GFP+ cells from electroporated P10 brains were stained
with the callosal projection neuron marker Satb2. The speciﬁcation of targeted cells was quantiﬁed in control and CB1 siRNA-electroporated cortices (F). (G) Subcortical
accumulations of pyramidal neurons were evident in CB1 siRNA-electroporated brains at P60. (G’, G””) Detail of the expression of the callosal projection neuron marker
Satb2 in SBH. Arrows point to Satb2+ GFP+ cells. (H) The SBH nature of the lesions was conﬁrmed by the identiﬁcation of a glial GFAP-immunoreactive capsule around the
ectopic cell accumulations. (I) Example of an SBH-like lesion in another P60 CB1 siRNA-electroporated brain. n = at least 3 different embryos from different litters per con-
dition. Graphs represent mean ± SEM. *P < 0.05; **P < 0.01. Scale bars: (A,E) 100 μm (insets, 20 μm); (C) 200 μm; (G’,H) 200 μm; (G””) 25 μm; (I) 100 μm.
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overall staining. Thus, to recapitulate CB1 receptor expression
in migrating pyramidal neurons, we used ISH of CB1 receptor
transcripts in GFP-positive cells in E16.5 embryonic cortices
subjected to IUE at E14.5 (Supplementary Fig. 1B). As developing
GABAergic interneurons also express CB1 receptor (Berghuis
et al. 2007; Morozov et al. 2009), to unequivocally assess the
presence of CB1 receptor in pyramidal neurons we took advan-
tage of the Dlx5/6-driven forebrain GABAergic neuron-selective
CB1-deﬁcient mice (Monory et al. 2007). Thus, in Dlx5/6-CB1
−/−
embryonic cortices, CB1 immunostaining was hardly distin-
guishable from their CB1
f/f littermates (Supplementary Fig. 1D),
while in the developing hippocampus a clear reduction of CB1
receptor expression was evident. Overall, these results conﬁrm
the expression of CB1 in radially migrating pyramidal neurons,
in addition to its presence in developing interneurons (Berghuis
et al. 2007; Morozov et al. 2009).
We then assessed the cell-autonomous role of CB1 receptor
signaling in pyramidal neuron migration during cortical devel-
opment. To this end, we acutely knocked down the CB1 recep-
tor in radially migrating neurons at E14.5 by IUE of a pool of
siRNAs directed against 4 sequences of the CB1 receptor mRNA
(hereafter CB1 siRNA) together with a GFP expression construct,
and subsequently analyzed the distribution of radially migrat-
ing cells at different time points. In our hands, transfection of
cortical cells with this siRNA pool reduces CB1 receptor expres-
sion by 50% (Díaz-Alonso et al. 2014). CB1 receptor knockdown
signiﬁcantly impaired newborn pyramidal cell migration
(Fig. 1A–C). Remarkably, after either 2 days (Supplementary Fig.
2A,B) or 3 days (Fig. 1A,B) in utero we observed a reduced colon-
ization of the CP by CB1-knockdown cells that, instead,
appeared stacked in the IZ and the VZ/SVZ. Moreover, when we
restricted our analyses to the cells that had reached the CP we
also found a signiﬁcant delay in CB1 siRNA-electroporated cells,
that were less abundant in upper cortical layers of the cortex,
to which E14.5-born neurons are committed to migrate (Greig
et al. 2013) (Fig. 1C). We conﬁrmed that acute CB1 receptor silen-
cing impairs radial migration by using additional strategies:
both a CB1 short-hairpin RNA (shRNA, not shown) and Cre
recombinase electroporation of CB1
f/f embryos (Supplementary
Fig. 2C,D) impaired migration of cortical projection neurons at
very similar extents than siRNA-mediated CB1 knockdown.
To invade the CP, migrating neurons must undergo a mor-
phological switch from their characteristic multipolar shape,
adopted to explore the SVZ and IZ environment, to a bipolar
morphology, which enables their radial glial-aided migration in
the CP (Heng et al. 2008; Pacary et al. 2011). siRNA-mediated
CB1 knockdown increased the number of primary neurites in
cultured E14.5 cortical neurons (Supplementary Fig. 2E–G).
Hence, we analyzed whether silencing of CB1 receptors affects
the morphology of migrating neurons in vivo. We quantiﬁed
the number of GFP+ cells with >2 primary processes in the CP
of control siRNA and CB1 siRNA-transfected brains, and found a
2-fold increase in the proportion of cells with this aberrant
morphology in CB1 siRNA-electroporated cortices (Fig. 1D,E),
thereby indicating that radial migration blockade occurs con-
currently with an impairment of the multipolar to bipolar
transition.
Transient CB1 Receptor Knockdown Long-Lastingly
Impairs Pyramidal Neuron Migration and Generates
SBH
To assess whether CB1-knockdown cells suffer from a transient
delay in their radial migration and ﬁnally reach the appropriate
cortical layer if given enough time, as is the case following the
silencing of other cell migration regulators (Creppe et al. 2009;
Figure 1. Cannabinoid CB1 receptor knockdown impairs pyramidal neuron migration. (A–C) Analysis of the migration of cortical neurons electroporated in utero with
CB1 siRNA or a control siRNA together with a GFP expression plasmid at E14.5 and analyzed 3 days later, at E17.5. Representative images are shown (A). The distribu-
tion of GFP+ cells in the VZ/SVZ, IZ, and CP of the developing cerebral cortex in both conditions was quantiﬁed (B). The migration of targeted cells within the CP (uCP,
upper CP; mCP, median CP; lCP, lower CP) was also analyzed (C). (D,E) The morphology of CP migrating cells was analyzed, and we quantiﬁed the proportion of cells
with >2 primary processes. Arrows point to abnormal primary processes in CB1-knockdown cells. n = at least 3 different embryos from different litters per condition.
Graphs represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Scale bars: (A) 100 μm; (D) 10 μm.
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Manent et al. 2009), we extended our IUE experiments until
early postnatal life (P2 and P10), when the siRNA is no longer
active. In P2 brains, the migration arrest observed upon CB1
expression manipulation was still present (Fig. 2A,B), thus
conﬁrming that temporally restricted CB1 receptor loss of func-
tion compromises radial migration of newborn neurons in the
developing cortex. In P10 brains, we observed a greater propor-
tion of GFP+ cells in the upper layers of CB1 siRNA-
Figure 2. Transient CB1 receptor knockdown generates long-lasting aberrant neuronal positioning and SBH. (A,B) Migration analysis of cortical neurons electroporated in
utero with CB1 siRNA or a control siRNA together with a GFP expression plasmid at E14.5 and analyzed at P2. Electroporated cell distribution was analyzed in the indicated
cortical layers and WM. (C,D) Brains electroporated at E14.5 were analyzed as above at P10. (E,F) Migration-arrested GFP+ cells from electroporated P10 brains were stained
with the callosal projection neuron marker Satb2. The speciﬁcation of targeted cells was quantiﬁed in control and CB1 siRNA-electroporated cortices (F). (G) Subcortical
accumulations of pyramidal neurons were evident in CB1 siRNA-electroporated brains at P60. (G’, G””) Detail of the expression of the callosal projection neuron marker
Satb2 in SBH. Arrows point to Satb2+ GFP+ cells. (H) The SBH nature of the lesions was conﬁrmed by the identiﬁcation of a glial GFAP-immunoreactive capsule around the
ectopic cell accumulations. (I) Example of an SBH-like lesion in another P60 CB1 siRNA-electroporated brain. n = at least 3 different embryos from different litters per con-
dition. Graphs represent mean ± SEM. *P < 0.05; **P < 0.01. Scale bars: (A,E) 100 μm (insets, 20 μm); (C) 200 μm; (G’,H) 200 μm; (G””) 25 μm; (I) 100 μm.
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upper cortical layers at this stage, we consistently found accu-
mulations of Dcx-Cre+ cells ectopically located in the WM
(Fig. 3F). These observations demonstrate that CB1 receptor sig-
naling promotes radial migration in postmitotic neurons inde-
pendently of the pyramidal precursor cell pool.
We sought for additional support to the postmitotic nature
of the CB1 receptor promigratory role by analyzing the migra-
tion of postmitotic neurons in CB1
−/− embryos. Constitutively
null mutation of CB1 receptors has been shown to affect several
aspects of pyramidal neuron development (Mulder et al. 2008),
although its precise impact on radial migration remains
unclear. Thus, we performed birthdate labeling experiments in
CB1-knockout embryos and control littermates by administer-
ing BrdU at E14.5 followed by double immunoﬂuorescence for
BrdU and Ki67 at E16.5 in order to discard cells that were still
proliferating. BrdU+Ki67− cells, that is, the cells that had exited
cell cycle between E14.5 and E16.5, were signiﬁcantly delayed in
their radial migration in CB1
−/− embryos when compared to WT
littermates (Supplementary Fig. 3A,B).
As the CB1 receptor is known to trigger prosurvival mechan-
isms in neurons (Galve-Roperh et al. 2008), we assessed
whether its knockdown interferes with neuronal migration by
affecting cell viability. Hence, we analyzed the apoptosis
marker cleaved caspase-3 in cortices subjected to IUE with the
CB1 siRNA. We did not ﬁnd signiﬁcant differences in apoptotic
cells in the developing cortex of CB1 siRNA-electroporated and
control siRNA-electroporated cortices (Supplementary Fig. 3C).
Likewise, no differences were observed by TUNEL staining in CB1
siRNA-electroporated versus control cortices (Supplementary
Fig. 3D), thus ruling out a contribution of neuronal survival in
the promigratory effect of the CB1 receptor.
The eCBs 2-AG and Anandamide Act as
Chemoattractant Cues for Newborn Pyramidal Neurons
To better understand the mechanism of CB1 receptor-driven
neuronal migration, we ﬁrst investigated the ability of
endogenous cannabinoid ligands to modulate pyramidal neu-
ron migration. We prepared E14.5 dorsal telencephalic explants
and exposed them to a conﬁned source of eCBs. Diacylglycerol
lipase alpha (DAGLα) is the key enzyme involved in 2-AG syn-
thesis, and mice lacking this enzyme show impaired eCB-
mediated neuromodulation and compromised adult neurogen-
esis (Gao et al. 2010). Neurons arising from cortical explants
showed a marked preference to migrate toward DAGLα-overex-
pressing COS7 cells when compared with control, GFP-
transfected cells (Fig. 4A,B). Importantly, this effect was blocked
by the CB1 receptor antagonist SR141716. Anandamide biosyn-
thesis is mainly achieved through the action of N-acylphospha-
tidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD).
Likewise, the migration of neurons from cortical explants was
favored toward COS7 cells overexpressing NAPE-PLD, this effect
being also blocked by SR141716. Thus, both eCBs promote pyr-
amidal neuron migration by acting through CB1 receptors.
The aforementioned observations could be explained by two
alternative mechanisms: eCBs might either promote neuronal
motility and/or instruct the directionality of neuronal migra-
tion. To dissect these 2 processes, we overexpressed DAGLα in
utero at E14.5 to disrupt the gradient of eCBs, and analyzed
neuronal migration at E17.5. DAGLα-overexpressing cells
showed a mild though signiﬁcant migration delay compared
with GFP-electroporated cells, thus suggesting that blurring the
cortical eCB gradient misleads neuronal migration (Fig. 4B). We
then evaluated the non-cell autonomous consequences of
disturbing the cortical gradient of 2-AG on the subsequent
waves of migrating neurons. Thus, we injected BrdU 12 h after
DAGLα electroporation to label proliferating cells, and then
tracked their migration at E17.5. BrdU-labeled cells accumu-
lated aberrantly in the VZ of DAGLα-electroporated brains,
where DAGLα-overexpressing cells were most abundant
(Fig. 4C–E), thus indicating that abnormally high levels of 2-AG
in the apical side of the cortex prevent proper newborn neuron
migration. These ﬁndings suggest that eCBs may act as spa-
tially regulated cues for the adequate migration of pyramidal
neurons in the developing cortex.
CB1 Receptor Signaling Promotes RhoA Degradation in
Migrating Pyramidal Neurons
Several signaling pathways involved in the regulation of neur-
onal migration converge in the modulation of the activity of
the small GTPase protein RhoA (Cappello et al. 2012; Pacary
et al. 2013; Azzarelli et al. 2014b). Given the morphological
alterations found in CB1-deﬁcient migrating cells described
above, and the previous evidence suggesting a functional link
between CB1 receptor signaling and RhoA activity in both neur-
onal (Berghuis et al. 2007) and non-neural (Nithipatikom et al.
2012; Mai et al. 2015) cells, we hypothesized that the promigra-
tory effect of the CB1 receptor in newborn pyramidal cells relies
on the modulation of this pathway. To investigate whether CB1
receptor signaling regulates RhoA activity in vivo, we measured
the amount of GTP-bound RhoA in cortical tissue extracts from
E17.5 embryos, when a large proportion of neurons are under-
going migration. We employed dorsal telencephalic glutama-
tergic neuron-speciﬁc CB1 receptor knockouts (Nex-CB1
−/−) to
determine the regulation of RhoA activity by CB1 signaling spe-
ciﬁcally in postmitotic cortical pyramidal neurons (Díaz-Alonso
et al. 2012). We found that active RhoA levels were increased by
2-fold in E17.5 Nex-CB1
−/− cortices compared with their CB1
f/f
littermates (Fig. 5A), suggesting that CB1 receptor signaling
dampens RhoA activity in migrating pyramidal neurons. This
observation indicates that in Nex-CB1
−/− cortical tissue either
the active fraction of RhoA is increased and/or there is an accu-
mulation of total RhoA protein. Hence, we examined total
RhoA protein levels by western blot and also found a 2-fold
increase in Nex-CB1
−/− tissue extracts compared with their CB1
f/f
littermates (Fig. 5B), thus indicating that CB1 inactivation in
postmitotic pyramidal neurons leads to an accumulation of
RhoA protein rather than to an increase in the active fraction of
RhoA. We subsequently analyzed RhoA expression in those sam-
ples by qPCR and found no signiﬁcant difference (Supplementary
Fig. 4A), suggesting that CB1 receptor signaling likely controls
RhoA at a post-translational level rather than by regulating its
gene transcription. The mRNA expression levels of other Rho-
family members involved in neuronal migration, RhoB, Rac1,
and Cdc42, were not affected either by CB1 receptor ablation
(Supplementary Fig. 4A).
To determine whether acute CB1 receptor knockdown strat-
egy also modiﬁes RhoA protein levels, we performed ex vivo
electroporation of CB1 siRNA or control siRNA together with
GFP into E14.5-mouse embryonic dorsal telencephalon, and
maintained dissociated cortical cells for 4 days in vitro (DIV). In
agreement with knockout mice-derived tissue, RhoA immunor-
eactivity was increased in CB1 siRNA-transfected compared
with control siRNA-transfected GFP+ cells (Fig. 5C,D).
It has been recently reported that RhoA expression in
pyramidal neurons is largely dispensable for their migration,
and that its overactivation results in radial migration arrest
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electroporated cortices, although we consistently found GFP+
cells in deep cortical layers. Remarkably, we also found accu-
mulations of GFP+ cells stacked in the WM of CB1-knockdown
brains (Fig. 2C,D). siRNA-electroporated mice that develop until
young adults (P60) were assessed for the deﬁnitive positioning
of transfected cells. Strikingly, we still found subcortical accu-
mulations of GFP+ neurons in 6 out of 9 CB1 siRNA-
electroporated brains (Fig. 2G–I).
We next determined the identity of GFP+ CB1-knockdown
cells at postnatal stages. Cells found in deep cortical layers of
CB1 siRNA-transfected brains at P10 were immunoreactive for
the callosal projection neuron speciﬁcation marker Satb2
(Alcamo et al. 2008) (Fig. 2E,F). We found that virtually all GFP+
cells in the subcortical heterotopias at P60 were also immuno-
positive for Satb2 (Fig. 2G–G””), even though the expression of
this transcriptional regulator in the telencephalon is normally
conﬁned to the cerebral cortex (Alcamo et al. 2008). This obser-
vation indicates that migration-arrested cells retain their corre-
sponding callosal speciﬁcation program even in ectopic
locations. We then asked about the nature of the ectopic neur-
onal accumulations found in CB1 siRNA-transfected brains. SBH
can be distinguished from PH because neuronal accumulations
are surrounded by a glial capsule in SBH but not in PH. Hence,
we stained samples from CB1 siRNA-electroporated P60 brains
for the astrocytic marker GFAP and conﬁrmed that the neur-
onal accumulations correspond to the SBH type (Fig. 2H).
We then explored whether the observed CB1 receptor-
dependent promotion of radial migration was unique of E14.5-born
cells. To this end, we performed IUE at E13.5 and conducted
analyses 3 days later (Supplementary Fig. 2H,I). Similarly to our
previous manipulations at E14.5, when targeting E13.5-born
cells an overall delay in GFP+ cell migration was observed in
CB1-knockdown brains after 3 days in utero. Furthermore,
delayed radial migration was still present at P2 in CB1
f/f neu-
rons electroporated at E13.5 with a Cre recombinase expression
vector (Supplementary Fig. 2C,D).
The CB1 Receptor Promotes Radial Migration of
Postmitotic Pyramidal Neurons
The CB1 receptor plays an active role in the regulation of cor-
tical progenitor cell proliferation and identity (Mulder et al.
2008; Díaz-Alonso et al. 2014). Hence, we determined whether
the observed CB1 receptor-dependent promotion of pyramidal
neuron migration involves CB1 receptors located on cortical
progenitor cells. To test this possibility, we electroporated a Cre
recombinase-encoding construct driven by the postmitotic
neuron-speciﬁc promoter Dcx in E14.5 CB1
f/f embryos, and ana-
lyzed the position of targeted cells at E17.5 (Fig. 3A–C). A clear
migration defect was evident upon CB1 receptor ablation exclu-
sively in postmitotic neurons. Importantly, this manipulation
also affected the morphology of migrating GFP+ cells (Fig. 3D,E).
Moreover, we tested whether postmitotic CB1 receptor ablation
results in a transient or permanent migration impairment by
allowing the electroporated embryos to develop until P2.
Although many of the electroporated cells were found in the
Figure 3. CB1 receptor signaling promotes radial migration postmitotically. (A–C) Migration of cortical neurons was analyzed in E17.5 CB1
f/f embryos electroporated in
utero at E14.5 with Dcx-Cre expression vector, to ablate the CB1 receptor in postmitotic neurons, or GFP as a control (see Materials and Methods). The distribution of
GFP+ cells along the developing cerebral cortex in E17.5 is indicated in (B). Quantiﬁcation of the migration of targeted cells within the CP is shown (C). (D, E) The
morphology of migrating cells was analyzed in the CP, and the proportion of cells with >2 processes was quantiﬁed. Arrows point to abnormal primary processes in
CB1-deﬁcient cells. (F) Migration analysis of cortical neurons electroporated in utero with Dcx-Cre or GFP at E14.5 and analyzed at P2. In Dcx-Cre-transfected cortices,
heterotopic GFP+ cell accumulations were consistently found in subcortical areas (asterisk). n = at least 3 different embryos from different litters per condition.
Graphs represent mean ± SEM. Scale bars: (A, F) 100 μm; (D) 10 μm. *P < 0.05; **P < 0.01; ***P < 0.001.
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upper cortical layers at this stage, we consistently found accu-
mulations of Dcx-Cre+ cells ectopically located in the WM
(Fig. 3F). These observations demonstrate that CB1 receptor sig-
naling promotes radial migration in postmitotic neurons inde-
pendently of the pyramidal precursor cell pool.
We sought for additional support to the postmitotic nature
of the CB1 receptor promigratory role by analyzing the migra-
tion of postmitotic neurons in CB1
−/− embryos. Constitutively
null mutation of CB1 receptors has been shown to affect several
aspects of pyramidal neuron development (Mulder et al. 2008),
although its precise impact on radial migration remains
unclear. Thus, we performed birthdate labeling experiments in
CB1-knockout embryos and control littermates by administer-
ing BrdU at E14.5 followed by double immunoﬂuorescence for
BrdU and Ki67 at E16.5 in order to discard cells that were still
proliferating. BrdU+Ki67− cells, that is, the cells that had exited
cell cycle between E14.5 and E16.5, were signiﬁcantly delayed in
their radial migration in CB1
−/− embryos when compared to WT
littermates (Supplementary Fig. 3A,B).
As the CB1 receptor is known to trigger prosurvival mechan-
isms in neurons (Galve-Roperh et al. 2008), we assessed
whether its knockdown interferes with neuronal migration by
affecting cell viability. Hence, we analyzed the apoptosis
marker cleaved caspase-3 in cortices subjected to IUE with the
CB1 siRNA. We did not ﬁnd signiﬁcant differences in apoptotic
cells in the developing cortex of CB1 siRNA-electroporated and
control siRNA-electroporated cortices (Supplementary Fig. 3C).
Likewise, no differences were observed by TUNEL staining in CB1
siRNA-electroporated versus control cortices (Supplementary
Fig. 3D), thus ruling out a contribution of neuronal survival in
the promigratory effect of the CB1 receptor.
The eCBs 2-AG and Anandamide Act as
Chemoattractant Cues for Newborn Pyramidal Neurons
To better understand the mechanism of CB1 receptor-driven
neuronal migration, we ﬁrst investigated the ability of
endogenous cannabinoid ligands to modulate pyramidal neu-
ron migration. We prepared E14.5 dorsal telencephalic explants
and exposed them to a conﬁned source of eCBs. Diacylglycerol
lipase alpha (DAGLα) is the key enzyme involved in 2-AG syn-
thesis, and mice lacking this enzyme show impaired eCB-
mediated neuromodulation and compromised adult neurogen-
esis (Gao et al. 2010). Neurons arising from cortical explants
showed a marked preference to migrate toward DAGLα-overex-
pressing COS7 cells when compared with control, GFP-
transfected cells (Fig. 4A,B). Importantly, this effect was blocked
by the CB1 receptor antagonist SR141716. Anandamide biosyn-
thesis is mainly achieved through the action of N-acylphospha-
tidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD).
Likewise, the migration of neurons from cortical explants was
favored toward COS7 cells overexpressing NAPE-PLD, this effect
being also blocked by SR141716. Thus, both eCBs promote pyr-
amidal neuron migration by acting through CB1 receptors.
The aforementioned observations could be explained by two
alternative mechanisms: eCBs might either promote neuronal
motility and/or instruct the directionality of neuronal migra-
tion. To dissect these 2 processes, we overexpressed DAGLα in
utero at E14.5 to disrupt the gradient of eCBs, and analyzed
neuronal migration at E17.5. DAGLα-overexpressing cells
showed a mild though signiﬁcant migration delay compared
with GFP-electroporated cells, thus suggesting that blurring the
cortical eCB gradient misleads neuronal migration (Fig. 4B). We
then evaluated the non-cell autonomous consequences of
disturbing the cortical gradient of 2-AG on the subsequent
waves of migrating neurons. Thus, we injected BrdU 12 h after
DAGLα electroporation to label proliferating cells, and then
tracked their migration at E17.5. BrdU-labeled cells accumu-
lated aberrantly in the VZ of DAGLα-electroporated brains,
where DAGLα-overexpressing cells were most abundant
(Fig. 4C–E), thus indicating that abnormally high levels of 2-AG
in the apical side of the cortex prevent proper newborn neuron
migration. These ﬁndings suggest that eCBs may act as spa-
tially regulated cues for the adequate migration of pyramidal
neurons in the developing cortex.
CB1 Receptor Signaling Promotes RhoA Degradation in
Migrating Pyramidal Neurons
Several signaling pathways involved in the regulation of neur-
onal migration converge in the modulation of the activity of
the small GTPase protein RhoA (Cappello et al. 2012; Pacary
et al. 2013; Azzarelli et al. 2014b). Given the morphological
alterations found in CB1-deﬁcient migrating cells described
above, and the previous evidence suggesting a functional link
between CB1 receptor signaling and RhoA activity in both neur-
onal (Berghuis et al. 2007) and non-neural (Nithipatikom et al.
2012; Mai et al. 2015) cells, we hypothesized that the promigra-
tory effect of the CB1 receptor in newborn pyramidal cells relies
on the modulation of this pathway. To investigate whether CB1
receptor signaling regulates RhoA activity in vivo, we measured
the amount of GTP-bound RhoA in cortical tissue extracts from
E17.5 embryos, when a large proportion of neurons are under-
going migration. We employed dorsal telencephalic glutama-
tergic neuron-speciﬁc CB1 receptor knockouts (Nex-CB1
−/−) to
determine the regulation of RhoA activity by CB1 signaling spe-
ciﬁcally in postmitotic cortical pyramidal neurons (Díaz-Alonso
et al. 2012). We found that active RhoA levels were increased by
2-fold in E17.5 Nex-CB1
−/− cortices compared with their CB1
f/f
littermates (Fig. 5A), suggesting that CB1 receptor signaling
dampens RhoA activity in migrating pyramidal neurons. This
observation indicates that in Nex-CB1
−/− cortical tissue either
the active fraction of RhoA is increased and/or there is an accu-
mulation of total RhoA protein. Hence, we examined total
RhoA protein levels by western blot and also found a 2-fold
increase in Nex-CB1
−/− tissue extracts compared with their CB1
f/f
littermates (Fig. 5B), thus indicating that CB1 inactivation in
postmitotic pyramidal neurons leads to an accumulation of
RhoA protein rather than to an increase in the active fraction of
RhoA. We subsequently analyzed RhoA expression in those sam-
ples by qPCR and found no signiﬁcant difference (Supplementary
Fig. 4A), suggesting that CB1 receptor signaling likely controls
RhoA at a post-translational level rather than by regulating its
gene transcription. The mRNA expression levels of other Rho-
family members involved in neuronal migration, RhoB, Rac1,
and Cdc42, were not affected either by CB1 receptor ablation
(Supplementary Fig. 4A).
To determine whether acute CB1 receptor knockdown strat-
egy also modiﬁes RhoA protein levels, we performed ex vivo
electroporation of CB1 siRNA or control siRNA together with
GFP into E14.5-mouse embryonic dorsal telencephalon, and
maintained dissociated cortical cells for 4 days in vitro (DIV). In
agreement with knockout mice-derived tissue, RhoA immunor-
eactivity was increased in CB1 siRNA-transfected compared
with control siRNA-transfected GFP+ cells (Fig. 5C,D).
It has been recently reported that RhoA expression in
pyramidal neurons is largely dispensable for their migration,
and that its overactivation results in radial migration arrest
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(Pacary et al. 2011; Cappello et al. 2012). This is consistent with
the expression pattern of RhoA in the developing cortex, which
shows a clear downregulation of RhoA in migrating neurons
compared with cortical progenitors (Azzarelli et al. 2014a). We
designed an experimental approach aimed at recapitulating the
cellular context of migrating pyramidal neurons to study how
CB1 signaling affects RhoA levels. Thus, we obtained adherent
cortical progenitor cell (CPC) cultures, which can be differen-
tiated into cortical neurons by changing the medium and with-
drawing growth factors (see Supplementary Methods).
Figure 5. CB1 signaling controls RhoA protein levels in pyramidal neurons. (A) Analysis of RhoA activity levels in CB1
f/f and Nex-CB1
−/− E17.5 embryonic cortices. (B)
RhoA protein levels were determined by western blot in cortical tissue in E17.5 Nex-CB1
−/− and CB1
f/f littermates. Loading control was performed with anti α-tubulin
antibody. (C, D) Analysis of RhoA levels in E14.5 primary cortical neurons electroporated with a CB1 siRNA or a control siRNA and maintained in differentiating condi-
tions for 4 DIV. Mean RhoA immunoreactivity (IR) ﬂuorescence intensity was calculated in the GFP+ area. Arrows point to RhoA-enriched processes in CB1-knockdown
cells. n = 3 independent experiments with at least 100 GFP+ cells from 6 imaging ﬁelds per experiment. (E) RhoA protein levels were determined by western blot upon
pharmacological manipulation with HU-210 (50 nM) for 6 h in primary differentiating CPCs. In addition, CPCs were incubated in the presence of the CB1 receptor
antagonist SR (1 μΜ) and with the proteasome inhibitor MG132 (10 μΜ). (F) RhoA protein levels were determined by western blot in cortical samples from E17.5
embryos exposed to the CB1 agonist WIN55,212-2 (5mg/kg) or its vehicle for 6 h. n = at least 3 different embryos per genotype or treatment. Graphs represent
mean ± SEM. *P < 0.05; **P < 0.01; #P < 0.05 versus HU-210-treated cells. Scale bar: 25 μm.
CB1 Receptor Signaling Drives Radial Migration Díaz-Alonso et al. | 9
 at C
ornell U
niversity Library on O
ctober 7, 2016
http://cercor.oxfordjournals.org/
D
ow
nloaded from
 
Figure 4. The eCBs 2-AG and AEA act as promigratory cues for newborn cortical neurons. (A) Representative images of pyramidal neuronal migration assays from
E14.5 cortical explants in response to DAGLα-, NAPE-PLD-, or mock (GFP)-transfected COS7 cells. (B) The promigratory action of eCBs was quantiﬁed by determining
the ratio of neurons in the proximal and distal (P/D) quadrants. The involvement of CB1 receptors was determined by including in the medium the CB1 antagonist
SR141716 (SR, 10 μΜ) or vehicle. n = 3 independent experiments with at least 5 explants per condition. (C–E) Migration analysis of cortical neurons electroporated in
utero with pCAG-DAGLα together with a GFP expression or a control pCAG-GFP plasmid at E14.5 and analyzed at E17.5. BrdU was injected 12 h after IUE to label the
subsequent migrating cells. Representative images are shown. Quantiﬁcation of GFP+ cell distribution in the indicated cortical compartments is shown (D). Analysis
of BrdU-labeled cells at E17.5 (E). n = at least 3 different embryos from different litters per condition. Graphs represent mean ± SEM. *P < 0.05; **P < 0.01 (Student’s t-
test). ***P < 0.001 versus GFP/Vehicle-treated slices of GFP-electroporated embryos; #P < 0.05; ###P < 0.001 versus the corresponding vehicle-treated explants. Scale bars:
(A) 100 μm; inset 500 μm; (C) 100 μm.
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(Pacary et al. 2011; Cappello et al. 2012). This is consistent with
the expression pattern of RhoA in the developing cortex, which
shows a clear downregulation of RhoA in migrating neurons
compared with cortical progenitors (Azzarelli et al. 2014a). We
designed an experimental approach aimed at recapitulating the
cellular context of migrating pyramidal neurons to study how
CB1 signaling affects RhoA levels. Thus, we obtained adherent
cortical progenitor cell (CPC) cultures, which can be differen-
tiated into cortical neurons by changing the medium and with-
drawing growth factors (see Supplementary Methods).
Figure 5. CB1 signaling controls RhoA protein levels in pyramidal neurons. (A) Analysis of RhoA activity levels in CB1
f/f and Nex-CB1
−/− E17.5 embryonic cortices. (B)
RhoA protein levels were determined by western blot in cortical tissue in E17.5 Nex-CB1
−/− and CB1
f/f littermates. Loading control was performed with anti α-tubulin
antibody. (C, D) Analysis of RhoA levels in E14.5 primary cortical neurons electroporated with a CB1 siRNA or a control siRNA and maintained in differentiating condi-
tions for 4 DIV. Mean RhoA immunoreactivity (IR) ﬂuorescence intensity was calculated in the GFP+ area. Arrows point to RhoA-enriched processes in CB1-knockdown
cells. n = 3 independent experiments with at least 100 GFP+ cells from 6 imaging ﬁelds per experiment. (E) RhoA protein levels were determined by western blot upon
pharmacological manipulation with HU-210 (50 nM) for 6 h in primary differentiating CPCs. In addition, CPCs were incubated in the presence of the CB1 receptor
antagonist SR (1 μΜ) and with the proteasome inhibitor MG132 (10 μΜ). (F) RhoA protein levels were determined by western blot in cortical samples from E17.5
embryos exposed to the CB1 agonist WIN55,212-2 (5mg/kg) or its vehicle for 6 h. n = at least 3 different embryos per genotype or treatment. Graphs represent
mean ± SEM. *P < 0.05; **P < 0.01; #P < 0.05 versus HU-210-treated cells. Scale bar: 25 μm.
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ﬁndings indicate that RhoA accumulation in CB1-deﬁcient cells
compromises neuronal migration by altering actin cytoskeleton
dynamics.
Neuronal Migration Arrest Induced by CB1 Receptor
Knockdown Increases Seizure Susceptibility in
Adulthood
We next examined whether the rescue of radial migration by
RhoA downregulation results in a correct neuronal positioning
in the adult cerebral cortex. Electroporated embryos that devel-
oped until P60 were analyzed for the distribution of GFP+ cells.
We found that the majority of CB1 siRNA-electroporated brains
showed SBH, while normal neuronal lamination and SBH were
absent in brains co-electroporated with the RhoA shRNA
(Fig. 7A). Taken together, these ﬁndings demonstrate that pre-
venting RhoA accumulation rescues the migration defects
caused by CB1 receptor silencing. Similarly to human MCDs,
experimentally induced ectopic accumulations of cortical neu-
rons are aberrantly wired to the cortical circuitry, thus leading
to an overall increased susceptibility to seizures (Manent et al.
2009; Feliciano et al. 2011). We studied whether migration deﬁ-
cits caused by in utero CB1 receptor knockdown sensitize the
offspring to seizures induced by the convulsant pentylenetetra-
zol (PTZ). We administered subconvulsive doses of PTZ intra-
peritoneally every 10 min to young adult (P60) mice, and
measured the latency and cumulative dose of PTZ necessary
for generalized seizures to occur. PTZ susceptibility was signiﬁ-
cantly increased in CB1 siRNA-electroporated mice, as shown
by the reduced threshold for generalized seizures. Noteworthy,
the rescue of CB1 siRNA-induced neuronal migration arrest
achieved by shRhoA co-electroporation also prevented the
increased seizure susceptibility (Fig. 7B,C). RhoA knockdown
alone did not signiﬁcantly alter PTZ susceptibility. These obser-
vations indicate that developmental alterations generated by
transient CB1 receptor silencing in migrating pyramidal neu-
rons decrease seizure threshold in adult offspring, and that the
rescue of neuronal migration induced by simultaneous RhoA
downregulation normalizes seizure susceptibility.
Discussion
Overall, this study reveals an unprecedented pivotal role of the
cannabinoid CB1 receptor signaling in the adequate migration
and positioning of cortical pyramidal neurons, which dysfunc-
tion can trigger profound long-lasting alterations in brain func-
tion. It has been long assumed that adult CB1-deﬁcient mice
have increased seizure susceptibility owing to the loss of eCB-
dependent retrograde suppression of glutamate release from
excitatory terminals (Katona and Freund 2008; Soltesz et al.
2015). Of note, our study adds to this classical view by demon-
strating that developmentally restricted loss of CB1 receptor
function also increases seizure susceptibility, likely by causing
aberrant positioning of cortical neurons, thus conceivably
affecting their wiring and sensitizing the resulting circuitry to
epileptogenesis.
Neuronal migration is largely dependent on the dynamic
regulation of the cytoskeleton (Valiente and Marín 2010). Actin
cytoskeleton remodeling plays a fundamental role in this pro-
cess, and the control of RhoA activity is a common feature of
different promigratory pathways (Hand et al. 2005; Nguyen
et al. 2006; Pacary et al. 2011; Tang et al. 2014; Azzarelli et al.
2014b). The expression pattern of RhoA in the developing cor-
tex, with high abundance in the VZ/SVZ and very low—if any—
levels in the IZ and CP (Azzarelli et al. 2014a), suggests that this
protein is dispensable for pyramidal neuron migration, as
Figure 7. Transient CB1 receptor knockdown in migrating pyramidal neurons increases seizure susceptibility in adulthood. (A) Representative images of GFP
+ cells in
adult mice (P60) subjected to IUE at E14.5 with CB1 or control siRNA together with RhoA or control shRNA . GFP
+ cell accumulation within the subcortical WM in CB1
siRNA/shControl condition is indicated (asterisk). (B, C) P60 mice subjected to IUE at E14.5 with CB1 or control siRNAs combined with RhoA or control shRNAs as above
were injected i.p. with PTZ (22.5mg/kg) every 10 min until generalized seizures occurred. The mean latency to the occurrence of generalized seizures is represented
(B) and the cumulative PTZ dose necessary for the onset of generalized seizures was calculated (C). n = 10–14 mice per group. Graphs represent mean ± SEM. *P < 0.05;
**P < 0.01 versus siRNA control-electroporated mice; #P < 0.05; ##P < 0.01; versus CB1 siRNA-electroporated brains. Scale bar: 200 μm.
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Characterization of CPC cultures (Supplementary Fig. 5A–E)
revealed their appropriateness to model the cellular context of
a migrating cortical neuron. As expected, neuronal differenti-
ation reduced nestin and Pax6 expression, while increasing the
expression of the neuronal marker Tuj1 and the CB1 receptor.
RhoA expression also decreased with differentiation, mirroring
the abrupt downregulation that occurs during pyramidal neu-
ron maturation in vivo. To evaluate whether CB1 receptor
manipulation during this process affects RhoA protein levels,
we stimulated CB1 signaling in differentiating CPCs with the
cannabinoid agonist HU-210 and observed that CB1 receptor
activation led to a decrease in total RhoA protein levels com-
pared with vehicle-treated CPCs (Fig. 5E). Noteworthy, HU-210-
induced reduction of RhoA levels was prevented by SR141716.
Differentiating CPCs were also co-incubated with HU-210 and
the proteasome inhibitor MG132, and HU-210-induced regula-
tion of RhoA levels was abolished (Fig. 5E). These results indi-
cate that CB1 receptor signaling promotes proteasomal
degradation of RhoA in newborn pyramidal neurons.
We also evaluated whether pharmacological stimulation of
the CB1 receptor affects RhoA protein levels in developing cor-
tical neurons in vivo. We administered the cannabinoid agonist
WIN55,212-2 or its vehicle to pregnant females in gestational
day 17 and embryos were collected 6 h later. Cannabinoid
administration resulted in the reduction of RhoA protein levels
(0.55 ± 0.08 vs. vehicle-treated RhoA levels) in embryonic cor-
tical extracts (Fig. 5F), without affecting the expression of RhoA,
RhoB, Cdc42, or Rac1 (Supplementary Fig. 4B). Considering that
RhoB is highly expressed during cortical development, its hom-
ology, and function redundancy with RhoA, we also analyzed
RhoB protein levels upon CB1 receptor genetic and
pharmacological manipulation. RhoB levels were increased in
Nex-CB1-deﬁcient mice cortical extracts, while WIN55,212-2
administration in vivo and HU-210 treatment of CPCs decreased
RhoB levels (Supplementary Fig. 6).
RhoA Downregulation Is Sufﬁcient to Rescue CB1
Receptor Knockdown-Induced Migration Arrest
The aforementioned ﬁndings indicate that CB1 receptor silen-
cing leads to RhoA protein accumulation in newborn pyramidal
neurons. To test whether this effect underlies the migration
impairment in CB1 siRNA-electroporated cells, we co-
electroporated a RhoA-directed shRNA together with the CB1
siRNA. The efﬁcacy of the RhoA shRNA to decrease RhoA
expression has previously been demonstrated (Pacary et al.
2011). As shown in Figure 6, knocking-down RhoA fully rescued
CB1 silencing-induced migration arrest, and restored both the
distribution of GFP+ cells along the different cortical compart-
ments (VZ/SVZ, IZ, and CP; Fig. 6B) and the adequate position-
ing of the cells within the CP (Fig. 6C). This observation
provides evidence for the notion that RhoA accumulation upon
CB1 knockdown underlies the impairment of neuronal migra-
tion. Coﬁlin is a downstream effector of RhoA that promotes
actin ﬁlament disassembly. Since F-actin depolymerization is
required for neuronal migration as it allows the continuous
dynamic recycling of actin cytoskeleton, we tested the ability of
a nonphosphorylatable form of coﬁlin (coﬁlinS3A , Pacary et al.
2011), which constitutively depolymerizes F-actin to rescue CB1
receptor knockdown-evoked migration arrest. Expression of
coﬁlinS3A rescued the siCB1-induced cell migration blockade as
quantiﬁed by IUE experiments from E14 to E17 (Fig. 6A–C). These
Figure 6. RhoA knockdown or expression of nonphosphorylatable coﬁlin rescues CB1 silencing-induced migration arrest. (A, B) Migration analysis of cortical neurons
electroporated in utero with a control siRNA or CB1 siRNA together or not with a RhoA shRNA or a plasmid encoding a nonphosphorylatable form of coﬁlin [coﬁlin
S3A]
and a GFP expression plasmid at E14.5 and analyzed 3 days later, at E17.5. Representative images are shown for the different conditions (A). GFP+ cell distribution in
the indicated developing cortical areas and within the CP was quantiﬁed (B, C). n = at least 3 different embryos from different litters per condition. Graphs represent
mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 versus siRNA control-electroporated brains; #P < 0.05; ##P < 0.01; ###P < 0.001 versus CB1 siRNA-electroporated brains.
Scale bar: 100 μm.
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ﬁndings indicate that RhoA accumulation in CB1-deﬁcient cells
compromises neuronal migration by altering actin cytoskeleton
dynamics.
Neuronal Migration Arrest Induced by CB1 Receptor
Knockdown Increases Seizure Susceptibility in
Adulthood
We next examined whether the rescue of radial migration by
RhoA downregulation results in a correct neuronal positioning
in the adult cerebral cortex. Electroporated embryos that devel-
oped until P60 were analyzed for the distribution of GFP+ cells.
We found that the majority of CB1 siRNA-electroporated brains
showed SBH, while normal neuronal lamination and SBH were
absent in brains co-electroporated with the RhoA shRNA
(Fig. 7A). Taken together, these ﬁndings demonstrate that pre-
venting RhoA accumulation rescues the migration defects
caused by CB1 receptor silencing. Similarly to human MCDs,
experimentally induced ectopic accumulations of cortical neu-
rons are aberrantly wired to the cortical circuitry, thus leading
to an overall increased susceptibility to seizures (Manent et al.
2009; Feliciano et al. 2011). We studied whether migration deﬁ-
cits caused by in utero CB1 receptor knockdown sensitize the
offspring to seizures induced by the convulsant pentylenetetra-
zol (PTZ). We administered subconvulsive doses of PTZ intra-
peritoneally every 10 min to young adult (P60) mice, and
measured the latency and cumulative dose of PTZ necessary
for generalized seizures to occur. PTZ susceptibility was signiﬁ-
cantly increased in CB1 siRNA-electroporated mice, as shown
by the reduced threshold for generalized seizures. Noteworthy,
the rescue of CB1 siRNA-induced neuronal migration arrest
achieved by shRhoA co-electroporation also prevented the
increased seizure susceptibility (Fig. 7B,C). RhoA knockdown
alone did not signiﬁcantly alter PTZ susceptibility. These obser-
vations indicate that developmental alterations generated by
transient CB1 receptor silencing in migrating pyramidal neu-
rons decrease seizure threshold in adult offspring, and that the
rescue of neuronal migration induced by simultaneous RhoA
downregulation normalizes seizure susceptibility.
Discussion
Overall, this study reveals an unprecedented pivotal role of the
cannabinoid CB1 receptor signaling in the adequate migration
and positioning of cortical pyramidal neurons, which dysfunc-
tion can trigger profound long-lasting alterations in brain func-
tion. It has been long assumed that adult CB1-deﬁcient mice
have increased seizure susceptibility owing to the loss of eCB-
dependent retrograde suppression of glutamate release from
excitatory terminals (Katona and Freund 2008; Soltesz et al.
2015). Of note, our study adds to this classical view by demon-
strating that developmentally restricted loss of CB1 receptor
function also increases seizure susceptibility, likely by causing
aberrant positioning of cortical neurons, thus conceivably
affecting their wiring and sensitizing the resulting circuitry to
epileptogenesis.
Neuronal migration is largely dependent on the dynamic
regulation of the cytoskeleton (Valiente and Marín 2010). Actin
cytoskeleton remodeling plays a fundamental role in this pro-
cess, and the control of RhoA activity is a common feature of
different promigratory pathways (Hand et al. 2005; Nguyen
et al. 2006; Pacary et al. 2011; Tang et al. 2014; Azzarelli et al.
2014b). The expression pattern of RhoA in the developing cor-
tex, with high abundance in the VZ/SVZ and very low—if any—
levels in the IZ and CP (Azzarelli et al. 2014a), suggests that this
protein is dispensable for pyramidal neuron migration, as
Figure 7. Transient CB1 receptor knockdown in migrating pyramidal neurons increases seizure susceptibility in adulthood. (A) Representative images of GFP
+ cells in
adult mice (P60) subjected to IUE at E14.5 with CB1 or control siRNA together with RhoA or control shRNA . GFP
+ cell accumulation within the subcortical WM in CB1
siRNA/shControl condition is indicated (asterisk). (B, C) P60 mice subjected to IUE at E14.5 with CB1 or control siRNAs combined with RhoA or control shRNAs as above
were injected i.p. with PTZ (22.5mg/kg) every 10 min until generalized seizures occurred. The mean latency to the occurrence of generalized seizures is represented
(B) and the cumulative PTZ dose necessary for the onset of generalized seizures was calculated (C). n = 10–14 mice per group. Graphs represent mean ± SEM. *P < 0.05;
**P < 0.01 versus siRNA control-electroporated mice; #P < 0.05; ##P < 0.01; versus CB1 siRNA-electroporated brains. Scale bar: 200 μm.
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demonstrated in a recent report (Cappello et al. 2012). RhoA
ubiquitination and degradation plays an important role in the
regulation of neuronal cell morphology (Bryan et al. 2005; Tian
et al. 2011) and affects cancer cell migration (Nethe and Hordijk
2010). However, to the best of our knowledge, this is the ﬁrst
study that identiﬁes a speciﬁc role of the proteasomal degrad-
ation of RhoA in the promotion of neuronal migration. Our
ﬁndings are in agreement with the involvement of the small
GTPase Rac1 degradation in cancer cell migration (Oberoi et al.,
2012). Taking into account the complementary expression pat-
tern of both the CB1 receptor and RhoA in the developing cor-
tex, it is conceivable that CB1-mediated RhoA degradation
ensures a complete clearance of the remaining RhoA protein in
newborn neurons to allow their migration. Our results are also
in line with previous ﬁndings supporting that the actin cyto-
skeleton is a major target of CB1 signaling in developing neu-
rons (Berghuis et al. 2007; Oudin et al. 2011; Roland et al. 2014;
Njoo et al. 2015). In addition, CB1 receptor activation can reduce
RhoB protein levels (Supplementary Fig. 6), and therefore we
cannot exclude a potential contribution of this related GTPase
in CB1 receptor-dependent neuronal migration.
We found that the migration defects caused by CB1 receptor
silencing affect more a subset of the targeted GFP+ cells. This
might be related to the unequal knockdown efﬁcacy among tar-
geted cells and/or to the heterogeneity of a neuronal population
in their capacity to compensate the loss of a given promigratory
mechanism. Similarly, in humans, MCDs frequently affect only
relatively small neuronal populations, even when caused by
germline mutations (Lim and Crino 2013). Interestingly, a
recent study supports that the migration deﬁcits caused by Dcx
shRNA are due to off-target effects of such manipulation onto
endogenous miRNAs (Baek et al. 2014). In line with this notion,
the speciﬁcity of our CB1 receptor genetic knockdown strategy
and its consequences on radial migration blockade are vali-
dated by the comparable phenotypes observed when using CB1
siRNA, CB1 shRNA, and Cre-mediated ablation of the CB1 recep-
tor in CB1
f/f mice. Noteworthy, the severe migration defects
observed upon acute CB1 receptor knockdown are notably subtler
upon constitutive CB1 receptor loss (Supplementary Fig. 3A,B).
This is most likely due to compensatory mechanisms occur-
ring in germline or lineage-speciﬁc knockout mice, as also
occurs for other migration regulatory proteins such as Dcx
(Bai et al. 2003), amyloid precursor protein (Young-Pearse
et al. 2007), and EF-hand domain-containing protein 1 (de Nijs
et al. 2009).
A wide variety of neurodevelopmental diseases are caused
by the disruption of neuronal migration. Understanding the
biological mechanisms responsible for a ﬁnely tuned cortico-
genesis emerges as a key requisite for the elaboration of
rational therapeutic strategies for the consequences of MCDs,
including epileptogenesis and neuropsychiatric disorders.
Noteworthy, a genetic origin has been identiﬁed for some
human diseases caused by neuronal migration alterations, and
the genes identiﬁed in such diseases correspond, in most cases,
to cytoskeletal or cytoskeleton-regulatory proteins (Lim and
Crino 2013). Therefore, the implications of the malfunctioning
of the eCB system in the origin of neurodevelopmental diseases
caused by cell migration defects are exciting perspectives for
future research. Of note, evidences in the literature associate
gene alterations (i.e., copy number variations) and gene poly-
morphisms of some of the eCB system elements CNR1, DAGLA,
NAPEPLD, ABHD12, or CNRIP1, with the occurrence of human
diseases, such as autism spectrum disorders, intellectual dis-
ability, or the polyneuropathy, hearing loss, ataxia, retinitis
pigmentosa and cataract syndrome named as PHARC
(Fiskerstrand et al. 2010; Blankman et al. 2013; Bragin et al.
2014). Particularly, the CB1 receptor encoding CNR1 gene has
even put forward as a strong autism-related candidate gene,
given the increased status of de novo mutations in this gene in
samples from a cohort of 2588 autistic patients (Girirajan et al.
2013) or the strikingly high probability of CNR1 haploinsufﬁ-
ciency (Huang et al. 2010). In agreement with these indications,
CB1 receptor signaling regulates the neuronal identity tran-
scriptional factor axis Ctip2-Satb2 (Díaz-Alonso et al. 2012) that
together with Tbr1 is responsible for neuronal connectivity def-
icits that associate with mental retardation and autism
(Carpentier et al. 2013; Deriziotis et al. 2014; Huang et al. 2014).
Alterations of multiple cellular mechanisms frequently con-
verge in the pathogenesis of MCDs, and an unbalanced activity
of CB1 receptor signaling can affect cortical development by
interfering with several processes in addition to neuronal
migration (Díaz-Alonso et al. 2012). While SBH is most fre-
quently originated from abnormal neuronal migration, some
neocortical heterotopias are associated with ectopic progenitor
cell divisions (Kielar et al. 2014). CB1 receptor signaling controls
the activity of the phosphatidylinositol-3-kinase/mammalian
target of rapamycin complex 1 pathway, both in neuronal pre-
cursors (Díaz-Alonso et al. 2014) and in mature neurons
(Puighermanal et al. 2009), and the deregulation of this signal-
ing route is at the origin of some focal MCDs, in particular
tuberous sclerosis, type 2 focal cortical dysplasia, and megalen-
cephaly (Lim and Crino 2013).
Beyond genetic alterations in elements of the cannabinoid
signaling machinery, environmental insults can affect CB1
receptor-dependent neuronal migration. In particular, prenatal
exposure to the cannabinoids present in marijuana has been
shown to affect fetal development in both mice and humans
(Hurd et al. 2005; Jutras-Aswad et al. 2009; Tortoriello et al.
2014). Although detrimental consequences in executive func-
tion have been reported in studies following children from
mothers that smoked marijuana (Fried 2002), the neurobio-
logical substrate of these changes remains unknown. Altered
CB1 receptor signaling induced by long half-life phytocannabi-
noids may eventually interfere with neuronal migration, as
previously shown for synthetic cannabinoids (Saez et al. 2014).
Likewise, gestational cannabinoid exposure may disturb cor-
tical laminarization and cause changes in social behavior and
cognition (Díaz-Alonso et al. 2012; Carpentier et al. 2013; de
Salas-Quiroga et al. 2015). Cannabinoids have a great potential
as medicines owing to the broad distribution of their receptor
targets throughout the body, together with their high safety
and fair tolerability (Pertwee 2012). In particular, cannabidiol,
the most relevant nonpsychoactive phytocannabinoid, has
recently received a huge attention as a promising pharmaco-
logic tool for the management of pediatric epilepsies such as
the Dravet and Gaston-Leroux syndromes (Devinsky et al.
2014). However, as our study and other pieces of evidence sup-
port (Maccarrone et al. 2014), cannabis intake, for both thera-
peutic and recreational use, must be exquisitely controlled if
not absolutely discouraged during pregnancy in order to avoid
interferences with the crucial role played by the CB1 receptor
during brain development.
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Alterations of the PI3K/Akt/mammalian target of rapamycin complex 1 (mTORC1)
signaling pathway are causally involved in a subset of malformations of cortical
development (MCDs) ranging from focal cortical dysplasia (FCD) to hemimegalencephaly
and megalencephaly. These MCDs represent a frequent cause of refractory pediatric
epilepsy. The endocannabinoid system -especially cannabinoid CB1 receptor- exerts a
neurodevelopmental regulatory role at least in part via activation of mTORC1 signaling.
Therefore, we sought to characterize the possible contribution of endocannabinoid
system signaling to FCD. Confocal microscopy characterization of the CB1 receptor
expression and mTORC1 activation was conducted in FCD Type II resection samples.
FCD samples were subjected to single nucleotide polymorphism screening for
endocannabinoid system elements, as well as CB1 receptor gene sequencing.
Cannabinoid CB1 receptor levels were increased in FCD with overactive mTORC1
signaling. CB1 receptors were enriched in phospho-S6-positive cells including balloon
cells (BCs) that co-express aberrant markers of undifferentiated cells and dysplastic
neurons. Pharmacological regulation of CB1 receptors and the mTORC1 pathway
was performed in fresh FCD-derived organotypic cultures. HU-210-evoked activation
of CB1 receptors was unable to further activate mTORC1 signaling, whereas CB1
receptor blockade with rimonabant attenuated mTORC1 overactivation. Alterations of
the endocannabinoid system may thus contribute to FCD pathological features, and
blockade of cannabinoid signaling might be a new therapeutic intervention in FCD.
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INTRODUCTION
Malformations of cortical development are associated with
refractory epilepsy in children and young adults (Iﬄand and
Crino, 2017). These alterations are originated by the disruption
of key processes during brain development, such as neural
progenitor cell proliferation or neuronal migration. Within
MCD, some types of FCD and TSC are associated with
overactivation of the mTORC1 signaling pathway (Aronica and
Crino, 2014; Najm et al., 2018). TSC has a clear genetic origin
on loss-of-function mutations of mTORC1 signaling regulators
such as TSC1/TSC2 (hamartin–tuberin), which leads to the
overactivation of mTORC1. Whereas the origin of the different
FCD subtypes is still unclear, recent research has demonstrated
the involvement of alterations of the PI3K/Akt/mTORC1
pathway particularly in FCD Type II (Jansen et al., 2015;
Lim et al., 2015; D’Gama et al., 2017). Characteristic features
of FCD Type II are the presence of balloon cells (BCs)
and cytomegalic neurons with overactive mTORC1 signaling
(usually revealed by the phosphorylation of one of its canonical
targets, the ribosomal protein S6). Hence, FCD Type II cases
are distinguishable at the molecular level from FCD Type
I by the overactivation of mTORC1 signaling. FCD Type
II cases are also distinguishable from Type I cases by the
expression of undifferentiated cell markers in BCs that suggests
a developmental origin (Orlova et al., 2010). Thus, this subtype
of FCDs and hemimegalencephaly are known to be originated
in the dorsal telencephalic progenitors and excitatory projection
neuron lineage (D’Gama et al., 2017; Iﬄand et al., 2018).
Further investigation on the mechanisms responsible for the
epileptogenic network is required for the development of novel
therapeutic strategies aimed to manage FCDs.
The ECS, and especially the cannabinoid CB1 receptor,
exerts an essential neuromodulatory role in the adult brain
via the retrograde lipid messengers 2-arachidonoylglycerol
and anandamide (Soltesz et al., 2015). In addition, CB1
receptors are expressed during human cortical development
(Mato et al., 2003; Wang et al., 2003). During early stages in
brain development, endocannabinoids act as neural cell fate
regulatory cues, and the CB1 receptor is coupled to activation
of the mTORC1 pathway, which allows the control of neural
progenitor identity and pyramidal neuron generation (Díaz-
Alonso et al., 2015). Cannabinoid signaling regulates long-
range axon projection (Mulder et al., 2008; Argaw et al.,
2011; Díaz-Alonso et al., 2012), but also local microcircuits
and interneuron development (Berghuis et al., 2005, 2007).
Moreover, CB1 receptors are required for proper radial migration
during cortical development, and their genetic inactivation
induces brain hyperexcitability (Díaz-Alonso et al., 2017).
Interestingly, transient loss of CB1 receptor function (induced
by pharmacological down-regulation or small-interfering RNA)
during embryonic development exerts long-lasting alterations in
cortical development that result in increased seizure susceptibility
in the adult offspring (de Salas-Quiroga et al., 2015; Díaz-
Alonso et al., 2017). CB1 receptors are expressed in FCD
(Zurolo et al., 2010), but their functional relevance is unclear.
Thus, here we sought to investigate the potential contribution
of aberrant cannabinoid signaling to FCD developmental
pathogenesis.
MATERIALS AND METHODS
Human Samples
The FCD cases included in this study were obtained from the
archives of the Departments of Neuropathology of the Academic
Medical Center (University of Amsterdam, Netherlands), the
University Medical Center in Utrecht (Netherlands), Hospital
Infantil Niño Jesús (Madrid, Spain) and Biobanc de l’Hospital
Infantil Sant Joan de Déu per a la Investigació (Barcelona, Spain)
integrated in the Spanish Biobank Network of ISCIII. A total
of 30 surgical specimens (10 FCD Type I and 20 FCD Type
II), resected from patients undergoing surgery for intractable
epilepsy, were examined (Table 1). Tissue was obtained and used
in accordance with the Declaration of Helsinki and informed
consent was obtained for the use of brain tissue and for access
to medical records for research purposes. All cases were reviewed
TABLE 1 | Clinical features of cortical development alterations in patients analyzed
in this study.
Patient Age range at
surgery
(years)
Duration of
epilepsy
(years)
Diagnosis Location Engel’s
class
1 10 ≤ 15 8 FCD Ia Parietal II
2 15 ≤ 20 10 FCD Ia Frontal I
3 >20 16 FCD Ia Temporal I
4 15 ≤ 20 11 FCD Ia Frontal I
5 >20 17 FCD Ia Temporal I
6 15 ≤ 20 12 FCD Ia Frontal II
7 0 ≤ 5 4 FCD Ia Temporal I
8 0 ≤ 5 3 FCD Ia Frontal I
9 0 ≤ 5 1.5 FCD Ia Multilobar IV
10 0 ≤ 5 2 FCD Ia Frontal I
11 >20 21 FCD IIb Temporal I
12 >20 18 FCD IIb Temporal I
13 >20 19 FCD IIb Frontal I
14 15 ≤ 20 9 FCD IIb Temporal I
15 10 ≤ 15 10 FCD IIb Frontal I
16 0 ≤ 5 5 FCD IIb Multilobar II
17 5 ≤ 10 5 FCD IIb Multilobar III
18 5 ≤ 10 7.5 FCD IIb Frontal II
19 0 ≤ 5 0.5 FCD IIb Multilobar III
20 15 ≤ 20 17 FCD IIb Multilobar II
21 0 ≤ 5 0.5 FCD IIb Multilobar II
22 >20 21 FCD IIb Multilobar III
23 0 ≤ 5 2.5 FCD IIb Temporal I
24 10 ≤ 15 15 FCD IIb Parietal II
25 10 ≤ 15 6 FCD IIb Occipital I
26 5 ≤ 10 5 FCD IIb Frontal I
27 0 ≤ 5 0.5 FCD IIa Occipital II
28 5 ≤ 10 5 FCD IIa Temporal I
29 5 ≤ 10 5 FCD IIa Multilobar I
30 0 ≤ 5 3 FCD IIb Frontal I
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by the corresponding neuropathologist and the diagnosis was
confirmed according to ILAE classification system (Blümcke
et al., 2011; Najm et al., 2018). Control brains from patients
that were not diagnosed with neurologic disorders were also
employed [n = 6; age (years): 53; 40; 34; 21; 51; 25; 58]. Formalin-
fixed, paraffin-embedded tissue (one representative paraffin block
per case containing the complete lesion or the largest part of
the lesion resected at surgery) was sectioned at 6 µm and
mounted on pre-coated glass slides (Star Frost, Waldemar Knittel
GmbH, Barunschweig, Germany). Sections of all specimens
were processed for hematoxylin eosin, luxol fast blue and Nissl
stainings and neuronal and glial markers for classification and
selection.
FCD Neuronal and Organotypic Cultures
Focal cortical dysplasia derived organotypic cultures were
obtained as described (Eugène et al., 2014). In brief, resection
tissue derived from refractory epilepsy surgery of FCD Type
II patients was sliced at 300 µm. Slices were cultured on
a transwell semiporous membrane for 7 days and subjected
to pharmacological regulation. After incubation, slices were
fixed and sectioned for immunofluorescence characterization.
Alternatively, proteins were extracted after cell lysis in a
buffer containing 50 mM Tris, 0.1% Triton X-100, 1 mM
ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic
acid, 50 mM NaF, 10 mM sodium b-glicerophosphate, 5 mM
sodium pyrophosphate and 1 mM sodium orthovanadate (pH
7.5) supplemented with a protease inhibitor cocktail (Roche,
Basel, Switzerland), 0.1 mM phenylmethane-sulphonylfluoride,
0.1% β-mercaptoethanol and 1 µMmicrocystin for Western blot
analyses.
CB1 Receptor Promoter Transcriptional
Assays
Embryonic carcinoma P19 cells were employed in reporter assays
as previously described (Díaz-Alonso et al., 2015). Cells were
transfected transiently with a construct encoding the −3016
to +142 sequence (referring to the first nucleotide of exon 1)
of the human CB1 receptor gene promoter fused to the CAT
reporter gene (phCB1-3016-CAT) (Blázquez et al., 2011). The
reporter gene construct was based on the pBLCAT2/pBLCAT3
system, in which the thymidine kinase minimal promoter
was replaced for the human CB1 receptor promoter upstream
of CAT. CAT activity was subsequently analyzed by ELISA
following manufacturer’s instructions (Roche, distributed by
Sigma #11363727001, Madrid, Spain).
Immunofluorescence Microscopy
P19 carcinoma cells, organotypic brain slices and FCD samples
were fixed and immunofluorescence performed. After blockade
with 5% goat serum, overnight incubation at 4◦C with the
indicated primary antibodies was performed: polyclonal
guinea pig anti-CB1 receptor (1:500, Frontier Institute, Japan),
polyclonal rabbit anti-phosphoS235/S236-S6 ribosomal protein
(1:100) and polyclonal rabbit anti-phosphoS240/S244-S6
ribosomal protein (1:800; Cell Signaling Technology, Barcelona,
Spain) and monoclonal mouse anti-c-Myc (1:500; Sigma,
Madrid, Spain). Specificity of CB1 immunoreactivity was
confirmed with an additional polyclonal anti-CB1 antibody
(kindly donated by K. Mackie, Indiana University, Bloomington,
IN, United States). The appropriate anti-mouse, rat, guinea pig,
and rabbit highly cross-adsorbed AlexaFluor 488, AlexaFluor
546, AlexaFluor 594, and AlexaFluor 647 secondary antibodies
(Invitrogen, Carlsbad, CA, United States) were used. Confocal
fluorescence images were acquired by using both Leica TCS-SP2
and LAS-X software (Wetzlar, Germany) with a SP2 or a SP8
microscope, respectively, with three passes by Kalman filter and
a 1024 × 1024 or a 2048 × 2048 collection box, respectively.
Immunofluorescence data were obtained in a blind manner by
an independent observer and sample code remained unsealed
during the whole data processing and analysis. mTORC1
activation status and CB1 immunoreactivity were quantified
in a minimum of 500 cells for each FCD patient or control
sample. Immunoreactivity was measured using Fiji (ImageJ)
software establishing a threshold to measure only specific signal.
The resulting binary mask was then used along the built-in
measure function to acquire the total integrated gray density
among all the pixels inside the binary mask overlayed on top
of the original image. The obtained value was then referred to
the number of DAPI+ cell nuclei present in the optic field. For
in vitro studies, P19 cells (n = 6 independent experiments) and
FCD organotypic cultures (n = 4 independent FCD cases) were
quantified.
Western Blot Assays
Equal amount of protein samples were electrophoretically
separated and transferred to PVDF membranes. After blocking
with 5% BSA, membranes were incubated overnight at 4◦C
with anti-phosphoS235/S236-S6 ribosomal protein (1:1000),
anti-phosphoS240/S244-S6 ribosomal protein (1:1000), anti-
CB1 (1:500) or anti-β-actin (1:5000) primary antibodies. PVDF
membranes were then incubated with the corresponding
secondary antibodies coupled to horseradish peroxidase. Optical
density of the specific immunoreactive band was quantified with
Fiji software. The values of pS6 were normalized to those of
β-actin in the same membranes.
DNA Single Nucleotide Polymorphisms
Analyses and Sequencing
Genomic DNA was obtained by standard methods and
Sequenom SNP analyses were performed by Centro Nacional de
Genotipado (CEGEN-PRB2 USC node, Santiago de Compostela,
Spain) using the iPlex R© Gold chemistry and MassARRAY
platform, according to manufacturer’s instructions (Sequenom,
San Diego, CA, United States). Genotyping assays were designed
using the Sequenom MassARRAY Assay Designer 4.1 software.
SNPs were genotyped in three assays, PCR reactions were set up
in a 5 µl volume and contained 20 ng of template DNA, 1×
PCR buffer, 2 mM MgCl2, 500 µM dNTPs and 1 U/reaction of
PCR enzyme. A pool of PCR primers (Metabion, Steinkirchen,
Germany) was made at a final concentration of each primer
of 100 nM. The thermal cycling conditions for the reaction
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consisted on an initial denaturation step at 94◦C for 2 min,
followed by 45 cycles of 94◦C for 30 s, 56◦C for 30 s and 72◦C
for 1 min, and a final extension step of 72◦C for 1 min. PCR
products were treated with 0.5 U shrimp alkaline phosphatase,
followed by enzyme inactivation to neutralize unincorporated
dNTPs.
The iPLEX GOLD reactions were set up in a final 9 µl
volume and contained 0.222x iPLEX buffer Plus, 1x iPLEX
termination mix and 1x iPLEX enzyme. An extension primer
mix (Metabion) was made to give a final concentration of each
primer between 0.52 µM and 1.57 µM. The thermal cycling
conditions for the reaction included an initial denaturation
step at 94◦C for 30 s, followed by 40 cycles of 94◦C for 5 s,
with an internal five cycles loop at 52◦C for 5 s and 80◦C
for 5 s, followed by a final extension step of 72◦C for 3 min.
The iPLEX Gold reaction products were desalted, dispensed
onto a 384 Spectrochip II using an RS1000 Nanodispenser
and spectra were acquired using the MA4 mass spectrometer,
followed by manual inspection of spectra by trained personnel
using MassARRAY Typer software, version 4.0. All assays were
performed in 384-well plates, including negative controls and
a trio of Coriell samples (Na10830, Na10831, and Na12147)
for quality control. Seven samples were tested in duplicate
and they were 100% concordant. Genomic DNA sequencing
of the CB1 receptor gene coding exon was performed by the
Sanger method under standard conditions by Secugen (Madrid,
Spain).
Data and Statistical Analyses
Results shown represent the means ± SEM, and the number of
experiments is indicated in every case. Statistical analysis was
performed with GraphPad Prism 6.07 (GraphPad Software, La
Jolla, CA, United States) using one-way ANOVA. A post hoc
analysis by the Student–Newman–Keuls test was made (Table 2).
Disease-Genotype association test was performed by the SNPator
online tool (Morcillo-Suarez et al., 2008) to examine genotype
and allele frequencies between patients and controls. P-values of
<0.05 were regarded as statistically significant.
RESULTS
CB1 Cannabinoid Receptor Expression in
FCD Is Associated With Overactive
mTORC1 Pathway
To assess the pathophysiological relevance of CB1 receptor
signaling in MCD we analyzed CB1 receptor immunoreactivity
in control and dysplastic brain areas (Figure 1). FCD cases
(n = 30) were included with a mean patient age of 11.4
years and a male/female distribution of n = 18 and 12,
respectively (Table 1). Double immunofluorescence analysis with
anti-phospho-S6 (recognizing the phosphoS240/S244 sites) and
anti-CB1 antibodies confirmed the selective overactivation of
the mTORC1 pathway in FCD Type II but not FCD Type I
samples (Figures 1A,B). Quantification of CB1 immunoreactivity
revealed that receptor expression is notably enriched in the
TABLE 2 | Statistical analyses.
Figure Comparison Statistic value Significance
Figure 1A One-way ANOVA F = 22.57 ∗∗∗∗
FCDI vs. Co q = 1.930 ns
FCDII vs. Co q = 7.833 ∗∗∗∗
FCDII vs. FCDI q = 7.005 ∗∗∗∗
Figure 1B One-way ANOVA F = 24.87 ∗∗∗∗
FCDI vs. Co q = 1.013 ns
FCDII vs. Co q = 8.856 ∗∗∗∗
FCDII vs. FCDI q = 7.271 ∗∗∗∗
Figure 1C One-way ANOVA F = 24.87 ∗∗∗∗
FCDI vs. Co q = 0.7072 ns
FCDII vs. Co q = 7.399 ∗∗∗∗
FCDII vs. FCDI q = 8.187 ∗∗∗∗
Figure 3A One-way ANOVA F = 8.749 ∗∗
RHEB vs. pCAG-GFP q = 4.450 ∗∗
shTSC2 vs. shCo q = 5.700 ∗∗
Figure 3B One-way ANOVA F = 2.917 ∗
Tbr2 vs. GFP q = 5.083 ∗∗
Figure 5A One-way ANOVA F = 16.77 ∗∗∗
RAPA vs. VEH q = 7.675 ∗∗∗
RAPA vs. HU-210 q = 6.139 ∗∗
Figure 5B One-way ANOVA F = 7.305 ∗∗∗
HU-210 vs. VEH q = 0.2946 ns
SR1 vs. VEH q = 4.164 ∗
RAPA vs. VEH q = 5.153 ∗∗
HU-210 + SR1 vs. VEH q = 5.208 ∗∗
One-way ANOVA followed by Student–Newman–Keuls post hoc test. Statistical
significance ∗∗∗∗p < 0.0001; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns, non-
significant.
dysplastic areas of FCD Type II when compared with control
brain tissue, but not in FCD Type I (Figures 1A,C). A more
detailed analysis of double immunofluorescence images showed
that CB1-positive cells largely colocalized with phospho-S6
immunoreactivity in FCD Type II, and CB1+pS6+ cells were
highly enriched in the dysplastic areas when compared to
control cortical tissue (Figure 1D). Equivalent findings of
CB1 enrichment in phospho-S6-positive cells were reproduced
when using as alternative readout, anti phosphoS235/S236-S6
antibody (Supplementary Figure 1). Moreover, the intensity of
phospho-S6 immunoreactivity was selectively increased when
comparing FCD Type II and I (1.61 ± 0.14 versus 1.00 ± 0.07,
respectively; p < 0.05, n = 4). Next, we analyzed CB1 receptor
expression in BCs and dysplastic neurons based in morphological
characterization and mTORC1 overactivation (Figure 2A). This
indicated that 2.43 ± 0.92 and 0.57 ± 0.29% of total CB1 tissue
immunoreactivity corresponded to these cell subpopulations,
respectively. FCD Type II is characterized by the expression
of undifferentiated markers in BC including Sox2, Oct4, Pax6,
Tbr1, Otx1, and others (Hadjivassiliou et al., 2010; Orlova et al.,
2010; Arai et al., 2012; Yao et al., 2016). Thus, we analyzed the
expression of CB1 receptors in FCD Type II neurons together
with undifferentiated-cell markers. Whereas in FCD Type II
sparse c-Myc-positive cells could be detected, this was never the
case in the FCDType I samples. Importantly, c-Myc-positive cells
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FIGURE 1 | The CB1 receptor is enriched in focal cortical dysplasia (FCD) Type II in cells with overactive mTORC1 signaling. (A) Representative immunofluorescence
images showing the presence of CB1 receptors in samples from Type I and II FCD and control brains, revealed with an anti-CB1 antibody (red). Cells with over-active
mTORC1 signaling are stained with phospho-S6Ser240/244 antibody (green). High magnification images of CB1 receptor expression associated with mTORC1
overactivation in FCD Type II are shown. (B,C) Phospho-S6+ cells and CB1 receptor immunoreactivity (IR) were quantified in the dysplastic area and referred to total
cell number (DAPI counterstaining). Control, FCD Type I and FCD Type II cases (B, n = 4, 7 and 18, respectively; C, n = 6, 8, 13). (D) CB1+ phospho-S6+
double-labeled cells were quantified and referred to total pS6+ cells. Control, FCD Type I and FCD Type II cases (n = 4, 7, and 18, respectively). Statistical
comparison versus control samples, ∗∗∗∗p < 0.0001; statistical comparison versus FCD Type I samples, ####p < 0.0001. Scale bar 45 µm, insets, 10 µm.
expressed CB1 receptors and showed active mTORC1 signaling
(pS6+) (Figure 2B). Hence, in FCD Type II we determined
that 72.74 ± 11.04% c-Myc-positive cells were also phospho-S6
positive.
CB1 Cannabinoid Receptor Expression Is
Not Induced by mTORC1 Signaling
To determine if CB1 receptor enrichment in FCD lesions was a
cause or a consequence of mTORC1 overactivation we analyzed if
this signaling pathway can regulate CB1 receptor expression. P19
cells were transfected with a plasmid encoding a constitutively
active mutant of the mTORC1 upstream activator Rheb
(RhebQ64L) or a Tsc2 specific short-hairpin RNA coding plasmid
(shTSC2). In these conditions, as compared to control cells,
mTORC1 pathway activity increased as evidenced by the strong
increase of pS6+ immunoreactive cells (Figure 3A). However,
under the same conditions of overactive mTORC1 signaling,
CB1 receptor protein levels were not induced (Figure 3B).
We also performed CB1 promoter transcriptional assays by co-
transfection with a CAT gene reporter in frame with a minimal
CNR1 promoter (Blázquez et al., 2011). Again, in cells with
overactive mTORC1 pathway CB1 promoter activity was not
induced (Figure 3C). As a control of the sensitivity of this
assay, P19 cells were transfected with the intermediate progenitor
transcription factor Tbr2 (Eomes). The CB1 promoter has several
putative Tbr2-binding sites [Table 3, Matinspector (Genomatix)],
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FIGURE 2 | CB1 receptors are present in undifferentiated cells. (A) Dysplastic
neurons (A1,A1′,A1′ ′ ) and balloon cells (A2,A2′,A2′ ′) were identified based in
morphological criteria in hematoxylin/eosin sections stained with NeuN
antibody (A1,A2). CB1 receptor expression and mTORC1 activity status were
analyzed by immunofluorescence with CB1 and phospho-S6 antibodies,
respectively (A1′,A1′ ′,A2′,A2′ ′). (B) Representative immunofluorescence
images showing the presence of CB1 receptor (red) in FCD Type II brain cells
labeled with the undifferentiated cell marker c-Myc (blue) and active mTORC1
signaling phospho-S6+ cells (green). High magnification insets are shown
(lower panels). Scale bar: 25 µm, insets, 10 µm.
and its expression was indeed sufficient to increase CB1 promoter
reporter activity (Figure 3C), but failed to increase protein levels
(Figure 3B). In summary, these results indicate that the increased
CB1 receptor levels in FCD are not a direct consequence of an
overactive mTORC1 pathway.
Genetic Characterization of the
Endocannabinoid System in FCD
The observation that CB1 receptor levels are increased in
the dysplastic cells of FCD Type II cases prompted us to
expand the analyses to other elements of the ECS that may
contribute to cannabinoid signaling deregulation. Genomic DNA
and messenger RNA from the FCD collection were obtained.
Real time PCR expression analysis confirmed increased levels
of CB1 receptor transcripts in FCD Type II versus control
brain extracts (Table 4), further supporting the results obtained
at the protein level by immunofluorescence characterization
(Figure 1). Transcript levels of other elements of the ECS
[DAGL alpha and beta isoforms, MAGL, FAAH and N-acyl
phosphatidylethanolamine phospholipase D (NAPE-PLD)] were
also quantified and no differences were observed (Table 4).
To further characterize if cannabinoid signaling alterations
may contribute to overactive mTORC1 in FCD Type II,
we performed single nucleotide polymorphism (SNP) analysis
of various genes of the ECS including the CB1 receptor,
DAGL alpha and beta, MAGL, FAAH and CB2 receptor
(Supplementary Table 1). A total 48 SNPs of the ECS were
selected, based on previous evidences that point to their potential
involvement in different nervous system disorders. Genotype
disease association analysis revealed the existence of three
polymorphisms in the DAGLA gene differentially expressed in
FCD Type II versus control specimens (Table 5). The rest of
SNPs analyzed for CNR1, DAGLB, MAGL, FAAH, and CNR2
did not show any difference between pathologic samples and
controls. To further investigate the potential involvement of
CB1 receptors in FCD we sequenced the CNR1 gene exon
in the FCD and control genomic DNA samples. CNR1 exon
1 sequencing revealed normal wild-type sequence in most
samples and only rs1049353 SNP (c.1359G>A; p.Thr453) was
identified with similar distribution among dysplastic and control
DNA.
In summary, these results suggest that the DAGLα-evoked
generation of the endocannabinoid 2-AG might be altered in
FCD Type II and can contribute to its etiopathology. However,
the exact contribution of endocannabinoid tone alterations in
MCD would require more complex genetic studies to identify its
potential association with the origin of the disease.
CB1 Cannabinoid Receptor Crosstalk
With the mTORC1 Pathway in FCD
Resections
Additional specimens derived from surgical resection for
intractable epilepsy were analyzed ex vivo for mechanistic studies.
3T magnetic resonance imaging (MRI), fluorodeoxyglucose
(FDG)-PET scan, scalp electroencephalography (EEG) recording
and invasive neurophysiological studies were employed
to identify the origin of epileptic seizures (Figure 4A).
Representative images of one case prior and after surgery
are shown. In this particular patient, a 5-year-old male, a small
FCD Type II involving the left rolandic region and superior
frontal gyrus (arrowheads, Figure 4A) was associated with daily
focal motor seizures and Epilepsia Partialis Continua involving
the left arm and the face. Scalp EEG analyses revealed continuous
focal epileptiform discharges (arrowhead, Figure 4B) in
accordance with a hypermetabolic FDG-PET focus. Intracraneal
EEG exploration of the dysplastic lesion, using a combination
of subdural electrodes and depth electrodes, better defined a
characteristic EEG pattern, indicative of FCD. This characteristic
EEG pattern shows continuous repetitive burst of epileptiform
activity turning into focal EEG ictal patterns (arrowhead,
Figure 4C), in association with the onset of clinical seizure
signs. After tailored resection of the epileptogenic zone, 1 year
follow-up after surgery revealed a seizure-free clinical status,
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FIGURE 3 | The mTORC1 pathway does not regulate CB1 receptor expression. (A) Characterization of mTORC1 activation in P19 cells after transfection with the
Rheb constitutive active mutant Q64L, shTSC2, a scrambled shRNA encoding vector (shCo), or GFP encoding plasmid. mTORC1 activation was analyzed by means
of phospho-S6-positive cells quantification. Scale bar: 50 µm. (B) Western blot analysis of CB1 receptor levels in the same conditions as above. Representative
immunoblot luminograms for CB1 and β-actin as loading control are shown and quantification is provided (mean ± SEM, n = 3). (C) CB1 receptor promoter activity
was analyzed using a CAT construct 24 h after transfection (n = 6). Statistical comparison versus the corresponding control samples, ∗∗p < 0.01.
MRI and EEG showed absence of the lesion and normalization
of hyperexcitability.
Considering the regulatory role of CB1 receptors in cortical
progenitor cell identity via mTORC1 signaling (Díaz-Alonso
et al., 2015), we next sought to investigate the impact of
the receptor in FCD-derived neurons. We obtained FCD
Type II organotypic cultures derived from fresh resections
that were maintained for 7 days in vitro and subjected to
pharmacological manipulation. Quantification of phospho-S6
immunoreactivity revealed that CB1 receptor activation with the
cannabinoid agonist HU-210 was without effect on mTORC1
activation, whereas the mTORC1 inhibitor rapamycin was
effective in reducing mTORC1 overactivation (Figure 5A).
Western blot analysis confirmed that CB1 receptor agonism
did not influence mTORC1 activation, whereas the CB1
inverse agonist SR141716 (rimonabant), as well as rapamycin,
reduced mTORC1 activation as assessed by phosphoS240/244-S6
levels (Figure 5B). Equivalent results were obtained with
the alternative phosphoS235/236-S6 antibody (Supplementary
Figure 2). Overall, these results indicate that inhibition, but not
activation of the CB1 receptor, may tune the overactive mTORC1
pathway found in FCD Type II dysplastic brain.
DISCUSSION
In the present study, we characterized the expression and
function of the ECS to assess its potential contribution to the
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TABLE 3 | Putative Tbr2 (Eomes) binding sites in the Cnr1 locus identified using
MatInspector software.
Species Gene
location
Binding site position Strand Matrix
similarity
Start End
Human 6q15 88164872 88164900 + 0.941
88166737 88166765 + 0.963
88166645 88166673 + 0.989
88166554 88166568 + 0.902
88168289 88168317 + 0.99
Mouse 4A5 33936594 33936608 − 0.896
33925880 33925908 + 0.901
33944561 33944589 − 0.999
TABLE 4 | Endocannabinoid system elements analyzed by qPCR in FCD Type II
and control samples.
Transcript Condition Mean SEM Significance
CB1 Control 1.00 0.2397 ∗
FCDII 33.70 5.3080
DAGLα Control 1.00 0.0004 ns
FCDII 0.45 0.1286
DAGLβ Control 1.00 0.0106 ns
FCDII 0.84 0.2274
MAGL Control 1.00 0.0005 ns
FCDII 0.88 0.3061
NAPE-PLD Control 1.00 0.0264 ns
FCDII 0.72 0.1176
FAAH Control 1.00 0.0182 ns
FCDII 0.36 0.1910
Statistical comparison versus control tissue ∗p < 0.05. CB1 transcript (n = 4 and
22, control and FCDII), other endocannabinoid system elements (n = 4 and 8
control and FCDII).
etiopathology of MCDs, in particular FCD Type II. Our results
reveal a striking increase in CB1 receptor expression levels in FCD
Type II, and this enrichment occurs in neurons with overactive
mTORC1 signaling. In addition, characterization of genomic
DNA in the dysplastic brain resections showed an enrichment of
three SNPs in the DAGLA gene in FCD Type II versus controls.
The SNPs analyzed in other ECS element genes did not show any
difference between groups. In addition, sequencing of the CNR1
coding exon did not reveal any SNP or mutation differentially
present in FCD Type II versus control brains.
Presynaptic CB1 receptors engaged by retrograde
endocannabinoid messengers constitute an efficient regulatory
mechanism of excessive neurotransmitter release. Hence,
endocannabinoid signaling is a crucial pathway controlling
neuronal activity and its activation or blockade modulates
seizures and epilepsy development (Soltesz et al., 2015). Patients
of temporal lobe epilepsy have decreased CB1 receptor expression
(Ludányi et al., 2008; Goffin et al., 2011). Likewise, selective loss
of function of presynaptic CB1 receptors in projection neuron
populations of the mouse brain results in an imbalance of the
excitatory/inhibitory tone and a higher susceptibility to seizures
FIGURE 4 | EEG characterization of a representative FCD case subject to
surgery. (A) FDG-PET scan co-registered with 3T MRI of a 5-year-old child
affected by a “malignant rolandic epilepsy” with daily motor seizures and
Epilepsia Partialis Continua. Hypermetabolic FDG-PET focus (arrowheads).
Small focal cortical dysplasia involving the left rolandic region and superior
frontal gyrus (arrowhead) and MRI 1 year after epilepsy surgery. (B,C) Scalp
and intracraneal EEG recording, respectively, of the previous patient, using a
combination of subdural electrodes and depth electrodes, prior resection of
the epileptogenic zone. Arrowheads, indicate epileptiform activity.
(Monory et al., 2006). Thus, the enrichment in CB1 receptor
expression in FCD lesions could represent a compensatory
mechanism to attenuate the imbalance of excitatory/inhibitory
neuronal activity. In addition, gene expression assays indicate
that, at least for the hCB1 receptor promoter employed (−3016
to +142 bp sequence), is not directly induced by overactive
mTORC1 pathway, indicating that other signaling events control
CB1 receptor expression in this context.
SNPs analyses and genomic DNA sequencing of the CNR1
exon did not reveal any mutation associated with FCD Type II.
Alternatively, the potential involvement of 2-AG metabolism
in FCD Type II is suggested by the existence of a selective
enrichment in three SNPs of the DAGLA gene. The impact
of the DAGLA SNPs found in our study in 2AG production
or DAGL regulation, is yet unknown as they correspond to
non-coding regions. Nevertheless DAGLA transcript levels were
slightly reduced in FCD when compared to control tissue. These
results are in agreement with a recent study that found DAGLA
polymorphisms associated with neurodevelopmental disorders
and seizures (Smith et al., 2017), while CB1 receptor associated
with pain sensitivity, sleep, memory or anxiety, but not seizures.
CB1 receptors are coupled to the mTORC1 signaling pathway
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TABLE 5 | SNPs analyzed in Focal cortical dysplasia Type II and control brain genomic DNA extracts.
SNP Alleles Major allele homozygous (%) Heterozygous (%) Minor allele homozygous (%) Disease
association
Major/Minor Controls FCD Controls FCD Controls FCD
rs806365 C/T 20.0 36.4 70.0 45.4 10.0 18.2
rs7766029 T/C 20.0 31.8 50.0 54.5 30.0 13.6
rs806366 T/C 40.0 31.8 40.0 31.8 20.0 36.4
rs806368 T/C 60.0 54.5 20.0 36.4 20.0 9.0
rsl2720071 A/G 60.0 86.4 40.0 13.6 0.0 0.0
rs4707436 G/A 60.0 59.1 30.0 40.9 10.0 0.0
rsl049353 G/A 80.0 68.2 10.0 31.8 10.0 0.0
rs806369 C/T 60.0 45.5 30.0 40.9 10.0 13.6
rs2023239 T/C 60.0 63.6 40.0 36.4 0.0 0.0
rsl535255 T/G 70.0 63.6 30.0 36.4 0.0 0.0
rs806379 A/T 30.0 18.2 60.0 77.3 10.0 4.5
rs9444584 C/T 60.0 54.5 30.0 45.5 10.0 0.0
rs9450898 C/T 70.0 63.6 30.0 36.4 0.0 0.0
rs806380 A/G 60.0 54.5 30.0 40.9 10.0 4.5
rs6454674 T/G 40.0 63.6 40.0 31.8 20.0 4.5
rs2180619 A/G 30.0 31.8 50.0 45.5 20.0 22.7
rs4963304 G/A 10.0 68.2 50.0 31.8 40.0 0.0 ∗
rs7931563 T/G 50.0 40.9 50.0 40.9 0.0 18.2
rs7942387 C/A 90.0 100.0 10.0 0.0 0.0 0.0
rsl98430 C/T 30.0 77.3 40.0 22.7 30.0 0.0 ∗
rsl98444 T/C 40.0 4.5 60.0 45.5 0.0 50.0 ∗
rs34365114 G/A 100.0 95.5 0.0 4.5 0.0 0.0
rsl44674730 C/T 100.0 100.0 0.0 0.0 0.0 0.0
rsl43650244 AAA/- 90.0 100.0 10.0 0.0 0.0 0.0
rsl87296513 C/T 100.0 100.0 0.0 0.0 0.0 0.0
rs3813518 G/A 50.0 77.3 50.0 18.2 0.0 4.5
rs3813517 A/G 100.0 95.5 0.0 4.5 0.0 0.0
rs836559 C/G 10.0 36.4 40.0 45.4 50.0 18.2
rs2303361 T/C 40.0 72.8 30.0 22.7 30.0 4.5
rs76802560 G/T 100.0 100.0 0.0 0.0 0.0 0.0
rs6801421 G/A 90.0 63.6 10.0 36.4 0.0 0.0
rs72969613 C/T 100.0 100.0 0.0 0.0 0.0 0.0
rs4881 A/G 70.0 81.8 20.0 18.2 10.0 0.0
rsll5970931 A/G 100.0 100.0 0.0 0.0 0.0 0.0
rs932816 G/A 80.0 50.0 20.0 45.5 0.0 4.5
rs4141964 G/A 30.0 40.9 30.0 40.9 40.0 18.2
rs324420 C/A 30.0 59.1 50.0 22.7 20.0 18.2
rs324419 G/A 80.0 81.8 20.0 18.2 0.0 0.0
rs2295632 C/A 30.0 54.5 40.0 27.3 30.0 18.2
rsl2029329 G/C 30.0 54.5 40.0 27.3 30.0 18.2
rsl2744386 C/T 10.0 31.8 70.0 50.0 20.0 18.2
rsll30321 A/G 20.0 27.3 80.0 54.5 20.0 18.2
rsll06 G/C 20.0 27.3 80.0 54.5 20.0 18.2
rs2229579 C/T 70.0 63.6 30.0 27.3 0.0 9.1
rs2501431 A/G 20.0 27.3 80.0 54.5 20.0 18.2
rs41311993 G/T 100.0 100.0 0.0 0.0 0.0 0.0
rs35761398 CC/TT 20.0 23.8 80.0 57.2 20.0 19.0
rs2501432 C/T 20.0 27.3 80.0 54.5 20.0 18.2
Major and minor allele’s distribution in control and focal cortical dysplasia (FCD) Type II. Disease association ∗p < 0.05.
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FIGURE 5 | CB1 receptors blockade attenuates mTORC1 overactivation in FCD organotypic cultures. Organotypic cultures of FCD resections were cultured 7 days
in vitro and exposed to the CB1 receptor agonist HU-210 (1 µM), and rapamycin (1 µM) 90 min. (A) Representative images of immunofluorescence characterization
with phospho-S6S240/244 antibody were quantified and phosphoS6 immunoreactivity was referred to the total number of cells revealed by DAPI counterstaining.
(B) Western blot analysis of phospho-S6S240/244 levels was performed in slice extracts after 90 min incubation with HU-210 alone or together with SR141716
(25 µM), SR141716 or rapamycin (n = 4 experiments). Statistical comparison versus vehicle samples, ∗p < 0.05; ∗∗p < 0.01. Scale bar: 80 µm.
at early stages of neocortex formation (Díaz-Alonso et al., 2015)
as well as in the adult brain (Puighermanal et al., 2009). We
therefore analyzed CB1 receptor downstream signaling in
FCD-derived organotypic slices. The CB1 agonist HU-210
was unable to further increase mTORC1 activation, reflecting
that the pathway is already overactive. Remarkably, the CB1
inverse agonist rimonabant was efficient in reducing phospho-
S6 levels. This is of interest, as dampening overactive CB1
receptor activity with rimonabant in other settings as the Fmr1
knockout mice efficiently decreases exacerbated mTORC1
activity and symptoms (Busquets-Garcia et al., 2013). Thus,
these results point to a basal cannabinoid signaling tone
that sustains exacerbated mTORC1 activity in FCD Type II.
The ribosomal S6 protein is regulated by phosphorylation
at multiple sites (Meyuhas, 2015). S6 phosphorylation at
Ser240/244 is selectively mediated by S6K1/2 providing a better
readout of mTORC1 upstream activation, while Ser235/236
phosphorylation is regulated by different signaling pathways
(cAMP/PKA, casein kinase 1, MAPK-activated protein kinase-1
and mTORC1/S6K1/2). Initial studies revealed increased levels
of phosphoS235/236-S6 protein in FCD and TSC (Baybis et al.,
2004; Aronica et al., 2007). More recently, somatic mutations
of MTOR signaling pathway and other upstream regulators
PI3K/Akt, TSC1, TSC2, DEPDC5 have been demonstrated
in FCD Type II (Jansen et al., 2015; Lim et al., 2015; Ricos
et al., 2016). Hence, phosphorylation of S6 protein by different
mechanisms may have different functional consequences in FCD
and may differ among neural cell types (Ljungberg et al., 2006;
Biever et al., 2015). Considering the finding that CB1 receptor
antagonism attenuates the phosphorylation of the ribosomal S6
protein at different amino acids (Ser235/236 and Ser240/244)
it can be predicted that different CB1 downstream signaling
effectors: cyclic AMP-mediated and cAMP-independent
(PI3K/Akt-mediated) contribute to its regulation. Hence,
regulation of cannabinoid signaling constitutes and attractive
target for various mTOR-associated disorders and symptoms -the
so-called “mTORopathies”. Cannabidiol, a non-psychotomimetic
cannabinoid with multiple targets, marketed as Epidiolex (GW
Pharma), has demonstrated its efficacy as antiepileptic drug in
refractory epilepsy including TSC, Dravet and Lennox-Gastaut
syndromes, and is under clinical trial for FCDs (Devinsky et al.,
2015; Hess et al., 2016; Thiele et al., 2018).
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Interestingly, FCD type II is believed to be originated
from the dorsal telencephalic progenitor cell compartment
and their excitatory neuronal progeny (D’Gama et al., 2017).
Noteworthy, in mTORopathies experimental models of MCDs
unbalanced deep and upper layer neuronal development
occurs as consequence of aberrant expression of neural fate
determinants. Hence, a contribution of CB1 receptor signaling
to neural precursor alterations responsible for FCD Type
II cannot be excluded. The consequences of CB1 receptor
activity during development and later in the adult brain
can be intrinsically different. During embryonic development,
CB1 receptor controls radial glial to intermediate progenitor
cell transition via mTORC1 signaling (Díaz-Alonso et al.,
2015), and later, at postmitotic stages, tunes deep cortical
neuronal differentiation (Mulder et al., 2008; Díaz-Alonso et al.,
2012). Thus, CB1 receptor activity during embryonic stages
controls progenitor proliferation and neuronal differentiation,
and alterations in cannabinoid signaling have the potential
to evoke long-term neuronal plasticity and abnormalities
underlying FCD neuronal hyperexcitability. In animal models,
conditional ablation of the CB1 receptor during embryonic
development results in increased RhoA levels, ectopic neuron
accumulations and increased seizure susceptibility (Díaz-Alonso
et al., 2017). Noteworthy, RhoA knockdown prevents brain
hyperexcitability and projection neuron alterations induced by
CB1 receptor ablation. Therefore, either hyper- or hypoactive
endocannabinoid signaling during cortical development can be
responsible for neuronal differentiation and positioning deficits
contributing to MCDs. Later, in adult brain, when neuronal
activity is established, the neuromodulatory function of the
ECS takes place. The precise consequences of CB1 receptor
activity in the hyperexcitability neuronal circuit of the dysplastic
brain remain unknown. Among other mechanisms involved in
FCD, decreased hyperpolarization-activated non-specific cation
currents contribute to pyramidal layer V hyperexcitability
(Albertson et al., 2011). Interestingly, a particular pool of
somatodendritic CB1 receptors can regulate Ih currents and this
explains in turn some of the cognitive consequences of CB1
signaling (Maroso et al., 2016).
This study highlights the pathological implications of
altered developmental cannabinoid signaling in refractory
epilepsy. Characterization of epileptogenic FCD tissue from
palliative surgery and dysplastic-derived organotypic cultures
indicates that increased CB1 receptor signaling may constitute
a compensatory mechanism to counteract FCD Type II
hyperexcitability, and its antagonism can dampen mTORC1
overactivation. We anticipate that in the near future new
genetic linkage association analyses using larger cohorts of
patients with pediatric epilepsy could provide further support
to cannabinoid signaling deregulation as a causal mechanism
underlying refractory epilepsy.
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Oral administration of the cannabigerol
derivative VCE-003.2 promotes
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Abstract
Background: The administration of certain cannabinoids provides neuroprotection in models of neurodegenerative
diseases by acting through various cellular and molecular mechanisms. Many cannabinoid actions in the nervous
system are mediated by CB1 receptors, which can elicit psychotropic effects, but other targets devoid of psychotropic
activity, including CB2 and nuclear PPARγ receptors, can also be the target of specific cannabinoids.
Methods: We investigated the pro-neurogenic potential of the synthetic cannabigerol derivative, VCE-003.2, in striatal
neurodegeneration by using adeno-associated viral expression of mutant huntingtin in vivo and mouse embryonic
stem cell differentiation in vitro.
Results: Oral administration of VCE-003.2 protected striatal medium spiny neurons from mutant huntingtin-induced
damage, attenuated neuroinflammation and improved motor performance. VCE-003.2 bioavailability was characterized
and the potential undesired side effects were evaluated by analyzing hepatotoxicity after chronic treatment. VCE-003.2
promoted subventricular zone progenitor mobilization, increased doublecortin-positive migrating neuroblasts towards
the injured area, and enhanced effective neurogenesis. Moreover, we demonstrated the proneurogenic activity of
VCE-003.2 in embryonic stem cells. VCE-003.2 was able to increase neuroblast formation and striatal-like CTIP2-
mediated neurogenesis.
Conclusions: The cannabigerol derivative VCE-003.2 improves subventricular zone-derived neurogenesis in
response to mutant huntingtin-induced neurodegeneration, and is neuroprotective by oral administration.
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Background
Huntington’s disease (HD) is a monogenic neurodegenera-
tive disease produced by the expression of mutant hun-
tingtin (htt) protein with expanded glutamine repeats in
the N-terminal portion of the protein [1]. Mutant htt ex-
pression induces striatal atrophy and medium spiny
neuron (MSN) death, which is responsible for the charac-
teristic motor symptoms of the disease. The length of the
polyglutamine tract expansion in the htt gene, higher than
40 repeats, is closely associated with disease onset. Hence,
although HD neurodegeneration occurs in adult brain,
mutant htt expression is also known to interfere with nor-
mal neurodevelopment at several levels. Mutant hunting-
tin interferes with the activity of various transcription
factors (GSX2+, ASCL1+, ISLT1+, NKX2.1) that are es-
sential in controlling cortical and striatal neurogenesis [2,
3]. Among others, mutant huntingtin decreases NeuroD1
activity, a transcription factor that acts as a major conflu-
ence node of different neurodevelopmental gene pathways
[3]. Mutant huntingtin also alters the mode of division of
subventricular zone (SVZ) progenitors by influencing mi-
totic spindle orientation, that in turn controls asymmetric
cell division and neurogenesis [4]. Moreover, mutant hun-
tingtin expression interferes with projection neuron mi-
gration as normal huntingtin regulates Rab11-mediated
N-cadherin trafficking [5].
Certain cannabinoids, the main active compounds of
Cannabis sativa, and their endogenous counterparts
2-arachidonoylglycerol and anandamide exert symptomatic
relief in various neurodegenerative and neuroinflammatory
conditions [6]. Neuroprotection in mouse HD models as
induced by Δ9-tetrahydrocannabinol (THC), the most
abundant bioactive compound of Cannabis sativa, occurs
at least in part in a cell-autonomous manner via the CB1
receptor [7]. Unfortunately, considering that CB1 receptor
levels notably diminish at early stages of HD [8–10], and
that CB1 receptor agonists produce undesired psychoactive
effects [11], the development of clinical treatments based
on CB1-receptor acting cannabinoids constitutes an ex-
tremely complicated task. Hence, investigating the potential
use of cannabinoids other than THC, with different
pharmacological profiles, constitutes an interesting research
area for the development of new candidate molecules with
reduced unwanted actions. Cannabigerol (CBG) is a
non-psychoactive cannabinoid that has been tested as a
candidate molecule for pharmacological therapies in HD
experimental models [12]. CBG via the nuclear receptor
peroxisome proliferator-activated receptor-γ (PPARγ) alle-
viates motor symptoms, neuroinflammation and neurode-
generation in murine models of HD based on either striatal
neurotoxicity (3-nitropropionic acid injection model) or
transgenic expression of human mutant huntingtin exon 1
(R6/2 model) [12]. Of interest, thiazolidinedione-induced
PPARγ activation is neuroprotective against mutant
huntingtin-induced cell death and reduce huntingtin aggre-
gates in the brain [13]. In order to improve the pharmaco-
logical profile of CBG, chemical modifications were
introduced, leading to the CBG quinone derivatives
VCE-003 and VCE-003.2 [14, 15]. VCE-003.2
([2-(3,7-dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydrox-
y-5-pentyl-(1,4) benzoquinone]), an aminoquinone deriva-
tive of CBG, improves the pharmacological profile of
VCE-003 by eliminating the characteristic side effects of
potent PPARγ activators. Fundamentally, VCE-003.2 is
neuroprotective in the quinolinic acid-administration
model of HD and increases neural progenitor survival [14].
In the present study, we evaluated the neuroprotective
efficacy of oral VCE-003.2 administration. Noteworthy,
oral VCE-003.2 was neuroprotective against mutant
huntingtin-induced damage, and also improved
SVZ-derived neurogenesis. Overall, these findings pro-
vide further support to the neuroprotective and anti-
inflammatory activities of VCE-003.2, and suggests its
potential as a disease-modifying agent, considering its
ability to improve the endogenous neurogenic response.
Methods
Cell culture and reagents
All reagents, unless indicated, were from Sigma-Aldrich
(St. Louis, MO, USA). The synthesis and structure of
VCE-003.2 were previously described [14, 15]. Mouse
embryonic teratocarcinoma P19 were cultured in
high-glucose DMEM (Invitrogen) supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin.
P19 cells were plated in 24-well plates and transfected
with Lipofectamine 2000 reagent according to the manu-
facture’s protocol (Invitrogen). Twenty-four hours post
transfection, cells were collected for RNA extraction or
luciferase assay determinations. P19 neurosphere forma-
tion assay was performed using dissociated P19 cells cul-
tured in high-glucose DMEM (Invitrogen) supplemented
with 5% of fetal bovine serum and 0. 5 μM retinoic acid.
Twenty-four hours later the mean neurosphere size was
quantified. Luciferase construct with the MAR sequence
A4 of the Ctip2 promoter was kindly provided (R.
Grosschedl, Max-Planck-Institute of Immunobiology
and Epigenetics, Freiburg, Germany).
Mouse embryonic stem cell differentiation
R1 mouse embryonic stem (mES) cell line was grown on
gelatin 0.1%, in Knockout DMEM supplemented with
20% Knockout Serum Replacement, 1000 Uml-1 of LIF,
0.1 mM of non-essential amino acids, 2 mM ultragluta-
mine, 50 Uml-1 of penicillin and streptomycin and 0.1
mM of 2-mercaptoethanol. Cells were then differentiated
at low density in Defined Default Medium (DDM) con-
taining DMEM/F12 + GlutaMAX supplemented with N2
supplement (1×), 5 mM of Hepes Buffer, 0.1 mM of
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non-essential amino acids, 1 mM of sodium pyruvate,
2.5 mgml-1 of AlbuMax-I, 30 mM of D-Glucose, 0.1
mM of non-essential amino acids, 0.1 mM of
2-mercaptoethanol, 50 Uml-1 of penicillin and strepto-
mycin for 12 days. The cells were then plated on polyly-
sine/laminin-coated dishes in 50% DDM and 50%
Neurobasal/B27 containing Neurobasal supplemented
with B27 (1×), 2 mM of Ultraglutamine and 50 Uml-1 of
penicillin and streptomycin for 9 days.
Luciferase transcriptional assays
To study CTIP2 transcriptional activity P19 cells were
seeded in 24-well plates and transiently co-transfected
with the luciferase reporter vector MARS-A4-luc [16]
using Roti-Fect (Carl Roth, Karlsruhe, Germany) follow-
ing the manufacturer’s instructions. To correct for trans-
fection efficacy, 100 ng Renilla luciferase (pRL-CMV)
was also cotransfected. After stimulation, the luciferase
activities were quantified using Dual-Luciferase Assay
(Promega, Madison, WI, USA).
Mutant huntingtin-induced neurodegeneration
Male C57BL/6 N mice (10 weeks old) were housed under
standard conditions (12-h light/dark cycle) in groups with
access to food and water ad libitum. All experiments were
performed in accordance with European Union guidelines
and approved by the Animal Research Ethics Committee
of Complutense and Córdoba University. Procedures were
designed to minimize the number of animals used and
their suffering. Constructs expressing CFP-tagged human
huntingtin exon 1 harboring a pathogenic polyQ tract of
94 CAG repeats or a normal, non-pathogenic polyQ tract
of 16 CAG repeats (kindly provided by Dr. José J. Lucas,
Severo Ochoa Molecular Biology Center, Madrid, Spain)
were employed using an AAV1/AAV2 mixed serotype,
generated by polyethyleneimine transfection of HEK293T
cells and subsequent purification in iodixanol gradient.
Vectors were injected stereotactically (in 3 μl PBS) into
the dorsal striatum in a bilateral manner at coordinates
(mm to bregma): antero-posterior + 0.5, lateral ±2.5,
dorso-ventral − 3.5 as previously described [17].
VCE-003.2 (10mg/kg) or vehicle (sesame oil) were orally
administered once daily (Fig. 1), and for neurogenesis ex-
periments BrdU (100mg/kg) was administered i.p. twice
daily on the first week after viral injection. RotaRod test
was conducted prior to drug injections to avoid acute ef-
fects of the compounds under investigation. RotaRod
started at 4 rpm, with an acceleration rate of 6 rpm/min
until either maximum speed is reached or the mouse falls
from the apparatus. Maximum time assay was 10min.
Basal RotaRod performance was determined 6 days prior
to striatal injury in 3 consecutive days with 3 trials/day
(30min of rest between each trial), and groups with
equivalent motor function were assigned. RotaRod test
was performed during 3 consecutive days prior to sacrifice
and plasma was obtained for peripheral biomarker ana-
lyses. All experiments included a minimum of 6 mice per
condition. The precise number of animals analyzed in
each experiment is indicated in the corresponding figure
legends.
Gene expression
Total RNA was isolated from striate using the Qiagen
RNeasy Lipid kit (Qiagen, Germany). Total RNA (1 μg)
was retrotranscribed using the iScript cDNA Synthesis
Kit and the cDNA analyzed by real-time PCR using the
iQTM SYBR Green Supermix and a CFX96 Real-time
PCR Detection System (Bio-Rad; Hercules, CA, USA).
The HPRT gene was used to standardize mRNA expres-
sion in each sample. Gene expression was quantified
using the 2-ΔΔCt method and the percentage of relative
expression against controls (untreated cells or mice) was
Fig. 1 Experimental design for pharmacological manipulation and characterization of in vivo model of Huntington’s disease based on adeno-associated
viral expression of mutant huntingtin exon1
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represented. The primers used in this study were: IL-6;
forward: 5’GAACAACGATGATGCACTTGC3’; reverse:
5’TCCAGGTAGCTATGGTACTCC3’; TNFα; forward:
5’AGAGGCACTCCC CCAAAAGA-3; reverse: CGAT
CACCCCGAAGTTCCCATT.
Pharmacokinetics
Six-week old male Sprague Dawley rats (Janvier Labs,
France) were located in the rodent area of Eurofins
ADME Bioanalyses (Vergèze, France) and housed under
standard conditions (12-h light/dark cycle) in groups
with access to food and water ad libitum. Each animal
was identified by an ear tag and examined for general
health and welfare. Process, treatment and euthanasia
were conducted according to the current procedures in
use at Eurofins ADME Bioanalyses. Animals were
treated with a single intravenous bolus of VCE-003.2
(10 mg/Kg in DMSO) or with oral VCE-003.2 (50 mg/Kg
in sesame oil). At the prescribed times, blood (0.5 ml)
was collected using a capillary tube and plasma frozen at
− 20 °C until analysis. After 24 h, the animals were anes-
thetized and perfused with 20 mL of saline solution dir-
ectly into the heart to extract the maximal blood sample
from the brain. Plasma samples (100 μl) were mixed with
300 μl of acetonitrile and after protein precipitation, ana-
lysis of VCE-003.2 content was performed using
LC-MS/MS (3 animals per each time point). For brain
samples, the tissues were homogenized with an
Ultra-turrax® using UHQ water (1/1, w/w). 100 μl of
each homogenate was mixed with 300 μl of acetonitrile
and the mixture centrifuged for 5 min at 25,000 g. Brain
homogenate supernatants were directly measured by
LC-MS/MS. Previous studies have shown that there are
not significant differences between mice and rats in the
main pharmacokinetic parameters of different cannabi-
noids, including CBG [18]. As the dose used here was
different between i.v. and oral routes of administration,
bioavailability was calculated taking into account the
dose as follows: [AUCt (oral)/dose (oral)]/[AUCt(i.v.)/
dose(i.v.)].
Proteome array
Plasma samples from wild-type and mutant huntingtin-
expressing C57BL/6 N mice were pooled (n = 6 animals
per group) and analyzed for cytokine and adipokine ex-
pression. The Proteome Profiler Mouse XL Cytokine
Array and the Proteome Profiler Mouse Adipokine
Array (R&D Systems) were used according to the manu-
facturer’s protocols to obtain protein expression profiles
using 100 μl plasma samples. Spot density was deter-
mined using Quick Spots image analysis software (R&D
Systems).
Immunofluorescence and confocal microscopy
Free floating coronal brain slices (30 μm) were processed
as previously described [17]. In brief, after blocking with
10% goat serum, brain sections were incubated with the
indicated primary antibodies followed by secondary anti-
body incubation (2 h at room temperature). The appro-
priate mouse, rat and rabbit highly cross-adsorbed
AlexaFluor 488, AlexaFluor 594 and AlexaFluor 647 sec-
ondary antibodies (1:500; Molecular Probes, Leyden, The
Netherlands) were used. Samples were subsequently in-
cubated with DAPI (1:5000, Roche) for 10 min, washed
with PBS and mounted in Mowiol. All immunofluores-
cence data were obtained in a blinded manner by inde-
pendent observers in a minimum of 6 correlative slices,
from 1-in-10 series located between − 0.4 to + 1.6 mm to
bregma. The lateral SVZ zone was delineated by using
DAPI-counterstained cell nuclei, and analyses were
performed in the upper dorsal tier, in which
positively-labelled cells and immunoreactivity were
quantified not beyond 100 μm of the SVZ. Confocal
fluorescence images were acquired by using LAS-X soft-
ware (Wetzlar, Germany) and SP8 microscope with 2
passes by Kalman filter, a 1024X1024 collection box, and
pinhole AU 1. Double-labelled positive cells (GFAP/
Ki-67 and BrdU/NeuN cells) were counted at a magnifi-
cation of 40×. Cells were quantified within a 20 × 20 μm
counting frame, which randomly sampled within a
122.8 × 68.9 μm counting grid. Cells that contacted the
lateral or upper exclusion plane were excluded. The total
number of cells counted was divided by the number of
sampled counting frames and multiplied by its size to
obtain the density of positive cells. Co-localization was
confirmed by orthogonal projection of 18 z-stack files
(1-μm each), and data were expressed as cells/mm2.
Neurodegeneration and glial activation was determined
by dopamine- and cAMP-regulated phosphoprotein of
32 kDa mouse anti-DARPP32 (1:500 BD Transduction
Laboratories, Lexington, KY), rabbit anti-Iba-1 (1:500
Wako Pure Chemical, Osaka, Japan) and mouse
anti-GFAP-Cy3 (1:500 Sigma, St. Louis, MO) immuno-
staining, and quantified with Image-J software designed by
the National Institutes of Health (NIH; Bethesda, MD,
USA). Neurogenesis and SVZ-progenitor mobilization
were characterized by immunofluorescence with rat
anti-CTIP2 antibodies (1:500 Abcam, Cambridge, United
Kingdom). Rabbit anti-Doublecortin (1:1000 from
Abcam), rat anti-BrdU (1:250 from Abcam) and mouse
anti-NeuN (1:500 from Chemicon) antibodies, or rabbit
anti-GFAP and rabbit anti-Ki67 (1:400 from Invitrogen
and 1:500 from ThermoScientific).
Statistical analysis
In vitro data are expressed as mean ± S.D. and in vivo re-
sults are represented as mean ± SEM. Data were subjected
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to Kolmogorov-Smirnov normality test and then, differ-
ences were analyzed by one-way ANOVA followed by
Tukey post hoc test. P < 0.05 was considered significant.
Statistical analysis was performed using GraphPad Prism
version 5.01 and is shown in figure legends. Images were
analyzed and quantified using the ImageJ.
Results
VCE-003.2 exerts a pro-neurogenic effect in vitro
To investigate the pro-neurogenic potential of VCE-003.2
we analyzed its influence in ES-neuronal differentiation.
The R1 line of mouse ES cells was treated with VCE-003.2
during neural differentiation for 21 days and we assessed
CTIP2-positive striatal MSN differentiation [19]. Im-
munofluorescence quantification revealed that VCE-003.2
increased the number of CTIP2-positive cells as well as
doublecortin immunoreactivity (Fig. 2a-b). Next, using
neuralized mouse embryonic teratocarcinoma P19 cells,
we performed CTIP2 transcriptional activity assays by
transfecting a luciferase reporter construct (A4-Mar) cor-
responding to one of the regulatory MARS sequences of
the CTIP2 promoter. VCE-003.2 promoted neuronal-like
differentiation as revealed by CTIP2 reporter activation
(Fig. 2c). Furthermore, using a P19 neurosphere formation
assay, VCE-003.2 generated larger neurospheres than
vehicle-treated cells (367.90 ± 15.20 μm and 268.70 ±
9.20 μm, respectively; Fig. 2d). These results support a
pro-neurogenic action of VCE-003.2 on neural stem cell
differentiation.
Pharmacokinetics and bioavailability of VCE-003.2
As VCE-003.2 was previously shown to exert a neuro-
protective action in preclinical HD models, and consid-
ering its pro-neurogenic profile, we evaluated the
pathophysiological impact and potential therapeutic
value of VCE-003.2 after oral administration. Pharmaco-
kinetic analyses were performed in rats after oral admin-
istration of VCE-003.2 (50 mg/kg) dissolved in sesame
oil. Plasma VCE-003.2 levels peaked at 8 h (Tmax) and
then slowly declined to basal levels. Oral VCE-003.2 re-
sulted in 13.8% bioavailability and after 24 h the concen-
tration of the compound in the brain was similar upon
oral or i.v. treatment (Table 1). We also investigated
some critical ADME/Tox parameters. By using human
liver microsomes we found that VCE-003.2 undergoes a
rapid intrinsic clearance in vitro, which was similar to
the parental compound CBG (Additional file 1). More-
over, VCE-003.2 did not inhibit significantly the activity
of relevant cytochrome P450 isoforms (Additional file 2).
We also determined the potential hepatotoxicity of
chronic VCE-003.2 administration by hematoxylin-eosin
staining. VCE-003.2- and vehicle-treated mouse-derived
livers did not show any evidence of fibrosis, steatosis,
vacuolization, ballooning or inflammation (data not
shown). In addition, VCE-003.2 administration did not
inhibit hERG channel activity, suggesting a potential lack
of cardiotoxicity (Additional file 3), and it was not geno-
toxic as assessed by AMES assays (Additional file 4). We
also determined the impact of VCE-003.2 administration
on peripheral biomarkers by quantifying the levels of cy-
tokines and other soluble mediators. Viral infection lead
to changes in various neuroinflammation biomarkers,
notably C-reactive protein and pentraxins 2, 3 were in-
creased by htt94Q and these changes were reverted by
VCE-003.2 treatment (Additional file 5). These data in-
dicate that mutant huntingtin induces a process of neu-
roinflammation that results in the release of soluble
factors that can be quantified in plasma and normalized
by VCE-003.2 oral administration.
Oral administration of VCE-003.2 attenuates
neuroinflammation and is neuroprotective in a viral
model of mutant huntingtin expression
To evaluate the neuroprotective profile of oral
VCE-003.2 administration, a viral model of HD was
employed [20] in which wild-type mice were subjected
to bilateral intrastriatal injection of adeno-associated
virus (AAV) expressing either exon 1 of human patho-
genic huntingtin with a polyQ tract of 94 CAG repeats,
or a normal, non-pathogenic huntingtin with a polyQ
tract of 16 CAG repeats (AAV-htt16Q and AAV-htt94Q,
respectively), and treated with VCE-003.2 (10 mg/kg/
day). Whereas expression of (exon1)-huntingtin-16Q
during 14 days did not affect motor coordination, mutant
huntingtin-94Q decreased RotaRod latency to fall (Fig. 3a).
Motor impairment in htt94Q mice was accompanied by
profound activation of microglial cells, as evidenced by Iba1
confocal immunofluorescence, in the area surrounding the
infection site (Fig. 3b). Mice treated with VCE-003.2 per-
formed better in the RotaRod test than their vehicle-treated
AAV-htt94Q counterparts, and showed reduced microglial
activation (Fig. 3a-b). Furthermore, VCE-003.2 admin-
istration prevented htt94Q-induced MSN degeneration
as evidenced by DARPP-32 and NeuN immunofluor-
escence (Fig. 4a-b). These results are in line with pre-
vious findings on the neuroprotective ability of
VCE-003.2 in toxin-based models of neurodegenera-
tion [14, 21] and expand its potential clinical profile
since oral administration was as effective as i.p. delivery.
Likewise, oral VCE-003.2 administration was also neuro-
protective and anti-inflammatory in the 3-NP model of
striatal neurodegeneration (Additional file 6).
Oral administration of VCE-003.2 promotes striatal
neurogenesis
The neuroprotective action of oral VCE-003.2 and its
pro-neurogenic impact in vitro prompted us to investi-
gate if this compound could contribute to striatal
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Fig. 2 VCE-003.2 exerts a pro-neurogenic effect in vitro. a-b Mouse embryonic stem cells (R1 line) were treated with Vehicle, VCE-003.2 (500 nM)
during neural differentiation for 21 days. Representative immunofluorescence images and quantification of CTIP2- and doublecortin-positive cells
is shown (n = 3). c Luciferase reporter assay of the A4-MARS sequence of the CTIP2 locus was performed 24 h after P19 cell transfection under
neuronal differentiation conditions and subject to pharmacological regulation as above. d P19 neurosphere formation assay was performed by
culturing the cells for 24 h in the presence of Vehicle or VCE-003.2. Statistics: Unpaired t-test vs Vehicle a * p < 0.05; t = 2.82; df = 4; 95% Confidence
interval (CI) = 0.3149 to 36.85; R2 = 0.66. b * p < 0.05; t = 2.91; df = 4; 95% CI = 0.02 to 1.03; R2 = 0.67. c * p < 0.05; t = 2.87; df = 5; 95% CI = 0.09 to 1.72;
R2 = 0.62. d ** < 0.01 t = 5.91; df = 362; 95% CI = 66.20 to 132.20; R2 = 0.08. Scale bar, 50 μm
Table 1 Pharmacokinetic parameters of VCE-003.2. Pharmacokinetic parameters of VCE-003.2 in plasma following a single intravenous
(i.v.) (10 mg/kg) and oral (50 mg/kg) dose in Sprague Dawley rats
Compound Route Cmax (ng/mL) Tmax (h) AUCt ng/mL*h) Bioavailability Brain Concentration (24 h) (ng/mL)
VCE-003.2 IV 83160 0.08 475094.96 93.7 ± 37.7
VCE-003.2 ORAL 20266.67 8 327154.14 13.77% 86.8 ± 34.0
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neurorepair in vivo by promoting SVZ-derived neuro-
genesis. We analyzed the SVZ neural stem cell popula-
tion, identified as double-labelled GFAP/Ki-67 cells,
which represents the radial glia type B cell compartment.
VCE-003.2 increased the number of proliferating
GFAP-positive cells in AAV-htt94Q-injected mice, indi-
cating its positive impact on NSC mobilization (Fig. 5).
Next, SVZ-derived neural progenitors were identified by
immunofluorescence against Ascl1 (a transcription fac-
tor characteristic of the transit amplifying progenitor
subpopulation). Mutant huntingtin expression induced
an increase in Ascl1+ cell number, and VCE-003.2 ad-
ministration further promoted Ascl1-positive cell expan-
sion in AAV-htt94Q-mice (Fig. 6). To determine the
impact of VCE-003.2 on striatal neurogenesis we next
evaluated doublecortin-positive neuroblasts after 30 days
of AAV-mediated huntingtin expression and daily
VCE-003.2 administration. AAV-htt94Q-induced injury
resulted in a slight increase in neuroblast formation
(Fig. 7a) and effective neurogenesis (BrdU+NeuN+ cells)
(Fig. 7b) as compared to AAV-htt16Q. Oral administra-
tion of VCE-003.2 was effective in promoting neurogen-
esis in AAV-htt16Q- and AAV-htt94Q-treated mice,
both determined as increased doublecortin-expressing
cells and double-positive NeuN/BrdU neurons (Fig.
7a-b). Hence, oral VCE-003.2 administration is able to
restore striatal neurogenesis affected by mutant hunting-
tin expression.
Discussion
VCE-003.2 is an aminoquinone derivative of CBG that
has been designated by the FDA as an orphan drug for
HD treatment (www.accessdata.fda.gov/scripts/opdlist-
ing/oopd/detailedIndex.cfm?cfgridkey=623717). In the
present study, we demonstrate the pro-neurogenic activ-
ity of this cannabinoid derivative in a preclinical model
a
b
Fig. 3 Oral administration of VCE-003.2 attenuates microglial activation and motor impairment induced by mutant-huntingtin expression. Wild
type C57Bl/6 N mice were injected bilaterally with mutant huntingtin expressing AAV-htt94Q and AAV-htt16Q as control. VCE-003.2 or vehicle
were administered orally daily (10 mg/kg) and mice analyzed at 2 after lesion. a Motor function was assessed in the RotaRod test and mean
latency to fold quantified. b Representative confocal microscopy images of huntingtin-CFP and immunoreactivity with an antibody for microglia
(Iba1). Iba1 immunoreactivity was quantified in the indicated experimental groups. AAV-htt16Q Vehicle and VCE-003.2 (n = 3 and 6, respectively),
AAV-htt94Q Vehicle and VCE-003.2 (n = 3 and 5, respectively). Statistics: One-way ANOVA. a F = 5.94; R2 = 0.29. **p < 0.01; q = 4.88 AAV-htt16Q Veh
vs. Mut-htt94q Veh and #p < 0.05; q = 3.90 vs AAV-htt94Q Veh vs. AAV-htt94Q VCE-003.2. b F = 5.87; R2 = 0.91. #p < 0.05; q = 5.32 vs AAV-htt16Q
VCE-003.2 vs. AAV-htt94Q Veh and ##p < 0.01; q = 3.49 vs AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh. **p < 0.01; q = 9.30 AAV-htt94Q Veh
vs. AAV-htt16Q Veh. Scale bar, 100 μm
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of HD that adds to its neuroprotective activity. Oral ad-
ministration of VCE-003.2 exerted an anti-inflammatory
and neuroprotective action in a HD experimental model.
In addition, VCE-003.2 was able to augment mutant
huntingtin-induced SVZ-derived neurogenesis, thus favor-
ing neural stem cell mobilization (double-labelled GFAP+/
Ki-67+ and Ascl1+ cells), neuronal differentiation (double-
cortin+ cells) and effective neurogenesis (double-labelled
Brdu+/NeuN+ cells). In agreement with previous studies,
mutant huntingtin expression induced a pro-neurogenic
response that was evident by the trend towards increased
Ascl1+, Dcx+ and double-labelled BrdU+/NeuN+ cells. The
molecular signals and mechanisms underlying injury-
induced neurogenesis are diverse, and numerous thera-
peutic approaches aim to promote this endogenous
process strategy [22]. Hence, the results obtained in this
study support that striatal neurogenesis is improved
by oral VCE-003.2 administration. This new mechan-
ism of action of VCE-003.2 is relevant when consider-
ing its potential clinical applications, as it suggests
that this molecule could constitute a disease-modifying
drug rather than merely symptom-palliative. It is worth
noting that the preclinical model of HD employed in this
study is based on the expression of exon 1 of either
mutant huntingtin or normal, non-pathogenic hun-
tingtin. The validity of this approach for mechanistic
and pharmacological investigations is demonstrated by
the high number of studies using it [23]. However,
improved animal models, for example based on the
expression of full-length huntingtin, are likely to pro-
vide novel insights of additional aspects of HD.
The use of plant derived-cannabinoid ligands has been
proposed to exert symptomatic relief of motor symp-
toms in neurodegenerative diseases, including
HD-associated dystonia and chorea, levodopa-induced
dyskinesia and tremor in Parkinson’s disease, and mul-
tiple sclerosis-associated spasticity [6, 24]. Despite the
great interest in the therapeutic potential of cannabi-
noids in neurodegenerative diseases, the undesired
side-effects of CB1 receptor agonists significantly limit
a
b
Fig. 4 Oral administration of VCE-003.2 is neuroprotective from mutant-huntingtin-induced neurodegeneration. Wild type mice were injected
bilaterally with mutant huntingtin expressing AAV-htt94Q (mtHtt) and AAV-htt16Q (wtHtt) as control. VCE-003.2 or vehicle were administered
orally daily (10 mg/kg) and mice analyzed 30 days after lesion. Confocal microscopy characterization of huntingtin-CFP and using an antibody for
the MSN marker DARPP32. Quantification of MSN survival after lesion for the indicated experimental groups. AAV-htt16Q (Vehicle and VCE-003.2,
n = 5 each) and AAV-htt94Q (Vehicle and VCE-003.2, n = 7 each). Statistics: One-way ANOVA. a F = 31.56; R2 = 0.80. ##p < 0.01; q = 5.28 AAV-
htt94Q VCE-003.2 vs. AAV-htt94Q Veh. **p < 0.01; q = 10.63 vs AAV-htt94Q Veh vs. AAV-htt94Q Veh vs. AAV-htt16Q Veh and **p < 0.01; q = 5.56 vs
AAV-htt94Q VCE-003.2 vs. AAV-htt16Q Veh. b F = 27.15; R2 = 0.78. ##p < 0.01; q = 10.74 AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh and **p < 0.01;
q = 10.85 vs AAV-htt94Q Veh vs. AAV-htt16Q Veh. Scale bar, 100 μm
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their use in clinical practice. In addition, during HD pro-
gression presynaptic CB1 receptor levels decline very
early, even at presymptomatic stages [7, 9, 10]. Hence,
despite the fact that corticostriatal projections preserve
CB1 receptor expression [17], the use of CB1 agonists
alone may have a limited therapeutic window, and the
development of new cannabinoid-derived molecules act-
ing via different signaling mechanisms and with reduced
a
Fig. 5 Subventricular zone neural progenitor mobilization is increased by oral administration of VCE-003.2. Mice were analyzed 4 weeks after
lesion induced by AAV-htt16Q and AAV-htt94Q bilateral injection and daily treatment with vehicle or VCE-003.2 (10 mg/kg). Confocal microscopy
characterization of the SVZ was performed with GFAP, htt and Ki-67-specific antibodies in the indicated experimental groups. Proliferating SVZ-
neural stem cells were quantified based on GFAP and Ki-67 immunofluorescence colocalization. AAV-htt16Q (Veh and VCE-003.2, n = 7 and 6,
respectively) and AAV-htt94Q (Veh and VCE-003.2, n = 7 and 8, respectively). Statistics: One-way ANOVA. F = 5.78; R2 = 0.42. ##p < 0.01; q = 5.29
AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh. Scale bar, 100 μm
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undesired side-effects constitutes an attractive strategy
to solve these limitations.
PPARγ receptors are required for appropriate neurogen-
esis as it controls neural progenitor cell proliferation and
differentiation [25]. Noteworthy, the positive effect of
PPARγ in neurogenesis, requires fine-tune regulation, as
either its ablation or overactivation may hamper neuronal
differentiation [26]. Under pathological conditions, for in-
stance under an inflammatory insult, PPARγ activation
can restore neurogenesis and cognitive impairment [27].
Similarly, PPARγ activation can restore neurogenesis in
the OH-DA model of Parkinson’s disease [28] and prevent
amyloid-beta-induced cell death of human neural stem
cells [29]. In HD models, the administration of PPARγ ag-
onists protects from striatal neurodegeneration, attenuates
neuroinflammation and decreases oxidative damage
[30–32], supporting PPARγ as a valid target for the
management of HD.
CBD is the most widely investigated phytocannabinoid
devoid of psychotomimetic actions, and whereas its pre-
cise molecular mechanism of action remains the subject
of research, some CBD actions, including its protective ef-
fect in counteracting amyloid-induced inflammation and
neurogenesis deficits, are mediated by PPARγ receptors
[33]. Hence, CBD administration can restore hippocampal
neurogenesis deficits induced by different nervous system
insults such as amyloid-beta pathology, chronic unpredict-
able stress and aging [34]. Other plant-derived cannabi-
noids such as CBG and tetrahydrocannabinolic acid
regulate PPARγ activity [15, 35] and, hence, constitute in-
teresting template structures for the development of new
molecules with improved selectivity, reduced side-effects
and better pharmacokinetic profile. Different strategies
have been applied to improve CBD pharmacological prop-
erties. Fluorinated derivatives or quinone modifications
have successfully generated new cannabinoid molecules
with better translational perspectives (e.g., HUF-101,
VCE-004). Thus, HUF-101 possesses improved anxiolytic,
antidepressant and antipsychotic properties compared to
the original CBD molecule [36]. Regarding CBG, its ami-
noquinone derivative VCE-003.2 has demonstrated effi-
cacy as a neuroprotective molecule in HD [14],
Parkinson’s disease [21] and amyotrophic lateral sclerosis
models [37]. Noteworthy, the VCE-003.2 compound is de-
void of the side effects seen with full PPARγ-agonists and,
hence, does not interfere with osteoblast differentiation
and is less adipogenic [14].
Cell replacement therapy has demonstrated efficacy in
HD experimental models and in preliminary studies in
patients [38]. Exogenous cell grafts of either fetal tissue
Fig. 6 Subventricular zone neural progenitor mobilization is increased by oral administration of VCE-003.2. Mice were analyzed 4 weeks after
lesion induced by AAV-htt16Q and AAV-htt94Q bilateral injection and daily treatment with vehicle or VCE-003.2 (10 mg/kg). Confocal microscopy
characterization of the SVZ was performed with Ascl1-specific antibody in the indicated experimental groups. Quantification of transit amplifying
progenitors labelled with Ascl1. AAV-htt-16Q (Vehicle and VCE-003.2, n = 5 each) and AAV-htt94Q (Vehicle and VCE-003.2, n = 5 each). Statistics:
One-way ANOVA. F = 10.12; R2 = 0.65. ##p < 0.01; q = 4.25 AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh and **p < 0.01; q = 7.12 AAV-htt94Q VCE-
003.2 vs. AAV-htt16Q Veh. Scale bar, 100 μm
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or stem-cell derived neurons are able to survive in the stri-
atum, as well as integrate and ameliorate motor symptoms
and survival, however they face various challenges that
impede their development for disease-modifying strategy.
Considering that in HD postmortem tissue an increased
SVZ cell proliferation and neurogenesis is evident [39],
promoting endogenous SVZ-derived striatal neurogenesis
constitutes an alternative approach of interest. Promoting
SVZ neurogenesis by gene therapy-mediated delivery of
BDNF and noggin successfully delayed progression of the
a b
Fig. 7 Oral administration of VCE-003.2 exerts a pro-neurogenic action. Mice were analyzed 4 weeks after lesion induced by AAV-htt16Q and AAV-
htt94Q bilateral injection and administered daily with vehicle or VCE-003.2 (10mg/kg). a Confocal microscopy characterization of migrating neuroblasts
identified with doublecortin antibody and quantification in the striatum of the indicated mice groups. b Effective neurogenesis was determined by
quantification of double positive cells labelled with BrdU and NeuN antibodies. AAV-htt16Q Vehicle and VCE-003.2 (n = 7 and 5, respectively); AAV-htt94Q
Vehicle and VCE-003.2 (n= 9 and 11, respectively). Statistics: One-way ANOVA. a F = 14.43; R2 = 0.69. ##p < 0.01; q = 6.95 AAV-htt94Q VCE-003.2 vs. AAV-
htt94Q Veh and **p < 0.01; q = 7.59 AAV-htt94Q VCE-003.2 vs. AAV-htt16Q Veh. b F = 13.99; R2 = 0.59. ##p < 0.01; q = 6.50 AAV-htt94Q VCE-003.2 vs. AAV-
htt94Q Veh and **p < 0.01; q = 7.59 AAV-htt94Q VCE-003.2 vs. AAV-htt16Q Veh. Scale bar, 100 μm
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disease in the R6/2 mouse model [40, 41], and the same
approach induced neurogenesis in adult squirrel monkeys
[40]. These findings evidence that, even if endogenous
newly-born neurons express mutant huntingtin, neuro-
genesis is effective and able to counteract, at least in part,
neurodegeneration-evoked symptoms. In this scenario,
pharmacological promotion of adult neurogenesis by can-
nabinoids [42, 43] may constitute a plausible alternative to
gene therapy. In addition, cannabinoids could be used to
promote ES-derived striatal neurogenesis ex vivo for
mechanistic studies or cell replacement therapies.
In summary, our findings demonstrate that oral ad-
ministration of VCE-003.2 exerts a neuroprotective ac-
tion in a striatal neurodegeneration model that is
accompanied by an improved endogenous neurogenic
response. The capability of VCE-003.2 to increase effect-
ive neurogenesis suggests that this CBG derivative may
possess the ability to act as a disease-modifying drug ra-
ther than only a symptomatic reliever.
Conclusions
Oral administration of the cannabigerol derivative
VCE-003.2 is neuroprotective and improves subventri-
cular zone-derived neurogenesis in response to mu-
tant huntingtin-induced neurodegeneration. These
findings are relevant in the search for novel thera-
peutic strategies against Huntington’s disease progres-
sion, considering the lack of undesired side actions of
this novel cannabinoid-derived molecule and good
bioavailability upon oral administration.
Additional files
Additional file 1: Microsomal Metabolic Stability. Pooled human liver
microsomes (final protein concentration 0.5 mg/mL), 0.1 M phosphate
buffer pH 7.4 and the test compounds (VCE-003.2, CBG, verapamil and
dextromethorphan) were pre-incubated at 37 °C prior to the addition of
1 mM NADPH to initiate the reaction. The final incubation volume was
25 μL. Each compound was incubated for 0, 5, 15, 30 and 45 min. The
control (minus NADPH) was incubated for 45 min only. The reactions
were stopped by the addition of 50 μL methanol containing internal
standard at the appropriate time points. The incubation plates were
centrifuged at 2500 rpm for 20 min at 4 °C to precipitate the protein.
Following protein precipitation, the sample supernatants were analyzed
using LC-MS/MS. From a plot of ln peak area ratio (compound peak area/
internal standard peak area) against time, the gradient of the line was
determined. Subsequently, half-life and intrinsic clearance was calculated
using the equations below: Elimination rate constant (k) = (− gradient).
Half-life (t1/2) (min) = 0:693k . Intrinsic Clearance (CLint) (μL/min/mg protein)
= V0:693t1=2 . where V=Incubation volume mL/mg microsomal protein.
(PDF 373 kb)
Additional file 2: Cytochrome P450 Inhibition (IC50 Determination).
CYP1A Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final
DMSO concentration = 0.3%) was incubated with human liver microsomes
(0.25mg/mL) and NADPH (1mM) in the presence of the probe substrate
ethoxyresorufin (0.5 μM) for 5 min at 37 °C. The selective CYP1A inhibitor,
alpha-naphthoflavone, was screened alongside the test compounds as a
positive control. CYP2B6 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.1mg/mL) and NADPH (1mM) in the presence of the probe
substrate bupropion (110 μM) for 5 min at 37 °C. The selective CYP2B6
inhibitor, ticlopidine, was screened alongside the test compounds as a
positive control. CYP2C8 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.25mg/mL) and NADPH (1mM) in the presence of the probe
substrate paclitaxel (7.5 μM) for 30min at 37 °C. The selective CYP2C8
inhibitor, montelukast, was screened alongside the test compounds as a
positive control. CYP2C9 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (1mg/mL) and NADPH (1mM) in the presence of the probe
substrate tolbutamide (120 μM) for 60min at 37 °C. The selective CYP2C9
inhibitor, sulphaphenazole, was screened alongside the test compounds as
a positive control. CYP2C19 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM
in DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.5mg/mL) and NADPH (1mM) in the presence of the probe
substrate mephenytoin (25 μM) for 60min at 37 °C. The selective CYP2C19
inhibitor, tranylcypromine, was screened alongside the test compounds as a
positive control. CYP2D6 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.5mg/mL) and NADPH (1mM) in the presence of the probe
substrate dextromethorphan (5 μM) for 5 min at 37 °C. The selective CYP2D6
inhibitor, quinidine, was screened alongside the test compounds as a
positive control. CYP3A4 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.1mg/mL) and NADPH (1mM) in the presence of the probe
substrate midazolam (2.5 μM) for 5 min at 37 °C. The selective CYP3A4
inhibitor, ketoconazole, was screened alongside the test compounds as a
positive control. CYP3A4 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.5mg/mL) and NADPH (1mM) in the presence of the probe
substrate testosterone (50 μM) for 5 min at 37 °C. The selective CYP3A4
inhibitor, ketoconazole, was screened alongside the test compounds as a
positive control. For the CYP1A incubations, the reactions were terminated
by methanol, and the formation of the metabolite, resorufin, was monitored
by fluorescence (excitation wavelength = 535 nm, emission wavelength =
595 nm). For the CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 incuba-
tions, the reactions were terminated by methanol. The samples were
centrifuged, and the supernatants combined for the simultaneous analysis
of 4-hydroxytolbutamide, 4-hydroxymephenytoin, dextrorphan, and 1-
hydroxymidazolam by LC-MS/MS. Hydroxybupropion, 6α-hydroxypaclitaxel
and 6ß-hydroxytestosterone were analyzed separately by LC-MS/MS. A
decrease in the formation of the metabolites compared to vehicle control
was used to calculate IC50 values. (PDF 323 kb)
Additional file 3: hERG Channel Inhibition (IC50 Determination). The
experiments were performed on an IonWorks™ HT instrument (Molecular
Devices Corporation), which automatically performs electrophysiology
measurements in 48 single cells simultaneously in a specialized 384-well
plate (PatchPlate™). The cells used were Chinese hamster ovary (CHO)
cells stably transfected with hERG (cell-line obtained from Cytomyx, UK).
A single-cell suspension was prepared in extracellular solution (Dulbecco’s
phosphate buffered saline with calcium and magnesium pH 7–7.2) and
aliquots added to each well of a PatchPlate™. Cells were positioned over
a small hole at the bottom of each well by applying a vacuum beneath
the plate to form an electrical seal. The resistance of each seal was
measured via a common ground-electrode in the intracellular
compartment and individual electrodes placed into each of the upper
wells. Electrical access to the cell was achieved by circulating a
perforating agent, amphotericin, underneath the PatchPlate™ and then
measuring the pre-compound hERG current. An electrode is positioned
in the extracellular compartment and a holding potential of − 80 mV
applied for 15 s. The hERG channels were then activated by applying a
depolarizing step to + 40 mV for 5 s and then clamped at − 50 mV for 4 s
to elicit the hERG tail current, before returning to − 80 mV for 0.3 s. VCE-
003.2 were added to the upper wells of the PatchPlate™. Solutions were
prepared by diluting 10 mM DMSO solutions of the test compound into
extracellular buffer such that the final concentrations tested are 0.008,
0.04, 0.2, 1, 5 and 25 μM (final DMSO concentration 0.25%). Quinidine, an
established hERG inhibitor, was included as a positive control and buffer
containing 0.25% DMSO was included as a negative control. Post-
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compound currents were then expressed as a percentage of pre-
compound currents and plotted against concentration for each
compound. Where concentration-dependent inhibition is observed, the
data are fitted and IC50 values were calculated. (PDF 322 kb)
Additional file 4: AMES Data Summary. AMES Experimental Procedure.
Approximately ten million bacteria are exposed in triplicate to VCE-003-.2
(7.8, 15.6, 31.3, 62.5, 125 and 250 μg/ml), a negative control (vehicle) and
a positive control for 90 min in medium containing a low concentration
of histidine (sufficient for about 2 doublings). The cultures were then
diluted into indicator medium lacking histidine and dispensed into 48
wells of a 384 well plate (micro-plate format, MPF). The plate was
incubated for 48 h at 37 °C, and the number of wells showing growth
were counted and compared to the vehicle control. An increase in the
number of colonies of at least two-fold over baseline (mean + SD of the
vehicle control) and a dose response indicates a positive response. An
unpaired, one-sided Student’s T-test was used to identify conditions that
are significantly different from the vehicle control. Where indicated, S9
fraction from the livers of Aroclor 1254-treated rats was included in the
incubation at a final concentration of 4.5%. An NADPH-regenerating
system is also included to ensure a steady supply of reducing equivalents.
The strains used in this study were S. typhimurium TA98 (hisD3052, rfa,
uvrB/pKM10 for detection of frame-shift mutations) and S. typhimurium
TA100 (hisG45, rfa, uvrB/pKM101 for detection of base-pair substitutions).
VCE-003.2 was assessed for its mutagenic potential in the AMES reverse
mutation assay. This test was performed in the absence and presence of S9
metabolic activation. VCE-003.2 was found to be negative for genotoxicity
in this AMES study. The positive controls all behaved as expected.
(PDF 568 kb)
Additional file 5: Effect of oral VCE-003.2 on plasmatic biomarkers.
Plasma samples from the indicated groups of animals (n = 6) were pooled
and subjected to mouse cytokine array (ARY028; R&D Systems) and
mouse adipokine array (ARY013; R&D Systems) analysis. The relative
expression of the indicated biomarkers is shown. (PDF 338 kb)
Additional file 6: 3-Nitroproprionic acid model of striatal
neurodegeneration. 16-week- old C57BL/6 N male mice (Harlan Ibérica,
Barcelona, Spain) were subjected to seven intraperitoneal (i.p.) injections
of 50 mg/kg 3-NP (one injection each every 12 h prepared in phosphate-
buffered saline (PBS)]. 3-NP-treated animals and their respective non-
lesioned controls (injected with PBS) were used for pharmacological
studies with VCE-003.2. Treatments consisted of oral gavage every 24 h
with VCE-003.2 at a dose of 10 mg/kg using sesame oil as vehicle. 12 h
after the last injection of 3-NP motor activity, hindlimb clasping and
kyphosis were evaluated as previously described [12]. Animals were
euthanized at the indicated time after huntingtin-AAV infection or 12 h
after the last injection of 3NP and their brains removed. Statistical
analysis: One-way ANOVA followed by the Tuckey’s post hoc test was
used to determine the statistical significance. All the in vivo data were
expressed as mean ± SEM. Kruskal-Wallis test was used to determine the
statistical in the case of non-parametric analysis. a) Hindlimb Clasping
(F = 8.069; p = 0.0047) post hoc test: p = 0.0036 3NP vs Veh; Locomotor
activity (F = 18.62; p = 0.0001) post hoc test p < 0.0001 3NP vs Veh, p =
0.0027 3NP + VCE-003.2 vs 3NP; Kyphosis (F = 28.24 p < 0.0001) post hoc
test: p < 0.0001 3NP vs Veh, p < 0.0001 3NP + VCE-003.2 vs 3NP. b) TNF-α
(F = 18.17 p = 0.0028) post hoc test: p = 0.0027 3NP vs Veh, p = 0.0138
3NP + VCE-003.2 vs 3NP. IL-6 (Kruskal-Wallis statistic = 6.880 p = 0.0071)
post hoc test: p = 0.0265 3NP vs Veh. c) Average number of neurons per
field (F = 15.69 p = 0.0012) post hoc test: p = 0.0011 3NP vs Veh, p = 0.0086
3NP + VCE-003.2 vs 3NP; Number of Iba1+ cells (F = 10.82 p = 0.0040) post
hoc test: p = 0.0101 3NP vs Veh, p = 0.0059 3NP + VCE-003.2 vs 3NP.
(PDF 325 kb)
Abbreviations
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